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1. Introduction
Stroke is the fourth leading causes of death in the United States. Annually, about 795,000 people
suffer from a stroke with about 140,000 people, or 1 in 19, dying each year due to stroke related
causes. [1] Between 1995-2005 overall stroke death rate fell 30%, even so, annual health care
related costs for stroke patients in 2012 were up to 38.6 billion. [1] It is well recognized that
cerebrovascular disease, specifically carotid atherosclerosis and subsequent stenosis, is a
leading cause of ischemic stroke, which makes up 87% of all strokes. Due to the significant
morbidity and mortality incurred by these patients the identification, management, and
treatment of carotid disease is of paramount importance.
2. Epidemiology
Cerebrovascular disease does not appear to affect all races and genders equally. In addition
to the usual cardiovascular risk factors of hypertension, diabetes, and smoking; age, gender
and race have also been shown to have an additive effect  on stroke risk.  In a study by
Rockman et al. they looked at a little over 3 million patients for evidence of carotid artery
stenosis.  After  controlling  for  gender  and  age  differences,  they  found that  there  was  a
marked variation in the prevalence of carotid artery stenosis with Native American subjects
having the highest prevalence followed by Caucasians. [2] Yet, based on CDC data, African
Americans’ risk of having a first stroke is nearly twice that of Caucasians. Overall, as would
be expected based on the prevalence of carotid disease, American Indians/Alaska Natives
are more likely to have a stroke than other groups. [1] Gender differences have also been
analyzed. In a large population based study carotid artery stenosis was detected in 3.8%
of men and 2.7% of women. [3] The reasons for these differences are thought in part to be
due  to  carotid  plaque  differences  between  men  and  women.  Sangiorgi  et  al.  evaluated
© 2014 Gates and Indes; licensee InTech. This is a paper distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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plaque specimens from 457 patients and found that women, as compared to men of the
same age, had a lower prevalence of thrombotic plaques and a smaller area of necrotic core
and hemorrhage extension. Also, they found inflammatory features were less pronounced
in women as compared to men. [4] These results correlate with similar studies done for
evaluation of patients with coronary artery disease that showed that sex hormones seem
to  play  a  fundamental  protective  role  in  women.  [5,  6]  More  studies  still  need  to  be
conducted to determine the true role of gender in carotid artery disease. Age greater than
70 also appears to be a risk for stroke. In the Framingham study they found that seventy
year olds with hypertension and the presence one additional risk factor, such as diabetes
mellitus, cigarette smoking, cardiovascular disease, atrial fibrillation or electrocardiograph‐
ic abnormalities had an increase in 10 year stroke risk from an average of less than 9% in
women and 12.3% in men, to greater than 80%. [7].
3. Evaluation
Significant carotid artery atherosclerosis can put patients at a risk for stroke and/or transient
ischemic attack (TIA) making it imperative that at risk populations be accurately evaluat‐
ed and followed for disease progression. An ideal diagnostic imaging test could accurate‐
ly and reproducibly determine the degree of luminal stenosis as well as plaque morphology
in both a non-invasive and cost effective way. No one single imaging test encompasses all
these traits however several have been shown to have benefit in the diagnosis and work
up of carotid disease. At this time the most clinically effective first line imaging modality
for  identifying patients  with  carotid  artery  disease  is  duplex ultrasound (DUS).  In  2006
Wardlaw et al published a meta-analysis looking at non-invasive imaging tests either alone
or combined to determine if they could replace intra-arterial angiography for evaluation of
carotid  stenosis.  They  included  41  studies  and  found  that  contrast-enhanced  magnetic
resonance angiography (CEMRA) was the most accurate imaging modality for patients with
70-99% stenosis, however it was not cost-effective. Alternatively, DUS had a sensitivity of
0.89  and  specificity  of  0.84  for  carotid  stenosis  between  70-90%,  was  cost  effective  and
allowed  for  expedient  diagnosis  and  treatment  for  patients  recommending  it  as  the
diagnostic  test  of  choice.  In  patients  with  lower  degrees  of  stenosis  around 50-69% the
sensitivity of  DUS dropped to 0.36.  [8]  Conversely,  another meta-analysis  performed by
Jahromi et al found improved sensitivities and specificities of 0.98 and 0.88 for detecting
greater than 50% ICA stenosis;  and 0.94 and 0.90 respectively for detecting greater than
70% ICA stenosis. [9] Due to the potential risk of surgical intervention in patients with a
questionable  or  50-69%  stenosis,  a  subsequent  CEMRA  or  a  multi  detector  computed
tomographic  angiogram  (MDCTA),  is  highly  recommended.  [8]  Principle  limitations  of
ultrasound  remain  primarily  operator  experience.  Occasionally,  plaque  calcification,
shadowing  and  patient  body  habitus  can  also  prevent  accurate  assessment  of  stenosis.
Currently the indications for carotid duplex ultrasonography are cervical bruit, amaurosis
fugax, focal or cerebral transient ischemic attacks, drop attacks, or syncope.
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Figure 1. 71 year old male presenting with history of transient ischemic attack presenting as left arm numbness and
weakness. A. Ultrasound of the right internal carotid artery showing elevated velocities (arrow) up to 442 cm/s corre‐
lating with a greater than 70% stenosis by NASCET criteria. B. Same patient US of right proximal common carotid ar‐
tery with baseline velocities (arrow) 75.6 cm/s.
Figure 2. 79 year old male presented after transient ischemic attack. CTA obtained showing proximal right internal
carotid artery stenosis (greater than 70%) with heavy calcification (arrow). Also shown cross-sectional view of area of
greatest stenosis (dashed arrow).
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carotid artery stenosis (greater than 70%) with heavy calcification (arrow). Also shown cross-sectional view of area of
greatest stenosis (dashed arrow).
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The degree of luminal stenosis has traditionally been the most important element when
considering the severity of carotid disease, however recently several studies have shown that
plaque structure and composition may be an additional marker for future cerebrovascular
events. [10, 11] DUS can provide only a basic view of plaque morphology, unable to consis‐
tently and accurately delineate characteristics of plaque vulnerability such as ulceration, a large
lipid necrotic ore, and a thin fibrous cap. [12, 13]. Gray-Weale developed a scale, later modified
by Geroulakos that identified 5 types of carotid artery plaques: type 1 (anechogenic with
echogenic fibrous cap), type 2 (predominately anechogenic but with echogenic areas repre‐
senting less than 25% of the plaque), type 3 (predominately hyperechogenic but with anecho‐
genic areas representing less than 25% of the plaque), type 4 (echogenic and homogeneous
plaque) and type 5 (unclassified plaques reflecting calcified plaques with areas of acoustic
shadowing which hide the deeper part of the arterial layers). [14, 15]. Using this type of
classification, a study by Polak et al. showed that asymptomatic elderly patients with a hypo-
echoic plaque have relative risk of ipsilateral ischemic stroke of 2.78, this was independent
from the degree of stenosis and other cardiovascular risk factors. [16]Another, similar inves‐
tigation by Mathiesen et al. found comparable results with the relative risk of ipsilateral
cerebrovascular events in patients with hypo-echoic plaques to be 3.52. [17] Nevertheless in
the Asymptomatic Carotid Surgery Trial (ACST), there was no evidence that the Gray-Weale
classification, or plaque echolucency, showed any influence on the risk of stroke over degree
of stenosis. [18]. The emergence of multi-detector computed tomographic angiography
(MDCTA) came with the increased advances of improved spatial and temporal resolution for
evaluating different arterial regions but also the ability to further differentiate plaque mor‐
phology between smooth, irregular and ulcerated surfaces. [19] Density of a plaque can also
be determined measured in Hounsfield units (HU). This can differentiate a “soft” plaque (<50
HU) which usually has a lipid-rich core and more likely to be associated with symptoms from
a “calcified” plaque (>120 HU) which generally remains asymptomatic. [20]. Even so, it seems
that MRA is probably the best modality for evaluating plaque morphology. Plaque compo‐
nents such as lipid cores, intraplaque hemorrhage, fibrotic tissue, fibrotic caps and calcifica‐
tions can all be evaluated with MRA to distinguish unstable plaques from stable ones. [21-23]
In a study by Sadat et al. MRA was used to evaluate plaque morphology in acute symptomatic,
recently symptomatic and asymptomatic patients. Results showed that MRA was clearly able
to identify plaque features including hemorrhage and thin fibrous caps in the acutely symp‐
tomatic group that varied from the recently symptomatic and asymptomatic groups. [23] The
use of MRA for further risk stratifying symptomatic patients or predicting high-risk asymp‐
tomatic patients, however requires further evaluation to determine its role in the evaluation
of carotid artery disease.
Even with all of the advances of DUS, MDCTA, and MDMRA, for many practitioners intra-
arterial digital subtraction arteriography (IADSA) still remains the gold standard for imaging
extra cranial and intracranial circulation. Although angiography allows for detailed evaluation
of the aortic arch, origins of the great vessels and the distal ICA, it is still an invasive imaging
modality potentially exposing patients to unnecessary complications and even possibly death.
Complications rates do vary among studies from as low as 0.4% in the Veterans Affair
Cooperative Study to 1.2% in the Asymptomatic Carotid Atherosclerosis Study and as high as
Carotid Artery Disease - From Bench to Bedside and Beyond4
12.5% in patients with severe bilateral carotid obstructive disease. [24-26]. IADSA can be
forgone in most situations where noninvasive diagnostic tests are available and now usually
only utilized in conjunction with planned carotid artery stenting.
3. Asymptomatic carotid stenosis
Patients with cerebrovascular disease can be divided into asymptomatic and symptomatic
disease. Patient’s with asymptomatic carotid disease generally come to the attention of
practitioners because they are found to have one or more risk factor for developing cerebro‐
vascular disease (age, diabetes mellitus, coronary artery disease, peripheral vascular disease,
hypertension, or hyperlipidemia) and/or signs on clinical exam, such as carotid bruit on
auscultation, that warrant further diagnostic evaluation. About 5% of the general population
over 65 years of age has an asymptomatic CAS of 50% or greater. [27-28]. This is increased in
patients with peripheral arterial disease up to 15% and in patients with abdominal aortic
aneurysms up to about 12%. [29] The overall annual risk of ipsilateral stroke for patients found
to have asymptomatic carotid stenosis that are treated medically is about 2%. Asymptomatic
carotid disease, in fact, seems to be a better indicator of generalized vascular disease than of
stroke risks. In this population the average annual non-stroke death rates are generally higher
than those of ipsilateral stroke with more than 50% of the non-stroke related deaths due to
ischemic heart disease and its complications. [30] For patients who are found to have carotid
disease, optimal medical management is the cornerstone to overall treatment. The goal of
medical therapy is to reduce overall cardiovascular events as well as stroke by a five pronged
attack including: treatment of hypertension, treatment of diabetes mellitus, treatment of lipid
abnormalities, smoking cessation, and antithrombotic treatment. As mentioned previously,
hypertension has been consistently found to be an independent risk factor for carotid artery
atherosclerosis with each 10-mm Hg increase in blood pressure resulting in an increase in risk
for stroke of 30-45%. Conversely each 10-mm Hg reduction in blood pressure in hypertensive
patients decreases risk for stroke by 33%. [31] Currently recommendations are for blood
pressures to be maintained less than 140 systolic and 90 diastolic. For patients with coronary
artery disease the relationship between lipid abnormalities and ischemic heart events has also
been clearly identified in the literature however at this time the relationship between elevated
cholesterol and stroke risk remain unclear. [32,33] Nevertheless, studies have shown that
patients with known atherosclerosis have demonstrated reduced stroke rates by 15-30% when
treated with lipid lowering therapy. [34] Smoking cessation is important for all patients with
vascular disease, and in carotid artery disease this is no different nearly doubling the overall
risk for stroke. [35] Finally both antithrombotic and anticoagulant therapy can also be utilized
for prevention in patients with carotid disease. There is more robust evidence for the use of
antithrombotic treatment for secondary prevention of recurrent stroke in symptomatic patients
than for prevention in asymptomatic patients, however it is still recommended that patients
who are at risk, or have known vascular disease, take a daily aspirin for prophylaxis. [36]
Anticoagulation with Coumadin is generally reserved for patients at risk for an embolic stroke
from atrial fibrillation and is not used as prophylaxis for asymptomatic or symptomatic carotid
disease. [37]
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of the aortic arch, origins of the great vessels and the distal ICA, it is still an invasive imaging
modality potentially exposing patients to unnecessary complications and even possibly death.
Complications rates do vary among studies from as low as 0.4% in the Veterans Affair
Cooperative Study to 1.2% in the Asymptomatic Carotid Atherosclerosis Study and as high as
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12.5% in patients with severe bilateral carotid obstructive disease. [24-26]. IADSA can be
forgone in most situations where noninvasive diagnostic tests are available and now usually
only utilized in conjunction with planned carotid artery stenting.
3. Asymptomatic carotid stenosis
Patients with cerebrovascular disease can be divided into asymptomatic and symptomatic
disease. Patient’s with asymptomatic carotid disease generally come to the attention of
practitioners because they are found to have one or more risk factor for developing cerebro‐
vascular disease (age, diabetes mellitus, coronary artery disease, peripheral vascular disease,
hypertension, or hyperlipidemia) and/or signs on clinical exam, such as carotid bruit on
auscultation, that warrant further diagnostic evaluation. About 5% of the general population
over 65 years of age has an asymptomatic CAS of 50% or greater. [27-28]. This is increased in
patients with peripheral arterial disease up to 15% and in patients with abdominal aortic
aneurysms up to about 12%. [29] The overall annual risk of ipsilateral stroke for patients found
to have asymptomatic carotid stenosis that are treated medically is about 2%. Asymptomatic
carotid disease, in fact, seems to be a better indicator of generalized vascular disease than of
stroke risks. In this population the average annual non-stroke death rates are generally higher
than those of ipsilateral stroke with more than 50% of the non-stroke related deaths due to
ischemic heart disease and its complications. [30] For patients who are found to have carotid
disease, optimal medical management is the cornerstone to overall treatment. The goal of
medical therapy is to reduce overall cardiovascular events as well as stroke by a five pronged
attack including: treatment of hypertension, treatment of diabetes mellitus, treatment of lipid
abnormalities, smoking cessation, and antithrombotic treatment. As mentioned previously,
hypertension has been consistently found to be an independent risk factor for carotid artery
atherosclerosis with each 10-mm Hg increase in blood pressure resulting in an increase in risk
for stroke of 30-45%. Conversely each 10-mm Hg reduction in blood pressure in hypertensive
patients decreases risk for stroke by 33%. [31] Currently recommendations are for blood
pressures to be maintained less than 140 systolic and 90 diastolic. For patients with coronary
artery disease the relationship between lipid abnormalities and ischemic heart events has also
been clearly identified in the literature however at this time the relationship between elevated
cholesterol and stroke risk remain unclear. [32,33] Nevertheless, studies have shown that
patients with known atherosclerosis have demonstrated reduced stroke rates by 15-30% when
treated with lipid lowering therapy. [34] Smoking cessation is important for all patients with
vascular disease, and in carotid artery disease this is no different nearly doubling the overall
risk for stroke. [35] Finally both antithrombotic and anticoagulant therapy can also be utilized
for prevention in patients with carotid disease. There is more robust evidence for the use of
antithrombotic treatment for secondary prevention of recurrent stroke in symptomatic patients
than for prevention in asymptomatic patients, however it is still recommended that patients
who are at risk, or have known vascular disease, take a daily aspirin for prophylaxis. [36]
Anticoagulation with Coumadin is generally reserved for patients at risk for an embolic stroke
from atrial fibrillation and is not used as prophylaxis for asymptomatic or symptomatic carotid
disease. [37]
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For asymptomatic patients who continue to have worsening carotid disease even with best
medical management the next step in treatment is to consider operative intervention. The
current recommendations from the Society for Vascular Surgery is for carotid endarterectomy
in asymptomatic patients with carotid stenosis of greater than or equal to 60% as long as the
expected combined stroke and mortality rate for the individual surgeon was not greater than
3%. [38] These recommendations are based on three major prospective, randomized trials the
Veterans Administration Asymptomatic Carotid Stenosis Study (VA ACS), the Asymptomatic
Carotid Atherosclerosis Study (ACAS), and the Asymptomatic Carotid Surgery Trial (ACST).
The VA ACS evaluated a total of 444 patients over an 8 year period randomizing them to a
surgical group (211) or and a medical group (233). Both groups were treated with aspirin and
best medical risk factor control. For the surgical arm, the 30-day mortality rate was 1.9% and
the incidence of stroke was 2.4% with a combined stroke and mortality rate of 4.3%. In total,
all neurologic events were 30 (14.2%). Conversely, the medical group had a total of 55 (23.6%)
neurologic events recorded. These findings were found to be statistically significant with a P
value of less than 0.006. [39] However, the study did not find any difference in overall survival
rates between groups. This trial gave credence that best medical treatment plus carotid
endarterectomy (CEA) would reduce stroke and TIAs versus medical treatment alone in
asymptomatic patients.
The ACAS was a NIH-funded randomized trial which included 1662 patients between the ages
of 40-79 years with greater than 60% asymptomatic stenosis. Patients were randomized to
optimal medical management versus CEA and medical management. The 30-day combined
mortality and stroke rate was 2.3%, which accounts for two preoperative deaths and seven
preoperative strokes making the actual stroke rate 1.3% and mortality rate 0.1%. After a mean
follow up of 2.7 years the overall 5-year risk for ipsilateral stroke, perioperative stroke and
death was 5.1% for surgical patients and 11% for the medical group (P=0.004). [40] An absolute
risk reduction for stroke and death in the surgical group was calculated to be 53%. [41] One
drawback of the ACAS study is that all patients with 60%-99% carotid stenosis were analyzed
together and there was no breakdown for event rates by deciles. Nevertheless, their results
again favored CEA plus medical management over medical management alone.
Finally a group of European investigators embarked on an additional randomized trial, ACST,
to try, in addition to validating CEA for asymptomatic patients with significant stenosis, to
identify a higher-risk group of patients. They randomized 3129 patients, both men and women,
with greater than 60% asymptomatic unilateral or bilateral carotid artery stenosis to CEA
versus best medical therapy. The found a 5 year stroke or death rate to be 6.4% versus 11.8 %
(p<0.0001) in the CEA versus medical group, respectively. Overall perioperative stroke or
death rate was 3.1%. These results were found to be significant for bother males and females
when analyzed separately [18].
4. Symptomatic carotid artery stenosis
When compared to asymptomatic patients the benefit of CEA with recent ipsilateral carotid
territory symptoms and moderated to severe carotid stenosis is much greater. In patients who
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experience a TIA or minor stroke the risk of subsequent stroke or death is very high, especially
during the first few days and weeks after an event. [42] Traditionally the mainstay of treatment
for symptomatic disease in these patients is surgical intervention with CEA. Recently there
has been literature advocating aggressive medical therapy alone may be adequate in certain
patients, preventing early stroke after TIA and reducing the need for urgent CEA. The Stroke
Prevention Aggressive Reduction of Cholesterol Levels (SPARCL) trail tested whether
treatment with atorvastatin reduced strokes in subjects with recent minor stroke or TIA. The
study included 4731 participants with a mean follow up of 4.9 years and found that high does
Atorvastatin use after TIA or stroke was associated with a 16% relative reduction in risk of
fatal or nonfatal stroke. Also patients treated were found to have a 56% reduction in later
carotid revascularization compared with placebo. Researchers postulated that the use of statins
might help stabilize the arterial wall decreasing events as well as reducing intraoperative
complications as well for patients who did proceed with surgery. [43,44] Merwick et al. also
evaluated early high dose statin use postulating that pretreatment at TIA onset would modify
early stroke risk. They found that non-procedural 7-day stroke risk was 3.8% with statin
treatment compared to 13.2% in those not pretreated. [45] Another study by Chimowitz et al.
evaluated a different medical treatment looking at recently symptomatic patients with
intracranial 79-99% stenosis who were treated with dual antiplatelet therapy versus percuta‐
neous transluminal angioplasty and stenting (PTAS) (gold standard for intracranial lesions).
This study found a 30-day rate of stroke or death was found to be 14.7% in the PTAS group
and 5.8% in the medical-management group. At one year follow this study concluded that
medical management with dual antiplatelet therapy was superior to PTAS and advocates belief
this data can be extrapolated to severe, symptomatic extra cranial disease as well. [46,47].
Several other older studies have compared the use of platelet antiaggregants with placebo in
treating patients with cerebral ischemia secondary to extra cranial atherosclerosis. [48-51]
These results however proved inferior to surgery, which was highlighted in the landmark
North American Symptomatic Carotid Endarterectomy Trial.
Two major randomized control  trials  have reported data to date advocating for CEA in
symptomatic patients with 50%-99% stenosis:  The North American Symptomatic Carotid
Endarterectomy Trial (NASCET) and Medical Research Council European Carotid Surgery Trial
(ECST). The NASCET trial was set up to evaluate two subsets of patients those with 70-99%
stenosis and those with 30-69% stenosis. In the high-grade stenosis group the 30-day opera‐
tive morbidity and stroke mortality rate for patients was 5%. In the surgical group at 2-year
follow-up the incidence of ipsilateral stroke was 9% compared to 26% in the medical treat‐
ment group. This difference represented an absolute risk reduction of 17% in favor of surgical
management and a relative risk reduction of 71% at the end of the 18-month follow up. Mortali‐
ty rates were also measured at the end of 18 months yielding 12% mortality rate in the medi‐
cal group compared to a significantly lower rate of 5% in the surgical group. [52,53]. The results
for the moderate stenosis group were also reported. The 30-day combined mortality, disa‐
bling stroke rate, and non-disabling stroke rate was 6.7%. At 5 year follow up in this group the
ipsilateral stroke rate was 22.2% in the medical patients and 16.7% in the surgical patients. [54]
The ECST trial was a European randomized control trial that enrolled patients over 10 years
almost concurrently with the NASCET trial. There were 2518 patients with nondisabling
ischemic stroke, TIA or retinal infarct due to a stenotic lesion in the ipsilateral carotid artery
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randomized to either medical management with aspirin or surgery. At 3 years, the risk of stroke
was found to be 26.5% in the medical group compared to 7% in the surgery group with an
absolute reduction of 14.9%. The actual incidence of ipsilateral stroke was 2.8% in the surgery
group versus 16.8% in the medical group. [55] ECST trial also evaluated gender, age, severity
of stenosis, plaque morphology, and time since last event. They found that risk of events
increased with age and with male gender. They did not find any benefit for surgery over
medical treatment in the mild stenosis group (10%-29%) unlike the severe stenosis group,
which showed a 6-fold reduction in subsequent strokes over 3 years. [56]
Based on these randomized studies there seems to be a consensus on which patients would
benefit from operative intervention after an ischemic event, however the timing of interven‐
tion has been much debated. The risk of recurrent stroke after TIA or minor stroke is the highest
within the first 7-10 days. According to a meta-analysis by Giles et al the risk of stroke after TIA
is 6.7% at 48 hours and 10% at 7 days with more than half of the strokes occurring within the
first 7 days doing so within the first 24 hours after the inciting event. [57,58] In another study
by Ois et al. the rate of recurrent stroke in symptomatic patients with greater then 50% stenosis
was determined to be 20.9% in the first 72 hours, 6.7% between 72 hours and 7 days and 3.7%
between 7 and 14 days. [59] These results support early intervention in the first 48 hours because
the risk of recurrent stroke appears to outweigh the operative risk in patients who are medical‐
ly stable and have relatively small or no infarcts on imaging studies. Alternatively, for a
completed stroke researchers advocate delayed surgical intervention for at least 4-6 weeks due
to the risk of converting an ischemic cerebral infarction into a hemorrhagic one. Giordano et al
reported on 49 CEAs done after a completed acute stroke. 27 of these were performed within 5
weeks of the event and 22 were done between 5 and 20 weeks. The early intervention group
had a morbidity and mortality of 18.5% compared to nothing for the later group. [60] These
results seem to corroborate with observations in both the NASCET and ECST trials.
5. Carotid artery stenting
Along with CEA, carotid artery stenting (CAS) has emerged as an alternative treatment
strategy for patients with carotid artery disease. Initially proponents of angioplasty and
stenting projected that this procedure could overcome the risks associated with CEA and
provide a minimally invasive alternative for patients. However at this time the utility of CAS
is highly debated with CEA remaining the standard of care in most asymptomatic and
symptomatic patients.
There have been very few studies that have specifically addressed CAS in asymptomatic
patients and most of the data available comes from high-risk registries which include patients
with lesions located at or above the level of C2, contralateral carotid occlusion, severe ulcera‐
tion and tandem intracranial stenosis, age over 80, active coronary artery disease or congestive
heart failure, and patient’s with “hostile necks” (immobile neck, previous irradiation, previous
surgery on the ipsilateral side or previous surgery on the contralateral side with vocal cord
paralysis). In the SAPPHIRE trial, which population included 70% asymptomatic high-risk
patients, their results found cumulative perioperative incidence of death, stroke, and MI of
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5.4% for CAS and 10.2% for CEA. [61] Their results found that CAS with cerebral protection
was not inferior to CEA. This study, however had several limitations including failure to
randomize >50% of patients, unaccounted for elevated incidence of perioperative stroke, and
possible reporting bias. The Carotid Revascularization Endarterectomy versus Stent Trial
(CREST) enrolled more than 1000 asymptomatic patients. Stroke and death rates after CAS
were 2.6% and 1.1% respectively with a difference between CAS and CEA in asymptomatic
patients for any periprocedural stroke being 2.5% versus 1.4%. [62-64] These results did not
show significant difference between CAS and CEA. The results from this study, however, were
based on procedures performed by highly experienced operators and have not been replicated




Figure 3. 70 year old Male with a history of squamous cell carcinoma status post neck radiation and hemiglossectomy
found to have a 90% asymptomatic left common carotid artery stenosis. A: Angiogram of left common carotid artery
stenosis (arrow) B. Angiogrom showing cerebral protection device located in the left internal carotid artery (dashed
arrow) and stent placed in common carotid artery stenosis (black arrow). C. Post stent placement angioplasty balloon
inflated (arrow) D. Completion angiogram showing minimal residual stenosis after stent placed.
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randomized to either medical management with aspirin or surgery. At 3 years, the risk of stroke
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For symptomatic patients several major randomized trials comparing CEA versus CAS have
been completed. These include the International Carotid stenting Study (ICSS), the Stent-
Supported Percutaneous Angioplasty of the Carotid Artery Versus Endarterectomy (SPACE)
trial, the Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid
Stenosis (EVA-3s) trial, the Stenting and Angioplasty with Protection in Patients at high risk
for Endarterectomy (SAPPHIRE) trial and the Carotid Revascularization Endarterectomy
Versus Stenting Trial (CREAST).
Trial Methods Results Conclusions
ICSS 1713 patient with
symptomatic stenosis >50%
CEA vs CEA
-Primary endpoint at 120
days was stroke, death or MI
-Primary endpoints:
Stroke: 7.7% CAS vs 4.1% CEA
Death: 2.3% CAS vs. 0.8% CEA
MI: 8.5% CAS vs. 5.2% CEA
-CAS higher rates of any stroke and all
cause death
-No significant difference between
groups in disabling stroke
SPACE European study 1196
patients with symptomatic
stenosis randomly assigned
180 days after TIA or stroke
to CAS vs. CEA
-Primary endpoint:
ipsilateral stroke or death at
30 days
-Stroke or Death:
-6.9% CAS vs. 6.5% CEA
-2 year follow up showed no
significant difference btw CAS
and CEA
- 9.5% CAS vs. 8.8% CEA
-failed to prove noninferiority of CAS
vs. CEA
-2 year restenosis more frequent in CAS
group
-10.7% vs 4.6%
EVA-3S French multicenter study




CAS in not inferior to CEA
(similar to SPACE)
-Primary endpoint: stroke or
death at 30 days
- Stroke and/or Death:
-9.6% CAS vs. 3.9% CEA
-RR 2.5
-4 year follow up Stroke
and/or Death
- 11.1% CEA vs. 6.2% CAS
-Stopped premature 2/2 deaths in CAS
group
-CEA needs to be safer before it can be
alternative to CEA
*CPD were optional
CREST RCT largest comparing CAS





0.7% CAS vs. 0.3% CE
- Stroke:
4.1% CAS vs. 2.3% CEA
- MI:
1.1% CAS vs. 2.3% CEA
- Combined endpoints:
7.2% CAS vs. 6.8% CEA
-4 year follow up combined
endpoints:
-overall effectiveness and safety were
similar
-similar results male vs. female and
symptomatic vs. asymptomatic
-Periprocedural higher risk of stroke
with CAS and higher risk MI with CEA
-Subanalysis:
- No difference in primary
endpoint
based
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Trial Methods Results Conclusions
6.4% CAS vs. 4.7% CEA on symptomatic status
- Periprocedure stroke and
death
lower in CEA in symptomatic
SAPPHIRE Multicenter RCT comparing






-CPD used in about 95%
-30 day Death stroke and MI:
5.4% CAS and 8.4% CEA
-1 year follow up death, stroke
and /or MI
-12.2% CAS vs. 20.1% CEA
- CAS with use of CPDs is not inferior to
CEA
Limitations:
-Mostly high risk patients enrolled
-747 patients enrolled only less then ½
randomized
-High periprocedural death rate
compared
to other trials
The ICSS was a randomized prospective, multicenter trial in 2010 composed of 1713 subjects
with recently symptomatic carotid artery stenosis greater than 50% who were randomized to
either CEA or CAS. At this time the 120-day reported results show that the CAS group had a
stroke, death, and MI rates of 7.7%, 2.3% and 8.5%, respectively. These were significantly
higher than rates in the CEA group, which were 4.1%, 0.8%, and 5.2% respectively. Also there
was an additional group that was analyzed by MRI. This analysis showed a greater number
of patients in the CAS group that had a new ischemic brain lesion compared to the surgery
counterpart. [66] The EVA-3S and SPACE trial had similar protocols as the ICSS trial. EVA-3S
study divided 259 patients to CAS with cerebral protection devices (CPD) and CEA. This study
found a significant, 2.5, higher risk for 30-day stroke and death in the CAS group than in the
CEA group (9.6% versus 3.9%). At 4 year follow-up the risk of periprocedural stroke or death,
and nonperiprocedural ipsilateral stroke was also higher in the CAS group (11.1% versus
6.2%). [67] This trial however was limited by operator experience were physicians were only
required to perform a minimum of two procedures with any device to qualify for enrollment.
In the SPACE trial, which was larger with 1196 patients, the rate of death or ipsilateral ischemic
stroke was 6.9% in the CAS group and 6.5% in the CEA group. At the end of two years results
showed a greater probability of recurrent carotid stenosis of more than 70% in the CAS group
Similar concerns were raised against the SPACE trial concerning the inexperience of the
operators. The inconsistent use of CPDs was another concern raised by opponents of this trial.
[68,69] Nevertheless, all three of these trials strongly favor CEA over CAS.
The SAPPHIRE trial previously mentioned was another one of the initial trials comparing CAS
versus CEA. This corporate sponsored study had a high proportion of patients who were
asymptomatic and at high risk for CEA. Results at one year found primary end-points of
ipsilateral stroke or death to be lower in the stenting group than in the CEA group (12.2%
versus 20.1%; P=0.5) supporting the superiority of CAS over CEA. The clinical correlation to
symptomatic patients however is unclear. The CREST trial, alternatively, was a randomized,
prospective, multicenter trial, which included 2502 patients. This trial had about an equal
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For symptomatic patients several major randomized trials comparing CEA versus CAS have
been completed. These include the International Carotid stenting Study (ICSS), the Stent-
Supported Percutaneous Angioplasty of the Carotid Artery Versus Endarterectomy (SPACE)
trial, the Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid
Stenosis (EVA-3s) trial, the Stenting and Angioplasty with Protection in Patients at high risk
for Endarterectomy (SAPPHIRE) trial and the Carotid Revascularization Endarterectomy
Versus Stenting Trial (CREAST).
Trial Methods Results Conclusions
ICSS 1713 patient with
symptomatic stenosis >50%
CEA vs CEA
-Primary endpoint at 120
days was stroke, death or MI
-Primary endpoints:
Stroke: 7.7% CAS vs 4.1% CEA
Death: 2.3% CAS vs. 0.8% CEA
MI: 8.5% CAS vs. 5.2% CEA
-CAS higher rates of any stroke and all
cause death
-No significant difference between
groups in disabling stroke
SPACE European study 1196
patients with symptomatic
stenosis randomly assigned
180 days after TIA or stroke
to CAS vs. CEA
-Primary endpoint:
ipsilateral stroke or death at
30 days
-Stroke or Death:
-6.9% CAS vs. 6.5% CEA
-2 year follow up showed no
significant difference btw CAS
and CEA
- 9.5% CAS vs. 8.8% CEA
-failed to prove noninferiority of CAS
vs. CEA
-2 year restenosis more frequent in CAS
group
-10.7% vs 4.6%
EVA-3S French multicenter study




CAS in not inferior to CEA
(similar to SPACE)
-Primary endpoint: stroke or
death at 30 days
- Stroke and/or Death:
-9.6% CAS vs. 3.9% CEA
-RR 2.5
-4 year follow up Stroke
and/or Death
- 11.1% CEA vs. 6.2% CAS
-Stopped premature 2/2 deaths in CAS
group
-CEA needs to be safer before it can be
alternative to CEA
*CPD were optional
CREST RCT largest comparing CAS





0.7% CAS vs. 0.3% CE
- Stroke:
4.1% CAS vs. 2.3% CEA
- MI:
1.1% CAS vs. 2.3% CEA
- Combined endpoints:
7.2% CAS vs. 6.8% CEA
-4 year follow up combined
endpoints:
-overall effectiveness and safety were
similar
-similar results male vs. female and
symptomatic vs. asymptomatic
-Periprocedural higher risk of stroke
with CAS and higher risk MI with CEA
-Subanalysis:
- No difference in primary
endpoint
based
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Trial Methods Results Conclusions
6.4% CAS vs. 4.7% CEA on symptomatic status
- Periprocedure stroke and
death
lower in CEA in symptomatic
SAPPHIRE Multicenter RCT comparing






-CPD used in about 95%
-30 day Death stroke and MI:
5.4% CAS and 8.4% CEA
-1 year follow up death, stroke
and /or MI
-12.2% CAS vs. 20.1% CEA
- CAS with use of CPDs is not inferior to
CEA
Limitations:
-Mostly high risk patients enrolled
-747 patients enrolled only less then ½
randomized
-High periprocedural death rate
compared
to other trials
The ICSS was a randomized prospective, multicenter trial in 2010 composed of 1713 subjects
with recently symptomatic carotid artery stenosis greater than 50% who were randomized to
either CEA or CAS. At this time the 120-day reported results show that the CAS group had a
stroke, death, and MI rates of 7.7%, 2.3% and 8.5%, respectively. These were significantly
higher than rates in the CEA group, which were 4.1%, 0.8%, and 5.2% respectively. Also there
was an additional group that was analyzed by MRI. This analysis showed a greater number
of patients in the CAS group that had a new ischemic brain lesion compared to the surgery
counterpart. [66] The EVA-3S and SPACE trial had similar protocols as the ICSS trial. EVA-3S
study divided 259 patients to CAS with cerebral protection devices (CPD) and CEA. This study
found a significant, 2.5, higher risk for 30-day stroke and death in the CAS group than in the
CEA group (9.6% versus 3.9%). At 4 year follow-up the risk of periprocedural stroke or death,
and nonperiprocedural ipsilateral stroke was also higher in the CAS group (11.1% versus
6.2%). [67] This trial however was limited by operator experience were physicians were only
required to perform a minimum of two procedures with any device to qualify for enrollment.
In the SPACE trial, which was larger with 1196 patients, the rate of death or ipsilateral ischemic
stroke was 6.9% in the CAS group and 6.5% in the CEA group. At the end of two years results
showed a greater probability of recurrent carotid stenosis of more than 70% in the CAS group
Similar concerns were raised against the SPACE trial concerning the inexperience of the
operators. The inconsistent use of CPDs was another concern raised by opponents of this trial.
[68,69] Nevertheless, all three of these trials strongly favor CEA over CAS.
The SAPPHIRE trial previously mentioned was another one of the initial trials comparing CAS
versus CEA. This corporate sponsored study had a high proportion of patients who were
asymptomatic and at high risk for CEA. Results at one year found primary end-points of
ipsilateral stroke or death to be lower in the stenting group than in the CEA group (12.2%
versus 20.1%; P=0.5) supporting the superiority of CAS over CEA. The clinical correlation to
symptomatic patients however is unclear. The CREST trial, alternatively, was a randomized,
prospective, multicenter trial, which included 2502 patients. This trial had about an equal
Evaluation and Treatment of Carotid Artery Stenosis
http://dx.doi.org/10.5772/57258
11
inclusion of symptomatic and asymptomatic patients. The primary endpoint of any stroke, MI
or death at 30-days were similar between CAS and CEA (6.8% versus 7.2%). Upon further
examination, patients in the CAS group had a lower rate of MI within 30 days (1.1% versus
2.3%) and patients in the CEA group had a lower 30-day rate of stroke (2.3% versus 4.1%). At
one-year follow up quality of life measurements were examined. Investigators found that
patients who had strokes reported significantly lower quality of life scores than those who had
MI or cranial nerve palsy. After one year, however, these measurements did not show any
significant difference. [62,64]The improved outcomes found in the CREST trial may reflect the
increased experience of vascular surgeons with endovascular procedures and stent placement
as well as the improvement in stents and device designs. This data supports that CAS is not
inferior to CEA and both procedures can be safely offered to patients for the treatment of
carotid artery disease.
Current overall recommendations by the Society of Vascular Surgery for intervention in
patients with carotid artery disease are:
1. For symptomatic patients with stenosis <50% or asymptomatic patients with stenosis <60%
optimal medical therapy is indicated
2. In patients who have >50% symptomatic lesions or >60% asymptomatic lesions CEA is
preferred to CAS
a. Asymptomatic patients >60% stenosis should be considered for CEA if that have a
3-5 year life expectancy and perioperative stroke/death rates are <3%
b. In patients with symptomatic stenosis >50% CEA is preferred, especially if patient is
>70, has a long lesion (>15mm), preocclusive stenosis, lipid-rich plaque that can be
completely removed, and have not had previous neck operations or radiation
3. CAS is preferred over CEA in symptomatic patients with >50% stenosis when
a. Patient has a tracheal stoma, scarred and fibrotic tissue from previous ipsilateral
surgery or radiation, prior cranial nerve injury, and lesions that extend proximal to
the clavicle or distal to the C2 vertebral body
b. Patient has severe uncorrectable CAD, CHF or COPD
4. Asymptomatic patients with >60% stenosis deemed “high risk” for CEA should be
managed with optimal medical therapy
a. Insufficient data to recommend CAS for asymptomatic patients that are normal or
high risk for CEA. [38]
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inclusion of symptomatic and asymptomatic patients. The primary endpoint of any stroke, MI
or death at 30-days were similar between CAS and CEA (6.8% versus 7.2%). Upon further
examination, patients in the CAS group had a lower rate of MI within 30 days (1.1% versus
2.3%) and patients in the CEA group had a lower 30-day rate of stroke (2.3% versus 4.1%). At
one-year follow up quality of life measurements were examined. Investigators found that
patients who had strokes reported significantly lower quality of life scores than those who had
MI or cranial nerve palsy. After one year, however, these measurements did not show any
significant difference. [62,64]The improved outcomes found in the CREST trial may reflect the
increased experience of vascular surgeons with endovascular procedures and stent placement
as well as the improvement in stents and device designs. This data supports that CAS is not
inferior to CEA and both procedures can be safely offered to patients for the treatment of
carotid artery disease.
Current overall recommendations by the Society of Vascular Surgery for intervention in
patients with carotid artery disease are:
1. For symptomatic patients with stenosis <50% or asymptomatic patients with stenosis <60%
optimal medical therapy is indicated
2. In patients who have >50% symptomatic lesions or >60% asymptomatic lesions CEA is
preferred to CAS
a. Asymptomatic patients >60% stenosis should be considered for CEA if that have a
3-5 year life expectancy and perioperative stroke/death rates are <3%
b. In patients with symptomatic stenosis >50% CEA is preferred, especially if patient is
>70, has a long lesion (>15mm), preocclusive stenosis, lipid-rich plaque that can be
completely removed, and have not had previous neck operations or radiation
3. CAS is preferred over CEA in symptomatic patients with >50% stenosis when
a. Patient has a tracheal stoma, scarred and fibrotic tissue from previous ipsilateral
surgery or radiation, prior cranial nerve injury, and lesions that extend proximal to
the clavicle or distal to the C2 vertebral body
b. Patient has severe uncorrectable CAD, CHF or COPD
4. Asymptomatic patients with >60% stenosis deemed “high risk” for CEA should be
managed with optimal medical therapy
a. Insufficient data to recommend CAS for asymptomatic patients that are normal or
high risk for CEA. [38]
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1. Introduction
Carotid plaque vulnerability has been reported to be associated with stroke and other
cerebrovascular events [1, 2]. Therefore, tissue characterization of carotid plaques is important
to evaluate the risk of cerebrovascular disease and outcome of treatment for carotid arterial
stenosis. Stabilization of vulnerable plaques rather than regression of plaque volume is
considered the major contributor to beneficial effects on cerebrovascular events [3].
With respect to the ultrasound technique, ultrasonic tissue characterization of the myocar‐
dium with  an  integrated  backscatter  (IBS)  analysis  was  developed,  which  is  capable  of
providing both conventional two-dimensional echographic (2DE) images and IBS images.
In studies of the myocardium, calibrated myocardial IBS was significantly correlated with
the volume fraction of interstitial fibrosis [4, 5]. In preliminary in vitro studies, IBS values
reflected the  structural  and biochemical  composition  of  atherosclerotic  lesion and could
differentiate  fibrofatty,  fatty  and  calcification  of  arterial  walls  [6-8].  However,  it  is  not
precise, because IBS values of lipid pool and intimal hyperplasia were similar. Discrimina‐
tion of  intimal  hyperplasia,  fibrous cap and thrombus,  and sensitivity and specificity of
these measurements were not studied in these papers. Furthermore, extent evaluation of
each composition, that is, two-dimensional (2D) tissue structure, in entire plaque has not
been examined.  Therefore,  we  measured IBS  values  in  carotid  arteries  in  patients  com‐
pared  before  and  immediately  after  death,  and  compared  these  IBS  values  with  their
histopathological features. Subsequently, we constructed 2D color-coded maps of arteries
with plaque to assess visually the arterial tissue characteristics.
© 2014 Kawasaki et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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© 2014 Kawasaki et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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2. Comparison between IB values and histological images in carotid
arteries
Conventional echo images and IBS images were acquired using an ultrasonic imaging system
(Sonos 5500, Philips Medical Systems) to characterize the carotid arterial tissue at the bedside
conveniently using a 5-12 MHz multifrequency transducer for all studies. This software
enabled the acquisition, storing and retrieving of a sequence of continuous 2D conventional
and IB images, forming a continuous loop digital recording of two seconds (60 frames in two
seconds). Off-line analysis of the 2D IBS images was performed by retrieving the previously
stored data from the built-in optical disc drive in the system. IBS value was calculated as the
average power of the ultrasound backscattered signal from a small volume of tissue measured
in decibels (dB). We used an 11 x 11 pixels (0.6 mm x 0.6 mm) rectangle shaped ROI and set
the time gain compensation at 0 dB and the lateral gain compensation at 50 dB at every
measurement in both ex vivo and in vivo study. At this setting, IBS values of stainless steel at a
distance of one to two centimeters from the transducer were 50 dB, which was within the
dynamic range of the system. IBS values of the posterior arterial wall were corrected (corrected
IBS) by subtracting the IBS values of the vessel lumen.
Carotid arteries were excised at autopsy and were fixed with 10% neutral buffered formalin.
Ring-like arterial specimens obtained at a similar level to the ultrasound study were decalcified
in a standard K-CX solution for five hours, and were embedded with paraffin and cut into 4
µm thick transverse sections perpendicular to the longitudinal axis of the artery. They were
stained with hematoxylin-eosin, elastic van Gieson and Masson’s trichrome. In addition,
immunohistochemical analysis using anti-actin antibody was performed for detection of
smooth muscle cells.
Histology of these sampling sites was divided into thrombus (n=5), lipid pool (n=31), intimal
hyperplasia (n=7), fibrosis (n=25), mixed lesion (n=12) and calcification (n=17) in the intima,
and the media (n=24). Each corrected IBS value of these tissues after fixation at autopsy was
7.3 ± 1.5, 13.0 ± 3.2, 10.9±1.0, 19.3 ± 2.4, 28.2 ± 3.3 and 39.3 ± 3.6 in the intima, respectively, and
11.3 ± 1.9 dB in the media. Also each corrected IBS value during lifetime was 4.9 ± 1.0, 10.0 ±
2.4, 8.0±0.8, 16.0 ± 2.0, 23.5 ± 3.4 and 30.5 ± 2.5 in the intima, respectively, and 8.4 ± 1.8 dB in
the media. The difference among thrombus, fibrosis (category-3), mixed lesion, calcification
and lipid pool, intimal hyperplasia or media were statistically significant. However, lipid pool,
intimal hyperplasia and media had similar IBS values (category-2) [9]. In category-2, the media
and intima were differentiated using conventional 2DE. Generally, the lipid pool (category-2)
is anatomically located under a fibrous cap consisting of fibrosis (category-3). Therefore, the
presence of ROIs with category-2 under a layer of ROIs with category-3 was defined as the
lipid pool, but not as intimal hyperplasia.
Based  on  the  above  definitions  using  in  vivo  2DE  and  IBS  color-coded  maps  of  tissue
characterizations were constructed in in vivo images. These also reflected the pathology well
(Figure 1).
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Figure 1. Integrated backscatter ultrasound color-coded maps of the carotid plaque. Left: color-coded maps (red: cal‐
cification, orange: mixed lesion, green: fibrosis, blue: lipid pool). Right: pathological specimen.
3. Effects of statin on carotid atherosclerotic plaques
Several large clinical trials have demonstrated that lipid-lowering therapy with HMG-Co-A
reductase inhibitors, (statins), reduces cerebrovascular events [10, 11]. Stabilization of vulner‐
able plaques rather than regression of plaque volume is considered the major contributor to
this beneficial effect (5). Stabilization of vulnerable plaques rather than regression of plaque
volume is considered the major contributor to this beneficial effect [3].
We assessed the effect of a strong lipophilic statin (atorvastatin) on the stabilization of carotid
plaques with ultrasound IBS color imaging by calculating the relative lipid volume. We
enrolled patients who were diagnosed with asymptomatic carotid artery stenosis (30-60%)
based on carotid ultrasonography and MR angiography. The patients were randomized to a
statin (atorvastatin 20mg/day) treatment group (n = 20) or a diet group (n = 20). Transverse
and longitudinal scans of carotid plaques were performed using an ultrasound imaging system
(SONOS 7500, Philips Medical Systems). The plaques which have unstable component such
as lipid core or necrotic core were also imaged with a 1.5-T magnetic resonance imaging (MRI)
system (Intera Achieva Nova Dual, Philips Medical Systems) equipped with standard neck
array coils. T1-weighted (T1W), proton density-weighted (PDW), and T2-weighted (T2W)
images as well as time-of-flight (TOF) images of the plaques were obtained by standardized
protocol. The components of plaque were assessed using previous established criteria [12]. We
calculated the ratio of the signal intensity of carotid plaques to that of sternocleidomastoid
muscle and defined this as the signal intensity ratio (SIR).
At baseline, clinical parameters did not differ between groups. After initiating statin therapy,
the lipid profile significantly improved in the statin group, but remained unchanged in the
diet group. Baseline IBS values and other characteristics and parameters were similar between
the study groups. At baseline, no significant differences were found in these parameters
between the statin and diet groups. The relative lipid volume significantly increased in the
statin group after 6 months (Figure 2). However, IBS values did not change significantly in the
diet group.
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Figure 2. Representative images of three dimensional IBS color-coded maps. Left: Three-dimensional cut out images
of color-coded maps of carotid arteries. Middle: Three-dimensional images of lipid pool. Right: High resolutional mag‐
netic resonance images of carotid plaques.
4. Prediction of silent ischemic lesions after carotid artery stenting using
IBS and MRI
Carotid artery stenting (CAS) has recently emerged as a potential alternative to carotid
endarterectomy (CEA) [13] because it is a less invasive procedure and results in a shorter
duration of hospitalization. Although many advantages of CAS have been reported, one of its
disadvantages is the considerably high incidence of distal emboli during CAS, even though
they are subclinical. Asymptomatic or silent ischemic lesions were detected by diffusion-
weighted magnetic resonance imaging (DWI) more often in CAS than in CEA patients [14].
We and other investigators reported that analysis of carotid plaques using IBS ultrasound or
black-blood magnetic resonance imaging (BB-MRI) can identify the histological components
of carotid plaques [9, 12, 15].
We evaluated carotid lesion with stenosis with a symptomatic carotid stenosis of > 70% or an
asymptomatic carotid stenosis of > 60% assessed with angiography, as recommended by the
North American Symptomatic Carotid Endarterectomy Trial collaborators [16]. In IBS analysis,
relative unstable component area (%UCA: area of intra-plaque hemorrhage and lipid pool /
area of plaque) were automatically measured in each plaque by computer software (T3D,
Fortner Research LLC, Sterling, Virginia). IN MRI analysis, we calculated the ratio of the signal
intensity of carotid plaques to that of sternocleidomastoid muscle and defined this as the signal
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intensity ratio (SIR). We assessed newly appearing ipsilateral silent ischemic lesions (NISIL)
detected by diffusion-weighted magnetic resonance imaging (DWI) before and after CAS. At
the same time, we performed quantitative analysis of plaque characteristics using IBS ultra‐
sound and BB-MRI before CAS in all patients.
After CAS, DWI showed 94 silent ischemic lesions in 19 patients (38%) (diffusion positive
group; P group). There were no differences in baseline patient characteristics between the P
group and diffusion negative group (N group). In the P group, %UCA analyzed by IBS was
significantly higher than in the N group (60.2 ± 23.4% and 35.3 ± 19.2%, respectively, p<0.001).
Also, the SIR of most stenotic lesions of carotid plaques analyzed by T1WI of BB-MRI was
significantly higher in the P group than in the N group (1.40 ± 0.19 and 1.18 ± 0.25, respectively,
p<0.01) (Figure 3). In multivariate logistic regression analysis, the independent predictors of
NISIL were SIR (p = 0.030), the CRP level (p = 0.041) and the %UCA measured by IBS (p =
0.049). In the analysis of receiver operating characteristic curves, 50% of the %UCA measured
by IBS analysis and an SIR of 1.25 measured by BB-MRI analysis were determined as the most
reliable cutoff values for predicting NISIL. Using these cutoff values, the respective positive
and negative predictive values were 76% and 82% in the IBS analysis and 62% and 88% in the
BB-MRI analysis.
Figure 3. Representative images of CAS for an internal carotid plaque that consisted of less unstable component. (A)
Pre-steting angiogram of the left internal carotid artery stenosis. (B) White arrow: Axial image of the most stenotic
lesion of the plaque on T1WI of BB-MRI. *: sternocleidomastoid muscle. The SIR was 1.37 (C) Cross-sectional color-cod‐
ed map of the most stenotic lesion of the plaque on IBS. Relative unstable component area was 62%. (D) Post-stenting
angiogram of the left internal carotid artery stenosis. After carotid artery stenting, the lumen of the right internal caro‐
tid artery was successfully dilated. (E) Diffusion-weighted magnetic resonance imaging. White arrows: multiple silent
ischemic lesions are detected in the left cerebral hemisphere after the post-stenting procedure.
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detected by diffusion-weighted magnetic resonance imaging (DWI) before and after CAS. At
the same time, we performed quantitative analysis of plaque characteristics using IBS ultra‐
sound and BB-MRI before CAS in all patients.
After CAS, DWI showed 94 silent ischemic lesions in 19 patients (38%) (diffusion positive
group; P group). There were no differences in baseline patient characteristics between the P
group and diffusion negative group (N group). In the P group, %UCA analyzed by IBS was
significantly higher than in the N group (60.2 ± 23.4% and 35.3 ± 19.2%, respectively, p<0.001).
Also, the SIR of most stenotic lesions of carotid plaques analyzed by T1WI of BB-MRI was
significantly higher in the P group than in the N group (1.40 ± 0.19 and 1.18 ± 0.25, respectively,
p<0.01) (Figure 3). In multivariate logistic regression analysis, the independent predictors of
NISIL were SIR (p = 0.030), the CRP level (p = 0.041) and the %UCA measured by IBS (p =
0.049). In the analysis of receiver operating characteristic curves, 50% of the %UCA measured
by IBS analysis and an SIR of 1.25 measured by BB-MRI analysis were determined as the most
reliable cutoff values for predicting NISIL. Using these cutoff values, the respective positive
and negative predictive values were 76% and 82% in the IBS analysis and 62% and 88% in the
BB-MRI analysis.
Figure 3. Representative images of CAS for an internal carotid plaque that consisted of less unstable component. (A)
Pre-steting angiogram of the left internal carotid artery stenosis. (B) White arrow: Axial image of the most stenotic
lesion of the plaque on T1WI of BB-MRI. *: sternocleidomastoid muscle. The SIR was 1.37 (C) Cross-sectional color-cod‐
ed map of the most stenotic lesion of the plaque on IBS. Relative unstable component area was 62%. (D) Post-stenting
angiogram of the left internal carotid artery stenosis. After carotid artery stenting, the lumen of the right internal caro‐
tid artery was successfully dilated. (E) Diffusion-weighted magnetic resonance imaging. White arrows: multiple silent
ischemic lesions are detected in the left cerebral hemisphere after the post-stenting procedure.
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5. Plaque feature of the internal carotid plaques evaluated by optical
coherence tomography
Recently, intravascular optical coherence tomography (OCT) provides high-resolution, cross-
sectional images of tissue in situ and has an axial resolution of 10 µm and a lateral resolution
of 20 µm [17, 18]. The OCT images of human coronary atherosclerotic plaques obtained in vivo
provide additional, more detailed structural information than intravascular ultrasound [19].
By applying this technique to carotid plaques, we previously reported the first case of cere‐
bral infarction due to plaque rupture that could be visualized by OCT in the internal carotid
artery [20]. An 83-year old male was admitted to our hospital due to newly developed motor
weakness of the left hand. MRI-DWI showed multiple high intensity spots in the territory of
the middle cerebral artery, and an initial MRA revealed significant stenosis at the origin of the
right internal carotid artery. After angiography, a 9-F guiding catheter with an occlusion balloon
was navigated to the right common carotid artery and a guidewire with an occlusion balloon
(Guardwire, Medtronic Japan Co., Ltd., Tokyo, Japan) was introduced into the external carotid
artery. Carotid angiography revealed apparent changes of the wall morphology of the stenotic
site, suggesting an enlargement of intraluminal thrombus (Figure 4), which is considered a risk
Figure 4. Optical coherence tomography of the internal carotid artery and pathological findings. A: An initial magnet‐
ic resonance angiography revealed severe stenosis of the internal carotid artery and high intensity plaque. B: The caro‐
tid angiogram showed internal carotid artery stenosis and enlargement of an intraluminal protrusion in the internal
carotid artery. C: Cross-sections by the optical coherence tomography (OCT) demonstrated intraluminal thrombus
with shadowing in the internal carotid artery. D: Cross-sections by intravascular ultrasound showed only eccentric and
low-echoic plaque in the internal carotid artery. E: Macroscopic view of surgical specimen revealed intraluminal
thrombus formed at the ruptured site of the soft plaque. F: Pathological analysis with Hematoxylin-Eosin staining con‐
firmed soft plaque and intraluminal red thrombus which coincided with OCT findings.
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factor for stenting. To confirm the presence of intraluminal thrombus, the stenotic site was
imaged with OCT (Image Wire, Light-lab imaging, Goodman, Co, Ltd, Nagoya, Japan) using
an automatic pull-back device from the distal portion at 1 mm/s. OCT clearly revealed an
intraluminal thrombus (Figure 4-C), and a tear of a fibrous cap with ulceration at the more
proximal internal carotid artery. Carotid artery stenting was cancelled due to enlarged thrombus
being considered a high risk factor, and carotid endarterectomy was performed the next day.
The specimen obtained during endarterectomy showed soft plaque and intraluminal throm‐
bus which coincided with OCT findings performed preoperatively (Figure 4-E, F).
6. Assessment of arterial medial characteristics in carotid arteries using
integrated backscatter ultrasound
In general, atherosclerotic changes consist of two components: atherosis and sclerosis.
According to a pathological study, these changes are recognized as thickening of intima-media
thickness (IMT) which is associated with structural atheromatous changes and decreased
Figure 5. Representative histological images of carotid media. (A) (C) Histological images stained by elastic van Gieson
staining. (B) (D) Digitized images, in which elastic fibers were selected by the following thresholding of the digital im‐
age LUZEX F (Nireco, Kyoto, Japan). (B) Elastic fiber index: 59.3 %, Elastic fragmentation index: 57.7 % and IBS value:
9.1 dB. (D) Elastic fiber index: 18.9 %, Elastic fragmentation index: 79.3 % and IBS value: 14.4 dB.
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an automatic pull-back device from the distal portion at 1 mm/s. OCT clearly revealed an
intraluminal thrombus (Figure 4-C), and a tear of a fibrous cap with ulceration at the more
proximal internal carotid artery. Carotid artery stenting was cancelled due to enlarged thrombus
being considered a high risk factor, and carotid endarterectomy was performed the next day.
The specimen obtained during endarterectomy showed soft plaque and intraluminal throm‐
bus which coincided with OCT findings performed preoperatively (Figure 4-E, F).
6. Assessment of arterial medial characteristics in carotid arteries using
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According to a pathological study, these changes are recognized as thickening of intima-media
thickness (IMT) which is associated with structural atheromatous changes and decreased
Figure 5. Representative histological images of carotid media. (A) (C) Histological images stained by elastic van Gieson
staining. (B) (D) Digitized images, in which elastic fibers were selected by the following thresholding of the digital im‐
age LUZEX F (Nireco, Kyoto, Japan). (B) Elastic fiber index: 59.3 %, Elastic fragmentation index: 57.7 % and IBS value:
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extensibility which is associated with functional sclerotic changes in elastic and collagen fibers.
There are several ultrasound parameters to evaluate atherosclerosis, such as IMT, which is
associated with atheromatous plaque formations and stiffness ß, which are associated with
decreased extensibility of the arterial wall. IMT measurement is widely performed for the
detection of atheromatous lesions and associated with age and coronary risk factors [21, 22].
However, IMT is not always associated with the severity of arterial sclerosis in patients with
hypertension [23]. This may be due to the degenerative changes in the medial smooth muscle
cells and variably increased amount of elastin and collagen in hypertensive vessels [24].
The elasticity of major arteries is also affected by cardiovascular risk factors such as hyper‐
tension, hyperlipidemia, diabetes and aging. Stiffness ß, which was defined by Hayashi et al
was found to be independent of blood pressure in the physiological range and associated with
the severity of coronary atherosclerosis [25-27]. An increase in arterial stiffness has been
reported as an early sign of atherosclerosis [28]. Therefore, it is very important to evaluate
arterial sclerosis non-invasively. We showed that IBS values of carotid media were correlated
with the stiffness of carotid arteries, and those were also correlated with elastic fiber fragmen‐
tation index (Figure 5) [29].
7. Conclusion
Recently, many techniques for the tissue characterization of human carotid arteries have been
established. IBS, MRI and OCT are promising techniques to assess the degree of atherosclerotic
lesions in carotid artery and predict cerebrovascular disease.
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1. Introduction
Carotid artery atherosclerosis is a major cause of disabling stroke and death [1] and it is thought
to be the predominant etiology of stroke in Western society [2]. Moreover, stroke is the third
leading cause of death and the primary cause of disability in the world [2].
Compared with medical therapy, surgical endarterectomy or carotid stenting have been
proven to decrease stroke in symptomatic patients with severe stenosis[3-7] and in a very
selective group of asymptomatic patients suffering of this pathology[8-9]
Nevertheless, clinical assessment of stroke risk had not progressed beyond the use of luminal
stenosis in spite of evidence to suggest that this is an inadequate predictor of stroke. [10]
More recently, imaging studies have suggested plaque composition as an independent risk
factor for ischemic stroke. [11]
Because of this, many efforts have been made to correlate symptoms and cerebral events with
histological studies, color doppler ultrasonography (CDU) and magnetic resonance imaging
(MRI).
Carotid dolichoarteriopathies were have also been proposed as a source of cerebral vascular
insufficiency but this issue remains very controversial in the literature.[12-14]. In this chapter,
our experience on CDU of neck vessels in 885 individuals with carotid dolichoarteriopathies
© 2014 Beigelman et al.; licensee InTech. This is a paper distributed under the terms of the Creative
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1. Introduction
Carotid artery atherosclerosis is a major cause of disabling stroke and death [1] and it is thought
to be the predominant etiology of stroke in Western society [2]. Moreover, stroke is the third
leading cause of death and the primary cause of disability in the world [2].
Compared with medical therapy, surgical endarterectomy or carotid stenting have been
proven to decrease stroke in symptomatic patients with severe stenosis[3-7] and in a very
selective group of asymptomatic patients suffering of this pathology[8-9]
Nevertheless, clinical assessment of stroke risk had not progressed beyond the use of luminal
stenosis in spite of evidence to suggest that this is an inadequate predictor of stroke. [10]
More recently, imaging studies have suggested plaque composition as an independent risk
factor for ischemic stroke. [11]
Because of this, many efforts have been made to correlate symptoms and cerebral events with
histological studies, color doppler ultrasonography (CDU) and magnetic resonance imaging
(MRI).
Carotid dolichoarteriopathies were have also been proposed as a source of cerebral vascular
insufficiency but this issue remains very controversial in the literature.[12-14]. In this chapter,
our experience on CDU of neck vessels in 885 individuals with carotid dolichoarteriopathies
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(age 1-day-old infants to 90-year-old adults),[15-16], the correlation of plaque appearance
between B ultrasonography and pathology, [17] and the histological assessment in 281 carotid
endarterectomy specimens [18] will be widely described and discussed.
In this connection, in a pioneer study we made a complete immunohistochemical characteri‐
zation in complicated carotid plaques. [18] The cellular components of carotid endarterectomy
specimens were analyzed to assess their role in the pathogenesis of plaque rupture and
intraplaque hemorrhage without rupture. The site of plaque rupture is associated with the
presence of an extensive infiltrate of macrophages, T-lymphocytes, scarce B-lymphocytes, mast
cells, and smooth muscle cells. Both the plaques showing these features and those with large
amounts of lipid and thin fibrous caps, should be considered as “plaques at risk”. Intraplaque
hemorrhages without plaque rupture may be caused by the breakdown of neoformed vessels
in the core, base, and periphery of the plaques. [18]
This paper emphasized the importance of the detection of vulnerable plaque for preventing
future cerebral events. The main factors in advanced plaque that are most likely to lead to
complications are the thickness of the fibrous cap, the size of the necrotic core and intraplaque
hemorrhage, and the extent of inflammatory activity within the plaque.
Later on, we analyzed the relation between the anatomy of the carotid plaques and the presence
of symptoms in 281 carotid endarterectomy specimens. [19] Almost 70% of plaque specimens
demonstrated thrombus, intraplaque hemorrhage, or both. Thrombosis was observed in one
fourth of specimens, and intraplaque hemorrhage in almost two thirds of specimens. Sixty four
percent of plaques demonstrated neovascularization. In spite of findings in some published
articles, [20] it was not possible to demonstrate that complicated plaques (plaque rupture,
thrombosis, intraplaque hemorrhage) are associated with symptoms, and it appears that
complicated plaques may occur at any time, irrespective of symptoms. [19]
Regarding the biology of the unstable atherosclerotic carotid plaque, an expression of c-fos,
p53 and PCNA was demonstrated by us. [21]
On the other hand, MRI has excellent soft tissue contrast and is able to quantify carotid plaque
size and composition with good accuracy and reproducibility and provides an opportunity to
prospectively examine the relationship between plaque features and subsequent cerebrovas‐
cular events. [22] In a paper by Takaya et al [23] 154 patients with an asymptomatic 50% to
79% carotid stenosis by ultrasound with > or =12 months of follow-up were included for
multicontrast-weighted carotid MRIs were included. Over a mean follow-up period of 38.2
months, arteries with thinned or ruptured fibrous caps, intraplaque hemorrhage, larger
maximum %lipid-rich/necrotic cores, and larger maximum wall thickness were associated
with the occurrence of subsequent cerebrovascular events. [23]
MRI imaging techniques have permitted serial monitoring of atherosclerotic disease evolution
and the identification of intraplaque risk factors for accelerated progresión. [22]
At last, based upon our research, carotid barochemoreceptor involvement in old patients who
died from stroke and suffering obstructive carotid atheromatosis will be discussed. [24]
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2. Pathology
Carotid atherosclerosis is commonly associated with symptoms of cerebral ischemia. However
little attention has been directed to intraplaque factors that precipitate the onset of symptoms.
[25] On the other hand, the treatment of coronary and carotid atherosclerosis, requires an
understanding of the pathogenesis of plaque fissure. [26] Advances in molecular biology,
coronary diagnostic techniques and cardiac treatments have suggested new factors leading to
plaque fissure. [26-28] It was suggested that the risk of plaque fissure depends on plaque
composition rather than plaque size, because only plaques rich in soft extracellular lipids are
prone to rupture. [27] Also, it was demonstrated that ruptured plaque caps have much larger
transverse gradients of connective tissue constituents than non-ruptured plaque caps, and that
the development of these transverse gradients may be critical in determining the propensity
of a plaque to rupture. [28] It was also shown that the site of rupture of thrombosed coronary
atherosclerotic plaques is marked by an inflammatory infiltration where the macrophages are
the dominant cells. [29]
However, the exact mechanisms causing plaque rupture are yet not complete known. [29] In
this connection, papers dealing with rupture of carotid plaque surface are few in spite of the
growing importance of the subject. [18,19,30] We analyzed in pioneer papers[18,19,30] the
cellular and vascular components of surgically excised carotid endarterectomies. Thus, the cell
populations involved in the inflammatory activity in atherosclerotic lesions were further
characterized with cell specific monoclonal antibodies in order to obtain information about
their role in the pathogenesis of plaque rupture and intraplaque hemorrhage.[30] In brief, 76
surgical specimens of 74 patients who were submitted to carotid endarterectomy were used
for these studies. There were 55 males and 19 females. Age ranged from 40 to 83 years (mean
69.4 years).Patients were divided into three clinical subgroups: asymptomatic (carotid lumen
obstruction > 70%), symptomatic (stable) and symptomatic (unstable). The usual unifying
pathologic feature in the plaques was the presence of large lipid cores with a fibrous cap
overlying the lipid core and a band of fibrous tissue of varying thickness separating the plaque
from the atrophic media (Figure 1). This collagen rim was in general extensively vascularized.
Exceptionally the plaque was composed of fibrocellular tissue without a clear lipid core. In
most cases, widespread chronic inflammatory infiltrates were observed either in the cap or in
the lipid core (Figure 2). In all cases the carotid bifurcation and the first 1.5 cm of the internal
carotid were involved.
The result of immunophenotyping of the cellular constituents of the plaques were described
in relation to the different layers (from the lumen to the media), namely: Endothelial lining
(Anti-CD31 and anti-CD34). The fibrous cap at the site of the rupture/erosion had an eroded
surface characterized by loss of the endothelial lining (Figure 3). On the other hand in the
remaining surface a continuous, not damaged row of endothelial cells stained with anti-CD31
and anti-CD34 was observed in all cases
Fibrous cap: the collagenous fibrous cap at the site of erosion was attenuated and the pheno‐
typic characterization of the cells showed inflammatory components consisting mainly of
macrophages (CD68 positive), approximately 2/3 of the total infiltration (Figure 4). The
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remaining 1/3 was composed of T-lymphocytes and rare B-lymphocytes. This pattern was
observed in 34/ 41 (83%) of ruptured plaques. A close interaction between macrophages and
the abundant capillaries of the lipid cores (Figure 4) and macrophages and T-lymphocytes was
commonly observed. Some foamy macrophages showed not only brown staining correspond‐
ing to the expression of CD68 but also weak red staining for CD31, thus suggesting that these
cells also contain this adhesion molecule. Plaques "at risk" (attenuated fibrous cap, large lipid
core and extensive macrophage infiltration) are represented in Figure 1.
Figure 1. A large lipid core with a thin fibrous cap (arrow) overlying the lipid core is observed.
Figure 2. A neoformed thin-walled vessel is shown with lymphocytes migrating to the highly vascularized lipid. Mag‐
nification ´250
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Figure 3. Intraplaque hemorrhage without plaque rupture. Superimposed parietal thrombus. A continuous non rup‐
tured thick cap is shown (arrow). A parietal thrombus is implanted in an eroded surface (arrowhead), and a rich lipid
core is heavily embedded by intraplaque hemorrhage(LC).Trichrome-stained collagen, blue; hemorrhage, light red;
thrombus blue-red (original magnification _200).
Lipid cores: two different types of lipid cores could be depicted, avascular or mildly vascu‐
larized lipid cores and highly vascularized, with neoformed vessels stained with CD34 and
CD31(Figure 5 and 6). These vessels varied from proliferated small, thin walled blood vessels
to bigger ones, in some cases presenting a hemangioma-like aspect. CD34 stained endothelia
of all kind of vessels; conversely, neoformed vessels showed a weak stain with CD31.T-
lymphocytes were found to be in contact with neoformed vessels, and in some cases, migrating
through the endothelial cells
Media: this tunic was composed of 5 to 12 rows of smooth muscle cells, with their long axes
oriented circumferentially, as the edge of the endarterectomy passed through that level. Some
thin walled normal capillaries oriented longitudinally to the long axis of the smooth muscle
cells were fairly showed by the CD34 and CD31 (Figure 8). Although this tunic did not belong
to the plaque itself, it is herein described because of its peculiar vascularization. It is therefore
necessary to make a clear distinction regarding the neoformed vessels of the base and periph‐
ery of the plaque, and the adjacent capillaries of the media originating from the vasavasorum.
Deeper layers of the plaque: the base and the shoulder of the plaques showed in 28/76 cases
neoformed vessels, thin or thick walled, CD34 positive (Figure 7), generally surrounded by
mild to extensive mononuclear infiltrates.
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Basically atherosclerotic plaques were found to be-long to six different lesions, namely: plaque
rupture plus thrombosis (18/76, 23.6%), plaque rupture plus intraplaque hemorrhage plus
thrombosis (18/76, 23.6%), intraplaque hemorrhage without plaque rupture (16/76, 21.0%),
plaque rupture plus intraplaque hemorrhage (5/76, 6.5%), stable calcified non complicated
plaque (14/76, 18.4%) and unstable, soft, non complicated plaque (5/76, 6.5%). The first four
lesions were considered as "complicated lesions".
Figure 4. Foamy macrophages show brown staining corresponding to the expression of CD68 and weak red staining
for CD31.
• Plaque rupture plus thrombosis (PR+T). The fibrous cap overlying the lipid core was highly
variable in thickness and cellular constituents. Plaques presented ulcerations with break‐
down of the surface of the cap. Their-regularity had a punched-out characteristic or was
simply a tear with borders; in rare cases plaques contained virtually no fibrous cap. The
rupture was covered by a thrombus, and in many cases the thrombus was found directly
overlying the lipid core of the lesion, entering a large pool of extracellular lipids. As said
the borders of the rupture presented a mononuclear infiltration with a high density of
macrophages.
• Plaque rupture plus intraplaque hemorrhage plus thrombosis (PR+IPH+T). (Figure 9)The
histological findings were similar to the ruptured-thrombosed plaques, but there was also
extensive disruption of the plaque by an intraplaque hemorrhage.
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Figure 5. Intense neovascularization of the lipid core. Immunoperoxidase technique for smooth muscle cells (α-actin).
In panel A, the asterisk indicates a thick neovascularization vessel. Panel B shows the middle arterial layer. In panel C:,a
central neoformed vessel outgrowth in "glove finger" is seen into the lipid core. Endothelial pyknotic cells surrounded
by scarse pericytes, macrophages, and lymphocytes in the periphery are shown.
Figure 6. Lipid-rich core is heavily vascularized by great number of thin-walled, neoformed,CD34-positive vessels.
Magnification ´250.
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Figure 7. Vascularization of the shoulder of the plaque. Note thin-walled neoformed vessels of different shapes and
sizes. Outer zone shows media and an extensive quantity of thin-walled normal capillaries,longitudinally oriented
(brown). Antiactin monoclonal antibody(HHF35) was used to demonstrate vascular structures (original magnification
_250).
Figure 8. Low magnification view of an entire endarterectomy specimen shows actin-positive vessel walls (HHF35)
and hyperplastic smooth muscle cells (asterisc). Media (arrowheads) shows normal arrangement and at this level is
composed of only 5 to 10 layers of smooth muscle cells (arrow). Magnification x25.
Intraplaque hemorrhage without plaque rupture (IPH) (Figure 10). None of them had a
connection between the hemorrhage and the arterial lumen, in spite of a careful search in serial
sections. Conversely the intimal surfaces were clean and none showed evidence or platelet or
fibrin deposition. Hemorrhages varied from microscopic, microfocal or slitlike foci of recent
hemorrhage, with no evident changes in the overall makeup of the plaque to massive hemor‐
rhage, elevation and disruption of the intima to massive hemorrhage,elevation and disruption
of the intima and occlusive stenosis. Only these massive lesions were considered. Of note,
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slitlike hemorrhages distant to the main lesion were found in 12 cases, in 5 of them without
the presence of a massive intraplaque hemorrhage.
Figure 9. Plaque rupture (arrow) plus intraplaque hemorrhage and parietal thrombosis. An entire specimen from a
carotid endarterectomy frontally cut is shown. 1, Common carotid artery; 2,external carotid artery. *Large lipid core
with huge intraplaque hemorrhage with thrombotic components, and small parietal thrombus are observed. Fibrous
cap is extremely thin (hematoxylin-eosin; original magnification 3).
Figure 10. Sample of carotid endarterectomy. Laminar hemorrhage, distal to the main lesion Trichrome-stained colla‐
gen, blue; hemorrhage, light red; Magnification ´250.
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Plaque rupture plus intraplaque hemorrhage (PR+IPH) (Figure 11). It was characterized by
an extensive hemorrhage within the plaque with separation of its varying components and
disruption of the intima.
Figure 11. Plaque rupture. A intraplaque hemorrhage (arrow ) B-. Breakdown of cap is clearly shown (between arrow‐
heads)
• Stable, calcified, non complicated plaque (S+C) (Figure 12).These plaques contained
neither thrombosis nor hemorrhages and consisted of laminated fibrous connective tissue
and irregular masses of calcified material. These areas appeared as acellular, roughly
circular masses of pale-staining debris.
Figure 12. Stable calcified plate. Lipid core (1), thick cover (2), and abundant calcified areas in black
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Unstable, soft, non complicated plaque (U+NC). These plaques consisted of thin fibrous caps
covering a lipid-rich core with extensive vascularization. As these are the ingredients of a
plaque "at risk", those may be plaques in which rupture hemorrhage and/or thrombosis might
have occurred in the future.
Complicated vs stable calcified, non complicated plaques.Complicated plaques presented
neoformed vessels in the periphery, shoulder and base of the plaque in 22/57 (38.5%) cases.
Conversely only 1/14 (7.1%) of non complicated, stable calcified plaques presented this type
of vessels (p < 0.05). Of note, the 5 cases of unstable, soft non complicated plaque presented
neoformed vessels surrounding the plaque. In 10/57 (17.5%) complicated plaques unequivocal
histological signs of old hemorrhages were found surrounding those vessels. Irrespective of
presenting no rupture, 11/35 plaques showed a mononuclear in-filtrate in the fibrous cap.
Clinical-pathological correlation. The risk factor variables (age, gender, hypertension, left
ventricular hypertrophy, diabetes, weight, smoking and uric acid) could not be correlated with
any of the pathological and immunohistochemical findings. Hypertension (70%) and smoking
(59%) were the risk factors more frequently found irrespective of the morphological find‐
ings.Therefore, carotid endarterectomies provided the material for phenotypic characteriza‐
tion of vascular and cellular components of the plaque. This permitted to known the
topography and the distribution of mononuclear infiltrates as well as endothelial cells.
Although the cellular composition of advanced atherosclerotic plaques is known to be
heterogeneous, [31] it can be summarized as:
Intimal plaque rupture-inflammatory process. We demonstrated for the first time[30] that
rupture of carotid plaques is characterized by the presence of a macrophagic infiltration of the
caps. The presence of a large number of foamy macrophages in plaque fissuring in human
coronary thrombosis had been reported previously [29,32-34] and it was suggested that
inflammation through enzymatic degradation of the fibrous cap by macrophages might
destabilize the plaque, causing weakening at the immediate site of rupture. In carotid endar‐
terectomies although the fibrous cap overlying the plaque was variable in thickness, the area
of rupture was dominated by macrophages as the main cellular component, T-lymphocytes
and scarce B-lymphocytes and granulated and/or degranulated mast cells. Complete rupture
of the fibrous cap was found to be the cause of thrombosis in 18 cases, intraplaque hemorrhage
plus thrombosis in 18 and intraplaque hemorrhage in 5 cases. It means that approximately 50%
of carotid endarterectomies have the plaque fissure as the anatomic substratum. Of note, only
23/41 (56%) of these cases have been symptomatic. Our studies in carotid plaques showed
direct apposition of T-lymphocytes to macrophages and a close relation of these cells to
endothelial cells. This highly suggests a cell-to-cell interaction, which results in an inflamma‐
tory process mediated by cellular adhesion molecules (such as CD31), cytokines, growth
factors and other substances as described in coronary arteries[29] and aorta. [35] Therefore,
the possibility of autocrine, juxtacrine or paracrine secretion was evident. [36]
Intraplaque hemorrhage without plaque rupture-plaque vascularization. Intraplaque
hemorrhage without rupture was present in 21% of the endarterectomies. This subset of carotid
lesions was not related to cap erosion, but to plaque vascularization. Most lipid cores were
highly vascularized with neoformed vessels with macrophages and T-cells in close contact and
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Plaque rupture plus intraplaque hemorrhage (PR+IPH) (Figure 11). It was characterized by
an extensive hemorrhage within the plaque with separation of its varying components and
disruption of the intima.
Figure 11. Plaque rupture. A intraplaque hemorrhage (arrow ) B-. Breakdown of cap is clearly shown (between arrow‐
heads)
• Stable, calcified, non complicated plaque (S+C) (Figure 12).These plaques contained
neither thrombosis nor hemorrhages and consisted of laminated fibrous connective tissue
and irregular masses of calcified material. These areas appeared as acellular, roughly
circular masses of pale-staining debris.
Figure 12. Stable calcified plate. Lipid core (1), thick cover (2), and abundant calcified areas in black
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Unstable, soft, non complicated plaque (U+NC). These plaques consisted of thin fibrous caps
covering a lipid-rich core with extensive vascularization. As these are the ingredients of a
plaque "at risk", those may be plaques in which rupture hemorrhage and/or thrombosis might
have occurred in the future.
Complicated vs stable calcified, non complicated plaques.Complicated plaques presented
neoformed vessels in the periphery, shoulder and base of the plaque in 22/57 (38.5%) cases.
Conversely only 1/14 (7.1%) of non complicated, stable calcified plaques presented this type
of vessels (p < 0.05). Of note, the 5 cases of unstable, soft non complicated plaque presented
neoformed vessels surrounding the plaque. In 10/57 (17.5%) complicated plaques unequivocal
histological signs of old hemorrhages were found surrounding those vessels. Irrespective of
presenting no rupture, 11/35 plaques showed a mononuclear in-filtrate in the fibrous cap.
Clinical-pathological correlation. The risk factor variables (age, gender, hypertension, left
ventricular hypertrophy, diabetes, weight, smoking and uric acid) could not be correlated with
any of the pathological and immunohistochemical findings. Hypertension (70%) and smoking
(59%) were the risk factors more frequently found irrespective of the morphological find‐
ings.Therefore, carotid endarterectomies provided the material for phenotypic characteriza‐
tion of vascular and cellular components of the plaque. This permitted to known the
topography and the distribution of mononuclear infiltrates as well as endothelial cells.
Although the cellular composition of advanced atherosclerotic plaques is known to be
heterogeneous, [31] it can be summarized as:
Intimal plaque rupture-inflammatory process. We demonstrated for the first time[30] that
rupture of carotid plaques is characterized by the presence of a macrophagic infiltration of the
caps. The presence of a large number of foamy macrophages in plaque fissuring in human
coronary thrombosis had been reported previously [29,32-34] and it was suggested that
inflammation through enzymatic degradation of the fibrous cap by macrophages might
destabilize the plaque, causing weakening at the immediate site of rupture. In carotid endar‐
terectomies although the fibrous cap overlying the plaque was variable in thickness, the area
of rupture was dominated by macrophages as the main cellular component, T-lymphocytes
and scarce B-lymphocytes and granulated and/or degranulated mast cells. Complete rupture
of the fibrous cap was found to be the cause of thrombosis in 18 cases, intraplaque hemorrhage
plus thrombosis in 18 and intraplaque hemorrhage in 5 cases. It means that approximately 50%
of carotid endarterectomies have the plaque fissure as the anatomic substratum. Of note, only
23/41 (56%) of these cases have been symptomatic. Our studies in carotid plaques showed
direct apposition of T-lymphocytes to macrophages and a close relation of these cells to
endothelial cells. This highly suggests a cell-to-cell interaction, which results in an inflamma‐
tory process mediated by cellular adhesion molecules (such as CD31), cytokines, growth
factors and other substances as described in coronary arteries[29] and aorta. [35] Therefore,
the possibility of autocrine, juxtacrine or paracrine secretion was evident. [36]
Intraplaque hemorrhage without plaque rupture-plaque vascularization. Intraplaque
hemorrhage without rupture was present in 21% of the endarterectomies. This subset of carotid
lesions was not related to cap erosion, but to plaque vascularization. Most lipid cores were
highly vascularized with neoformed vessels with macrophages and T-cells in close contact and
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some cases disrupting the endothelium The abrupt growing of the lipid cores and/or an
overproduction of oxygen free radicals could lead to the breakdown of core vessels and
intraplaque hemorrhage. This seems to be the most plausible mechanism. The periphery and
shoulder of the plaques had in 30% of the cases neoformed vessels surrounded by extensive
mononuclear infiltrates. Theseneoformed vessels showed a weak stain with CD31. Consider‐
ing that CD31 (PECAM-1) is a molecular adhesion molecule, the lack of expression could be
pointing out a functional difference between normal and neoformed vessels. PECAM- 1 is
required for transendothelial migration of leucocytes.
The same mechanism postulated for the vessels of the core may operate in neoformed vessels.
The presence of histological signs of old hemorrhages and the existence of slitlike hemorrhages
at that level strongly suggest that a local origin of bleeding may operate. Lusby et al[25]
demonstrated that the resultant angiogenesis associated with hemorrhages might make those
lesions prone to mechanical stress and subsequent hemorrhages. Accordingly, our observa‐
tions and those by other authors suggest that intraplaque hemorrhages may occur at any time
in the history of carotid plaque. [37] Hypertension may be a predisposing factor in the rupture
of neoformed vessels and the development of the hemorrhage within the plaque.
Our results in 76 endarterectomies suggest that the site of plaque rupture is associated with
the presence of a large macrophagic infiltration, [38] as well as T-lymphocytes rare B-lympho‐
cytes and mast cells and lack of smooth muscle cells. These peculiar type of plaque should be
considered as a "plaque at risk”[29] in addition to plaques containing large amounts of lipid
pools and a thin fibrous cap. [34] Conversely, intraplaque hemorrhages without plaque
rupture might be due to the breakdown of neo-formed core vessels and/or neoformed vessels
of the base and shoulder of the plaque.
The decision of whether to perform endarterectomy in patients with asymptomatic disease
should be made on the basis of data including degree of stenosis and activity of the carotid
lesion, as well as issues of medical and surgical morbidity. [39]
The relationship between anatomy of carotid plaques and the presence or not of symp‐
toms. For this purpose we carried out an investigation[19] in order to analyze in a large sample
the relation between the anatomy of carotid plaques and the presence of symptoms in 281
endarterectomy specimens. To avoid an excessive number of plaque subtypes that might blur
the relationship with symptoms, [31] only complicated and non-complicated plaques and
ruptured and nonruptured plaques were used for statistical analysis. Patients (mean age, 68
+/-8 y.o.,range,40-84 y.o.) were 213 men (mean age, 68 y.o.s; range, 45-83 y.o.) and 68 women
(mean age,68.7 y.o.; range, 40-84 y.o.).[19] In all cases the bifurcation and the first 10 to 15 mm
of the internal carotid artery were involved. In 196 plaques, large lipid cores with a fibrous cap
and a band of fibrous tissue separating the plaque from the remainder of the media were
observed. The cap was frequently vascularized. In most cases, extensive inflammatory
infiltrates consisting of macrophages, smaller numbers of T lymphocytes, a few B lymphocytes,
and mast cells were observed. In the remaining cases, the plaque was composed of fibrocellular
tissue only.[19]
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For statistical purposes, plaques were divided into two subsets: complicated (types PR+T, PR
+IPH+T, PR+IPH, ulcerated calcified plaques and IPH) vs. non-complicated, and ruptured
(types 1 through 4) vs non-ruptured (types IPH,S+C and U+NC).
Complicated plaques (205 of 281) exhibited mononuclear infiltrates in the periphery, should‐
ers,and bases in 137 of 205 (67%) plaques, compared with only 22 of 76 (29%) noncomplicated
plaques (p< 0.001). Complicated plaques demonstrated neoformed vessels in the periphery,
shoulders, and bases in 146 of 205 (71%) plaques, compared with only 38 of 76 (50%) noncom‐
plicated plaques (p<0.001). Twelve of 18 unstable, soft, non complicated plaques exhibited
neoformed vessels surrounding the plaques. The remaining 6 plaques had huge lipid cores
without evident neoformed vessels, suggesting very recent development. In 34 of 205(17%)
complicated plaques, old hemorrhages were found surrounding neoformedvessels. Ruptured
versus non-ruptured plaques. Infiltrates were noted in the caps and shoulders in 108 of 130
(83%) ruptured plaques and 22 of 151 (15%) unruptured plaques (p< 0.0001).External carotid
arteries arteries exhibited typical histopathologic findings of advanced atheromatosis in 51 of
281 cases(18%).Only 2 of 51 affected cases demonstrated complicated plaques.This resulted in
a significant difference when compared with the internal carotid artery ruptures (1of40 vs 85
of 165 p< 0.001).Risk factors could not be associated with any pathologic findings. Hyperten‐
sion (74%), smoking (61%), hyperlipidemia (61%), and diabetes mellitus (24%) were the risk
factors most frequently noted. No correlation could be established between plaque type and
symptoms (Table I). Of note, although 99 of 205 (48%) complicated plaques were found in
patients with symptomatic disease, a high percentage (106 of 205, 52%) were also found in
patients with asymptomatic disease. The same was observed for ruptured plaques; 67 of 130
(52%) were found in patients with symptomatic disease, compared with 63 of 130 (48%) in
patients with asymptomatic disease. No relation could be found between symptomatic versus
asymptomatic disease with regard to old hemorrhage (18 [12%] vs 26 [19%]), distal IPH(19
[13%] vs 13 [10%]), laminar hemorrhage (14 [9%] vs 22 [16%]), and parietal thrombosis (14 [9%]
vs18 [13%]).
Differences in flow velocity profiles and wall shear stress might explain the lower atheroscler‐
otic involvement and rare complications of the external carotid artery as compared with the
internal carotid artery (205 of 281 vs 2 of 281; P<0.0001). Areas of carotid plaque rupture were
characterized by macrophagic infiltration at the rupture. This finding suggests that inflam‐
mation, through enzymatic degradation of the fibrous cap by macrophages, might destabilize
the plaque, causing weakening at the site of rupture.[25,30,40] Complete rupture of the cap
(46% of cases) was the cause of thrombosis in 7%, IPH plus thrombosis in 18%, and IPH in 19%.
Therefore plaque rupture was the cause of thrombosis in only 25% of cases. Many factors can
modulate the development of thrombus. Long-term preoperative administration of aspirin
and use of heparin during surgery may explain the relatively low frequency of thrombosis
observed in ruptured plaques. Other possibilities are that fibrin or platelet deposition was
missed at previous embolization orduring microscopic examination because of sampling.
However, inasmuch as excisionwas in bloc, without “touching” the lesion, thrombus displace‐
ment seems unlikely. IPH without rupture represented 27% of endarterectomy specimens in
the present study. This subset of lesions was not related to rupture of the cap, but to plaque
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some cases disrupting the endothelium The abrupt growing of the lipid cores and/or an
overproduction of oxygen free radicals could lead to the breakdown of core vessels and
intraplaque hemorrhage. This seems to be the most plausible mechanism. The periphery and
shoulder of the plaques had in 30% of the cases neoformed vessels surrounded by extensive
mononuclear infiltrates. Theseneoformed vessels showed a weak stain with CD31. Consider‐
ing that CD31 (PECAM-1) is a molecular adhesion molecule, the lack of expression could be
pointing out a functional difference between normal and neoformed vessels. PECAM- 1 is
required for transendothelial migration of leucocytes.
The same mechanism postulated for the vessels of the core may operate in neoformed vessels.
The presence of histological signs of old hemorrhages and the existence of slitlike hemorrhages
at that level strongly suggest that a local origin of bleeding may operate. Lusby et al[25]
demonstrated that the resultant angiogenesis associated with hemorrhages might make those
lesions prone to mechanical stress and subsequent hemorrhages. Accordingly, our observa‐
tions and those by other authors suggest that intraplaque hemorrhages may occur at any time
in the history of carotid plaque. [37] Hypertension may be a predisposing factor in the rupture
of neoformed vessels and the development of the hemorrhage within the plaque.
Our results in 76 endarterectomies suggest that the site of plaque rupture is associated with
the presence of a large macrophagic infiltration, [38] as well as T-lymphocytes rare B-lympho‐
cytes and mast cells and lack of smooth muscle cells. These peculiar type of plaque should be
considered as a "plaque at risk”[29] in addition to plaques containing large amounts of lipid
pools and a thin fibrous cap. [34] Conversely, intraplaque hemorrhages without plaque
rupture might be due to the breakdown of neo-formed core vessels and/or neoformed vessels
of the base and shoulder of the plaque.
The decision of whether to perform endarterectomy in patients with asymptomatic disease
should be made on the basis of data including degree of stenosis and activity of the carotid
lesion, as well as issues of medical and surgical morbidity. [39]
The relationship between anatomy of carotid plaques and the presence or not of symp‐
toms. For this purpose we carried out an investigation[19] in order to analyze in a large sample
the relation between the anatomy of carotid plaques and the presence of symptoms in 281
endarterectomy specimens. To avoid an excessive number of plaque subtypes that might blur
the relationship with symptoms, [31] only complicated and non-complicated plaques and
ruptured and nonruptured plaques were used for statistical analysis. Patients (mean age, 68
+/-8 y.o.,range,40-84 y.o.) were 213 men (mean age, 68 y.o.s; range, 45-83 y.o.) and 68 women
(mean age,68.7 y.o.; range, 40-84 y.o.).[19] In all cases the bifurcation and the first 10 to 15 mm
of the internal carotid artery were involved. In 196 plaques, large lipid cores with a fibrous cap
and a band of fibrous tissue separating the plaque from the remainder of the media were
observed. The cap was frequently vascularized. In most cases, extensive inflammatory
infiltrates consisting of macrophages, smaller numbers of T lymphocytes, a few B lymphocytes,
and mast cells were observed. In the remaining cases, the plaque was composed of fibrocellular
tissue only.[19]
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For statistical purposes, plaques were divided into two subsets: complicated (types PR+T, PR
+IPH+T, PR+IPH, ulcerated calcified plaques and IPH) vs. non-complicated, and ruptured
(types 1 through 4) vs non-ruptured (types IPH,S+C and U+NC).
Complicated plaques (205 of 281) exhibited mononuclear infiltrates in the periphery, should‐
ers,and bases in 137 of 205 (67%) plaques, compared with only 22 of 76 (29%) noncomplicated
plaques (p< 0.001). Complicated plaques demonstrated neoformed vessels in the periphery,
shoulders, and bases in 146 of 205 (71%) plaques, compared with only 38 of 76 (50%) noncom‐
plicated plaques (p<0.001). Twelve of 18 unstable, soft, non complicated plaques exhibited
neoformed vessels surrounding the plaques. The remaining 6 plaques had huge lipid cores
without evident neoformed vessels, suggesting very recent development. In 34 of 205(17%)
complicated plaques, old hemorrhages were found surrounding neoformedvessels. Ruptured
versus non-ruptured plaques. Infiltrates were noted in the caps and shoulders in 108 of 130
(83%) ruptured plaques and 22 of 151 (15%) unruptured plaques (p< 0.0001).External carotid
arteries arteries exhibited typical histopathologic findings of advanced atheromatosis in 51 of
281 cases(18%).Only 2 of 51 affected cases demonstrated complicated plaques.This resulted in
a significant difference when compared with the internal carotid artery ruptures (1of40 vs 85
of 165 p< 0.001).Risk factors could not be associated with any pathologic findings. Hyperten‐
sion (74%), smoking (61%), hyperlipidemia (61%), and diabetes mellitus (24%) were the risk
factors most frequently noted. No correlation could be established between plaque type and
symptoms (Table I). Of note, although 99 of 205 (48%) complicated plaques were found in
patients with symptomatic disease, a high percentage (106 of 205, 52%) were also found in
patients with asymptomatic disease. The same was observed for ruptured plaques; 67 of 130
(52%) were found in patients with symptomatic disease, compared with 63 of 130 (48%) in
patients with asymptomatic disease. No relation could be found between symptomatic versus
asymptomatic disease with regard to old hemorrhage (18 [12%] vs 26 [19%]), distal IPH(19
[13%] vs 13 [10%]), laminar hemorrhage (14 [9%] vs 22 [16%]), and parietal thrombosis (14 [9%]
vs18 [13%]).
Differences in flow velocity profiles and wall shear stress might explain the lower atheroscler‐
otic involvement and rare complications of the external carotid artery as compared with the
internal carotid artery (205 of 281 vs 2 of 281; P<0.0001). Areas of carotid plaque rupture were
characterized by macrophagic infiltration at the rupture. This finding suggests that inflam‐
mation, through enzymatic degradation of the fibrous cap by macrophages, might destabilize
the plaque, causing weakening at the site of rupture.[25,30,40] Complete rupture of the cap
(46% of cases) was the cause of thrombosis in 7%, IPH plus thrombosis in 18%, and IPH in 19%.
Therefore plaque rupture was the cause of thrombosis in only 25% of cases. Many factors can
modulate the development of thrombus. Long-term preoperative administration of aspirin
and use of heparin during surgery may explain the relatively low frequency of thrombosis
observed in ruptured plaques. Other possibilities are that fibrin or platelet deposition was
missed at previous embolization orduring microscopic examination because of sampling.
However, inasmuch as excisionwas in bloc, without “touching” the lesion, thrombus displace‐
ment seems unlikely. IPH without rupture represented 27% of endarterectomy specimens in
the present study. This subset of lesions was not related to rupture of the cap, but to plaque
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neovascularization. Lipid cores were highly vascularized with heterogeneous neoformed
vessels and with macrophages and T cells in close contact with the endothelial wall. An
increase in the amount of lipid in the core, mechanicalstresses,[25] and overproduction of
oxygen free radicals by macrophages could lead to breakdown of core neoform vessels and
IPH production.[27] The same mechanisms might also act in neoform vessels in the periphery
of the plaques. Old hemorrhages in 17% of complicated plaques and presence of distant slitlike
hemorrhages strongly suggest that the bleeding may be of local origin.[30,41] Hemorrhages
were attributed to mechanical stress of turbulent flow and to wall vibration secondary to
stiffness of the carotid wall,[30] and have also been associated with an increase in matrix
metalloproteinase 1 expression in the macrophages of the fibrous cap, suggesting a role for
inflammatory mediators in vessel disruption.[31] Therefore, IPH may occur at any time in the
course of a carotid plaque.[18,30,37,38]
Complicated and noncomplicated plaques versus symptomatic and asymptomatic disease.
Plaque rupture was present in 46% of endarterectomy specimens. However, only 67 of 130
(52%) of these were found in patients with symptomatic disease. On the other hand, a high
proportion  of  patients  with  asymptomatic  disease  (48%)  demonstrated  complicated
plaques.Coronary plaque ruptures have been identified in patients  who died of  noncar‐
diac  causes.[18]  Accordingly,  occurrence of  carotid plaque rupture or  hemorrhage with‐
out  symptomatic  manifestation  seems  likely.The  frequency  of  plaque  hemorrhage  and
plaque  disruption  varied  greatly  among the  various  series  from both  symptomatic  and
asymptomatic specimens In a review of several studies,[25,37,42-46] Fisher et al observed
that the pooled frequency of plaque hemorrhage and rupture demonstrated a significant‐
ly  increased frequency  in  the  symptomatic  group.  However,pooling  data  from multiple
sources when methods of  analysis  are different  (histologicvs macroscopic)  is  hazardous.
[47] Therefore studies in which only macroscopic assessment was performed[25,37,48-53]
must be discarded. Some authors stress that IPH indicates only the severity of atherosclero‐
sis;[50,51,54-57] others suggest IPH has a direct role in pathogenesis of transient ischemic
attack or stroke. [25,35,44,46,57] When most studies are considered, the incidence of IPH in
symptomatic and asymptomatic disease spreads considerably In the symptomatic group,
incidence varied from 17% to 97%, compared with 2% to 91% in the asymptomatic group.
In  the  European  Carotid  Plaque  Study,  [58]  a  high  incidence  of  IPH  was  observed  in
symptomatic (94%) and asymptomatic (71%) groups A higher incidence of IPH was reported
in patients without symptoms.[55,59,60] Lennihan et al[54] scored the occurrence of IPH
only in patients with symptoms, and found ipsilateral symptoms in 57% of patients with
IPH and 65% of patients without IPH, indicating little difference between the two groups.
IPH seems to be more common in plaques causing high-grade stenosis.[47,54,55] Carr et
al[52]  found patients  with  symptomatic  plaques  to  have  more  frequent  plaque  rupture,
fibrous cap thinning, and cap foam cell infiltration, compared with patients with asympto‐
matic plaques. IPH was also seen in all specimens from symptomatic specimens and in 68%
of asymptomatic specimens. However, this study included too few patients to be signifi‐
cant. Despite a close relationship between IPH and symptoms,[37,61-63] and carotid plaque
rupture, thrombosis, and symptoms, [25,60,61] it has also been claimed that patients with
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symptomatic plaques typically have large necrotic cores within the carotid arteries.[31] Some
studies indicate that the association of complicated plaque and symptomatic disease does
not exist.[55,62-64] It  is  conceivable that patients presumed to have no symptoms might
have had embolic episodes and that  emboli  became impacted in silent  cerebral  areas or
occurred during sleep.[25,37,44,57] Also, symptoms may not be recalled by patients, who
are often elderly or frail. Of note, in a high-risk subgroup of patients with asymptomatic
carotid stenosis the annual stroke rate was more than 4%.[33] Inzitari et al[10] confirmed
that cardioembolic and small  vessel  stroke can occur,  in addition to large vessel  athero‐
thrombotic  stroke,  in  patients  with  asymptomatic  carotid  stenosis.  Finally,  NASCET[3]
demonstrated that most carotid strokes occur without warning symptoms, and only 5% to
15%  of  patients  have  a  transient  ischemic  attack  as  an  impending  symptom  of  stroke.
Nevertheless  nowadays  carotid  endarterectomy or  stenting  should  not  be  performed in
asymptomatic  patients  except  those  in  which  some  clinical  conditions  are  present,  as
recommended by the American Heart Association/American Stroke Association. [65]
Patients with asymptomatic carotid artery stenosis should be screened for other treatable
risk factors for stroke with institution of appropriate lifestyle changes and medical therapy
(Class I; Level of Evidence C).
1. Selection of asymptomatic patients for carotid revascularization should be guided by an
assessment of comorbid conditions and life expectancy, as well as other individual factors,
and should include a thorough discussion of the risks and benefits of the procedure with
an understanding of patient preferences (Class I; Level of Evidence C).
2. The use of aspirin in conjunction with carotid endarterectomy (CEA) is recommended
unless contraindicated because aspirin was used in all of the cited trials of CEA as an
antiplatelet drug (Class I; Level of Evidence C).
3. Prophylactic CEA performed with <3% morbidity and mortality can be useful in highly
selected patients with an asymptomatic carotid stenosis (minimum 60% by angiography,
70% by validated Doppler ultrasound) (Class IIa; Level of Evidence A). It should be noted
that the benefit of surgery may now be lower than anticipated based on randomized trial
results, and the cited 3% threshold for complication rates may be high because of interim
advances in medical therapy.
4. Prophylactic carotid artery stenting (CAS) might be considered in highly selected patients
with an asymptomatic carotid stenosis (≥60% on angiography, ≥70% on validated Doppler
ultrasonography, or ≥80% on computed tomographic angiography or MRA if the stenosis
on ultrasonography was 50% to 69%). The advantage of revascularization over current
medical therapy alone is not well established (Class IIb; Level of Evidence B).
5. The usefulness of CAS as an alternative to CEA in asymptomatic patients at high risk for
the surgical procedure is uncertain (Class IIb; Level of Evidence C).
6. Population screening for asymptomatic carotid artery stenosis is not recommended (Class
III; Level of Evidence B).
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neovascularization. Lipid cores were highly vascularized with heterogeneous neoformed
vessels and with macrophages and T cells in close contact with the endothelial wall. An
increase in the amount of lipid in the core, mechanicalstresses,[25] and overproduction of
oxygen free radicals by macrophages could lead to breakdown of core neoform vessels and
IPH production.[27] The same mechanisms might also act in neoform vessels in the periphery
of the plaques. Old hemorrhages in 17% of complicated plaques and presence of distant slitlike
hemorrhages strongly suggest that the bleeding may be of local origin.[30,41] Hemorrhages
were attributed to mechanical stress of turbulent flow and to wall vibration secondary to
stiffness of the carotid wall,[30] and have also been associated with an increase in matrix
metalloproteinase 1 expression in the macrophages of the fibrous cap, suggesting a role for
inflammatory mediators in vessel disruption.[31] Therefore, IPH may occur at any time in the
course of a carotid plaque.[18,30,37,38]
Complicated and noncomplicated plaques versus symptomatic and asymptomatic disease.
Plaque rupture was present in 46% of endarterectomy specimens. However, only 67 of 130
(52%) of these were found in patients with symptomatic disease. On the other hand, a high
proportion  of  patients  with  asymptomatic  disease  (48%)  demonstrated  complicated
plaques.Coronary plaque ruptures have been identified in patients  who died of  noncar‐
diac  causes.[18]  Accordingly,  occurrence of  carotid plaque rupture or  hemorrhage with‐
out  symptomatic  manifestation  seems  likely.The  frequency  of  plaque  hemorrhage  and
plaque  disruption  varied  greatly  among the  various  series  from both  symptomatic  and
asymptomatic specimens In a review of several studies,[25,37,42-46] Fisher et al observed
that the pooled frequency of plaque hemorrhage and rupture demonstrated a significant‐
ly  increased frequency  in  the  symptomatic  group.  However,pooling  data  from multiple
sources when methods of  analysis  are different  (histologicvs macroscopic)  is  hazardous.
[47] Therefore studies in which only macroscopic assessment was performed[25,37,48-53]
must be discarded. Some authors stress that IPH indicates only the severity of atherosclero‐
sis;[50,51,54-57] others suggest IPH has a direct role in pathogenesis of transient ischemic
attack or stroke. [25,35,44,46,57] When most studies are considered, the incidence of IPH in
symptomatic and asymptomatic disease spreads considerably In the symptomatic group,
incidence varied from 17% to 97%, compared with 2% to 91% in the asymptomatic group.
In  the  European  Carotid  Plaque  Study,  [58]  a  high  incidence  of  IPH  was  observed  in
symptomatic (94%) and asymptomatic (71%) groups A higher incidence of IPH was reported
in patients without symptoms.[55,59,60] Lennihan et al[54] scored the occurrence of IPH
only in patients with symptoms, and found ipsilateral symptoms in 57% of patients with
IPH and 65% of patients without IPH, indicating little difference between the two groups.
IPH seems to be more common in plaques causing high-grade stenosis.[47,54,55] Carr et
al[52]  found patients  with  symptomatic  plaques  to  have  more  frequent  plaque  rupture,
fibrous cap thinning, and cap foam cell infiltration, compared with patients with asympto‐
matic plaques. IPH was also seen in all specimens from symptomatic specimens and in 68%
of asymptomatic specimens. However, this study included too few patients to be signifi‐
cant. Despite a close relationship between IPH and symptoms,[37,61-63] and carotid plaque
rupture, thrombosis, and symptoms, [25,60,61] it has also been claimed that patients with
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symptomatic plaques typically have large necrotic cores within the carotid arteries.[31] Some
studies indicate that the association of complicated plaque and symptomatic disease does
not exist.[55,62-64] It  is  conceivable that patients presumed to have no symptoms might
have had embolic episodes and that  emboli  became impacted in silent  cerebral  areas or
occurred during sleep.[25,37,44,57] Also, symptoms may not be recalled by patients, who
are often elderly or frail. Of note, in a high-risk subgroup of patients with asymptomatic
carotid stenosis the annual stroke rate was more than 4%.[33] Inzitari et al[10] confirmed
that cardioembolic and small  vessel  stroke can occur,  in addition to large vessel  athero‐
thrombotic  stroke,  in  patients  with  asymptomatic  carotid  stenosis.  Finally,  NASCET[3]
demonstrated that most carotid strokes occur without warning symptoms, and only 5% to
15%  of  patients  have  a  transient  ischemic  attack  as  an  impending  symptom  of  stroke.
Nevertheless  nowadays  carotid  endarterectomy or  stenting  should  not  be  performed in
asymptomatic  patients  except  those  in  which  some  clinical  conditions  are  present,  as
recommended by the American Heart Association/American Stroke Association. [65]
Patients with asymptomatic carotid artery stenosis should be screened for other treatable
risk factors for stroke with institution of appropriate lifestyle changes and medical therapy
(Class I; Level of Evidence C).
1. Selection of asymptomatic patients for carotid revascularization should be guided by an
assessment of comorbid conditions and life expectancy, as well as other individual factors,
and should include a thorough discussion of the risks and benefits of the procedure with
an understanding of patient preferences (Class I; Level of Evidence C).
2. The use of aspirin in conjunction with carotid endarterectomy (CEA) is recommended
unless contraindicated because aspirin was used in all of the cited trials of CEA as an
antiplatelet drug (Class I; Level of Evidence C).
3. Prophylactic CEA performed with <3% morbidity and mortality can be useful in highly
selected patients with an asymptomatic carotid stenosis (minimum 60% by angiography,
70% by validated Doppler ultrasound) (Class IIa; Level of Evidence A). It should be noted
that the benefit of surgery may now be lower than anticipated based on randomized trial
results, and the cited 3% threshold for complication rates may be high because of interim
advances in medical therapy.
4. Prophylactic carotid artery stenting (CAS) might be considered in highly selected patients
with an asymptomatic carotid stenosis (≥60% on angiography, ≥70% on validated Doppler
ultrasonography, or ≥80% on computed tomographic angiography or MRA if the stenosis
on ultrasonography was 50% to 69%). The advantage of revascularization over current
medical therapy alone is not well established (Class IIb; Level of Evidence B).
5. The usefulness of CAS as an alternative to CEA in asymptomatic patients at high risk for
the surgical procedure is uncertain (Class IIb; Level of Evidence C).
6. Population screening for asymptomatic carotid artery stenosis is not recommended (Class
III; Level of Evidence B).
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Other points to consider is the necessity of interventionally treating an asymptomatic carotid
artery disease are: age 80 years or less, life expectancy higher tan 5 years, hemispheric
hypoperfusion, significant intracerebral vascular disease,unstable carotid plaque, rapid
progression of the stenoses, presence of silent cerebral infarcts, neck radiotherapy and the
necessity of a coronary by pass surgery. [66-74]
As it can be seen, up to date criterium for percentage stenoses in this group of patients are
higher than in the ACAS study (60%). [75]
Finally and taking into consideration the mechanisms of atherosclerosis: cells component
behavior, IPH, biology and gene expression, it can be seen in the literature a new tendency of
treatment in animal models. However, attention should therefore focus on the processes of
plaque breakdown andt hrombus formation in humans, whereas the use of animal models
should probably be reserved for studying the function of particular genes and for investigating
isolated features of plaques,such as the relationshipbetween cap thickness and plaque stability.
[76] In this connection, Peter et al [77] described a ApoE(-/-) mice mouse model reflecting
human atherosclerotic plaque instability in which atorvastatinwas used aimed at preventing
plaque rupture. They concluded that distinctly expressed genes andmicroRNAscan be linked
to plaque instability.On the other hand, Forte et al described the role of polyamines in reducing
carotid arteriotomy-induced (re)stenosis s in vitro and in a rat model suggesting a novel
therapeutic approach for this pathophysiological process. [78]
3. Plaque morphology
The atherosclerotic process in the carotid arteries begins with a thickening of the intima-media
complex and, according to factors of disease progression can reach arterial occlusion, through‐
out intermediate stages of mild, moderate and severe stenosis. Moreover, depending on
several factors, the structure of the plaque can show different evolutionary behaviors, from
simple stable plaque, fibrotic, and non stenotic, to that hemorrhagic, ulcerated, with rupture
that produces severe stenosis and strokes. Carotid risk factors are identical to those mentioned
for coronary disease.[79,80]
3.1. Correlation between plaque morphology and cerebral symptoms
The incidence of cerebrovascular events depends primarily on the degree of carotid stenosis
but plaque structure is also relevant, as well as the speed of progression of plaque, and
consequent carotid disease stenosis and also the presence of systemic thrombogenic factors.
[81-83]
Several studies have described a good correlation between intraplaque hemorrhage (IPH) with
ulceration and cerebrovascular symptoms.[25,53] According to Bluth the plaque structure is
even more important than the degree of stenosis, in predicting neurologic events. [84]
Bearing in mind than more than 40 % of the patients with transient ischemic attacks later may
suffer a stroke some authors believe that these stroke occur because plaques with IPH are
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unstable.[25,28,53] Embolization of fibrin and platelets and/or atherosclerotic material from
the plaque itself will continue.
As was mentioned, Geroulakos et al[81] classified ultrasonographic carotid plaques in 5
different types of stenosis, and correlated plaque type with symptomatology (not with
pathology), showing the predominance of echolucent plaques in symptomatic patients with
stenosis > 70 percent (see below) From the histologic point of view it was found that 50 % of
the IPH had connections with the lumen while 20 % had not.[30] Lusby et al[25] showed that
"haemorrhage in carotid atheromatous plaques plays a unique and major role in the develop‐
ment of cerebrovascular disease". IPH was not only identified in most symptomatic patients
but also a close relationship was established between the onset of symptoms and the presence
of plaque haemorrhage. Seeger et al[81-85] reported that the composition of plaques from
symptomatic patients is significantly different from those asymptomatic. The former contains
more total lipid and cholesterol, and less collagen and calcium.
Johnson et al [86] classified asymptomatic plaques according to ultrasonographic characteris‐
tics into calcified, dense and soft. At the end of a 3 year follow-up a large proportion of
asymptomatic patients with soft plaques had become symptomatic, while a small proportion
of those with calcified plaques have developed symptoms. Hennerici et al [87] reported that
patients with fibrous carotid plaques had a tendency to remain stable while plaque progression
was common in those with soft and complex calcified plaques. Spontaneous regression of
minor carotid atheroma occurred in soft plaques corresponding to a reduction in plaque
volume while fibrous and calcified plaques did not regress. [87]
Despite that currently the presence of symptoms and percentage of luminal narrowing remain
the most useful predictors of transitory ischemic cerebral attacks or stroke risk, [3,75,88,89]
there is a body of evidence that plaque morphology is crucial in the development of its natural
history.
Regarding the relationship of IPH with a higher prevalence of symptoms or hemorrhagic
stroke, the results are contradictory. [23-64] However, current guidelines recommend report‐
ing the plaque structure in question and that in occasions define therapeutic behaviors. [82-83]
There are several reasons that make knowledge of plaques structure very important. It is well
known that fibrous plaques, are predominantly collagen in content, showing a highly echo‐
genic quality and being generally homogeneous in texture. When lipid content of the plaque
increased, the plaque turns more echolucent. [84] Complex plaques protrude more frequently
into the lumen presenting high incidence of surface irregularities and ulcers. [60] Several
authors found that the incidence of IPH, histologically assessed, in symptomatic carotid
stenosis is higher than 90 %. [25,44,53,99] Imparato et al, prospectively studied 376 carotid
artery plaques concluding that IPH was strongly associated with the presence of cerebrovas‐
cular symptoms and it was the main characteristic of the carotid plaque that correlated
statistically with the presence of symptoms. [44] O´Donnel theorized that IPH is the most
common morphologic characteristic in symptomatic patients. [60]
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Other points to consider is the necessity of interventionally treating an asymptomatic carotid
artery disease are: age 80 years or less, life expectancy higher tan 5 years, hemispheric
hypoperfusion, significant intracerebral vascular disease,unstable carotid plaque, rapid
progression of the stenoses, presence of silent cerebral infarcts, neck radiotherapy and the
necessity of a coronary by pass surgery. [66-74]
As it can be seen, up to date criterium for percentage stenoses in this group of patients are
higher than in the ACAS study (60%). [75]
Finally and taking into consideration the mechanisms of atherosclerosis: cells component
behavior, IPH, biology and gene expression, it can be seen in the literature a new tendency of
treatment in animal models. However, attention should therefore focus on the processes of
plaque breakdown andt hrombus formation in humans, whereas the use of animal models
should probably be reserved for studying the function of particular genes and for investigating
isolated features of plaques,such as the relationshipbetween cap thickness and plaque stability.
[76] In this connection, Peter et al [77] described a ApoE(-/-) mice mouse model reflecting
human atherosclerotic plaque instability in which atorvastatinwas used aimed at preventing
plaque rupture. They concluded that distinctly expressed genes andmicroRNAscan be linked
to plaque instability.On the other hand, Forte et al described the role of polyamines in reducing
carotid arteriotomy-induced (re)stenosis s in vitro and in a rat model suggesting a novel
therapeutic approach for this pathophysiological process. [78]
3. Plaque morphology
The atherosclerotic process in the carotid arteries begins with a thickening of the intima-media
complex and, according to factors of disease progression can reach arterial occlusion, through‐
out intermediate stages of mild, moderate and severe stenosis. Moreover, depending on
several factors, the structure of the plaque can show different evolutionary behaviors, from
simple stable plaque, fibrotic, and non stenotic, to that hemorrhagic, ulcerated, with rupture
that produces severe stenosis and strokes. Carotid risk factors are identical to those mentioned
for coronary disease.[79,80]
3.1. Correlation between plaque morphology and cerebral symptoms
The incidence of cerebrovascular events depends primarily on the degree of carotid stenosis
but plaque structure is also relevant, as well as the speed of progression of plaque, and
consequent carotid disease stenosis and also the presence of systemic thrombogenic factors.
[81-83]
Several studies have described a good correlation between intraplaque hemorrhage (IPH) with
ulceration and cerebrovascular symptoms.[25,53] According to Bluth the plaque structure is
even more important than the degree of stenosis, in predicting neurologic events. [84]
Bearing in mind than more than 40 % of the patients with transient ischemic attacks later may
suffer a stroke some authors believe that these stroke occur because plaques with IPH are
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unstable.[25,28,53] Embolization of fibrin and platelets and/or atherosclerotic material from
the plaque itself will continue.
As was mentioned, Geroulakos et al[81] classified ultrasonographic carotid plaques in 5
different types of stenosis, and correlated plaque type with symptomatology (not with
pathology), showing the predominance of echolucent plaques in symptomatic patients with
stenosis > 70 percent (see below) From the histologic point of view it was found that 50 % of
the IPH had connections with the lumen while 20 % had not.[30] Lusby et al[25] showed that
"haemorrhage in carotid atheromatous plaques plays a unique and major role in the develop‐
ment of cerebrovascular disease". IPH was not only identified in most symptomatic patients
but also a close relationship was established between the onset of symptoms and the presence
of plaque haemorrhage. Seeger et al[81-85] reported that the composition of plaques from
symptomatic patients is significantly different from those asymptomatic. The former contains
more total lipid and cholesterol, and less collagen and calcium.
Johnson et al [86] classified asymptomatic plaques according to ultrasonographic characteris‐
tics into calcified, dense and soft. At the end of a 3 year follow-up a large proportion of
asymptomatic patients with soft plaques had become symptomatic, while a small proportion
of those with calcified plaques have developed symptoms. Hennerici et al [87] reported that
patients with fibrous carotid plaques had a tendency to remain stable while plaque progression
was common in those with soft and complex calcified plaques. Spontaneous regression of
minor carotid atheroma occurred in soft plaques corresponding to a reduction in plaque
volume while fibrous and calcified plaques did not regress. [87]
Despite that currently the presence of symptoms and percentage of luminal narrowing remain
the most useful predictors of transitory ischemic cerebral attacks or stroke risk, [3,75,88,89]
there is a body of evidence that plaque morphology is crucial in the development of its natural
history.
Regarding the relationship of IPH with a higher prevalence of symptoms or hemorrhagic
stroke, the results are contradictory. [23-64] However, current guidelines recommend report‐
ing the plaque structure in question and that in occasions define therapeutic behaviors. [82-83]
There are several reasons that make knowledge of plaques structure very important. It is well
known that fibrous plaques, are predominantly collagen in content, showing a highly echo‐
genic quality and being generally homogeneous in texture. When lipid content of the plaque
increased, the plaque turns more echolucent. [84] Complex plaques protrude more frequently
into the lumen presenting high incidence of surface irregularities and ulcers. [60] Several
authors found that the incidence of IPH, histologically assessed, in symptomatic carotid
stenosis is higher than 90 %. [25,44,53,99] Imparato et al, prospectively studied 376 carotid
artery plaques concluding that IPH was strongly associated with the presence of cerebrovas‐
cular symptoms and it was the main characteristic of the carotid plaque that correlated
statistically with the presence of symptoms. [44] O´Donnel theorized that IPH is the most
common morphologic characteristic in symptomatic patients. [60]
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3.2. B-mode ultrasound and pathology correlation
In the 80´s, several authors attempted to describe plaque morphology and the presence of
ulceration by ultrasonographic imaging. However, results were not convincing [90,91]. Other
authors mentioned only relevant the percentage of carotid stenosis [92,93].
The accuracy of the carotid ultrasonography procedure in assessing the percentage of luminal
diameter narrowing is well established [94,95].Percentage of stenosis has been the main point
of interest for noninvasive carotid testing due to its correlation with stroke risk.[96,97]
Developed technics in ultrasound (US) permit a more detailed analysis and accurate informa‐
tion about the plaque morphology. This technique is useful to evaluate the natural history and
the stroke risk associated to the lesions.
High-resolution B-mode ultrasonography (B-mode) seems advantageous over arteriography
for characterizing atherosclerotic plaque. [53] The method can identify those lesions that place
the patient at risk for transient ischemic attacks.
It was suggested that echolucent plaques have increased lipid and cholesterol levels, making
them unstable and prone to rupture and hemorrhage. On the other hand, the echogenic plaques
which contain significantly more fibrin and collagen are more stable and therefore less likely
to cause complications. [81,85] There is a paper correlating these two ultrasonic types of
plaques with whole frontal and/or transverse histological sections, correlating the B mode
ultrasonographic diagnosis of at carotid arteries with their respective pathological examina‐
tions assessing US accuracy. [98]
According to Lehay, [99] Bluth, [84] Goes [100] and the recommendations from the Commit‐
tee on Standards in Non - invasive Vascular Testing, [101] carotid plaques were classified as
homogeneous or heterogeneous. But these two groups arose from categorizing the plaques into
4 types according to the scale of l to 4 based on the Geroulakos' classification [81]. In this
classification, Type 1 corresponded to uniformly sonolucent; type 2, predominantly sonolu‐
cent; type 3 predominantly echogenic and type 4 uniformly echogenic. In this way types l and
2 corresponded to heterogeneous plaques and types 3 and 4 to homogeneous plaques. (Figures
13 and 14)
The analysis of the complex plaque structure regards defining histological types [98]:
• Thrombus, described “a brightly eosinophilic mass of compacted fibrin and degenerating
erythrocytes sometimes accompanied by evidence of organization".
• Ruptured plaque was defined as "disruption of the fibrous cap of a lesion that provoked
exposure of the thrombogenic lipid core region to the flowing blood and was classified
histologically as an irregular plaque surface with breaks in of loss of the fibrous cap often
associated with surface thrombus directly overlying the lipid~rich necrotic core of the
lesion"[26]
• Inflammation was described as chronic inflammatory infiltrates (lymphocytes, histiocytes,
macrophages and mast cells) within the plaque itself. Hemorrhage was identified by a
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macroscopic hematoma within the arterial wall with or without extension through the
luminal surface.
• Hemorrhage is identified by disruption of red blood cells and macrophage engulfment of
hemosiderin, to distinguish it from surgical related hemorrhage consisting in preserved
erythrocytes.
Figure 13. Panels A and B correspond to type 1 plaques-. The arrows indicate fully anechoic stenotic plaques which
may correspond to fatty tissue and / or blood which indicate the instability of the same. Panel C Carotid plaque type 2
showing dense echoes (white color) alternating with most hypoechoic or anechoic areas(in black) which indicate pla‐
que instability
Figure 14. Panel A: it can be seen between arrows a carotid plaque containing predominantly echogenic areas (type
3 )that generally correspond to fibrous tissue which gives it stability Panel B.This carotid plaque (type 4) is practically
composed by echogenic areas (between arrows).
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cent; type 3 predominantly echogenic and type 4 uniformly echogenic. In this way types l and
2 corresponded to heterogeneous plaques and types 3 and 4 to homogeneous plaques. (Figures
13 and 14)
The analysis of the complex plaque structure regards defining histological types [98]:
• Thrombus, described “a brightly eosinophilic mass of compacted fibrin and degenerating
erythrocytes sometimes accompanied by evidence of organization".
• Ruptured plaque was defined as "disruption of the fibrous cap of a lesion that provoked
exposure of the thrombogenic lipid core region to the flowing blood and was classified
histologically as an irregular plaque surface with breaks in of loss of the fibrous cap often
associated with surface thrombus directly overlying the lipid~rich necrotic core of the
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• Hemorrhage is identified by disruption of red blood cells and macrophage engulfment of
hemosiderin, to distinguish it from surgical related hemorrhage consisting in preserved
erythrocytes.
Figure 13. Panels A and B correspond to type 1 plaques-. The arrows indicate fully anechoic stenotic plaques which
may correspond to fatty tissue and / or blood which indicate the instability of the same. Panel C Carotid plaque type 2
showing dense echoes (white color) alternating with most hypoechoic or anechoic areas(in black) which indicate pla‐
que instability
Figure 14. Panel A: it can be seen between arrows a carotid plaque containing predominantly echogenic areas (type
3 )that generally correspond to fibrous tissue which gives it stability Panel B.This carotid plaque (type 4) is practically
composed by echogenic areas (between arrows).
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Plaque morphology analyzed by US, identifying those unstable or complicated plaques found
a very good correlation unless calcium deposits exist. [98]
Ultrasonographically, calcium deposits are characterized by a highly echoreflective area with
acoustical shadowing masking the real plaque structure below, resulting in a worse correlation
between US and pathology.
Carotid plaques having calcium deposits correspond to a third classification (stable, unstable
and calcium), as their evolution can be unpredictable. The presence of "acoustic shadows" that
mask the true tissue structure is characteristic of this type of plaque on ultrasonography,
making morphological interpretation difficult. [81] (Figure 15)
Figure 15. A type 5 calcified carotid plaque significantly reduces the lumen in the carotid bulb (between small arrows)
The typically acoustic shadowing is clearly seen (big arrow)
In this sense, we published the results of an investigation showing ultrasonic vs pathologic
correlation of carotid atheromatous plaques. This manuscript involved two ultrasonographers
and one pathologist. [98] This work implied seventy-four carotid ultrasonographic studies
randomly selected from a registry of 250 carotid endarterectomy specimens. (Thirteen of them
had poor quality images and were excluded). The remaining 61 studies, belonging to 59
patients (2 bilateral endarterectomies) had been sent from five different laboratories and were
analyzed blindly and independently by two different observers. There were 17 females and
42 males. Age ranged from 52 to 83 years (mean 68 years). A very good interobserver corre‐
lation was observed and, in turn, with histopathological findings. However, calcium plaques
produced less agreement.
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In our research regarding interobserver agreement, there were 2 non-coincidences vs. 59
coincidences (efficacy 98%), K = 0.956, demonstrating very good agreement.
Regarding the strictly classification in heterogeneous, homogeneous and calcified plaques,
there were 59 coincidences, (96.7%) and 2 non-coincidences (3.3%), accuracy 98 %, K = 0.95
(very good agreement).
Coincidences not always were total. If we consider the fourth group in which operators agreed
in plaques being heterogeneous but with difficulties in distinguishing IPH, calcium and lipids
as non-coincidences, then the accuracy falls to 88.5 %.
When we considered agreement between observers and pathologist and taking into consid‐
eration the overall results from both observers, there was an agreement of 84% with the
pathologist. When calcified plaques were not considered it is expected with 95% of confidence
that US will agree with pathology in 70-93% of the cases (CI0,95).
When calcified plaques were considered, the percentage of coincidence fell to 67% (CI 0,95
54-79%). In others words calcified plaques clearly blurred the diagnosis of plaque structure.
Operator l had an agreement of 67% with 18% of calcified plaques. Operator 2 had an agree‐
ment of 79% with 8% of calcified plaques.
Regarding the coincidence of IPH between B - mode and pathology, operator 1 had an
agreement of 50% (11/22) while operator 2 agreed in 65 % of the cases (11 / l7). The pathologist
diagnosed IPH in 33 cases, therefore both observers, together were able to detect IPH in only
l / 3 of the cases.
This investigation has correlated the ultrasound aspect of carotid atheromatous plaques with
pathology demonstrating the highest incidence of intraplaque hemorrhage (IPH) in those
complex, irregular and heterogeneous producing stenosis 98. (Figure 16)
Figure 16. A.Two dimensional and color ultrasound image displays a very tight stenosis (between arrows) caused by
an anechoic plaque (large arrow) B. The corresponding gross morphology shows an irregular stenotic plaque com‐
posed by a brownish tissue (arrow). C. Microscopically this plaque belongs to an intraplaque hemorrhage (arrow).
Mallory Trichrome
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Plaque morphology analyzed by US, identifying those unstable or complicated plaques found
a very good correlation unless calcium deposits exist. [98]
Ultrasonographically, calcium deposits are characterized by a highly echoreflective area with
acoustical shadowing masking the real plaque structure below, resulting in a worse correlation
between US and pathology.
Carotid plaques having calcium deposits correspond to a third classification (stable, unstable
and calcium), as their evolution can be unpredictable. The presence of "acoustic shadows" that
mask the true tissue structure is characteristic of this type of plaque on ultrasonography,
making morphological interpretation difficult. [81] (Figure 15)
Figure 15. A type 5 calcified carotid plaque significantly reduces the lumen in the carotid bulb (between small arrows)
The typically acoustic shadowing is clearly seen (big arrow)
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lation was observed and, in turn, with histopathological findings. However, calcium plaques
produced less agreement.
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(very good agreement).
Coincidences not always were total. If we consider the fourth group in which operators agreed
in plaques being heterogeneous but with difficulties in distinguishing IPH, calcium and lipids
as non-coincidences, then the accuracy falls to 88.5 %.
When we considered agreement between observers and pathologist and taking into consid‐
eration the overall results from both observers, there was an agreement of 84% with the
pathologist. When calcified plaques were not considered it is expected with 95% of confidence
that US will agree with pathology in 70-93% of the cases (CI0,95).
When calcified plaques were considered, the percentage of coincidence fell to 67% (CI 0,95
54-79%). In others words calcified plaques clearly blurred the diagnosis of plaque structure.
Operator l had an agreement of 67% with 18% of calcified plaques. Operator 2 had an agree‐
ment of 79% with 8% of calcified plaques.
Regarding the coincidence of IPH between B - mode and pathology, operator 1 had an
agreement of 50% (11/22) while operator 2 agreed in 65 % of the cases (11 / l7). The pathologist
diagnosed IPH in 33 cases, therefore both observers, together were able to detect IPH in only
l / 3 of the cases.
This investigation has correlated the ultrasound aspect of carotid atheromatous plaques with
pathology demonstrating the highest incidence of intraplaque hemorrhage (IPH) in those
complex, irregular and heterogeneous producing stenosis 98. (Figure 16)
Figure 16. A.Two dimensional and color ultrasound image displays a very tight stenosis (between arrows) caused by
an anechoic plaque (large arrow) B. The corresponding gross morphology shows an irregular stenotic plaque com‐
posed by a brownish tissue (arrow). C. Microscopically this plaque belongs to an intraplaque hemorrhage (arrow).
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Correlation with histology shows that lipid rich regions are the least echogenic on US and
calcified areas are the most. [81,98] Dense collagen is also very echogenic not associated with
acoustic shadowing. For example O´Donnel [60] emphasized that plaque haemorrhage could
be differentiated from lipid-laden plaque because the former was more irregular, echolucent,
frequently associated with irregular borders, and randomly distributed through the plaque
producing a non-homogeneous texture. The surface of the plaque with hemorrhage is usually
irregular and ulcerated. Surface ulceration is unusual in lipid plaques. By contrast, plaque
hemorrhage produces an echolucent area within the plaque, in which its degree may be
correlated with the age of hemorrhage. [60]
The anechoic or highly echolucent qualities of fresh hemorrhage are comparable with those of
the lumen, being irregular and randomly distributed through the plaque (heterogeneous
shape).
On the other hand, Bluth et al [84] found that the incidence of IPH in theheterogeneous type
was 81 % vs. 3 % in the homogeneous plaques. Thus, the sensitivity and specificity of US to
detect this lesion was 94 % and 88 % respectively.
Ultrasonography fails in detecting plaque ulceration even using color-flow Doppler assisted
duplex, as was recently demonstrated by Sitzer et al. [102]
Hartmann et al [103] reported poor results between US and pathology concluding that visual
assessment of B-mode images is not reliable. Lehay et al [99] found that plaques that caused a
narrowing greater than 50% in the carotid lumen were more likely to be heterogeneous,
suggesting that plaque appearance is a more relevant finding on preoperative duplex scanning
than the percentage of carotid narrowing.
Taking all these concepts into consideration, decreased echogenicity would correspond either
to lipid deposits or to hemorrhage within a plaque being both of them characteristic of
instability. Lipid deposits appear more uniform and are less randomly distributed throughout
the plaque.
Julian et al [104] divided plaques into two categories: "simple" composed of fibrous material
and that do not generally cause stenosis greater than 50 %, and "complex" consisting of an
atherosclerotic material, calcified deposits, surface fibrin, platelet material and hemorrhagic
areas.
The European Carotid Plaque Study Group [105] correlated B-mode imaging studies with
histology in 270 patients undergoing carotid endarterectomy. They concluded that US
appearance of carotid plaque is related to histological composition being the echogenicity
inversely related to the relative amount of soft tissue.
Backscattered radiofrequency derived signals devices have been applied for better character‐
ization of the different components of plaque structure[106-108].But this technique is more
expensive and not always available in most laboratories so we consider that conventional good
quality B-mode images allow a reliable differentiation between the three types of plaques.
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3.3. Magnetic resonance imaging – Patholgy correlation
Although carotid ulltrasound is the method of choice to study the structure of carotid plaques
MRI also plays a significant role. Singh et at, [109] in an interesting paper describing structural
MRI findings in 98 asymptomatic carotid arteries with moderate stenosis (50-70%) and
subsequent one year evolution to symptomatic status: 36 (36.7%) had IPH on NMR, with 6
cerebrovascular events, ie 16%, (2 stroke and 4 AIT) related to carotid IPH showed, compared
to the absence of events in the carotid without IPH. Their statistical analyzes confirmed that
the detection of IPH on NMR was associated with an increased risk of cerebrovascular events.
In another relevant work involving MRI, Cheung et al [110] investigated the presence of IPH
in the carotid arteries of 217 patients who had symptomatic stenosis less than 50%. IPH was
detected in 13% related to the hemisphere ipsilateral symptoms and 7% contralateral.
In summary, we believe necessary to describe and report the B-mode characteristic of carotid
plaques together with the percentage of luminal stenosis. Ultrasonic plaque description
correlates with histogy. The adoption of plaque characterization despite of the degree of
carotid stenosis would allow recognition of a high-risk subset of patients that may benefit from
carotid intervention.
4. Carotid artery dolichoarteriopathies
Atherosclerosis is the most frequent cause of extracranial carotidartery disease. [111] However,
although atheromatous pathology of the carotid bulb and bifurcation is a major causes of
stroke, other causes of carotid disease may also cause vessel occlusion, such as fibrodysplasia,
trauma (with subsequent dissection of carotid arteries), aortic arch pathology as in Takayasu
disease, and aortic dissection. [112]
Among nonatheromatous alterations of the carotid arteries, interest has long been placed on
specific anatomical abnormalities called dolichoarteriopathies.
Carotid dolichoarteriopathies can be classified into three different types [113](Figure 17).Type
1: tortuosity – a nonrectilinear stretch of an artery with an angulation >90; type 2: loop – a 360
angulation of an artery on its transverse axis (‘‘coil’’ configuration) (Figure 18); type 3: kinking
– the inflection of 2 or more segments of an artery with an internal angle of 90° or less. (Figures
19 and 20).
Dolichoarteriopathies of carotid arteries are frequent, ranging between 10% and 45%. [114] For
type 3, a prevalence of 5% to 25% has been described.[115,116]
Published studies have reached disparate conclusions with regard to the origin or cause of
carotid dolichoarteriopathies, as well as their hemodynamic and prognostic significance.
[114-119] Mukherjee and Inahara [119] proposed that carotid kinking would induce turbulent
flow, thus favoring intimal ulceration, platelet deposition, and distal thrombus embolism.
Other investigators similarly believe that a causal connection exists between cerebral flow
alteration and severe carotid dolichoarteriopathies, to the point of proposing surgical correc‐
tion of kinking and coiling to prevent stroke. [14,120,121]
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Correlation with histology shows that lipid rich regions are the least echogenic on US and
calcified areas are the most. [81,98] Dense collagen is also very echogenic not associated with
acoustic shadowing. For example O´Donnel [60] emphasized that plaque haemorrhage could
be differentiated from lipid-laden plaque because the former was more irregular, echolucent,
frequently associated with irregular borders, and randomly distributed through the plaque
producing a non-homogeneous texture. The surface of the plaque with hemorrhage is usually
irregular and ulcerated. Surface ulceration is unusual in lipid plaques. By contrast, plaque
hemorrhage produces an echolucent area within the plaque, in which its degree may be
correlated with the age of hemorrhage. [60]
The anechoic or highly echolucent qualities of fresh hemorrhage are comparable with those of
the lumen, being irregular and randomly distributed through the plaque (heterogeneous
shape).
On the other hand, Bluth et al [84] found that the incidence of IPH in theheterogeneous type
was 81 % vs. 3 % in the homogeneous plaques. Thus, the sensitivity and specificity of US to
detect this lesion was 94 % and 88 % respectively.
Ultrasonography fails in detecting plaque ulceration even using color-flow Doppler assisted
duplex, as was recently demonstrated by Sitzer et al. [102]
Hartmann et al [103] reported poor results between US and pathology concluding that visual
assessment of B-mode images is not reliable. Lehay et al [99] found that plaques that caused a
narrowing greater than 50% in the carotid lumen were more likely to be heterogeneous,
suggesting that plaque appearance is a more relevant finding on preoperative duplex scanning
than the percentage of carotid narrowing.
Taking all these concepts into consideration, decreased echogenicity would correspond either
to lipid deposits or to hemorrhage within a plaque being both of them characteristic of
instability. Lipid deposits appear more uniform and are less randomly distributed throughout
the plaque.
Julian et al [104] divided plaques into two categories: "simple" composed of fibrous material
and that do not generally cause stenosis greater than 50 %, and "complex" consisting of an
atherosclerotic material, calcified deposits, surface fibrin, platelet material and hemorrhagic
areas.
The European Carotid Plaque Study Group [105] correlated B-mode imaging studies with
histology in 270 patients undergoing carotid endarterectomy. They concluded that US
appearance of carotid plaque is related to histological composition being the echogenicity
inversely related to the relative amount of soft tissue.
Backscattered radiofrequency derived signals devices have been applied for better character‐
ization of the different components of plaque structure[106-108].But this technique is more
expensive and not always available in most laboratories so we consider that conventional good
quality B-mode images allow a reliable differentiation between the three types of plaques.
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3.3. Magnetic resonance imaging – Patholgy correlation
Although carotid ulltrasound is the method of choice to study the structure of carotid plaques
MRI also plays a significant role. Singh et at, [109] in an interesting paper describing structural
MRI findings in 98 asymptomatic carotid arteries with moderate stenosis (50-70%) and
subsequent one year evolution to symptomatic status: 36 (36.7%) had IPH on NMR, with 6
cerebrovascular events, ie 16%, (2 stroke and 4 AIT) related to carotid IPH showed, compared
to the absence of events in the carotid without IPH. Their statistical analyzes confirmed that
the detection of IPH on NMR was associated with an increased risk of cerebrovascular events.
In another relevant work involving MRI, Cheung et al [110] investigated the presence of IPH
in the carotid arteries of 217 patients who had symptomatic stenosis less than 50%. IPH was
detected in 13% related to the hemisphere ipsilateral symptoms and 7% contralateral.
In summary, we believe necessary to describe and report the B-mode characteristic of carotid
plaques together with the percentage of luminal stenosis. Ultrasonic plaque description
correlates with histogy. The adoption of plaque characterization despite of the degree of
carotid stenosis would allow recognition of a high-risk subset of patients that may benefit from
carotid intervention.
4. Carotid artery dolichoarteriopathies
Atherosclerosis is the most frequent cause of extracranial carotidartery disease. [111] However,
although atheromatous pathology of the carotid bulb and bifurcation is a major causes of
stroke, other causes of carotid disease may also cause vessel occlusion, such as fibrodysplasia,
trauma (with subsequent dissection of carotid arteries), aortic arch pathology as in Takayasu
disease, and aortic dissection. [112]
Among nonatheromatous alterations of the carotid arteries, interest has long been placed on
specific anatomical abnormalities called dolichoarteriopathies.
Carotid dolichoarteriopathies can be classified into three different types [113](Figure 17).Type
1: tortuosity – a nonrectilinear stretch of an artery with an angulation >90; type 2: loop – a 360
angulation of an artery on its transverse axis (‘‘coil’’ configuration) (Figure 18); type 3: kinking
– the inflection of 2 or more segments of an artery with an internal angle of 90° or less. (Figures
19 and 20).
Dolichoarteriopathies of carotid arteries are frequent, ranging between 10% and 45%. [114] For
type 3, a prevalence of 5% to 25% has been described.[115,116]
Published studies have reached disparate conclusions with regard to the origin or cause of
carotid dolichoarteriopathies, as well as their hemodynamic and prognostic significance.
[114-119] Mukherjee and Inahara [119] proposed that carotid kinking would induce turbulent
flow, thus favoring intimal ulceration, platelet deposition, and distal thrombus embolism.
Other investigators similarly believe that a causal connection exists between cerebral flow
alteration and severe carotid dolichoarteriopathies, to the point of proposing surgical correc‐
tion of kinking and coiling to prevent stroke. [14,120,121]
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Conversely,other authors consider carotid dolichoarteriopathies as a mere anatomical variety,
devoid of clinical consequences. [122]
Establishing the clinical impact of dolichoarteriopathies is further complicated by the fact that
the mechanisms responsible for their formation are still debated.
Figure 17. The different types of dolichoarteriopathies, according to the definition of Weibel and Fields.
Figure 18. Color flow Doppler imaging shows circular-shaped internal carotid artery
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Figure 19. A: Color flow Doppler imaging discloses an internal carotid artery kinking.B: Color and pulsed-wave Dop‐
pler showed turbulences at the site of the kinking. However, both maximum systolic velocity and end-diastolic velocity
of internal carotid arteries were substantially unaffected by kinking
Figure 20. A double angled internal carotid artery showing a S shaped configuration (image corresponding to color
Doppler ultrasound)
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Conversely,other authors consider carotid dolichoarteriopathies as a mere anatomical variety,
devoid of clinical consequences. [122]
Establishing the clinical impact of dolichoarteriopathies is further complicated by the fact that
the mechanisms responsible for their formation are still debated.
Figure 17. The different types of dolichoarteriopathies, according to the definition of Weibel and Fields.
Figure 18. Color flow Doppler imaging shows circular-shaped internal carotid artery
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Figure 19. A: Color flow Doppler imaging discloses an internal carotid artery kinking.B: Color and pulsed-wave Dop‐
pler showed turbulences at the site of the kinking. However, both maximum systolic velocity and end-diastolic velocity
of internal carotid arteries were substantially unaffected by kinking
Figure 20. A double angled internal carotid artery showing a S shaped configuration (image corresponding to color
Doppler ultrasound)
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4.1. Origin of carotid dolichoarteriopathies — Congenital or acquired?
One theory maintains that they are pathological alterations caused by arterial aging and/or
changes induced by atherosclerotic remodeling, which would cause the vessel to bend,
[114,123-126] while other reports do not support an association between dolichoarteriopathies
and cardiovascular risk status. [122,127,128] Alternatively, it has therefore been postulated that
they have an embryological origin. Indeed, Kelly [129] observed that carotid arteries may be
kinked or show loops at some point during intrauterine development, when the descent
toward the mediastinum occurs enabling the union of the third aortic arch with the dorsal
aorta.
Obviously, as these 2 etiological theories are so different from each other, they may also entail
different implications both clinically and prognostically. Part of the uncertainty derives from
the fact that previous observations had been made in small studies or in selected populations.
[122-128] Therefore, it would be important to establish which theory has more solid basis.
Prevalence varies according to different diagnostic methodology and patients’ inclusion
criteria, but in aggregate they concur to indicate that this is a rather frequent finding. In
contrast, lack of consensus exists over the clinical and prognostic significance of these altera‐
tions or even about their etiology. Much of the controversy revolves around a ‘‘nature- or-
nurture’’ type of issue, that is, whether carotid dolichoarteriopathies develop late in life as a
manifestation of vessel remodeling, particularly in individuals at risk of atherosclerosis, or
rather they originate from alterations of embryological development.
With regard to the possibility that dolichoarteriopathies may be the result of a degenerative
process, over the years several hypotheses have been put forward trying to explain how they
may develop. Some of these seem quite unlikely, such as the possibility that carotid kinking
could be due to kyphosis or lordosis of the spine, which might deviate the carotid axis, [130]
or that inflammation of the tissues around the carotid arteries would cause them to retract.
[131] Other investigators have proposed that arterial hypertension would produce alterations
in the wall over time, which would favor its weakening withsubsequent kinking of the artery,
[121-123] while other authors hypothesized a relationship between aging and arterial ana‐
tomical abnormalities. [114,126]
Data gathered in modern times also do not help in establishing firm conclusions. Two rather
large reports by Ghilardi et al [125] and Del Corso et al [132] described a great prevalence of
hypertension and atherosclerosis in patients with carotid dolichoarteriopathies; however, both
studies lack a group of normal participants, and deal with a population of patients selected
for vascular pathology, and in whom predominance of such cardiovascular risk factors is
expected. Pancera et al [127] have reported an association between carotid artery kinking and
age and with hypertension as well. However, in that study, prevalence of carotid abnormalities
was actually identical across the age groups from 60 to>80 years, which represented 87% of
their cohort: younger patients, in whom prevalence was apparently lower, were instead too
few to make a solid comparison. This same reasoning applies to the effect of hypertension
reported in that study, which was actually based on about a dozen patients. [127]
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The possibility that carotid dolichoarteriopathies may have an embryological origin had also
been suggested in the past. Again, however, those reports were not conclusive. Sometimes,
this was because of the small numbers of cases studied. In this respect, Weibel and Fields [113]
described at angiography 14 cases of anatomical abnormalities in patients aged between1 and
20 years, while Sarkari et al [133] reported 8 children (aged 9 months to 16 years) with
symptomatic carotid kinkings and coilings. In a substantially largerstudy, there may have been
a selection bias [134] in that case, 282 angiographies of neck vessels were obtainedin patients
aged between 6 months and 82 years. The authors found that prevalence ofcarotid abnormal‐
ities in adults was 24% and even greater (43%) in children. Although that finding may
seemingly support the view that in fact there is no association with aging and that dolichoar‐
teriopathies have an embryological origin, the significance of such a high frequence in children
might have been restricted to the peculiar population studied, as it is quite conceivable that
children who were subjected to an invasive procedure such as angiography underwent it
because of a high clinical suspicion of carotid abnormalities.
Togay-Isikay et al,through noninvasive Doppler ultrasonography assessment, observed
carotid dolichoarteriopathies in 24.6% of a consecutive patient series, with no apparent relation
between carotid alterations and cardiovascular risk factors. [122] In 1924,Cairney [135] had
already reported autoptic findings in fetuses from the fifth month in whom morphological
carotid arteries abnormalitieswere observed. In this respect, it is important to notice that the
vascular wall in fetus develops from mesenchymal cells islets; in any artery, the tunica
muscularis develops first in the main trunk and later in its branches. The proximal portion of
the internal carotid artery originates from the third aortic arch while the more distal parts
originate from the left dorsal aorta. [130] Harrison and Dávalos [130] suggested that develop‐
ment of carotid arteries and of skeletal system might be asynchronous, the different velocity
explaining the tortuous path.Ochsner et al [136] proposed that fibromuscular dysplasia
occurring during fetal life, located in a sector of the carotid artery, would be responsible for
subsequent weakening and kinking of the wall at that level. Contrary to this specific hypoth‐
esis, however, is the fact that presence of fibromuscular dysplasia in areas with dolichoarter‐
iopathies is very rare.[137-139]
Regarding the issue of congenital or adquired condition of dolichoarteriopathies, our group
conducted an observational study involving 885 participants of either sex, aged between
newborn(4 hour 30 minutes) to 90 years old. [16]
Patients were divided into 2 groups (G): G1 (control, healthy participants) n = 245. It consisted
of infants, children, and adolescents up to 15 years of age (mean 6 + 3 years) from a town of 43
000 inhabitants just outside of Buenos Aires; these children participated in a voluntary
screening health program, approved by their parents, under the patronage of the local
municipality that was performed in the hospital and different schools. Group 2 (G2; n = 640)
consisted of patients from 16 to 90 years of age (mean 57+8 years) in whom diagnostic color
Doppler ultrasonography investigation of neck vessels had been requested for clinical
suspicion of atherosclerotic disease. Patients were assessed with regard to presence of
cardiovascular risk factors (hypertension, dyslipidemia, smoking). Presence of atheromatous
plaques in the regions affected by dolichoarteriopathies was also evaluated.
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they have an embryological origin. Indeed, Kelly [129] observed that carotid arteries may be
kinked or show loops at some point during intrauterine development, when the descent
toward the mediastinum occurs enabling the union of the third aortic arch with the dorsal
aorta.
Obviously, as these 2 etiological theories are so different from each other, they may also entail
different implications both clinically and prognostically. Part of the uncertainty derives from
the fact that previous observations had been made in small studies or in selected populations.
[122-128] Therefore, it would be important to establish which theory has more solid basis.
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criteria, but in aggregate they concur to indicate that this is a rather frequent finding. In
contrast, lack of consensus exists over the clinical and prognostic significance of these altera‐
tions or even about their etiology. Much of the controversy revolves around a ‘‘nature- or-
nurture’’ type of issue, that is, whether carotid dolichoarteriopathies develop late in life as a
manifestation of vessel remodeling, particularly in individuals at risk of atherosclerosis, or
rather they originate from alterations of embryological development.
With regard to the possibility that dolichoarteriopathies may be the result of a degenerative
process, over the years several hypotheses have been put forward trying to explain how they
may develop. Some of these seem quite unlikely, such as the possibility that carotid kinking
could be due to kyphosis or lordosis of the spine, which might deviate the carotid axis, [130]
or that inflammation of the tissues around the carotid arteries would cause them to retract.
[131] Other investigators have proposed that arterial hypertension would produce alterations
in the wall over time, which would favor its weakening withsubsequent kinking of the artery,
[121-123] while other authors hypothesized a relationship between aging and arterial ana‐
tomical abnormalities. [114,126]
Data gathered in modern times also do not help in establishing firm conclusions. Two rather
large reports by Ghilardi et al [125] and Del Corso et al [132] described a great prevalence of
hypertension and atherosclerosis in patients with carotid dolichoarteriopathies; however, both
studies lack a group of normal participants, and deal with a population of patients selected
for vascular pathology, and in whom predominance of such cardiovascular risk factors is
expected. Pancera et al [127] have reported an association between carotid artery kinking and
age and with hypertension as well. However, in that study, prevalence of carotid abnormalities
was actually identical across the age groups from 60 to>80 years, which represented 87% of
their cohort: younger patients, in whom prevalence was apparently lower, were instead too
few to make a solid comparison. This same reasoning applies to the effect of hypertension
reported in that study, which was actually based on about a dozen patients. [127]
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The possibility that carotid dolichoarteriopathies may have an embryological origin had also
been suggested in the past. Again, however, those reports were not conclusive. Sometimes,
this was because of the small numbers of cases studied. In this respect, Weibel and Fields [113]
described at angiography 14 cases of anatomical abnormalities in patients aged between1 and
20 years, while Sarkari et al [133] reported 8 children (aged 9 months to 16 years) with
symptomatic carotid kinkings and coilings. In a substantially largerstudy, there may have been
a selection bias [134] in that case, 282 angiographies of neck vessels were obtainedin patients
aged between 6 months and 82 years. The authors found that prevalence ofcarotid abnormal‐
ities in adults was 24% and even greater (43%) in children. Although that finding may
seemingly support the view that in fact there is no association with aging and that dolichoar‐
teriopathies have an embryological origin, the significance of such a high frequence in children
might have been restricted to the peculiar population studied, as it is quite conceivable that
children who were subjected to an invasive procedure such as angiography underwent it
because of a high clinical suspicion of carotid abnormalities.
Togay-Isikay et al,through noninvasive Doppler ultrasonography assessment, observed
carotid dolichoarteriopathies in 24.6% of a consecutive patient series, with no apparent relation
between carotid alterations and cardiovascular risk factors. [122] In 1924,Cairney [135] had
already reported autoptic findings in fetuses from the fifth month in whom morphological
carotid arteries abnormalitieswere observed. In this respect, it is important to notice that the
vascular wall in fetus develops from mesenchymal cells islets; in any artery, the tunica
muscularis develops first in the main trunk and later in its branches. The proximal portion of
the internal carotid artery originates from the third aortic arch while the more distal parts
originate from the left dorsal aorta. [130] Harrison and Dávalos [130] suggested that develop‐
ment of carotid arteries and of skeletal system might be asynchronous, the different velocity
explaining the tortuous path.Ochsner et al [136] proposed that fibromuscular dysplasia
occurring during fetal life, located in a sector of the carotid artery, would be responsible for
subsequent weakening and kinking of the wall at that level. Contrary to this specific hypoth‐
esis, however, is the fact that presence of fibromuscular dysplasia in areas with dolichoarter‐
iopathies is very rare.[137-139]
Regarding the issue of congenital or adquired condition of dolichoarteriopathies, our group
conducted an observational study involving 885 participants of either sex, aged between
newborn(4 hour 30 minutes) to 90 years old. [16]
Patients were divided into 2 groups (G): G1 (control, healthy participants) n = 245. It consisted
of infants, children, and adolescents up to 15 years of age (mean 6 + 3 years) from a town of 43
000 inhabitants just outside of Buenos Aires; these children participated in a voluntary
screening health program, approved by their parents, under the patronage of the local
municipality that was performed in the hospital and different schools. Group 2 (G2; n = 640)
consisted of patients from 16 to 90 years of age (mean 57+8 years) in whom diagnostic color
Doppler ultrasonography investigation of neck vessels had been requested for clinical
suspicion of atherosclerotic disease. Patients were assessed with regard to presence of
cardiovascular risk factors (hypertension, dyslipidemia, smoking). Presence of atheromatous
plaques in the regions affected by dolichoarteriopathies was also evaluated.
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Coiling prevalence was similar in healthy participants (G1 4%; n ¼ 10) and in patients (G2 3%;
n = 19; NS;). At the same time, kinking prevalence in G1 was 27% (n = 67), and it was 22% (n =
143) in G2, which did not show any statistically significant association either Atheromatous
plaques intrakinking were only observed in 3 G2 patients (0.47%). In this group, 56.2% of
patients presented carotid atherosclerotic disease. Within G2 patients, prevalence of cardio‐
vascular risk factors evaluated individually was similar when patients were divided according
to presence or absence of kinking and/or coiling.
We observed that the dolichoarteriopathies, namely, kinking and coiling of carotid arteries,
had similar frequency across all ages, from newborn infants to elderly individuals. Further‐
more, their prevalence was unrelated to the presence of cardiovascular risk factors or of frank
atherosclerotic pathology of carotid artery. Collectively, these findings suggest that carotid
dolichoarteriopathies are a result of alterations in embryological development rather than of
vascular remodeling secondary to aging and/or atherosclerosis. [16]
5. Hemodinamical behavior of dolichoarteriopathies: Ischemic or not?
As was previously mentioned, there a wide span of clinical consequences have been atributed
to the presence of carotid dolichoarteriopathies, ranging from asymptomatic carotid anatom‐
ical variety to carotid induced cerebral ischemia. [122] As referred, Mukherjee et al [119]
proposed that carotid kinking would generate distal thrombus embolism, by means of the
turbulent flow, intimal ulceration and platelet deposition. Surgical correction of kinking and
coiling carotid arteries has been proposed to prevent stroke. [14,121]
The prevalence of cerebrovascular symptoms in patients with carotid dolichoarteriopathies
varies between 15 and 23%. [140-141] But, there is not uniform criterion about the role of carotid
dolichoarteriopathies in the development of neurological symptoms. If dolichoarteriopathies
were certainly responsible for these events, cerebral ischemia could be demonstrated by
functional hemodynamic tests.
In 1997, Oliviero et al. [128] demonstrated, in 36 patients suffering from hypertension and with
kinks, that the percentage of neurological events was similar to the other 36 patients with
hypertension but without kinks. The same author published new results of the follow-up of
these patients, confirming the former conclusions as in the group of hypertensive patients with
kinkings there were 10 neurological events registered, whereas 14 occurred in the control
group (hypertensive patients without kinkings). [142]
Several previous papers [62,120,121,143-157] considered that carotid dolichoarteriopathies can
produce neurological symptoms and proposed surgery and furthermore, they describe
different surgical techniques.
A recent report of 7 kinkings of internal carotid arteries, defined five asymptomatic, one
syptomatic for odynophagia and another symptomatic for pharyngeal bulge considering that
no typical clinical symptoms were shown in the malformation of cervical segment of internal
carotid artery. Pharyngeal bulge with pulsation could be encountered.
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Grego et al. [156] assured that natural history of carotid dolichoarteriopathies is practically
unknown but in some cases surgery would be justified, such as: a) transient ischemic attack
(hemispheric symptoms); b) asymptomatic patients with a kinking angle less than 30° together
with contralateral carotid occlusion; c) patients with non-hemispheric symptoms after
evaluating that there were no other possible neurological or non-neurological causes through
positive results of the following studies: 1) Doppler ultrasonography of neck vessels with
increase in circulatory velocity; 2) computerized cerebral tomography and MRI angiography
of ischemic lesions in the ipsilateral hemisphere and 3) Inversion of the circulatory flow in the
anterior cerebral artery and its reduction in the middle cerebral artery, in both cases in relation
to the rotation and flexo-extension maneuvers of the head.
Recent papers regarding surgical intervention on carotid arteries kinking, totalizing roughly
150 patients, flaw to show convincing evidence on the benefits of intervention.[158-160]
Up to now, there are no guidelines nor is there consensus (with a level of recommendation)
for surgical treatment of dolichoarteriopathies.
Taking into account the pitfalls in measuring stenotic percentage in bended arteries, it is our
point of view that manuscripts reporting big number of operated patients with carotid
dolichoareriopathies failed in the diagnostic ultrasonographic criterions of stenotic kinkings
and coils, furthermore, there is no mention about which method for angiographic measures
were used. Also, most of their patients had cardiovascular risk factor which could have been
the responsible of the neurological symptoms remaining doubts about their true relation with
carotid abnormalities. [157,161]
Our group conducted an investigation study regarding the clinical implications in the genesis
of neurological complications related to kinking and looping (coiling) of the carotid arteries.
[162] Sixty patients with non-atheromatous carotid kinkings were subjected to head rotation
tests, and were studied by carotid artery B-mode, color Doppler ultrasonography, and
scanning the ophthalmic artery in order to assess the hemodynamic behavior of carotid
dolichoarteriopathies. Results suggested that carotid dolichoarteriopathies are not the cause
of neurological events or symptoms taking into account that no events were recorded during
the study, and registering significant reduction in the velocities in the ophthalmic artery in
only 3 of the 60 cases studied, in performing the head rotation tests.in the patient cohort. 23 %
(n=14) were asymptomatic as only 6 patients were referred for stroke or transient ischemic
attack. Consecuently we concluded that carotid dysembryoplasias, would not cause neuro‐
logical events nor symptoms.
Computerized tomography angiography (CTA) and magnetic resonance angiography (MRA)
showed excellent ability to depict the malformation of cervical segment of internal carotid
artery and its relationship with surrounding structures, which could protect carotid artery
from unintended damage. [163]
It may be concluded that dolichoartheriopathies recognize a congenital origin other than an
acquired condition, based on controlled studies regarding juvenile control cases. Additionally,
in the current state of knowledge, it unlikely appears that these dolichoartheriorpathies induce
relevant symptomatic cerebral ischemia
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6. Carotid sinus baroreceptor
The significance of the ability of the carotid sinus baroreceptor to sense and regulate blood
pressure has been known since Hering’s publications in 1927. [164]. Later, in1930, Heymans
unequivocally demonstrated the chemoreceptor activity of the carotid (or glomus) bodies.
[165] However, there have been few human necropsies and therefore, evidence relies on case
patients with damage to the carotid sinus and glomus following surgery, radiotherapy and
carotid endarterectomy. [166,167] Therefore, little information is available on the morphology
of barochemoreceptor structures in disease. [168]
The baroreflex is very important for the maintenance of arterial pressure, particularly during
orthostatic stress. Chemoreflexes play an important role in maintaining blood gas homeostasis.
[169] Thus, barochemoreflex failure is a disabling and potentially life-threatening condition.
Data on the long-term effect of human bilateral carotid sinus denervation on arterial blood
pressure are limited and controversial. [166,170-173]
In patients submitted to bilateral tumoral carotid glomus resection it was found a long-term
effect on the level, variability and rapid reflex control of arterial pressure included increased
daytime and nighttime blood pressure variability, unopposed sympathetic activation in
response to physical and mental stress, and the elimination of orthostatic hypotension and
normocapnic hypoxic drive as a result of peripheral chemoreflex failure. [174] Barochemore‐
ceptors are compromised in diseases such as diabetic autonomic neuropathy, Guillain-Barré
syndrome, arterial hypertension and heart failure. [175] Fatal complications in most stroke
patients likely result from baroreceptor malfunction. [175]
The available experimental and clinical evidence suggests that a pattern of chronic intermittent
hypoxia, with short episodes of hypoxia followed by normoxia, selectively enhances the
chemosensory and ventilatory responses of the carotid body to hypoxia, suggesting this sensor
has an essential role in the enhanced ventilatory and cardiovascular responses observed in
animals and obstructive sleep apnea patients. [176]
In a previous study we found a strong involvement of the chemoreceptor structures and
corresponding supplying arterioles in a selected group of elderly patients who had died from
cerebral vascular disorders with critical carotid artery lesions. [177] Despite the accepted
dogma that the amount of connective tissue separating the glomic lobules increases with age,
[166] the significant fibrotic involvement and the unquestionable reduction in the vascularity,
could not merely be explained by the aging process. However, a possible limitation to the
interpretation of those results was the superposition of arterial hypertension, atherosclerosis
and aging in the patients.
Due to these facts, and to characterize the potential damage of the carotid glomus related to
hemodynamic stress alone, we performed experiments using spontaneously hypertensive rats
(SHRs), an animal model with arterial hypertension, in which other factors such as dyslipide‐
mia, high blood sugar or aging were absent. In SHRs, we found a significant increase in
extracellular matrix expansion in the carotid glomus and autonomic nerves, along with a
decreased number of neurons in autonomic ganglia compared with normotensive controls.
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All these findings were highly correlated with high blood pressure and an increase in plasmi‐
nogen activator inhibitor 1 (PAI-1) and transforming growth factor beta-1 (TGF-β-1) deposits
in the carotid glomus and autonomic ganglia. Additionally, SHRs presented a higher wall to
lumen arteriole ratio in small periglomic vessels, a higher number of S100 protein-positive cells
(sustentacular or type 2 cells) and a decreased number of type 1 cells in the carotid glomus.
Interestingly, extracellular matrix expansion was highly correlated with the blood pressure
level. Because of this, these structures must be considered as target organs in the model of
systemic hypertension. [178]
Our group carried out an investigation in which the objective was to morphometrically
characterize the alterations of the carotid barochemoreceptor structures and their supplying
arteries in patients who died from stroke with complicated versus noncomplicated internal
carotid atheromatosis. [179] For this purpose, samples consisting of bilateral or unilateral
carotid segments were obtained at autopsy from 23 elderly patients who died from ischemic
neurological disorders. Transient ischemic attacks preceding their strokes, with extensive
cerebral damage precipitated their deaths.
Plaques were pathologically characterized) into seven categories (see page 3). [18]
Patients were also divided arbitrarily by age. Group 1 was older than 80 years, Group 2 was
65 to 80 years and Group 3 was younger than 65 years of age. The carotid bifurcation and the
first 10 mm to 15 mm of the internal carotid artery were involved in all cases by atherosclerotic
lesions. Large lipid cores with a fibrous cap and a band of fibrous tissue of variable thickness
separating the plaque from the extensively damaged media were observed in all plaques. In
one-third of cases, extensive calcified deposits were also found. The collagen border was
frequently vascularized. In most cases, extensive chronic inflammatory infiltrates were
observed, consisting of macrophages and minor numbers of lymphocytes as well as extensive
neoangiogenesis and calcified deposits. Complicated plaques presented with mononuclear
infiltrates in the periphery, shoulders and bases in two-thirds of the cases. In contrast, only
one-third of noncomplicated plaques had inflammatory infiltrates (P<0.0001).
The carotid glomus was located in the carotid fork, measuring approximately 3 mm X 1.5 mm,
and formed by lobules compactly arranged, separated by connective tissue [177,180-182]
(Figure 21). The functional units consisted of numerous small groups of cells arranged in
clusters. They were grouped to form lobules organized as compact nests that were embedded
in a fibrous stroma through which numerous nerve fibrils and small blood vessels were
observed (Figure 22). Parenchymal cells consisted of two types: the ‘chief cells’ (epithelioid or
type 1 cells), which were large cells with a round nucleus and a large amount of cytoplasm
containing vesicles and granules stained by the Grimelius silver reaction; and elongated cells,
known as ‘sustentacular cells’ or type 2 cells. Chief cells were arranged in the centre and
sustentacular cells at the periphery. [177] Complex arrangements of afferent nerves and
postganglionic sympathetic nerves, as well as autonomic ganglion cells, were found sur‐
rounding the lobules. [181] The carotid glomus showed moderate atrophy and fibrosis to
severe atrophy with extensive fibrosis (cirrhotic appearance) (Figure 23).
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6. Carotid sinus baroreceptor
The significance of the ability of the carotid sinus baroreceptor to sense and regulate blood
pressure has been known since Hering’s publications in 1927. [164]. Later, in1930, Heymans
unequivocally demonstrated the chemoreceptor activity of the carotid (or glomus) bodies.
[165] However, there have been few human necropsies and therefore, evidence relies on case
patients with damage to the carotid sinus and glomus following surgery, radiotherapy and
carotid endarterectomy. [166,167] Therefore, little information is available on the morphology
of barochemoreceptor structures in disease. [168]
The baroreflex is very important for the maintenance of arterial pressure, particularly during
orthostatic stress. Chemoreflexes play an important role in maintaining blood gas homeostasis.
[169] Thus, barochemoreflex failure is a disabling and potentially life-threatening condition.
Data on the long-term effect of human bilateral carotid sinus denervation on arterial blood
pressure are limited and controversial. [166,170-173]
In patients submitted to bilateral tumoral carotid glomus resection it was found a long-term
effect on the level, variability and rapid reflex control of arterial pressure included increased
daytime and nighttime blood pressure variability, unopposed sympathetic activation in
response to physical and mental stress, and the elimination of orthostatic hypotension and
normocapnic hypoxic drive as a result of peripheral chemoreflex failure. [174] Barochemore‐
ceptors are compromised in diseases such as diabetic autonomic neuropathy, Guillain-Barré
syndrome, arterial hypertension and heart failure. [175] Fatal complications in most stroke
patients likely result from baroreceptor malfunction. [175]
The available experimental and clinical evidence suggests that a pattern of chronic intermittent
hypoxia, with short episodes of hypoxia followed by normoxia, selectively enhances the
chemosensory and ventilatory responses of the carotid body to hypoxia, suggesting this sensor
has an essential role in the enhanced ventilatory and cardiovascular responses observed in
animals and obstructive sleep apnea patients. [176]
In a previous study we found a strong involvement of the chemoreceptor structures and
corresponding supplying arterioles in a selected group of elderly patients who had died from
cerebral vascular disorders with critical carotid artery lesions. [177] Despite the accepted
dogma that the amount of connective tissue separating the glomic lobules increases with age,
[166] the significant fibrotic involvement and the unquestionable reduction in the vascularity,
could not merely be explained by the aging process. However, a possible limitation to the
interpretation of those results was the superposition of arterial hypertension, atherosclerosis
and aging in the patients.
Due to these facts, and to characterize the potential damage of the carotid glomus related to
hemodynamic stress alone, we performed experiments using spontaneously hypertensive rats
(SHRs), an animal model with arterial hypertension, in which other factors such as dyslipide‐
mia, high blood sugar or aging were absent. In SHRs, we found a significant increase in
extracellular matrix expansion in the carotid glomus and autonomic nerves, along with a
decreased number of neurons in autonomic ganglia compared with normotensive controls.
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All these findings were highly correlated with high blood pressure and an increase in plasmi‐
nogen activator inhibitor 1 (PAI-1) and transforming growth factor beta-1 (TGF-β-1) deposits
in the carotid glomus and autonomic ganglia. Additionally, SHRs presented a higher wall to
lumen arteriole ratio in small periglomic vessels, a higher number of S100 protein-positive cells
(sustentacular or type 2 cells) and a decreased number of type 1 cells in the carotid glomus.
Interestingly, extracellular matrix expansion was highly correlated with the blood pressure
level. Because of this, these structures must be considered as target organs in the model of
systemic hypertension. [178]
Our group carried out an investigation in which the objective was to morphometrically
characterize the alterations of the carotid barochemoreceptor structures and their supplying
arteries in patients who died from stroke with complicated versus noncomplicated internal
carotid atheromatosis. [179] For this purpose, samples consisting of bilateral or unilateral
carotid segments were obtained at autopsy from 23 elderly patients who died from ischemic
neurological disorders. Transient ischemic attacks preceding their strokes, with extensive
cerebral damage precipitated their deaths.
Plaques were pathologically characterized) into seven categories (see page 3). [18]
Patients were also divided arbitrarily by age. Group 1 was older than 80 years, Group 2 was
65 to 80 years and Group 3 was younger than 65 years of age. The carotid bifurcation and the
first 10 mm to 15 mm of the internal carotid artery were involved in all cases by atherosclerotic
lesions. Large lipid cores with a fibrous cap and a band of fibrous tissue of variable thickness
separating the plaque from the extensively damaged media were observed in all plaques. In
one-third of cases, extensive calcified deposits were also found. The collagen border was
frequently vascularized. In most cases, extensive chronic inflammatory infiltrates were
observed, consisting of macrophages and minor numbers of lymphocytes as well as extensive
neoangiogenesis and calcified deposits. Complicated plaques presented with mononuclear
infiltrates in the periphery, shoulders and bases in two-thirds of the cases. In contrast, only
one-third of noncomplicated plaques had inflammatory infiltrates (P<0.0001).
The carotid glomus was located in the carotid fork, measuring approximately 3 mm X 1.5 mm,
and formed by lobules compactly arranged, separated by connective tissue [177,180-182]
(Figure 21). The functional units consisted of numerous small groups of cells arranged in
clusters. They were grouped to form lobules organized as compact nests that were embedded
in a fibrous stroma through which numerous nerve fibrils and small blood vessels were
observed (Figure 22). Parenchymal cells consisted of two types: the ‘chief cells’ (epithelioid or
type 1 cells), which were large cells with a round nucleus and a large amount of cytoplasm
containing vesicles and granules stained by the Grimelius silver reaction; and elongated cells,
known as ‘sustentacular cells’ or type 2 cells. Chief cells were arranged in the centre and
sustentacular cells at the periphery. [177] Complex arrangements of afferent nerves and
postganglionic sympathetic nerves, as well as autonomic ganglion cells, were found sur‐
rounding the lobules. [181] The carotid glomus showed moderate atrophy and fibrosis to
severe atrophy with extensive fibrosis (cirrhotic appearance) (Figure 23).
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Figure 21. Whole specimen of a frontally cut carotid segment. The arrow points to the glomus located in the intersti‐
tial tissue between the internal and external carotid arteries and its corresponding nerves. Multiple nonstenotic fibroli‐
pidic and fibrotic plaques are observed along the carotid axis.Also an intraplaque hemorrhage is shown
(asterisk)Hematoxylin and eosin stain; ×20 objective lens. 1 Common carotid artery;2 External carotid artery showing
an atheroma inside (P)
Figure 22. Carotid glomus showing almost normal structure and vascularization.Veins are dilated (arrow) and there is
a mild increase in interstitial fibrosis (asterisk). Hematoxylin and eosin stain; ×100 objective lens
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Figure 23. Carotid glomus. A Marked decrease in cells and moderate fibrosis. Typical rounded chief cells are shown in
the centre of the section (arrowhead).Hematoxylin and eosin stain; ×400 objective lens. B Severe atrophy and, in some
areas, absence of acinar structures with replacement by dense connective tissue with a so-called ‘cirrhotic’ appearance
(asterisk). Hematoxylin and eosin stain; ×100 objective lens
There was a loss of the characteristic chief cells (more than 50%) and loss of their argyrophilic
Grimelius-staining granules, suggesting a decrease in their catecholamine content. Fibrosis
and glomic cell loss was assessed as 2.6±0.5. A focal reduction of glomus vascularization (more
than 50%) was also observed in the areas of atrophy and fibrosis when capillaries were stained
with anti-CD34, which was assessed as 2.76±0.6 (Figure 24) In a few cases, it was possible to
observe autonomic ganglia showing moderate fibrosis, mild-to-moderate neuronal damage
and lipofuscin deposits (Figure 25). Interestingly, the arterioles to the glomus showed severe
fibrointimal proliferation and disruption of the internal elastic lamina, marked thickening of
the media and luminal narrowing. Luminal thrombi were also observed, as well as focal areas
of medial homogenization (Figure 26). At the outer media of the carotid sinus, corresponding
to the deeper layers of the plaques, it was possible to identify damaged nerve endings that
reacted specifically with S100 protein. No differences were found among groups for glomus
area, number of type 1 cells, number of type 2 cells or the wall to lumen arteriole ratio. Also,
no statistical differences could be demonstrated when complicated (intraplaque hemorrhage
and/or rupture and/or thrombosis) and noncomplicated plaques were compared or when
comparing age groups 1, 2 and 3. No correlation between morphometric data and age was
found. Patients with stenosis of the extracranial carotid arteries constitute a multimorbid
population that frequently shows several vascular risk factors, including hypertension and
diabetes. Our study [179] demonstrated that, in patients who died from cerebral vascular
disorders with critical carotid artery lesions, a strong involvement of the chemoreceptor
structures and their supplying arterioles was found.
Accordingly, at the outer media of the carotid sinus, corresponding to the deeper fibrocalcified
layers of the plaques and in periglomic areas, damaged nerve endings were observed as well
as fibrotic autonomic ganglia. Therefore, a strong involvement of the baro-(carotid sinus) and
chemoreceptor (carotid body or glomus) structures and their corresponding nerves and
arterioles was observed in the group of elderly patients. These lesions were independent of
patient age, as well as the presence of a complicated carotid plaque. Despite the observation
that the connective tissue separating the glomic lobules increases with age, [166] the marked
fibrotic involvement and the clear decrease in its rich vascularity, shown by the CD34 immu‐
nophenotyping, cannot be explained only in terms of aging. Several studies have found the
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Figure 21. Whole specimen of a frontally cut carotid segment. The arrow points to the glomus located in the intersti‐
tial tissue between the internal and external carotid arteries and its corresponding nerves. Multiple nonstenotic fibroli‐
pidic and fibrotic plaques are observed along the carotid axis.Also an intraplaque hemorrhage is shown
(asterisk)Hematoxylin and eosin stain; ×20 objective lens. 1 Common carotid artery;2 External carotid artery showing
an atheroma inside (P)
Figure 22. Carotid glomus showing almost normal structure and vascularization.Veins are dilated (arrow) and there is
a mild increase in interstitial fibrosis (asterisk). Hematoxylin and eosin stain; ×100 objective lens
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Figure 23. Carotid glomus. A Marked decrease in cells and moderate fibrosis. Typical rounded chief cells are shown in
the centre of the section (arrowhead).Hematoxylin and eosin stain; ×400 objective lens. B Severe atrophy and, in some
areas, absence of acinar structures with replacement by dense connective tissue with a so-called ‘cirrhotic’ appearance
(asterisk). Hematoxylin and eosin stain; ×100 objective lens
There was a loss of the characteristic chief cells (more than 50%) and loss of their argyrophilic
Grimelius-staining granules, suggesting a decrease in their catecholamine content. Fibrosis
and glomic cell loss was assessed as 2.6±0.5. A focal reduction of glomus vascularization (more
than 50%) was also observed in the areas of atrophy and fibrosis when capillaries were stained
with anti-CD34, which was assessed as 2.76±0.6 (Figure 24) In a few cases, it was possible to
observe autonomic ganglia showing moderate fibrosis, mild-to-moderate neuronal damage
and lipofuscin deposits (Figure 25). Interestingly, the arterioles to the glomus showed severe
fibrointimal proliferation and disruption of the internal elastic lamina, marked thickening of
the media and luminal narrowing. Luminal thrombi were also observed, as well as focal areas
of medial homogenization (Figure 26). At the outer media of the carotid sinus, corresponding
to the deeper layers of the plaques, it was possible to identify damaged nerve endings that
reacted specifically with S100 protein. No differences were found among groups for glomus
area, number of type 1 cells, number of type 2 cells or the wall to lumen arteriole ratio. Also,
no statistical differences could be demonstrated when complicated (intraplaque hemorrhage
and/or rupture and/or thrombosis) and noncomplicated plaques were compared or when
comparing age groups 1, 2 and 3. No correlation between morphometric data and age was
found. Patients with stenosis of the extracranial carotid arteries constitute a multimorbid
population that frequently shows several vascular risk factors, including hypertension and
diabetes. Our study [179] demonstrated that, in patients who died from cerebral vascular
disorders with critical carotid artery lesions, a strong involvement of the chemoreceptor
structures and their supplying arterioles was found.
Accordingly, at the outer media of the carotid sinus, corresponding to the deeper fibrocalcified
layers of the plaques and in periglomic areas, damaged nerve endings were observed as well
as fibrotic autonomic ganglia. Therefore, a strong involvement of the baro-(carotid sinus) and
chemoreceptor (carotid body or glomus) structures and their corresponding nerves and
arterioles was observed in the group of elderly patients. These lesions were independent of
patient age, as well as the presence of a complicated carotid plaque. Despite the observation
that the connective tissue separating the glomic lobules increases with age, [166] the marked
fibrotic involvement and the clear decrease in its rich vascularity, shown by the CD34 immu‐
nophenotyping, cannot be explained only in terms of aging. Several studies have found the
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grade of fibrosis to be dependent on age, [183] while others have demonstrated considerable
differences, not only within comparable age groups but, in a few cases, between the right and
left sides. [184]
Figure 24. A :Acinar structure belonging to a carotid glomus showing a moderate-to-severe decrease in the number
of chief cells, and loss of argyrophilic intracellular granules (shown in black). Grimelius stain; ×200 objective lens. B:
Carotid glomus. A focal absence and global decrease of vascularization is shown in the areas of acinar atrophy and
fibrosis. anti-CD34 stain; ×100 objective lens
Figure 25. Autonomic ganglia showing moderate fibrosis and mild-to moderate neuronal damage with intracytoplas‐
mic lipofuscin deposits (arrowhead).Hematoxylin and eosin stain; ×200 objective lens
On the other hand, examination of surgical specimens removed from patients older than 60
years of age showed that the organ almost had a ‘cirrhotic’ appearance. [181] This suggests an
arteriolar involvement leading to fibrosis by a chronic hypoxic mechanism. Most of the
autonomic parameters, including heart rate variability and baroreflex sensitivity, decline with
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age. [185] However, in the rat, aging of the cardiovascular system may not be associated with
the attenuation of the baroreflex function. [184] Accordingly, the carotid baroreceptor reflex
is well maintained in both young and old dogs, suggesting a lack of morphological involve‐
ment. [186] Nevertheless, the attenuation of the baroreflex is far less pronounced in patients
in whom the possible effects of disease counteract the age effects. [187]
Therefore, it is possible that the age-related baroreflex attenuation observed in humans may
not be due to aging per se but may instead reflect atherosclerotic and/or hypertensive processes.
[188-189] There are few data concerning the dependency of the various kinds of chemoreflex
sensitivity on age in healthy human subjects. A study [185] however, showed no significant
correlation between chemoreflex sensitivity and age in patients with multiple organ dysfunc‐
tion syndrome. The authors hypothesized that this lack of correlation can be interpreted as a
confirmation that the effect of the disease prevails over aging in pathological conditions.
Early studies [187-189] speculated that a high systemic arterial pressure may deactivate the
baroreceptor function by damaging the nerve endings in the arterial wall. An alternative
explanation was issued by Heath and Smith, [190] who suggested that an increased stiffness
of the arterial wall would splint the baroreceptor endings, reducing their sensitivity to changes
in arterial pressure instead. These authors pointed out that, to some extent, atherosclerosis
must depend on the orientation of the receptors in the arterial wall. If they are pulled circum‐
ferentially, an increased rigidity of the arterial wall should lead to a decreased baroreceptor
response. In contrast, if the structure is compressed outwards from within, an increased
rigidity of the vessel wall may not have such an effect. [191]
Baroreflex is aroused by changes in blood pressure that are collected by autonomic nerve
‘sensors’ that are distributed in the arterial tree and convey the stimuli elicited by mean
pressure, rate of change in pressure (dP/dt), pulse pressure and heart rate. These mechanore‐
ceptors, typically gathered in the outer tunica media of the carotid sinus, are found as nerve
terminals and, occasionally, with the features of drumstick swellings. The smooth muscle layer
is thinner there to allow for an increased vessel compliance favouring an enhanced mechanical
stimulation. [192]
Figure 26. A::Glomic arteriole showing marked intimal fibrosis with moderate thickening of the media and focal areas
of medial homogenization, and severe adventitial fibrosis. Hematoxylin and eosin stain; ×100 objective lens. B: Glomic
arteriole with marked fibrointimal proliferation and thickening of the wall with luminal narrowing. Azan stain; ×100
objective lens. C: Small artery supplying the glomus. Marked fibrointimal fibrosis with reduction of the lumen and me‐
dial fibrosis. Azan stain; ×100 objective lens
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grade of fibrosis to be dependent on age, [183] while others have demonstrated considerable
differences, not only within comparable age groups but, in a few cases, between the right and
left sides. [184]
Figure 24. A :Acinar structure belonging to a carotid glomus showing a moderate-to-severe decrease in the number
of chief cells, and loss of argyrophilic intracellular granules (shown in black). Grimelius stain; ×200 objective lens. B:
Carotid glomus. A focal absence and global decrease of vascularization is shown in the areas of acinar atrophy and
fibrosis. anti-CD34 stain; ×100 objective lens
Figure 25. Autonomic ganglia showing moderate fibrosis and mild-to moderate neuronal damage with intracytoplas‐
mic lipofuscin deposits (arrowhead).Hematoxylin and eosin stain; ×200 objective lens
On the other hand, examination of surgical specimens removed from patients older than 60
years of age showed that the organ almost had a ‘cirrhotic’ appearance. [181] This suggests an
arteriolar involvement leading to fibrosis by a chronic hypoxic mechanism. Most of the
autonomic parameters, including heart rate variability and baroreflex sensitivity, decline with
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age. [185] However, in the rat, aging of the cardiovascular system may not be associated with
the attenuation of the baroreflex function. [184] Accordingly, the carotid baroreceptor reflex
is well maintained in both young and old dogs, suggesting a lack of morphological involve‐
ment. [186] Nevertheless, the attenuation of the baroreflex is far less pronounced in patients
in whom the possible effects of disease counteract the age effects. [187]
Therefore, it is possible that the age-related baroreflex attenuation observed in humans may
not be due to aging per se but may instead reflect atherosclerotic and/or hypertensive processes.
[188-189] There are few data concerning the dependency of the various kinds of chemoreflex
sensitivity on age in healthy human subjects. A study [185] however, showed no significant
correlation between chemoreflex sensitivity and age in patients with multiple organ dysfunc‐
tion syndrome. The authors hypothesized that this lack of correlation can be interpreted as a
confirmation that the effect of the disease prevails over aging in pathological conditions.
Early studies [187-189] speculated that a high systemic arterial pressure may deactivate the
baroreceptor function by damaging the nerve endings in the arterial wall. An alternative
explanation was issued by Heath and Smith, [190] who suggested that an increased stiffness
of the arterial wall would splint the baroreceptor endings, reducing their sensitivity to changes
in arterial pressure instead. These authors pointed out that, to some extent, atherosclerosis
must depend on the orientation of the receptors in the arterial wall. If they are pulled circum‐
ferentially, an increased rigidity of the arterial wall should lead to a decreased baroreceptor
response. In contrast, if the structure is compressed outwards from within, an increased
rigidity of the vessel wall may not have such an effect. [191]
Baroreflex is aroused by changes in blood pressure that are collected by autonomic nerve
‘sensors’ that are distributed in the arterial tree and convey the stimuli elicited by mean
pressure, rate of change in pressure (dP/dt), pulse pressure and heart rate. These mechanore‐
ceptors, typically gathered in the outer tunica media of the carotid sinus, are found as nerve
terminals and, occasionally, with the features of drumstick swellings. The smooth muscle layer
is thinner there to allow for an increased vessel compliance favouring an enhanced mechanical
stimulation. [192]
Figure 26. A::Glomic arteriole showing marked intimal fibrosis with moderate thickening of the media and focal areas
of medial homogenization, and severe adventitial fibrosis. Hematoxylin and eosin stain; ×100 objective lens. B: Glomic
arteriole with marked fibrointimal proliferation and thickening of the wall with luminal narrowing. Azan stain; ×100
objective lens. C: Small artery supplying the glomus. Marked fibrointimal fibrosis with reduction of the lumen and me‐
dial fibrosis. Azan stain; ×100 objective lens
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Adjustment  of  the  respiration  rate  in  response  to  changes  in  levels  of  oxygen,  carbon
dioxide and hydrogen ions in body fluids are mediated by a complex interplay between
central and peripheral chemoreceptors. The peripheral arterial chemoreceptors, located in
the carotid and aortic glomus, are responsible for the immediate ventilatory and arterial
pressure  increments  during  acute  hypoxia.  [165]  Type  1  cells  in  the  carotid  and  aortic
glomus release neurotransmitters in response to hypoxia, causing depolarization of nearby
afferent nerve endings. [191,192]
Unquestionably, permanent high blood pressure causes a deleterious effect in peripheral
nervous structures. However, few studies deal with the findings reported in our papers
[18,177,178] regarding the deleterious effect of arterial hypertension on carotid glomus and
autonomic ganglia.
As said, our studies in SHRs has demonstrated a strong correlation between arterial hyper‐
tension and the development of lesions in the carotid glomus and autonomic ganglia charac‐
terized by extracellular matrix expansion, as well as a reduction in the number of ganglia
neurons. [178]
Because lowering blood pressure is the first  step in controlling the deleterious effects of
arterial hypertension, we have evaluated the possible differences between the effects of the
beta-blocker  atenolol  (AT) and the ACEI ramipril  (RAM) regarding a protective role  on
these  structures,  as  target  organs  in  SHRs.  [193]  At  the  end  of  the  experiment,  SHRs
receiving  AT and SHRs receiving  RAM (SHR-RAM) showed a  similar  control  in  blood
pressure compared with untreated SHRs.  However,  SHR-RAM presented with a signifi‐
cant  reduction  in  extracellular  matrix  expansion  in  the  carotid  glomus,  autonomic  gan‐
glia and autonomic nerves. Moreover, the number of neurons was preserved with AT and
even more with RAM compared with the untreated SHR group. TGF-β-1 and PAI-1 were
increased in the carotid glomus and autonomic ganglia in SHRs and in SHRs receiving AT,
whereas  SHR-RAM  showed  a  similar  expression  to  the  normotensive  group  (Wistar-
Kyoto rats), indicating that RAM, but not AT, provided a significant protective role against
structural changes in these structures caused by arterial hypertension in SHRs. This effect
seems to be independent of blood pressure reduction. [194]
These structures were well preserved by an ACEI because permanent high blood pressure
stimulates extracellular matrix expansion as a result of enhanced TGF-β-1 and PAI-1 produc‐
tion, through a mechanism regulated by the renin-angiotensin-aldosterone system. [193]
Previous studies have shown the existence of a local reninangiotensin-aldosterone system in
the carotid glomus. [194] In agreement with this information, ACEIs could prevent fibrosis in
barochemoreceptor structures observed in SHR by reducing local angiotensin II production.
[194] The clinical importance of these data could be that the baroreflex attenuation in humans
might be a consequence of atherosclerotic and/or hypertensive processes. [177,187,188]
Also the relationship between atherosclerosis and baroreflex sensitivity has been well docu‐
mented in animal models. [55,63,194,195] Similar evidence in humans is both limited and
indirect. [64] It is possible that the age-related baroreflex attenuation observed in humans may
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not be due to aging per se, but it may reflect atherosclerotic and/or hypertensive processes.
[177,188,189]
Carotid barochemoreceptors are of utmost importance in the rapid adjustment of circulation
and ventilation; the different degrees of involvement of these structures may explain various
clinical responses. [196] These may encompass chronic hypertension, isolated systolic hyper‐
tension, blood pressure lability, postural lightheadedness and periodic orthostatic hypoten‐
sion. [196] Elderly hypertensive patients with these relatively common conditions could be
considered as a high-risk stroke group. [19,177]
Cooper et al [197] reported that the effect of both peripheral and central chemoreceptors on
baroreflex function may contribute to promoting hypertension in patients with obstructive
sleep apnea.Accordingly, Kario et al [196] investigated the clinical significance and mechanism
of orthostatic blood pressure dysregulation in elderly hypertensive patients. They found that
silent cerebrovascular disease is advanced in elderly patients with orthostatic hyperten‐
sion.Elderly hypertensive patients with orthostatic hypertension or orthostatic hypotension
may have an increased risk for developing cerebrovascular disease. In conclusion Severe
carotid chemoreceptor damage exists in elderly patients who died from stroke and suffered
from carotid atheromatosis, independently from aging and plaque type. The damage is
plausibly related to a marked narrowing of their supplying arterioles as a consequence of
hemodynamic (hypertension) and/or metabolic (diabetes, dyslipidemia) disturbances.
A high density of angiotensin II receptors was observed in the rat carotid body by in vitro
autoradiography employing 125I- [SarÁ,IleÌ]-angiotensin II as radioligand. Displacement
studies demonstrated that the receptors were of the AT1 subtype. [198]
As written above, the renin-angiotensin system has been shown to be responsible for ageing
and hypertension which are the major risk factors for the development of cardiovascular and
renal diseases.[197,199-202] We conducted an investigation [203] in which the the aim was to
compare the effects of losartan, an angiotensin II type-1 receptor blocker, on systolic blood
pressure, (SBP), and histopathologycal changes in the carotid body and autonomic lymphs in
14 spontaneously normotensive rats (WKY) They were divided into two groups, one of them
treated with Losartan (n=7) and the other was a control group (n=7) not receving this drug. We
also compared to spontaneously hypertensive rats (SHRs). As expected, at the end of the study
the rats treated with losartan had a SBP of 105 ± 8.3 mm Hg, significantly less than controls
(115 ± 8.1 mm Hg, p = 0.0375).The carotid body was found in the area fork or carotid bifurcation,
formed by lobes compact traversed separated by connective tissue by numerous small blood
vessels and nerve fibers blood (Figure 1). Parenchyma was formed by two cell types: primary
cells or type I, large round nuclei and cells Hold or type II, elongated and located peripherally
of the first (Figure 2). Lobes comprise the functional units of the structure they were best
preserved in the group treated with losartan (Figure 3, A). Also, fibrous stroma was much
more apparent in the control group, where the gap was increased with cell replacement and
decreased in number (Figure 4, A). Clearly losartan treated rats showed glomus area more, a
smaller thickness wall in the arterioles and a light periglómicas higher compared with the
control group (Figures 3 and 4, A, B, C). All this made that the losartan group had a wall /
lumen ratio significantly lower than controls in these vessels. These findings strongly suggest
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Adjustment  of  the  respiration  rate  in  response  to  changes  in  levels  of  oxygen,  carbon
dioxide and hydrogen ions in body fluids are mediated by a complex interplay between
central and peripheral chemoreceptors. The peripheral arterial chemoreceptors, located in
the carotid and aortic glomus, are responsible for the immediate ventilatory and arterial
pressure  increments  during  acute  hypoxia.  [165]  Type  1  cells  in  the  carotid  and  aortic
glomus release neurotransmitters in response to hypoxia, causing depolarization of nearby
afferent nerve endings. [191,192]
Unquestionably, permanent high blood pressure causes a deleterious effect in peripheral
nervous structures. However, few studies deal with the findings reported in our papers
[18,177,178] regarding the deleterious effect of arterial hypertension on carotid glomus and
autonomic ganglia.
As said, our studies in SHRs has demonstrated a strong correlation between arterial hyper‐
tension and the development of lesions in the carotid glomus and autonomic ganglia charac‐
terized by extracellular matrix expansion, as well as a reduction in the number of ganglia
neurons. [178]
Because lowering blood pressure is the first  step in controlling the deleterious effects of
arterial hypertension, we have evaluated the possible differences between the effects of the
beta-blocker  atenolol  (AT) and the ACEI ramipril  (RAM) regarding a protective role  on
these  structures,  as  target  organs  in  SHRs.  [193]  At  the  end  of  the  experiment,  SHRs
receiving  AT and SHRs receiving  RAM (SHR-RAM) showed a  similar  control  in  blood
pressure compared with untreated SHRs.  However,  SHR-RAM presented with a signifi‐
cant  reduction  in  extracellular  matrix  expansion  in  the  carotid  glomus,  autonomic  gan‐
glia and autonomic nerves. Moreover, the number of neurons was preserved with AT and
even more with RAM compared with the untreated SHR group. TGF-β-1 and PAI-1 were
increased in the carotid glomus and autonomic ganglia in SHRs and in SHRs receiving AT,
whereas  SHR-RAM  showed  a  similar  expression  to  the  normotensive  group  (Wistar-
Kyoto rats), indicating that RAM, but not AT, provided a significant protective role against
structural changes in these structures caused by arterial hypertension in SHRs. This effect
seems to be independent of blood pressure reduction. [194]
These structures were well preserved by an ACEI because permanent high blood pressure
stimulates extracellular matrix expansion as a result of enhanced TGF-β-1 and PAI-1 produc‐
tion, through a mechanism regulated by the renin-angiotensin-aldosterone system. [193]
Previous studies have shown the existence of a local reninangiotensin-aldosterone system in
the carotid glomus. [194] In agreement with this information, ACEIs could prevent fibrosis in
barochemoreceptor structures observed in SHR by reducing local angiotensin II production.
[194] The clinical importance of these data could be that the baroreflex attenuation in humans
might be a consequence of atherosclerotic and/or hypertensive processes. [177,187,188]
Also the relationship between atherosclerosis and baroreflex sensitivity has been well docu‐
mented in animal models. [55,63,194,195] Similar evidence in humans is both limited and
indirect. [64] It is possible that the age-related baroreflex attenuation observed in humans may
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not be due to aging per se, but it may reflect atherosclerotic and/or hypertensive processes.
[177,188,189]
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sion. [196] Elderly hypertensive patients with these relatively common conditions could be
considered as a high-risk stroke group. [19,177]
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sleep apnea.Accordingly, Kario et al [196] investigated the clinical significance and mechanism
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silent cerebrovascular disease is advanced in elderly patients with orthostatic hyperten‐
sion.Elderly hypertensive patients with orthostatic hypertension or orthostatic hypotension
may have an increased risk for developing cerebrovascular disease. In conclusion Severe
carotid chemoreceptor damage exists in elderly patients who died from stroke and suffered
from carotid atheromatosis, independently from aging and plaque type. The damage is
plausibly related to a marked narrowing of their supplying arterioles as a consequence of
hemodynamic (hypertension) and/or metabolic (diabetes, dyslipidemia) disturbances.
A high density of angiotensin II receptors was observed in the rat carotid body by in vitro
autoradiography employing 125I- [SarÁ,IleÌ]-angiotensin II as radioligand. Displacement
studies demonstrated that the receptors were of the AT1 subtype. [198]
As written above, the renin-angiotensin system has been shown to be responsible for ageing
and hypertension which are the major risk factors for the development of cardiovascular and
renal diseases.[197,199-202] We conducted an investigation [203] in which the the aim was to
compare the effects of losartan, an angiotensin II type-1 receptor blocker, on systolic blood
pressure, (SBP), and histopathologycal changes in the carotid body and autonomic lymphs in
14 spontaneously normotensive rats (WKY) They were divided into two groups, one of them
treated with Losartan (n=7) and the other was a control group (n=7) not receving this drug. We
also compared to spontaneously hypertensive rats (SHRs). As expected, at the end of the study
the rats treated with losartan had a SBP of 105 ± 8.3 mm Hg, significantly less than controls
(115 ± 8.1 mm Hg, p = 0.0375).The carotid body was found in the area fork or carotid bifurcation,
formed by lobes compact traversed separated by connective tissue by numerous small blood
vessels and nerve fibers blood (Figure 1). Parenchyma was formed by two cell types: primary
cells or type I, large round nuclei and cells Hold or type II, elongated and located peripherally
of the first (Figure 2). Lobes comprise the functional units of the structure they were best
preserved in the group treated with losartan (Figure 3, A). Also, fibrous stroma was much
more apparent in the control group, where the gap was increased with cell replacement and
decreased in number (Figure 4, A). Clearly losartan treated rats showed glomus area more, a
smaller thickness wall in the arterioles and a light periglómicas higher compared with the
control group (Figures 3 and 4, A, B, C). All this made that the losartan group had a wall /
lumen ratio significantly lower than controls in these vessels. These findings strongly suggest
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atrophy of the structures analyzed. Through the increasing age is mainly linked with decreased
arterial blood supply them and that the inhibition of AT1 receptor would a prominent role in
the prevention of such alterations.
In conclusion, a severe carotid chemoreceptor damage does exist in old patients who died from
stroke and suffering from carotid atheromatosis. The damage involved the glomic structures
and of note, a ‘‘culprit’’ narrowing of the arterioles belonging to those structures was also
observed. The clinical implications of these findings related to the development and/or
worsening of all types of blood pressure and ventilatory disturbances in elderly patients are
obvious. Hypertension could play aa very important role in the development of carotid body
lesions -Beta blockade or Ramipril or Losartan could prevent morphologic and functional
abnormalities
7. Final conclusions
This chapter was based on our experience in the pathology of the carotid arteries and barror‐
eceptor as well as what exists in the international literature. The importance of knowing the
biological phenomena that produces the formation of carotid atheromatous plaque is clearly
emphasized. We also mentioned different plaque types (stable, unstable and calcified) and its
correlation with diagnostic techniques. Concepts approached in the chapter offer the reader
elements to enhance decision making in patients suffering carotid atheromatous disease.
Additionally we emphasized the need to report on the origin and hemodynamic behavior of
the carotid dolichoarteriopathies. Finally, we have highlighted the functions and the various
pathological processes that can be observed in the carotid glomus.
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1. Introduction
Stroke is one of the major health care problems in the world today. It is the third leading
cause of mortality in the western countries and the most common cause of mortality of any
neurological disorder. Incidence of stroke is 160 per 100,000 population per year; 40 percent
of  victims require some type of  special  services and 10 percent require total  care.  [1,  2]
Consequently, stroke rehabilitation places a large drain on national health care resources.
A significant proportion of strokes are ischemic in nature, one of leading causes for which
is internal carotid artery (ICA) atherosclerosis. It is estimated that 20-25 percent of all strokes
can be attributed directly to carotid bifurcation atherosclerosis. [1, 2]
Both internal carotid artery endarterectomy and carotid stenting in patients with preopera‐
tive ocular or cerebral embolic events are well established as procedures that reduce the
risk of future ischaemic events. [3-7] In addition to the management of hypertension and
commencement of antiplatelet and statin therapy, these interventions form the corner stone
of stroke prevention policy in patients with significant ICA stenosis. As it is recognised that
a significant proportion of patients have a disabling embolic stroke attributable to severe
ICA stenosis without any prior symptoms, [8, 9] it would be advantageous if patients who
are at highest risk of stroke from ICA stenosis could be identified and treated in advance
of any ischaemic neurological events.
© 2014 Mofidi and Green; licensee InTech. This is a paper distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Atherosclerotic plaque morphology
Atherosclerotic plaques are not static lesions; they undergo dynamic changes in their size and
morphological characteristics. These changes manifest themselves as changes in plaque
volume and consistency, otherwise known as plaque progression and regression. These, together
with adaptive responses of the arterial wall, determine the degree of stenosis in the diseased
artery. [10-12] This degree of stenosis is the measurable clinical finding which, together with
timing and nature of symptoms and co-morbidities, correlates with the risk of developing
further neurological events. [13]
Over the last 20 years a lot has been learned about the morphological characteristics of an
atherosclerotic plaque responsible for plaque progression and instability. [10-12] Morpholog‐
ical characteristics of atherosclerotic plaques can be discussed in the context of plaque surface
characteristics and the composition of the atherosclerotic lesion.
3. Plaque surface characteristics
Julian et al in 1963 were the first to discuss the issue of carotid plaque ulceration. They reported
17 cases of macroscopic plaque ulceration with thrombosis in the ulcer crater and suggested
this as a source for embolisation. [12] Ulceration has been described as an observable disruption
of intima exposing the adjacent atheromatous plaque or media [13] (figure 1).
There	 has	 been	 conflicting	 evidence	 regarding	 the	 significance	 of	 plaque	
ulceration	in	the	evolution	of	symptomatic	disease.		In	a	large	study,	Imparato	et	
al	did	not	 find	any	significant	difference	 in	the	 incidence	of	ulceration	between	
symptomatic	and	asymptomatic	groups.14‐16	
		
Figure-1:  A carotid endarterectomy specimen containing a large ulcer which is 




Figure 1. A carotid endarterectomy specimen containing a large ulcer which is associated with intra-plaque haemor‐
rhage.
There has been conflicting evidence regarding the significance of plaque ulceration in the
evolution of symptomatic disease. In a large study, Imparato et al did not find any significant
difference in the incidence of ulceration between symptomatic and asymptomatic groups.
[14-16]
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Other researchers have found a definite increase in the incidence of plaque ulceration in
patients with symptomatic carotid artery disease. Most notably, following review of 593
angiograms in the North American Symptomatic Carotid Endarterectomy Trial (NASCET), 34
percent of medically treated patients were found to have ulcerated plaques with reasonable
certainty; this figure was 36 percent for those assigned to surgery. At 2 years, 30 percent of the
medically treated group with ulceration had suffered a non-fatal stroke or vascular death
compared to only 17 percent of those without plaque ulceration [17].
One reason for this difference may be the time interval between the duration of symptoms and
surgery in some of the studies. Lusby et al reported re-endothelialisation of several plaques,
and suggested that this is particularly likely when the time span between the onset of symp‐
toms and endarterectomy exceeds 3 weeks. [18]
The strength of the evidence from the NASCET trial has meant that most clinicians recognise
plaque cap ulceration as a risk factor for development of further carotid territory embolic
neurological events. Preoperative evidence of plaque cap ulceration has been included in
stroke risk calculators such as the Oxford Stroke Risk calculator. [19]
4. Composition of an atherosclerotic plaque
The raised lesion or fibro-lipid plaque is the archetypal lesion of atherosclerosis and compli‐
cations of this lesion (fissure and ulceration) form the basis of the vast majority of cases of
occlusive arterial disease. All atherosclerotic plaques share two basic morphological compo‐
nents:
Fibrous cap: a thick layer of fibrous connective tissue, which is significantly thicker and much
less cellular than the normal intima and contains lipid-filled macrophages, collagen and
smooth muscle cells;
Atheroma: A necrotic mass of lipid that forms the core of the lesion. Loss of continuity of the
endothelium is the main step in the progression of a plaque and increases the permeability of
the intima to lipoproteins, permits platelet-vessel wall interaction and release of growth factors
leading to formation of thrombus on the vessel wall.
Leahy demonstrated that various elements of the plaque are available as potential emboli. [20]
This includes the fibrous cap overlying complex plaques, the contents that include cholesterol
crystals, the breakdown products of intra-plaque haemorrhage, and fibrous or cartilaginous
material as well as calcified tissue. Hollenhorst showed the presence of cholesterol emboli in
the retinal artery of patients suffering from amaurosis fugax, in the form of bright plaques that
were seen in the extra-cranial carotid vessels. [21] Bock et al reported that soft plaques (lipid
laden and haemorrhagic plaque) behave in an unstable way and tend to ulcerate, whilst fibrous
or calcified plaques behave differently. [22]
Based on the natural history and pathological changes within the plaque the American Heart
Association (AHA) has classified atherosclerotic lesions [23] (table 1). This classification that
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has been modified by Virmani and Naghavi et al divides the atheromatous lesions into non-
atherosclerotic intimal lesions and progressive atherosclerotic plaques. [24, 25] The classifica‐
tion, although not particularly directed at the carotid atherosclerotic lesions, is however
applicable when classifying carotid plaques. Progressive atherosclerotic plaques (AHA plaque
types V and VI) are relevant in the setting of clinically significant carotid disease (figure-2).
Type I Adaptive Lesion: Intimal Smooth Muscle Cells (SMC)
Type II Fatty Streak, Foamy Macrophages and underlying SMCs
Type III Pre Atheroma, Intimal Macrophages, deeper pools of extracellular lipid
Type IV Atheroma (Fibrous Plaque), dense large extra cellular lipid core deep to intima, and close to media.
Type V Fibroatheroma, multiple layers of lipid core encased in a fibrous cap
Type VI
Complicated plaque:
VI a Disruption of the intimal surface
VI b Intra Plaque Haemorrhage
VI c Thrombosis related to the atherosclerotic plaque
Table 1. American Heart Association has classification of atherosclerotic lesions [23] (Circulation 1995;92: 1355-74)
Figure 2. American Heart Association Type VI (Complicated atherosclerotic lesion) obtained from a carotid endarter‐
ectomy specimen. (Br J Surg. 2001;88:945–950.)
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5. The concept of unstable atherosclerotic plaque
The  concept  that  a  sub-group  of  atherosclerotic  plaques  are  prone  to  embolisation  or
thrombosis is not new. As early as 1926, Benson postulated that coronary thrombosis results
from disruption of intima that exposes lipids to flowing blood. [26] Constantinides was the
first  to  establish conclusively that  plaque rupture was the immediate  cause of  coronary
thrombosis. [27] In a series of subsequent studies Davies et al  established the importance
of  plaque  fissuring,  ulceration  and subsequent  thrombosis  in  the  development  of  acute
coronary syndromes.  [28-30]  Further clinical  and angiographic  work has led to progres‐
sion of  this  concept  and introduction of  thrombolytic  therapy in  the  treatment  of  coro‐
nary artery atherosclerosis. [31-34]
Atherosclerotic plaques that are prone to rupture are known to have certain cellular, molecular
and structural features. Notably these include an intense inflammatory process within the
plaque, angiogenesis, and intra-plaque haemorrhage with gradual thinning of the fibrous cap,
subsequent loss of plaque cap integrity and ulceration. [35] Burke et al defined a vulnerable
plaque in the coronary arteries as a lesion with a cap thickness of less than 65 µM [36]. Gertz
et al noted that the lipid cores were much larger in areas of atherosclerotic plaque disruption
than in lesions with intact surfaces. [37-38] Inflammatory activity within the plaque is associ‐
ated with plaque ulceration and has a role in pathogenesis of intimal damage. [39]
The evolution of atheroma is modulated by innate and adaptive immune responses which are
recognized histologically as presence of an inflammatory infiltrate within the lesion [40]. These
processes are responsible for replication and phenotypic change within the smooth muscle cell
from contractile to secretory which results in formation of plaque cap and lesion growth.
Intimal endothelial cell activation results in recruitment of macrophages and lymphocytes
(predominantly CD4 positive T-cells) into evolving lesion. [40] Activation of Th-1 T-cells is
known to initiate a potent inflammatory cascade which in turn leads to plaque instability [41].
Inflammatory cell infiltrate is a marker for plaque vulnerability. [42-47] Several factors such
as oxidized lipoproteins, infectious agents or auto-antigens (heat shock protein) have been
considered as the putative cause of the chronic inflammatory reaction in an atherosclerotic
plaque. [40] This in turn results in weakening of the connective tissue framework of the plaque.
[48, 49] Smooth muscles may help to counteract some of these effects by producing matrix
protein, collagen and inhibitors of matrix degrading enzymes known as metalloproteinases.
[50, 51] The net result of these two processes is thought to define whether or not the plaque
ruptures or remains contained by the fibrous cap.
6. Angiogenesis in carotid atherosclerotic lesions
Normal human intima is devoid of blood vessels, [52] however newly formed blood vessels
are often seen within atherosclerotic plaques [53-56] (figure-3). The presence and density of
these new blood vessels in carotid atherosclerotic lesions has been associated with the
histological features of plaque instability and intra-plaque haemorrhage as well as the
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histological features of plaque instability and intra-plaque haemorrhage as well as the
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development and timing of ipsilateral ischaemic or ocular events and presence of ipsilateral
cerebral infarction on computer tomography (CT) scanning. [57-62] Microarray gene chip
analysis revealed that the presence of newly formed vessels is associated with increased
angiogenic gene expression. [63, 64] These new blood vessels are weak and could be respon‐
sible for intraplaque haemorrhage. Moreover, the endothelial lining of these microvessels
express high levels of E-Selectin, ICAM-1, and VCAM-1, which indicates that these endothelial
cells are in an activated state. Activated endothelial cells act as local site of inflammatory cell
recruitment into the atherosclerotic plaque, perpetuating the inflammatory process within the
lesion and contribute to plaque destabilization. [65-69]
7. Plaque haemorrhage
Haemorrhage is a common feature of unstable carotid atherosclerotic lesions. [68-72] Intra-
plaque haemorrhage has been associated with the development and growth of the necrotic
plaque core, rapid changes in plaque volume, development of plaque instability, and ischaemic
neurological events. [73-76]
The origin of plaque haemorrhage is uncertain. It has been suggested that it may occur from
fissures within the plaque cap. [76] Alternatively the new blood vessels within the athero‐
sclerotic plaque may represent the first site of morphologic change that leads to intra-plaque
haemorrhage; features such as microvessel density and perivascular inflammatory infiltrate
have been associated with the presence and quantity of intra-plaque haemorrhage. [55, 77, 78]
Structural:





Increased macrophage density and activity
T Lymphocyte accumulation near site of rupture
Increased Neovascularity
Reduced Smooth muscle cell density
Increased number and activity of mast cells
Expression of markers of inflammatory activation
Molecular
Matrix Metalloproteinase Secretion
Increased Tissue Factor Expression
Table 2. Features of Rupture prone (Unstable) Plaques [40]
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There is ample clinical and histological evidence that carotid atherosclerotic plaques with large
necrotic lipid core, thin plaque cap or ulceration, dense inflammatory infiltrate, intra-plaque
haemorrhage and angiogenesis are vulnerable to rupture and development of ischaemic
neurological and ocular events. In vivo identification of these changes within carotid athero‐
sclerotic plaques gives these findings clinical significance in the context of patients with
significant carotid atherosclerosis. For over two decades, non-invasive imaging modalities
such as duplex ultrasound and magnetic resonance imaging have been in clinical use. They
have been used for the measurement of internal carotid artery stenosis. [79-81] These imaging
modalities can also be used to study morphological changes associated with plaque instability
and development of ischaemic neurological events. [82-85]
8. Duplex ultrasound assessment of carotid plaque morphology
Duplex ultrasound is arguably the most important imaging modality for preoperative
assessment of patients with carotid atherosclerotic disease. It is non-invasive, relatively
inexpensive and very accurate at identification of significant ICA stenosis. [87-92] In measuring
the degree of stenosis, the flow and velocity characteristics assessed by colour flow Doppler
are utilized. Duplex devices also generate high resolution B-mode ultrasound images of the
atherosclerotic lesion. These images do not contribute significantly to the assessment of carotid
Figure 3. New blood vessels in a carotid atherosclerotic plaque. (Ann Vasc Surg 2008; 22(2): 266–272.)
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artery stenosis. However the B-mode ultrasound image can be used to assess morphologic
characteristics of an atherosclerotic lesion. It has been known for some time that plaques that
have low echogenicity (appear dark on Duplex ultrasound) or a high degree of heterogeneity
are associated with histologic characteristics of plaque instability, ipsilateral neurological or
ocular events, [93] CT evidence of carotid territory cerebral infarction or evidence of emboli‐
sation on trans-cranial ultrasound. [94] These ultrasound characteristics can be assessed
subjectively and classified by a trained observer.
B-mode ultrasound assessment of atherosclerotic plaque morphology started some 30 years
ago. Reilly et al recognised two distinct types of carotid atherosclerotic lesion. The first was
termed homogenous and was defined as lesion with uniformly high or medium level echoes.
Histologically, homogenous plaques are fibrous lesions. [95] The second type was termed
heterogeneous and was defined as plaque with high, medium and low level echoes. [95]
Histologically heterogeneous plaques contain variable amounts of intra-plaque haemorrhage,
lipids, cholesterol crystal and a loose stroma. A further refinement of subjective assessment of
plaque morphology was the Gray-Wheal classification method (table-3). [96] In the Cardio‐
vascular Health Study, which enrolled 5,201 individuals aged 65 years and over without prior
cerebrovascular symptoms, and followed them for an average of 3.3 years demonstrated a
significantly increased incidence of stroke in individuals who had echo-lucent plaques. [97]
Plaque Type Ultrasound characteristics
Type-1 Predominantly echolucent with a thin echogenic cap
Type-2 Intermediate echolucent lesions with small areas of echogenicity
Type-3 Intermediate echogenic lesions with small areas of echolucency (<25%)
Type-4 Uniformly echogenic lesions (equivalent to homogenous).
Table 3. Gray-Wheal Classification of atherosclerotic plaques
Subjective observer dependent assessment of plaque morphology, whilst useful, is limited by
high inter- and intra-observer variability, significantly limiting its clinical application. [98-99]
Echogenicity and heterogeneity of an atherosclerotic plaque can be objectively assessed using
image analysis techniques through the measurement of median grey scale (GS) value of the
ultrasound image, percentage of echo-lucent pixels and entropy in GS characteristics of the
lesion(figure-4). [99-103] In order to remove variability associated with acquisition of the
ultrasound image, the US images are normalised using linear scaling so that the adventitia
would have a grey scale median value of 185-195 and blood 0-5. Plaques with a low GS median
were associated with a significantly higher annual risk of stroke. [99-104]
Interestingly, although characterisation of the internal structure of the plaque assessed by
image analysis correlates closely with clinical symptoms, the correlation between computer‐
ised assessment of plaque morphology and histological features of the lesion is less strong. [94]
This indicates that values such as GS median represent a median value of the whole athero‐
sclerotic area and do not necessarily reflect the presence of particular regional components.
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The use of stratified GS median measurements which create a profile of the regional GS median
as a function of distance from plaque surface combined with colour mapping correlates better
with the presence of various histopathological components and identify determinants of
plaque instability with a high degree of accuracy. [94]
Figure 4. Calculation of Grey Scale Median of a hypo-echoic plaque. (Swiss Med 2005; 135:635–643.)
9. Magnetic resonance imaging assessment of plaque morphology
Magnetic resonance imaging (MRI) is a promising modality for characterisation of carotid
plaque morphology and assessment of composition of atherosclerotic plaques. It can accu‐
rately identify the presence of ulcerated or thin plaque cap, [105-107] quantify intra-plaque
haemorrhage [105-107], or the presence of a large necrotic plaque core [105-107]. Serial MRI
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9. Magnetic resonance imaging assessment of plaque morphology
Magnetic resonance imaging (MRI) is a promising modality for characterisation of carotid
plaque morphology and assessment of composition of atherosclerotic plaques. It can accu‐
rately identify the presence of ulcerated or thin plaque cap, [105-107] quantify intra-plaque
haemorrhage [105-107], or the presence of a large necrotic plaque core [105-107]. Serial MRI
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examinations in asymptomatic patients with moderate (50-70-percent) ICA stenosis have
revealed correlation between these plaque findings and development of subsequent ipsilateral
ocular and ischaemic neurological events [108] (Figure-5).
Figure 5. Identification of intra-plaque haemorrhage using high spatial resolution, multi-contrast MRI image. (JACC
Cardiovasc Imaging. 2009; 2:883-96.)
One of the strengths of MRI is the availability of multi-contrast weighted protocols. The most
common application of carotid MRI remains the acquisition of an angiogram which uses a
bright blood sequence using a 3-dimensional time of flight sequence. This attenuates the signal
from stationary (plaque) tissues. Black blood sequences eliminate the luminal signal and help
to characterise plaque morphology. [105-109] Combining the information, multiple-contrast
weightings can be used to identify all plaque components. [105-110] Plaque compositional
characteristics can be assessed using automatic classifiers such as morphology enhanced
probabilistic plaque segmentation (MEPPS) algorithms with a high degree of accuracy
(Figure-6). [111, 112] Administration of gadolinium-DTPA together with T1-weighted
sequences in addition to bright blood time of flight sequence can be used to create maximal
intensity projection (MIP) images for measurement of the degree of ICA stenosis [105-107] and
accurately measure the thickness of plaque cap in relation to the necrotic core volume. [105-107]
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Figure 6. Automated segmentation of bright–and black-blood, high-spatial resolution, Multi-contrast in vivo MR im‐
ages compared with histological characteristics of plaque. (JACC Cardiovasc Imaging. 2009; 2:883-96.)
High resolution MRI can identify and age intra-plaque haemorrhage. [113-115] Prospective
serial MRI studies have demonstrated that haemorrhage in atherosclerotic plaques is associ‐
ated with sudden increases in plaque volume, necrotic core, and progression of degree of
stenosis. [115]
In addition to Duplex and MRI, other modalities such as fludeoxyglucose (FDG) positron
emission tomography (PET) CT scanning has been used to assess the level of metabolic activity
in carotid atherosclerotic plaque. This is used in turn as a surrogate marker of plaque insta‐
bility.
PET CT scanning has shown some promise as a tool for assessment of plaque instability. [116]
However it is unlikely to gain mainstream applicability due to its limited availability, expense,
and the significant exposure to ionising radiation (meaning serial assessments are not possible)
and availability of non-invasive accurate imaging modalities to assess plaque morphology.
10. Conclusion
Over the last 20 years the advances in technology have led to the evolution of non-invasive
imaging modalities with high spatial resolution. The application of this technology in the
assessment of carotid plaque morphology has advanced our understanding of the natural
history of atherosclerotic lesions more than the assessment of histological characteristics of
atherosclerotic plaques. Consequently for the first time, plaque morphology could be assessed
against the two functions that ultimately matter the most: time and occurrence of future
embolic ischaemic events.
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New and continuing advances in MRI technology such as higher field strength, phased-array
coils, and the application of 3-dimensional and contrast enhanced ultrasound will provide
even more tools for assessment of carotid plaque morphology. Gradual application of these
modalities in clinical practice will help clinicians select patients with significant ICA stenosis
who are likely to benefit from carotid intervention prior to occurrence of ischaemic neurolog‐
ical events.
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1. Introduction
In the era of evidence-based medicine, doctors rely on clinical trials to guide their decisions.
The best method of treating carotid stenosis is still debatable after six decades from the first
carotid surgical revascularization performed. Despite the conduct and publication of dozens
of trials on carotid revascularization, the truth remains shaggy. The interpretation of these
trials is influenced by the design, inclusion criteria, credentialing of the operators and even
their specialties. We will try to discuss the trials of carotid endarterectomy and carotid artery
stenting trying to reach a conclusion of where is the truth regarding carotid revascularization.
We will discuss the trials of CEA versus medical therapy, then the initials registries of CAS,
then the trials that compared CEA against CAS, we will elaborate on the two techniques in
peculiar situations and finally we will give a short notice about ongoing trials and future
directions.
2. Carotid endarterectomy
Carotid endarterectomy (CEA) started in the early 1950s and is now the most commonly
performed peripheral arterial surgery in the USA. The aim of CEA is to remove the entire
atherosclerotic plaque from the carotid bifurcation en bloc leaving a rough surface to be
endothelialized over the following weeks. Most procedures are performed under general
anesthesia. However, local anesthesia and mild intravenous sedation are sometimes successful
and can allow monitoring of neurologic functions during surgery. Local anesthesia also should
© 2014 Kassem et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
In the era of evidence-based medicine, doctors rely on clinical trials to guide their decisions.
The best method of treating carotid stenosis is still debatable after six decades from the first
carotid surgical revascularization performed. Despite the conduct and publication of dozens
of trials on carotid revascularization, the truth remains shaggy. The interpretation of these
trials is influenced by the design, inclusion criteria, credentialing of the operators and even
their specialties. We will try to discuss the trials of carotid endarterectomy and carotid artery
stenting trying to reach a conclusion of where is the truth regarding carotid revascularization.
We will discuss the trials of CEA versus medical therapy, then the initials registries of CAS,
then the trials that compared CEA against CAS, we will elaborate on the two techniques in
peculiar situations and finally we will give a short notice about ongoing trials and future
directions.
2. Carotid endarterectomy
Carotid endarterectomy (CEA) started in the early 1950s and is now the most commonly
performed peripheral arterial surgery in the USA. The aim of CEA is to remove the entire
atherosclerotic plaque from the carotid bifurcation en bloc leaving a rough surface to be
endothelialized over the following weeks. Most procedures are performed under general
anesthesia. However, local anesthesia and mild intravenous sedation are sometimes successful
and can allow monitoring of neurologic functions during surgery. Local anesthesia also should
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be considered in the hemodynamically unstable patient or in situations where general
anesthesia may be too risky.
3. The early years of carotid endarterectomy
Early attempts at reconstruction of the carotid artery at the bifurcation were carried out by
Carrea, Molins, and Murphy in 1951 and subsequently by Eastcott, Pickering, and Robb in
1954. In 1965 DeBakey reported that he performed the first CEA in 1953. Although not
published, there is controversy about this claim.[1] Subsequently, a group of neurologists,
vascular surgeons, and neurological surgeons performed a study on the “new technique”
comparing it with medical therapy. Interestingly, the surgical mortality was surgical mortality
of 4.5% in 2400 operations. This early study the study delineated careful methods of measuring
common carotid and internal carotid and vertebral artery stenosis. The study also determined
the upper level of ready surgical accessibility as well as the contraindications to the operation.
[2] Additionally, myocardial infarction was identified as the principal cause of late mortality
in those patients undergoing successful surgical treatment. Providing the patients survived
the surgical therapy, the occurrence of new stroke was 4% in the surgical group. However, the
superiority of surgery over medical therapy was not definitive. Despite criticism, CEA became
extremely popular. It became the most commonly performed peripheral arterial procedure in
the United States, reaching a peak of 107,000 operations in nonveteran hospitals in the United
States in 1985.[1] At that time, however, neurologists were skeptical. Their fears were sup‐
ported by reports that the rates of death or stroke from CEA were 10%. Endarterectomy turned
from a great procedure to an operation “that has escaped critical analysis to be let loose on an
unsuspecting public”![3] These concerns stressed the need to perform well-designed random‐
ized trials under independent neurological audit. Those trials established the role of CEA
versus medical treatment for stroke prevention.
4. The landmark trials of CEA versus medical therapy; NASCET, ACAS and
ECST
The role of CEA in prevention of stroke was established based on large randomized trials
performed mostly in the early 1990s.
This meta-analysis of ECST and NASCET trials showed that surgery increased the 5-year
risk of ipsilateral ischemic stroke in patients with <30% stenosis (absolute risk reduction of
–2.2%, P = 0.05), had no effect in patients with 30-49% stenosis (absolute risk reduction of
3.2%, P = 0.6),  was of marginal benefit  in those with 50% to 69% stenosis (absolute risk
reduction of 4.6%, P =0.04),  and was highly beneficial in those with ≥70% stenosis with‐
out near-occlusion (absolute risk reduction of 16.0%, P < 0.001). There was a trend toward
benefit  from surgery in patients with near occlusion at 2 years’  follow up (absolute risk
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reduction of 5.6%, P = 0.19), but no benefit at 5 years (absolute risk reduction of –1.7%, P
=0.9).  Both  ACST and  ACAS studies  showed benefit  from  CEA  in  >60% asymptomatic
































































































70-99% NASCET 659 21.4 8.6 12.8 60 8 5.8
70-99%ECST** 501 19.9 7.0 12.9 65 8 5.6
50-69% NASCET 858 14.2 9.2 5.0 35 20 7.1
50-69% ECST** 684 9.7 11.1 -1.4 -14 - 9.8
<50%NASCET 1368 11.6 10.1 1.5 13 67 6.5
<50% ECST** 1882 4.3 9.5 -5.2 -109 - 6.1
Asymptomatic patients
≥50%, VA, men only 444 7.7† 5.6† 2.1 27 48 4.4




5.8 -0.8 - - 4.6
ACE=aspirin and carotid endarterectomy trial.




‡Assigning a perioperative risk of 2.6% based on 724 of 825 patients who actually received endarterectomy in the
surgical arm of ACAS, and utilizing the 0.6% risk of stroke in each of the two years after endarterectomy. The same
1.2% risk is assumed for the ACE patients and VA patients.
§No medical arm—assumed from ACAS data.
Table 1. Number needed to treat by endarterectomy to prevent one stroke in 2 years in patients with carotid stenosis
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be considered in the hemodynamically unstable patient or in situations where general
anesthesia may be too risky.
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Carrea, Molins, and Murphy in 1951 and subsequently by Eastcott, Pickering, and Robb in
1954. In 1965 DeBakey reported that he performed the first CEA in 1953. Although not
published, there is controversy about this claim.[1] Subsequently, a group of neurologists,
vascular surgeons, and neurological surgeons performed a study on the “new technique”
comparing it with medical therapy. Interestingly, the surgical mortality was surgical mortality
of 4.5% in 2400 operations. This early study the study delineated careful methods of measuring
common carotid and internal carotid and vertebral artery stenosis. The study also determined
the upper level of ready surgical accessibility as well as the contraindications to the operation.
[2] Additionally, myocardial infarction was identified as the principal cause of late mortality
in those patients undergoing successful surgical treatment. Providing the patients survived
the surgical therapy, the occurrence of new stroke was 4% in the surgical group. However, the
superiority of surgery over medical therapy was not definitive. Despite criticism, CEA became
extremely popular. It became the most commonly performed peripheral arterial procedure in
the United States, reaching a peak of 107,000 operations in nonveteran hospitals in the United
States in 1985.[1] At that time, however, neurologists were skeptical. Their fears were sup‐
ported by reports that the rates of death or stroke from CEA were 10%. Endarterectomy turned
from a great procedure to an operation “that has escaped critical analysis to be let loose on an
unsuspecting public”![3] These concerns stressed the need to perform well-designed random‐
ized trials under independent neurological audit. Those trials established the role of CEA
versus medical treatment for stroke prevention.
4. The landmark trials of CEA versus medical therapy; NASCET, ACAS and
ECST
The role of CEA in prevention of stroke was established based on large randomized trials
performed mostly in the early 1990s.
This meta-analysis of ECST and NASCET trials showed that surgery increased the 5-year
risk of ipsilateral ischemic stroke in patients with <30% stenosis (absolute risk reduction of
–2.2%, P = 0.05), had no effect in patients with 30-49% stenosis (absolute risk reduction of
3.2%, P = 0.6),  was of marginal benefit  in those with 50% to 69% stenosis (absolute risk
reduction of 4.6%, P =0.04),  and was highly beneficial in those with ≥70% stenosis with‐
out near-occlusion (absolute risk reduction of 16.0%, P < 0.001). There was a trend toward
benefit  from surgery in patients with near occlusion at 2 years’  follow up (absolute risk
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reduction of 5.6%, P = 0.19), but no benefit at 5 years (absolute risk reduction of –1.7%, P
=0.9).  Both  ACST and  ACAS studies  showed benefit  from  CEA  in  >60% asymptomatic
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of stenosis. This observation was assumed to be attributable to a lack of statistical power
of the trials. The benefit from CEA relates to the complication rates. Reported benefits were
predicated  on  operative  risks  of  stroke  or  death  of  7.5%  in  the  ECST  and  6.5%  in  the
NASCET. If the disabling stroke and death rates exceed this by as little as 2%, the benefit
from CEA disappears.[4]
5. The spread of CEA among vascular surgeons worldwide
There have been a dramatic fall and a rise in the rates of carotid endarterectomy in both the
United States and Canada, which correlate with the publication of first unfavorable and then
favorable clinical studies. The absence of selective referral of patients to centers with the lowest
mortality rates raises questions about whether the benefits of carotid endarterectomy in the
general population are similar to those demonstrated in the clinical trials. Rates of carotid
endarterectomy fell in all three regions from 1984 to 1989 (from 126 to 66 per 100,000 adults 40
years of age or older in California, from 65 to 40 per 100,000 in New York, and from 40 to 15
per 100,000 in Ontario), after the publication of studies demonstrating that the rates of
complications of carotid endarterectomy were unacceptably high. However, the clinical trials
of the 1990s, which showed benefit from carotid endarterectomy, were associated with a
dramatic resurgence in the rates of the procedure from 1989 to 1995 (from 66 to 99 per 100,000
in California, from 40 to 96 per 100,000 in New York, and from 15 to 38 per 100,000 in Ontario).
These increased rates were not associated with proportionally greater numbers of referrals of
patients to hospitals with low mortality rates.[5]
6. The limitations of carotid endarterectomy
This NASCE, ACAS and ESCT trial as well as the spread of carotid endarterectomy worldwide
unveiled the problems and limitations inherent to the procedure. It became clear that the
coexistence of cardiac co-morbidity is a powerful predictor of mortality and that myocardial
infarction can be the most dreaded complication, even more than stroke. This was evident,
despite the fact that patients with myocardial infarction in the prior six months, congestive
heart failure and patients scheduled for coronary revascularization were excluded from the
large CEA trials.[6] Other limitations of the procedure were more located to the local envi‐
ronment in the neck as prior endarterectomy, prior neck dissection or radiation, cranial nerve
palsies and inaccessible high/low carotid bifurcations. The presence of contra-lateral carotid
occlusion also posed a problem during cross clamping that increased the risk of CEA.
7. Carotid angioplasty
While carotid endarterectomy was growing to maturity, anther contender was born. After the
fundamental work in endovascular therapy by Charles Dotter and Andreas Grüntzig, it was
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inconceivable at the end of the 1970s to apply their work to arteries supplying the brain. Klaus
Mathias chose to ignore this strict limit and was able to successfully perform angioplasty of
atherosclerotic stenoses at the carotid bifurcation in 1980.[7] The technique evolved slowly
from simple balloon dilatation to involve stenting, used first by Théron in 1990 and then
widespread use of cerebral protection devices.
8. The initial case-series and registries of carotid stenting
While carotid endarterectomy was growing to maturity, anther contender was born. After the fundamental work in endovascular 
therapy by Charles Dotter and Andreas Grüntzig, it was inconceivable at the end of the 1970s to apply their work to arteries 
supplying the brain. Klaus Mathias chose to ignore this strict limit and was able to successfully perform angioplasty of 
atherosclerotic stenoses at the carotid bifurcation in 1980.[7] The technique evolved slowly from simple balloon dilatation to 
involve stenting, used first by Théron in 1990 and then widespread use of cerebral protection devices.  

















































































































Roubin 146 210 37 99 NS 1 / 0.65 1.3 4.6 6 mo, ,5%; 12 mo, ID 
Theron 69 69 NS 100 NS … … … 4% (time not specified) 
Diethrich 110 129 72 99.1 7.3 2 / 1.8% 2 4.5 6 mo, NS; 12 mo, NS 
Yadav 107 189 36 100 7.9 1 / 0.9% 1.9 6.5 6 mo, 4.9%; 12 mo, NS 
Vozzi 22 19 55 96 NS 1 / 4.5% 4.5 4.5 6 mo, NS; 12 mo, ID 
Criado 33 NS 27 100 NS 0 0 0 3% (mean 8-mo follow-up) 
Wholey 108 NS 44 95 NS 2/ 1.9% 1.8 1.8 1% (mean 6-mo follow-up) 
Henry 163 178 35 99.4 NS 0/ .. 1.8 1.2 6 mo, 2.3%; 12 mo, ID 
Teitelbau
m 22 31 32 96.2 27.3 1 / 4.5% 13.6 9.0 
6 mo, 14.3%; 
12 mo, NS 
Waigand 50 56 72 100 2 1 / 2% 2 2 8.7% (mean 8- mo follow-up 
Bergeron 99 99 42 97 2.0 0/… 0 1 4.2% (mean 13- mo follow-up) 
Table 2. Carotid Stent Series [8] 
9. Results of multicenter registries 
The Global Carotid Artery Stent Registry: In 1998, Wholey et al collected data from major interventional centers worldwide as well 
as from peer-reviewed journals. The total number of procedures that have been performed till that date included 2,048 cases, with a 
technical success of 98.6%. The stroke rate was 3.08%. The 30-day post-procedure mortality rate was 1.37%. The registry was 
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of stenosis. This observation was assumed to be attributable to a lack of statistical power
of the trials. The benefit from CEA relates to the complication rates. Reported benefits were
predicated  on  operative  risks  of  stroke  or  death  of  7.5%  in  the  ECST  and  6.5%  in  the
NASCET. If the disabling stroke and death rates exceed this by as little as 2%, the benefit
from CEA disappears.[4]
5. The spread of CEA among vascular surgeons worldwide
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United States and Canada, which correlate with the publication of first unfavorable and then
favorable clinical studies. The absence of selective referral of patients to centers with the lowest
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general population are similar to those demonstrated in the clinical trials. Rates of carotid
endarterectomy fell in all three regions from 1984 to 1989 (from 126 to 66 per 100,000 adults 40
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per 100,000 in Ontario), after the publication of studies demonstrating that the rates of
complications of carotid endarterectomy were unacceptably high. However, the clinical trials
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These increased rates were not associated with proportionally greater numbers of referrals of
patients to hospitals with low mortality rates.[5]
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This NASCE, ACAS and ESCT trial as well as the spread of carotid endarterectomy worldwide
unveiled the problems and limitations inherent to the procedure. It became clear that the
coexistence of cardiac co-morbidity is a powerful predictor of mortality and that myocardial
infarction can be the most dreaded complication, even more than stroke. This was evident,
despite the fact that patients with myocardial infarction in the prior six months, congestive
heart failure and patients scheduled for coronary revascularization were excluded from the
large CEA trials.[6] Other limitations of the procedure were more located to the local envi‐
ronment in the neck as prior endarterectomy, prior neck dissection or radiation, cranial nerve
palsies and inaccessible high/low carotid bifurcations. The presence of contra-lateral carotid
occlusion also posed a problem during cross clamping that increased the risk of CEA.
7. Carotid angioplasty
While carotid endarterectomy was growing to maturity, anther contender was born. After the
fundamental work in endovascular therapy by Charles Dotter and Andreas Grüntzig, it was
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inconceivable at the end of the 1970s to apply their work to arteries supplying the brain. Klaus
Mathias chose to ignore this strict limit and was able to successfully perform angioplasty of
atherosclerotic stenoses at the carotid bifurcation in 1980.[7] The technique evolved slowly
from simple balloon dilatation to involve stenting, used first by Théron in 1990 and then
widespread use of cerebral protection devices.
8. The initial case-series and registries of carotid stenting
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procedures that have been performed till that date included 2,048 cases, with a technical
success of 98.6%. The stroke rate was 3.08%. The 30-day post-procedure mortality rate was
1.37%. The registry was updated in 2003. The total number of stent procedures performed then
became 12392 with a technical success rate of 98.9%. Overall, there was TIA rate of 3.07%, minor
strokes of 2.14%, major strokes of 1.20%, and procedure-related deaths of 0.64%. There were
6753 cases done without protection and which incurred a 5.29% rate of strokes and procedure-
related deaths. In the 4221 cases with cerebral protection, there was a 2.23% rate of strokes and
procedure-related deaths. The rate of neurologic events was 1.2%, 1.3%, and 1.7% at 1, 2, and
3 years, respectively.[9]
In the following years, several registries that were supported by the device industry were
reported. These registries included patients who are considered high risk for CEA because one
or more of the following features:
1. Class-III/IV congestive heart failure
2. Left ventricular ejection fraction<30%
3. Open heart surgery within 6 weeks
4. Recent myocardial infarction (>24 h <30 d)
5. Unstable angina: class III/IV
6. Concurrent requirement for coronary revascularization
7. Severe pulmonary disease
8. Contralateral carotid occlusion
9. Previous radiation to head/neck
10. Previous CEA
11. Age >80 y
12. Surgically inaccessible lesions
Acronym Sponsor Stent Protection device
Result; 30-day death/
stroke/MI rate
BEACH Boston Scientific WallStent Ex filter 5.4%
CABERNET Boston Scientific/ Endotex Nex Stent EPI Filter 3.9%
ARCHER Guidant AccuLink AccuNet 7.8%
MAVErIC Medtronic Exponent PercuSurge 4%
PASCAL Medtronic Exponent Any approved 8%
SECuRITY Abott Xact Emboshield 7.2%
Table 3. Carotid stent industry-supported high-risk registries
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10. Comparisons of stenting versus endarterectomy
Markus et al studied the effect of carotid PTA compared to CEA on cerebral hemodynamics
of symptomatic stenoses as reflected by CO2 reactivity. After PTA there was a significant
improvement in ipsilateral hypercapnic reactivity. There was a similar improvement in
ipsilateral hypercapnic reactivity after CEA.[10]
Golledge et al performed a systematic comparison of the 30-day outcome of angioplasty with
or without stenting and CEA for symptomatic carotid disease reported in single-center studies,
published between 1990 and 1999. All the results were in favor of CEA. Mortality within 30
days of angioplasty was 0.8% compared with 1.2% after CEA (P=0.6). The stroke rate was 7.1%
for angioplasty and 3.3% for CEA (P<0.001).[11]
11. The UK Leicester halted trial
The most outstanding negative trial of carotid angioplasty was form Leicester Royal Infirmary.
The study consisted of 23 patients with focal carotid territory symptoms and severe ICA
stenosis (>70%) who were randomized to either CEA or CAS. However, only 17 had received
their allocated treatment before trial suspension. All 10 CEA operations proceeded without
complication, but 5 of the 7 (71.4%) patients who underwent CAS had a stroke, 3 of which were
disabling at 30 days. The Data Monitoring Committee invoked the stopping rule and the trial
was suspended. The investigators and the Ethics Committee subsequently decided that the
trial should not be restarted even in an amended format because of problems with informed
consent.[12, 13]
The CAVATAS (Carotid and Vertebral Artery Transluminal Angioplasty Study), was the first
randomized trial of CEA versus CAS. 504 patients were randomized from 22 centers in between
1992 and 1997. The majority of patients had recently symptomatic lesions. Only 26% of the
angioplasty patients received a stent. The rates of major outcome events within 30 days of first
treatment did not differ significantly between endovascular treatment and surgery (6.4% vs.
5.9%, respectively, for disabling stroke or death; 10.0% vs. 9.9% for any stroke lasting more
than 7 days, or death). (Figure 21) At 1 year after treatment, restenosis was more usual after
endovascular treatment (14%vs. 4%, p<0.001). Complications of cranial nerve injury and
myocardial ischemia were only reported in the surgical group. The trial described rates of
death and disabling stroke after 3 years of 14.3% in the endovascular group and 14.2% in the
surgical group.[14]
Crawley et al compared cerebral hemodynamics and microembolization during CAS versus
CEA using TCD. The period during which the ICA was occluded by PTA balloon or by clamp
during CEA was timed. Ischemic time was defined as the period during which mean MCA
velocity fell to a third or less of baseline. CEA resulted in significantly longer occlusion time
and ischemic time than PTA. There were significantly more microembolic signals during PTA
than during CEA. There was no correlation between any of the parameters measured and
periprocedural stroke.[15]
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The SAPPHIRE trial (Stenting and Angioplasty with Protection in Patients at High Risk for
Endarterectomy) randomized patients with co-morbid conditions that represented exclusion
criteria from the previous major randomized trials of CEA. The rationale was that patients
with these co-morbid conditions appear to represent the majority of patients undergoing CEA,
and concerns have been raised about the generalizability of the CEA trial results in view of the
exclusion of those patients in major CEA trials. SAPPHIRE was designed to test “non-
inferiority” of CAS versus CEA in the high-risk population with >50% symptomatic or >80%
asymptomatic stenosis.[16, 17]
All carotid stenting procedures were done with the Angioguard protection device. The trial
was conducted at 29 US centers which all had mean complication rate less than 3% for CEA
and 4% for CAS. All patients were seen by a team made up of a neurologist, a surgeon, and an
interventionist. If the surgeon felt that he or she could not operate, and the interventionist felt
that intervention was possible, the patient was entered into a stent registry. Conversely, if the
interventionist did not feel that he or she could perform the intervention, and the surgeon felt
that surgery was possible, the patient was entered into a surgical registry. 723 patients were
enrolled initially. Consensus was achieved in 307 patients who were randomized to either
stenting (n = 156) or CEA (n = 151). The stent registry consisted of 409 patients, and the surgical
registry included seven. Individual endpoints of death, stroke, and MI at 30 days were lower
in patients randomized to stenting. The combined endpoint of death/stroke/MI was statisti‐
cally significantly lower in patients randomized to stenting vs. CEA. The death, stroke or
myocardial infarction rate was 11.9% in the CAS group and 19.9 % in the CEA group after 1-
year. The SAPPHIRE results indicated that CAS has become a promising alternative to CEA,
at least “not inferior”.
12. SAPPHIRE long-term results
At 3 years, data were available for 260 patients (77.8%), including 85.6% of patients in the
stenting group and 70.1% of those in the endarterectomy group. There was no significant
difference could be shown in long-term outcomes between patients who underwent carotid
artery stenting with an emboli-protection device and those who underwent endarterectomy
The prespecified major secondary end point occurred in 41 patients in the stenting group
(cumulative incidence, 24.6%; Kaplan–Meier estimate, 26.2%) and 45 patients in the endarter‐
ectomy group (cumulative incidence, 26.9%; Kaplan–Meier estimate, 30.3%) (absolute differ‐
ence in cumulative incidence for the stenting group, −2.3%; 95% confidence interval, −11.8 to
7.0). There were 15 strokes in each of the two groups, of which 11 in the stenting group and 9
in the endarterectomy group were ipsilateral.[18]
The SAPPHIRE data are specific to patients who are at high surgical risk, and they provide no
insight into outcomes of treatment of a carotid artery stenosis in patients at low-to-moderate
risk. On the basis of the similar long-term outcomes among high-risk patients in the two
treatment groups, it may be tempting to infer that endarterectomy is preferable for lower-risk
patients.
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13. The CARESS trial
Carotid REvascularization with Stenting Systems was a prospective, multicenter non-random‐
ized industry-sponsored trial compared standard CEA to carotid stenting in patients with
symptomatic (≥50%) and asymptomatic (≥75%) carotid stenosis. There was no significant
difference in the 30-day combined all-cause mortality and stroke rate between CEA (2%) and
CAS (2%). There was no significant difference in the secondary endpoint of combined 30-day
all-cause mortality, stroke, and myocardial infarction between CEA and CAS.[19]
Following the publication of the SAPPHIRE and the CARESS trials, carotid artery stenting
rocketed. There was a general felling that carotid artery stenting will prevail and become the
preferred choice for carotid revascularization. However, the following randomized trials did
not come in favor of carotid stenting.
14. SPACE
Stent-protected angioplasty versus carotid endarterectomy in symptomatic patients included
1183 patients with symptomatic carotid-artery stenosis. Patients were randomly assigned
within 180 days of transient ischemic attack or moderate stroke (modified Rankin scale score
of < or =3) to carotid-artery stenting (n=605) or carotid endarterectomy (n=595). The primary
endpoint of this hospital-based study was ipsilateral ischemic stroke or death from time of
randomization to 30 days after the procedure. The non-inferiority margin was defined as less
than 2.5% on the basis of an expected event rate of 5%. Analyses were on an intention-to-treat
basis. The rate of death or ipsilateral ischemic stroke from randomization to 30 days after the
procedure was 6.84% with carotid-artery stenting and 6.34% with carotid endarterectomy
(absolute difference 0.51%, 90% CI -1.89% to 2.91%). The one-sided p value for non-inferiority
is 0.09. SPACE failed to prove non-inferiority of carotid-artery stenting compared with carotid
endarterectomy for the periprocedural complication rate.[20]
Lon term data showed that in both the intention-to-treat and per-protocol analyses the Kaplan-
Meier estimates of ipsilateral ischemic strokes up to 2 years after the procedure and any
periprocedural stroke or death do not differ between the carotid artery stenting and the carotid
endarterectomy groups (intention to treat 9 5% vs. 8 8%; hazard ratio (HR) 1 10, 95%CI 0 75 to
1 61; log-rank p=0 62; per protocol 9 4% vs. 7 8%; HR 1 23, 95%CI 0 82 to 1 83; log-rank p=0 31).
In both the intention-to-treat and per-protocol populations, recurrent stenosis of 70% or more
is significantly more frequent in the carotid artery stenting group compared with the carotid
endarterectomy group, with a life-table estimate of 10 7% versus 4 6% (p=0 0009) and 11 1%
versus 4 6% (p=0 0007), respectively.[21]
15. EVA-3S
262 patients were randomly assigned to endarterectomy and 265 to stenting. The cumulative
probability of periprocedural stroke or death and non-procedural ipsilateral stroke after 4
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years of follow-up was higher with stenting than with endarterectomy (11 1% vs. 6 2%, hazard
ratio [HR] 1 97, 95% CI 1 06–3 67; p=0 03). The HR for periprocedural disabling stroke or death
and non-procedural fatal or disabling ipsilateral stroke was 2 00 (0 75–5 33; p=0 17). A hazard
function analysis showed the 4-year differences in the cumulative probabilities of outcomes
between stenting and endarterectomy were largely accounted for by the higher periprocedural
(within 30 days of the procedure) risk of stenting compared with endarterectomy. After the
periprocedural period, the risk of ipsilateral stroke was low and similar in both treatment
groups. For any stroke or periprocedural death, the HR was 1 77 (1 03–3 02; p=0 04). For any
stroke or death, the HR was 1 39 (0 96–2 00; p=0 08). The results of this study suggest that
carotid stenting is as effective as carotid endarterectomy for middle-term prevention of
ipsilateral stroke, but the safety of carotid stenting needs to be improved before it can be used
as an alternative to carotid endarterectomy in patients with symptomatic carotid stenosis.[22]
In the same study, the rate of carotid restenosis of ≥50% or occlusion was significantly higher
after CAS (12.5%) than after CEA (5.0%; time ratio, 0.16; 95% CI, 0.03–0.76; P=0.02). The rates
of severe restenosis of ≥70% or occlusion were low and did not differ significantly between the
2 groups (3-year rates are 3.3% in the CAS group and 2.8% in the CEA group). Age at baseline
was the only vascular risk factor significantly associated with carotid restenosis. Our study
could not detect any effect of carotid restenosis on ipsilateral stroke.[23]
It was notable that the risk of ipsilateral stroke or death increased significantly with age in the
CAS group (p=0 001) but not in the CEA group (p=0 534). Classification and regression tree
analysis showed that the age that gave the greatest separation between high-risk and low-risk
populations who had CAS was 68 years: the rate of primary outcome events was 2 7% (8/293)
in patients who were 68 years old or younger and 10 8% (34/314) in older patients.[24]
In the first 120 days after randomization (ITT analysis), the primary outcome event occurred
in 153/1725 patients in the CAS group (8.9%) compared with 99/1708 patients in the CEA group
(5.8%, risk ratio [RR] 1.53, 95% confidence interval [CI] 1.20–1.95, p = 0.0006; absolute risk
difference 3.2, 95% CI 1.4–4.9). Age was the only subgroup variable which significantly
modified the treatment effect: in patients <70 years old (the median age), the 120-day stroke
or death risk was 5.8% in CAS and 5.7% in CEA (RR 1.00, 0.68–1.47); in patients 70 years or
older, there was an estimated two-fold increase in risk with CAS over CEA (12.0% vs. 5.9%,
RR 2.04, 1.48–2.82, interaction p = 0.0053).[25]
Endarterectomy was safer in the short-term than stenting, because of an increased risk of stroke
associated with stenting in patients over the age of 70 years. Stenting should be avoided in
older patients, but may be as safe as endarterectomy in younger patients. Determination of the
efficacy and ultimate balance between the two procedures requires further data on long-term
stroke recurrence.[25]
16. ICSS study
The incidence of stroke, death, or procedural myocardial infarction was 8.5% in the stenting
group compared with 5.2% in the endarterectomy group (72 vs. 44 events; HR 1.69, 1.16-2.45,
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p=0.006), Risks of any stroke (65 vs. 35 events; HR 1.92, 1.27-2.89) and all-cause death (19 vs.
seven events; HR 2.76, 1.16-6.56) were higher in the stenting group than in the endarterectomy
group. Three procedural myocardial infarctions were recorded in the stenting group, all of
which were fatal, compared with four, all non-fatal, in the endarterectomy group.[26]
At 1 month, there were changes on fluid-attenuated inversion recovery sequences in 28 (33%)
of 86 patients in the stenting group and six (8%) of 75 in the endarterectomy group (adjusted
OR 5 93, 95% CI 2 25–15 62; p=0 0003). In patients treated at a center with a policy of using
cerebral protection devices, 37 (73%) of 51 in the stenting group and eight (17%) of 46 in the
endarterectomy group had at least one new DWI lesion on post-treatment scans (adjusted OR
12 20, 95% CI 4 53–32 84), whereas in those treated at a center with a policy of unprotected
stenting, 25 (34%) of 73 patients in the stenting group and ten (16%) of 61 in the endarterectomy
group had new lesions on DWI (adjusted OR 2 70, 1 16–6 24; interaction p=0 019).[27]
These discordant results may be explained by the fact that the EVA-3S and SPACE studies
differ from ours in numerous ways, including in the selection criteria (e.g., the EVA-3S and
SPACE trials included neither patients with a high surgical risk nor asymptomatic patients),
the rate of use of specific emboli-protection devices (in 92% of cases in the EVA-3S trial
and 27% in the SPACE trial), and the experience level of the physician who placed the stent
(in the EVA-3S trial, stents could be placed by physicians who had performed as few as
five  previous  carotid-stent  procedures  or,  if  working under  the  direction  of  a  tutor,  no
previous procedures).[18]
The results of the previous studies were a major setback for stenting. They created a general
belief among practicing physicians and neurologists that carotid artery stenting has only a
limited role in the prevention of stroke. This set the stage ready for a more comprehensive
larger trial trying to reach the truth.
17. CREST trial
The CREST (Carotid Revascularization Endarterectomy vs. Stent Trial) was a multicenter trial
supported by the National institute of health. The study includes symptomatic (>50% stenosis)
and asymptomatic (>70% stenosis) patients. The CREST was probably the largest study on
carotid revascularization and had the best design. Centers were required to have a team
consisting of a neurologist, an interventionist, a surgeon, and a research coordinator. Patients
could not be randomly assigned to a treatment group until the operators performing carotid
artery stenting and carotid endarterectomy had been certified. Certification was achieved by
477 surgeons, whose clinical results were audited by means of a validated selection process
documenting that they performed more than 12 procedures per year and that the rates of
complications and death were less than 3% among asymptomatic patients and less than 5%
among symptomatic patients. The 224 interventionists were certified after satisfactory
evaluation of their endovascular experience, carotid-stenting results, participation in hands-
on training, and participation in a lead-in phase of training.[28]
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years of follow-up was higher with stenting than with endarterectomy (11 1% vs. 6 2%, hazard
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function analysis showed the 4-year differences in the cumulative probabilities of outcomes
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(within 30 days of the procedure) risk of stenting compared with endarterectomy. After the
periprocedural period, the risk of ipsilateral stroke was low and similar in both treatment
groups. For any stroke or periprocedural death, the HR was 1 77 (1 03–3 02; p=0 04). For any
stroke or death, the HR was 1 39 (0 96–2 00; p=0 08). The results of this study suggest that
carotid stenting is as effective as carotid endarterectomy for middle-term prevention of
ipsilateral stroke, but the safety of carotid stenting needs to be improved before it can be used
as an alternative to carotid endarterectomy in patients with symptomatic carotid stenosis.[22]
In the same study, the rate of carotid restenosis of ≥50% or occlusion was significantly higher
after CAS (12.5%) than after CEA (5.0%; time ratio, 0.16; 95% CI, 0.03–0.76; P=0.02). The rates
of severe restenosis of ≥70% or occlusion were low and did not differ significantly between the
2 groups (3-year rates are 3.3% in the CAS group and 2.8% in the CEA group). Age at baseline
was the only vascular risk factor significantly associated with carotid restenosis. Our study
could not detect any effect of carotid restenosis on ipsilateral stroke.[23]
It was notable that the risk of ipsilateral stroke or death increased significantly with age in the
CAS group (p=0 001) but not in the CEA group (p=0 534). Classification and regression tree
analysis showed that the age that gave the greatest separation between high-risk and low-risk
populations who had CAS was 68 years: the rate of primary outcome events was 2 7% (8/293)
in patients who were 68 years old or younger and 10 8% (34/314) in older patients.[24]
In the first 120 days after randomization (ITT analysis), the primary outcome event occurred
in 153/1725 patients in the CAS group (8.9%) compared with 99/1708 patients in the CEA group
(5.8%, risk ratio [RR] 1.53, 95% confidence interval [CI] 1.20–1.95, p = 0.0006; absolute risk
difference 3.2, 95% CI 1.4–4.9). Age was the only subgroup variable which significantly
modified the treatment effect: in patients <70 years old (the median age), the 120-day stroke
or death risk was 5.8% in CAS and 5.7% in CEA (RR 1.00, 0.68–1.47); in patients 70 years or
older, there was an estimated two-fold increase in risk with CAS over CEA (12.0% vs. 5.9%,
RR 2.04, 1.48–2.82, interaction p = 0.0053).[25]
Endarterectomy was safer in the short-term than stenting, because of an increased risk of stroke
associated with stenting in patients over the age of 70 years. Stenting should be avoided in
older patients, but may be as safe as endarterectomy in younger patients. Determination of the
efficacy and ultimate balance between the two procedures requires further data on long-term
stroke recurrence.[25]
16. ICSS study
The incidence of stroke, death, or procedural myocardial infarction was 8.5% in the stenting
group compared with 5.2% in the endarterectomy group (72 vs. 44 events; HR 1.69, 1.16-2.45,
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p=0.006), Risks of any stroke (65 vs. 35 events; HR 1.92, 1.27-2.89) and all-cause death (19 vs.
seven events; HR 2.76, 1.16-6.56) were higher in the stenting group than in the endarterectomy
group. Three procedural myocardial infarctions were recorded in the stenting group, all of
which were fatal, compared with four, all non-fatal, in the endarterectomy group.[26]
At 1 month, there were changes on fluid-attenuated inversion recovery sequences in 28 (33%)
of 86 patients in the stenting group and six (8%) of 75 in the endarterectomy group (adjusted
OR 5 93, 95% CI 2 25–15 62; p=0 0003). In patients treated at a center with a policy of using
cerebral protection devices, 37 (73%) of 51 in the stenting group and eight (17%) of 46 in the
endarterectomy group had at least one new DWI lesion on post-treatment scans (adjusted OR
12 20, 95% CI 4 53–32 84), whereas in those treated at a center with a policy of unprotected
stenting, 25 (34%) of 73 patients in the stenting group and ten (16%) of 61 in the endarterectomy
group had new lesions on DWI (adjusted OR 2 70, 1 16–6 24; interaction p=0 019).[27]
These discordant results may be explained by the fact that the EVA-3S and SPACE studies
differ from ours in numerous ways, including in the selection criteria (e.g., the EVA-3S and
SPACE trials included neither patients with a high surgical risk nor asymptomatic patients),
the rate of use of specific emboli-protection devices (in 92% of cases in the EVA-3S trial
and 27% in the SPACE trial), and the experience level of the physician who placed the stent
(in the EVA-3S trial, stents could be placed by physicians who had performed as few as
five  previous  carotid-stent  procedures  or,  if  working under  the  direction  of  a  tutor,  no
previous procedures).[18]
The results of the previous studies were a major setback for stenting. They created a general
belief among practicing physicians and neurologists that carotid artery stenting has only a
limited role in the prevention of stroke. This set the stage ready for a more comprehensive
larger trial trying to reach the truth.
17. CREST trial
The CREST (Carotid Revascularization Endarterectomy vs. Stent Trial) was a multicenter trial
supported by the National institute of health. The study includes symptomatic (>50% stenosis)
and asymptomatic (>70% stenosis) patients. The CREST was probably the largest study on
carotid revascularization and had the best design. Centers were required to have a team
consisting of a neurologist, an interventionist, a surgeon, and a research coordinator. Patients
could not be randomly assigned to a treatment group until the operators performing carotid
artery stenting and carotid endarterectomy had been certified. Certification was achieved by
477 surgeons, whose clinical results were audited by means of a validated selection process
documenting that they performed more than 12 procedures per year and that the rates of
complications and death were less than 3% among asymptomatic patients and less than 5%
among symptomatic patients. The 224 interventionists were certified after satisfactory
evaluation of their endovascular experience, carotid-stenting results, participation in hands-
on training, and participation in a lead-in phase of training.[28]
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There was no differential treatment effect with regard to the primary end point according to
symptomatic status (P = 0.84) or sex (P = 0.34). The 4-year rate of stroke or death was 6.4% with
stenting and 4.7% with endarterectomy (hazard ratio, 1.50; P = 0.03); the rates among symp‐
tomatic patients were 8.0% and 6.4% (hazard ratio, 1.37; P = 0.14), and the rates among
asymptomatic patients were 4.5% and 2.7% (hazard ratio, 1.86; P = 0.07), respectively. Peri‐
procedural rates of individual components of the end points differed between the stenting
group and the endarterectomy group: for death (0.7% vs. 0.3%, P = 0.18), for stroke (4.1% vs.
2.3%, P = 0.01), and for myocardial infarction (1.1% vs. 2.3%, P = 0.03). After this period, the
incidences of ipsilateral stroke with stenting and with endarterectomy were similarly low
(2.0% and 2.4%, respectively; P = 0.85).[28]
The results of the CREST were “satisfying” for both surgeons and interventionists. Surgeons
were glad to prove that CEA resulted in lower stroke rates in the short term and the long term.
Interventionists were reassured that the primary end-point was similar in the two methods.
Restenosis and occlusion were infrequent and rates were similar up to 2 years after carotid
endarterectomy and carotid artery stenting. Subsets of patients could benefit from early and
frequent monitoring after revascularization.[29]
CAS was associated with better health-related quality of life HRQOL during the early recovery
period as compared with CEA-particularly with regard to physical limitations and pain-but
these differences diminish over time and are not evident after 1 year. Although CAS and CEA
are associated with similar overall quality of life at 1 year, event-specific analyses confirm that
stroke has a greater and more sustained impact on HRQOL than MI.[30]
The MI rates were slightly lower after CAS (1.3% vs. 2.6%; P =.24). In performing CAS, vascular
surgeons had outcomes for the periprocedural primary end point comparable to the outcomes
of all interventionists (HR, 0.99; 95% CI, 0.50-2.00) after adjusting for age, sex, and symptomatic
status. Vascular surgeons also had similar results after CEA for the periprocedural primary
end point compared with other surgeons (HR, 0.73; 95% CI, 0.42-1.27).[31]
18. Carotid endarterectomy and stenting in specific situations
18.1. Restenosis after carotid stenting
The restenosis rate after carotid stenting is remarkably low at 2.3-10% compared to other
endovascular interventions. Although self-expanding carotid stents generate considerable
neointimal hyperplasia, the process is balanced by marked late stent enlargement. Small stent
dimensions immediately post-procedure were associated with a higher risk of restenosis.[32]
In the 2003 global carotid stent registry, restenosis rates have been 2.7%, 2.6%, and 2.4% at 1,
2, and 3 years, respectively.[9] A retrospective, single-center review was conducted of 399
carotid stent procedures in 363 patients over 9 years, with a mean follow-up of 24 months
(range 6-99 months). Overall, restenosis occurred in 15 patients (3.8%). However, the restenosis
occurred in 7 of 35 (20%) patients who had previous neck radiation, 6 of 57 (10.5%) patients
who had previous CEA, and 2 of 9 (22%) patients who previously had both CEA and neck
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radiation. The only analyzed variables that were significantly associated with an increased risk
of restenosis were previous CEA (OR 4.28, P = 0.008) or XRT (OR 11.3, P <or=<or= 0.0001).[33]
In another study, among 215 CAS procedures that had clinical and serial carotid duplex
ultrasound investigations, restenosis was detected in 6.1% of patients. Contralateral carotid
occlusion (OR 10.11, 95% CI 2.06-49.63, p = 0.004), carotid endarterectomy (CEA) restenosis
(OR 8.87, 95% CI 1.68-46.84, p = 0.010) and postprocedural carotid duplex ultrasound with a
PSV >/=120 cm/s (OR 6.33, 95% CI 1.27-31.44, p = 0.024) were independent predictors of stent
restenosis.[34] Most restenoses occur within 6 to 12 months after the intervention. Usually they
are located either in the mid or at the distal end of the stent. Restenoses are often overestimated
by ultrasound compared to angiography. Most of restenoses can be treated by balloon
angioplasty. Drug-eluting balloons can be a promising modality[35] and only rarely, stent
removal and eversion endarterectomy will be required.[36]
18.2. Restenosis after carotid endarterectomy
The incidence ranges from 1.2% to 23.9% depending on the operative technique. The highest
rates of restenosis, 21.4%, after CEA came with direct suture and the lowest rate 3.9% were
after patch angioplasty only Long-term risk of recurrence is about 1% per year. The risk is
highest in the first few years after CEA and is very low later.[37]. Most of restenoses are
asymptomatic and only 1.2-3.6% require re-intervention.[38]
The type of operative technique for reoperations depends on the cause of the recurrent disease.
Myointimal hyperplasia has a smooth luminal surface and appears to be associated with a low
potential for embolization therefore simple patching may be all that is necessary. By contrast,
the soft nature of the plaque in recurrent atherosclerosis, which appears later, has a greater
potential for embolization therefore repeat CEA with carotid patch angioplasty is preferable.
AbuRahma et al showed the 30-day perioperative stroke and transient ischemic attack rates
for reoperation and primary CEA were 4.8% versus 0.8% (P=0.015) and 4% versus 1.1%,
respectively. There was an increase in the number of transient cranial nerve injuries in the
reoperation group compared with the primary CEA group (15.3% versus 4.9%).[39]
CAS for restenosis after CEA has a complication rate lower than primary CAS. The time
interval between CEA and CAS did not influence micro embolic load.[40] Statistical analysis
demonstrated that post-CEA restenosis was the most important predictive factor for the
development of in-stent restenosis after CAS. This review of our 10-year experience confirms
that patients who develop restenosis after CEA are also prone to developing in-stent restenosis
after CAS.[41]
18.3. Carotid stenosis in patients requiring bypass cardiac surgery
Patients who have concomitant severe carotid and coronary artery disease pose a serious
dilemma. Stroke remains a major non-cardiac complication after CABG and myocardial
infarction is the major non-neurological cause of early and late morbidity after CEA. The risk
of stroke after CABG ranges from 0.7-5.2%[42]
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There was no differential treatment effect with regard to the primary end point according to
symptomatic status (P = 0.84) or sex (P = 0.34). The 4-year rate of stroke or death was 6.4% with
stenting and 4.7% with endarterectomy (hazard ratio, 1.50; P = 0.03); the rates among symp‐
tomatic patients were 8.0% and 6.4% (hazard ratio, 1.37; P = 0.14), and the rates among
asymptomatic patients were 4.5% and 2.7% (hazard ratio, 1.86; P = 0.07), respectively. Peri‐
procedural rates of individual components of the end points differed between the stenting
group and the endarterectomy group: for death (0.7% vs. 0.3%, P = 0.18), for stroke (4.1% vs.
2.3%, P = 0.01), and for myocardial infarction (1.1% vs. 2.3%, P = 0.03). After this period, the
incidences of ipsilateral stroke with stenting and with endarterectomy were similarly low
(2.0% and 2.4%, respectively; P = 0.85).[28]
The results of the CREST were “satisfying” for both surgeons and interventionists. Surgeons
were glad to prove that CEA resulted in lower stroke rates in the short term and the long term.
Interventionists were reassured that the primary end-point was similar in the two methods.
Restenosis and occlusion were infrequent and rates were similar up to 2 years after carotid
endarterectomy and carotid artery stenting. Subsets of patients could benefit from early and
frequent monitoring after revascularization.[29]
CAS was associated with better health-related quality of life HRQOL during the early recovery
period as compared with CEA-particularly with regard to physical limitations and pain-but
these differences diminish over time and are not evident after 1 year. Although CAS and CEA
are associated with similar overall quality of life at 1 year, event-specific analyses confirm that
stroke has a greater and more sustained impact on HRQOL than MI.[30]
The MI rates were slightly lower after CAS (1.3% vs. 2.6%; P =.24). In performing CAS, vascular
surgeons had outcomes for the periprocedural primary end point comparable to the outcomes
of all interventionists (HR, 0.99; 95% CI, 0.50-2.00) after adjusting for age, sex, and symptomatic
status. Vascular surgeons also had similar results after CEA for the periprocedural primary
end point compared with other surgeons (HR, 0.73; 95% CI, 0.42-1.27).[31]
18. Carotid endarterectomy and stenting in specific situations
18.1. Restenosis after carotid stenting
The restenosis rate after carotid stenting is remarkably low at 2.3-10% compared to other
endovascular interventions. Although self-expanding carotid stents generate considerable
neointimal hyperplasia, the process is balanced by marked late stent enlargement. Small stent
dimensions immediately post-procedure were associated with a higher risk of restenosis.[32]
In the 2003 global carotid stent registry, restenosis rates have been 2.7%, 2.6%, and 2.4% at 1,
2, and 3 years, respectively.[9] A retrospective, single-center review was conducted of 399
carotid stent procedures in 363 patients over 9 years, with a mean follow-up of 24 months
(range 6-99 months). Overall, restenosis occurred in 15 patients (3.8%). However, the restenosis
occurred in 7 of 35 (20%) patients who had previous neck radiation, 6 of 57 (10.5%) patients
who had previous CEA, and 2 of 9 (22%) patients who previously had both CEA and neck
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radiation. The only analyzed variables that were significantly associated with an increased risk
of restenosis were previous CEA (OR 4.28, P = 0.008) or XRT (OR 11.3, P <or=<or= 0.0001).[33]
In another study, among 215 CAS procedures that had clinical and serial carotid duplex
ultrasound investigations, restenosis was detected in 6.1% of patients. Contralateral carotid
occlusion (OR 10.11, 95% CI 2.06-49.63, p = 0.004), carotid endarterectomy (CEA) restenosis
(OR 8.87, 95% CI 1.68-46.84, p = 0.010) and postprocedural carotid duplex ultrasound with a
PSV >/=120 cm/s (OR 6.33, 95% CI 1.27-31.44, p = 0.024) were independent predictors of stent
restenosis.[34] Most restenoses occur within 6 to 12 months after the intervention. Usually they
are located either in the mid or at the distal end of the stent. Restenoses are often overestimated
by ultrasound compared to angiography. Most of restenoses can be treated by balloon
angioplasty. Drug-eluting balloons can be a promising modality[35] and only rarely, stent
removal and eversion endarterectomy will be required.[36]
18.2. Restenosis after carotid endarterectomy
The incidence ranges from 1.2% to 23.9% depending on the operative technique. The highest
rates of restenosis, 21.4%, after CEA came with direct suture and the lowest rate 3.9% were
after patch angioplasty only Long-term risk of recurrence is about 1% per year. The risk is
highest in the first few years after CEA and is very low later.[37]. Most of restenoses are
asymptomatic and only 1.2-3.6% require re-intervention.[38]
The type of operative technique for reoperations depends on the cause of the recurrent disease.
Myointimal hyperplasia has a smooth luminal surface and appears to be associated with a low
potential for embolization therefore simple patching may be all that is necessary. By contrast,
the soft nature of the plaque in recurrent atherosclerosis, which appears later, has a greater
potential for embolization therefore repeat CEA with carotid patch angioplasty is preferable.
AbuRahma et al showed the 30-day perioperative stroke and transient ischemic attack rates
for reoperation and primary CEA were 4.8% versus 0.8% (P=0.015) and 4% versus 1.1%,
respectively. There was an increase in the number of transient cranial nerve injuries in the
reoperation group compared with the primary CEA group (15.3% versus 4.9%).[39]
CAS for restenosis after CEA has a complication rate lower than primary CAS. The time
interval between CEA and CAS did not influence micro embolic load.[40] Statistical analysis
demonstrated that post-CEA restenosis was the most important predictive factor for the
development of in-stent restenosis after CAS. This review of our 10-year experience confirms
that patients who develop restenosis after CEA are also prone to developing in-stent restenosis
after CAS.[41]
18.3. Carotid stenosis in patients requiring bypass cardiac surgery
Patients who have concomitant severe carotid and coronary artery disease pose a serious
dilemma. Stroke remains a major non-cardiac complication after CABG and myocardial
infarction is the major non-neurological cause of early and late morbidity after CEA. The risk
of stroke after CABG ranges from 0.7-5.2%[42]
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Hemodynamically significant carotid stenoses are associated with 30% of early post-CABG
strokes. The perioperative stroke risk is <2% when carotid stenoses are <50%, 10% when
stenoses are 50% to 80%, 11% to 18.8% in patients with stenoses >80%. The risk shoots to 20%
with untreated, bilateral, high-grade stenoses or an occluded carotid artery and contralateral
high-grade stenosis.[43]
The majority of strokes happen after the first 24 hours post CABG. This suggests that majority
of strokes cannot be simply be ascribed to an adverse intra-operative event (low flow, hypo‐
tension and carotid embolism). The overall case fatality following post-CABG stroke as 23.1%.
[43]In real life, it is not possible to state how often carotid stenosis of any degree of severity
contributes to the incidence of ischemic stroke after CABG. Naylor et al concluded that primary
carotid thromboembolic disease alone was not responsible for up to 59% of post CABG strokes.
A significant proportion of post-operative strokes was in the vertebro-basilar territory or
located contralateral to the severely stenosed carotid or ipsilateral to an insignificant stenosis.
Aortic arch atherosclerosis embolization may be an important cause of stroke in the majority
of cases.[43]
19. Approaches to treatment
1. Staged approach: Advocates of a staged procedure perform CEA several days prior to
CABG or several weeks following cardiac surgery. The rationale of the staged procedure
is to decrease the risk of stroke in the cardiac procedure and eliminate the need for longer
and more stressful combined procedure. Increased cardiac morbidity and mortality
resulting from CEA may offset potential benefits of this approach.[42]
In those with a history of TIA or stroke who have a significant carotid artery stenosis (50% to
99% in men or 70% to 99% in women), the likelihood of a post-CABG stroke is high; as a result,
they are likely to benefit from carotid revascularization. Conversely, CABG alone can be
performed safely in patients with asymptomatic unilateral carotid stenoses, because a carotid
revascularization procedure offers no discernible reduction in the incidence of stroke or death
in these individuals. Men with asymptomatic bilateral severe carotid stenoses (50% to 99%) or
a unilateral severe stenosis in conjunction with a contralateral carotid artery occlusion may be
considered for carotid revascularization in conjunction with CABG. Little evidence exists to
suggest that women with asymptomatic carotid artery disease benefit from carotid revascu‐
larization in conjunction with CABG. Whether the carotid and coronary revascularization
procedures are performed simultaneously or in a staged, sequential fashion is usually dictated
by the presence or absence of certain clinical variables. In general, synchronous combined
procedures are performed only in those with both cerebrovascular symptoms and ACS.[44]
2. Combined approach: performing CEA and CABG in the same setting: If the combined
approach can be done safely, a second surgical procedure and hospital stay may be
eliminated, with significant cost reduction. Long-term stroke free survival may also be
significantly improved.[42] The problem with this approach is that the stroke rate is
exceedingly high.
Carotid Artery Disease - From Bench to Bedside and Beyond118
3. Ignoring the carotid disease initially and addressing it weeks to months later after the
CABG procedure may be another approach. This idea is supported by a retrospective
review of 94 patients with asymptomatic high-grade carotid stenosis undergoing CABG.
There was one perioperative stroke and no deaths in this group of patients. These data
combined with findings of Naylor et al that prophylactic CEA could barely prevent < 40%
of post-CABG strokes [43] would support this approach in asymptomatic carotid stenoses.
In the absence of clear guidelines, the decision is better individualized dealing with the
more symptomatic vascular bed first. The simultaneous performance of CABG and CEA
carries a high risk but is warranted in patients with recent symptoms of both severe
coronary disease (unstable angina) and severe carotid stenosis.
Carotid stenting can be an alternative in endarterectomy in this subset of patients.[45, 46] A
recent Comparison of Early and Late Outcomes with Three Approaches to Carotid Revascu‐
larization and Open Heart Surgery showed that Staged CAS-OHS and combined CEA-OHS
are associated with similar risk of death, stroke or MI in the short term, with both being better
than staged CEA-OHS. However, the outcomes are significantly in favor of staged CAS-OHS
after the first year.[47]
20. CEA in the presence of contralateral occlusion
Patients with contralateral carotid occlusion have higher surgical risk for CEA due to multiple
reasons; reduced collateral circulation during carotid clamping, cerebral hemorrhage secon‐
dary to hyperperfusion syndrome, and the overall advanced status of the vascular disease.
Surgical mortality was extremely high in patients with a contralateral carotid occlusion and
only 34% of the surgically treated patients were alive at 66 months in contrast to 63% of
medically treated patients.(88) Results from the NASCET study demonstrated that medically
treated patients with a contralateral occluded carotid were more than twice as likely to have
a stroke compared to patients with a patent contralateral artery. However, when compared
with medically treated patients, the overall risk of stroke contralateral to an occluded carotid
artery was significantly reduced in the surgical patients. The risk of stroke in medically treated
patients was 69% at 2 years versus 22% in patients treated surgically. (2) Thus, CEA with
contralateral occlusion is a risky procedure but its risk may be justified considering the natural
history of the disease.
21. CEA vs. CAS in the real world
21.1. The limitations of published trials comparing CEA and CAS
The influence of the industry is strong, where all the industry-sponsored registries had lower
rates of complications compared to randomized trials. The levels of expertise of operators vary
significantly among trials as well as the obligatory use of protection devices. The percentage
of symptomatic and asymptomatic patients also varies rendering interpretation of results and
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Hemodynamically significant carotid stenoses are associated with 30% of early post-CABG
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carotid thromboembolic disease alone was not responsible for up to 59% of post CABG strokes.
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19. Approaches to treatment
1. Staged approach: Advocates of a staged procedure perform CEA several days prior to
CABG or several weeks following cardiac surgery. The rationale of the staged procedure
is to decrease the risk of stroke in the cardiac procedure and eliminate the need for longer
and more stressful combined procedure. Increased cardiac morbidity and mortality
resulting from CEA may offset potential benefits of this approach.[42]
In those with a history of TIA or stroke who have a significant carotid artery stenosis (50% to
99% in men or 70% to 99% in women), the likelihood of a post-CABG stroke is high; as a result,
they are likely to benefit from carotid revascularization. Conversely, CABG alone can be
performed safely in patients with asymptomatic unilateral carotid stenoses, because a carotid
revascularization procedure offers no discernible reduction in the incidence of stroke or death
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2. Combined approach: performing CEA and CABG in the same setting: If the combined
approach can be done safely, a second surgical procedure and hospital stay may be
eliminated, with significant cost reduction. Long-term stroke free survival may also be
significantly improved.[42] The problem with this approach is that the stroke rate is
exceedingly high.
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3. Ignoring the carotid disease initially and addressing it weeks to months later after the
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coronary disease (unstable angina) and severe carotid stenosis.
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contralateral occlusion is a risky procedure but its risk may be justified considering the natural
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The influence of the industry is strong, where all the industry-sponsored registries had lower
rates of complications compared to randomized trials. The levels of expertise of operators vary
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generalizing them to the general practice an intriguing issue. There also seems a publication
bias in reporting the trial results. Vascular surgery periodicals tend to note better results with
CEA while cardiology journals tend to report superiority or non-inferiority of CAS.
22. Ongoing trials and future directions
The modern medical treatment and optimized medical therapy (OMT) were not available at
the time of some landmark trials like NASCET and ECST. There is a growing enthusiasm to
test if OMT renders intervention unnecessary or only restricted to high risk patients. A new
set of trials called “Trials 2” are now developing and ongoing:
• European Carotid Surgery Trial-2 (ECST-2): The trial will include patients with sympto‐
matic or asymptomatic moderate or severe carotid stenosis at low or intermediate risk of
future stroke. The trial compares the risks and benefits of treatment by modern optimized
medical management alone versus the addition of immediate carotid surgery (or stenting)
to optimize medical management.
• Asymptomatic Carotid Surgery Trial-2 (ACST-2): To compare carotid endarterectomy with
carotid artery stenting in the prevention of stroke in patients with asymptomatic carotid
stenosis.
• Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy
Trial-2 (SPACE-2): A three-arm randomized-controlled clinical trial. The trial based on
German speaking countries. The trial initially randomized patients with asymptomatic
stenosis between carotid artery stenting vs. Carotid endarterectomy and recently the trial
modified to include third arm with optimized medical therapy (OMT) only.
• Carotid Revascularization Endarterectomy versus Stenting Trial-2(CREST-2): North
American trial testing revascularization vs. contemporary medical management alone.
23. Conclusion
What we can infer from these trials that CEA has a lower stroke rate than CAS but CAS has a
lower MI rate than CEA. If mortality, stroke and MI are mingled together as a single end-point,
then both strategies are equivalent on the long-term. Advancing age is strongly against
selecting CAS as the initial choice of revascularization. The results of either technique are
critically dependent on the skills of the performing physician. Restenosis after CAS may be
slightly more than restenosis after CEA but the severe, clinically significant restenosis is
uncommon. In patients with concomitant coronary and carotid disease, stenting may have an
advantage over CEA.
There remains a need for more trials assessing the future roles of medical management, carotid
stenting, and carotid endarterectomy. Future trials should be designed with the assumption
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that some patients will be best managed medically, some with medical therapy plus stenting,
and some with medical therapy plus endarterectomy. These treatments are complementary
and not competing. Varying treatment algorithms including more or less liberal use of each
modality can be designed, patients randomly assigned to one of the algorithms, and their
results compared.[48]
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1. Introduction
1.1. Carotid stenosis and atheromatous process
Carotid artery stenosis due to atherosclerosis is a major complication of hyperlipidemia,
diabetes mellitus and hypertension. Moreover, the extent of carotid intima media thickness is
a measure of atheromatosis and therefore of cardiovascular disease (CVD).
The effect of cholesterol in the process of atheromatosis is now well established. High levels
of total cholesterol, as well as of low-density lipoprotein (LDL), very low-density lipoprotein
(VLDL), intermediate-density lipoprotein (IDL), lipoprotein a (Lp-α), and triglycerides,
coupled with decreased levels of high-density lipoprotein (HDL) are responsible for the
creation of atheromatous plaques [1-3]. Of the above factors, LDL cholesterol, and especially
the oxidized LDL is considered as the most important contributor of atheromatosis [4].
The atheromatous process is completed in the following three stages:
1. In the first stage, LDL cholesterol enters the vessel wall, binds to gluxosaminoglucanes,
which are part of the extracellulat matrix of the intima. This binding is facilitated by
apolipoprotein B-100 (ApoΒ–100). The accumulation of LDL in the vessel wall contributes
to the formation of fatty strikes. Following LDL adhesion in the vessel wall, it undergoes
oxidation by free radicals produced locally, the molecule is altered and chemokines are
produced by adjacent vessel wall cells, such as MCP – 1, together with growth factors,
which are responsible for the accumulation of monocytes and macrophages. The latter,
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cause further oxidation of LDL, resulting in negative charge, recognition by scavenger
receptors on macrophage membrane and increased uptake of LDL inside the macrophag‐
es, as these receptors are not inhibited by increased intracellular concentration of choles‐
terol. The final result is an enormous accumulation of LDL in the macrophages, which are
transformed to foamy cells. These cells represent the first step in the atheromatous process
[5] (figure 1).
2. During the second stage, the atheromatous plaque is formed. Foamy cells produce growth
factors and together with oxidized LDL result to the attraction of smooth muscle cells. The
latter, are then differentiated to fibroblasts and start producing collagen. This collagen
covers foamy cells, which either are destroyed or are forced to apoptosis. The final result
is the formation of a pool of extracellular cholesterol trapped under a fibrous capsid (figure
2). The part which is close to the yet intact vessel wall is the active one of the plaque, where
the foamy cells are produced. As the plaque extents to the inner layers of the vessel wall,
the point of foamy cell formation becomes instable and may cause rapture of the plaque
[5] (figure 3).
Figure 1. Atherogenesis. Fatty strikes are characterized by macrophages containing an excess of lipids (foamy cells).
Foamy cells are derived by blood monocytes which are attracted to vessel intima and start phagocytosing lipoproteins,
such as oxidized LDL. The convertion of fatty strike to atheroma depends on proliferation and differentiation of
smooth muscle cells to fibroblasts. The latter produce collagen resulting in intima thickening. As the lesion extents
further, foamy cells are destroyed releasing large amounts of cholesterol trapped in a fibrous capsid. The active site of
atheroma is the point which is adjacent to normal endothelium, where foamy cells are formed (adopted from Durring‐
ton & Sinderman, 2002).
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3. In the third stage, that of the complicated lesion, the rapture of the fibrous capsid of the
atheromatous plaque leads to massive evacuation of the cholesterol reservoir. The artery
may occult due to the accumulation of platelets and clotting, leading to infarction (figure
4). If not so, then the plaque will be further enlarged [5].
Avoiding the formation and the instability of the atheromatous plaque is top priority for
patients at risk for cardiovascular events. Statins may contribute towards this direction [6,7]
Figure 2. Advanced atheromatous plaque causing arterial lumen occlusion of 70% (adopted from Durrington & Sin‐
derman, 2002).
Figure 3. The point of the atheromatous plaque which active enlargement is occurring. Formation of new foamy cells,
increased cholesterol uptake and increased instability of the plaque (adopted from Durrington & Sinderman, 2002).
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Figure 4. A raptured ahteromatous plaque, in which the cholesterol reservoir has evacuated itself under the fibrous
capsid. A clot has in the endothelial surface at the site of rapture is completely occulting the lumen (adopted from
Durrington & Sinderman, 2002).
1.2. Oxidised LDL
Oxidized low density lipoprotein LDL (oxLDL) cholesterol in humans is found mainly in two
types:
a. conjugated form, attached to the atheromatous plaque and
b. circulating form found in serum.
Oxidized LDL is produced following oxidation of LDL by free radicals and other oxidadive
factors, a procedure called oxidative stress. The circulating oxidized LDL is the measurable
fraction of oxidized LDL in plasma. Oxidised LDL is a key element of the pathway leading to
the formation of the atheromatous plaque and has been extensively studied both as a marker
of atheromatosis and as a possible target of therapeutic intervention. Circulating oxLDL is
considered a risk marker for atherosclerosis [8] and coronary heart disease (CHD) [8-10].
Increased oxLDL levels in circulation and the vessel wall are associated with endothelial
dysfunction [11] in such patients [9,10,12], contributing to atheromatous plaque instability [9].
Oxidative modification of LDL leads to rapid focal accumulation in macrophages [13], which
is the first step in atheromatous process. The increased retention time of LDL in the intima
offers enhanced probability to be oxidized by free radicals produced by endothelium, smooth
muscle cells or macrophages [14]. Oxidized LDL then acts chemotactic for monocytes and
smooth muscle cells through binding to scavenger receptors [15], leading to the formation of
foam cells. Oxidized LDL is also capable to elicit endothelial dysfunction by altering the
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secretory activity of endothelial cells [15], inhibiting the nitric oxide-mediated vasodilatation
through reduction of the expression of endothelial nitric-oxide synthase (eNOS), inducing the
expression of adhesion molecules on the endothelium thus mediating the adhesion of mono‐
cytes to intima [15], and inducing the expression of inflammatory cytokines [16]. Indeed,
oxLDL is a potent inducer of inflammation [17], contributing to the chronic inflammatory
process which results to atherosclerosis [18].
1.3. Statins
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, reduce total
cholesterol (TC), LDL cholesterol, apolipoprotein B (apoB), and, to a lesser degree, triglycerides
and lipoprotein a (Lp-a). Statins also have pleiotropic effects [19], such as the modulation of
inflammatory molecules and monocyte maturation and differentiation [19], the suppression
of smooth muscle-cells migration and proliferation [19], the reduction of the monocyte
adhesion to the endothelium [20], the restoration of the impaired endothelium-dependent
vessel wall relaxation [21], and the modification of cell-mediated LDL oxidation [22,23]. All of
the above mechanisms contribute to the reversion of atheromatosis. Undeniably, statins reduce
the incidence of coronary events and are a cornerstone in the primary and secondary preven‐
tion of CHD [24]. Previous studies have detected some efficacy in reducing the circulating
oxLDL levels, but whether this effect is due to the reduction of LDL or is an independent,
pleiotropic phenomenon remains a matter of controversy [25,26]. Furthermore, little is known
about the definite clinical benefit of such oxidative marker reduction.
The aim of the present study was to evaluate the efficacy of atorvastatin in reducing stenosis,
to investigate the effect on oxLDL and to search for possible associations of oxLDL modification
with changes of stenosis in patients managed conservatively and in pre-treated with percuta‐
neous catheter interventional procedures patients with carotid atheromatosis. We hypothesise
that atorvastatin therapy will confer remission of oxLDL levels in vivo and this will be
associated with significant reduction of carotid artery stenosis.
2. Patients and methods
Between January 2005 and February 2008 a total of 100 patients were randomly selected from
the lipid clinic and the carotid angioplasty clinic of a large tertiary hospital in Athens for
inclusion in the study. Informed consent was obtained from each patient at recruitment
according to our institutional policies. Eligible were patients with carotid artery stenosis from
various causes and with a range of predisposing factors. Exclusion criteria included: acute
cardiovascular disease, severe or unstable angina pectoris, clinically evident cardiac failure,
severe arrhythmias, recent surgical procedures, inflammatory diseases, active liver disease or
liver impairment, excessive alcohol consumption (>4 units/day) or history of alcohol abuse,
known allergic reaction to statins, poorly controlled diabetes mellitus as defined by a haemo‐
globin A1c (HbA1c) level of >7mg/dl, uncontrolled hypertension indicated by systolic blood
pressure (SBP) >140mmHg and/or diastolic pressure >85mmHg, history of deep vein throm‐
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associated with significant reduction of carotid artery stenosis.
2. Patients and methods
Between January 2005 and February 2008 a total of 100 patients were randomly selected from
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severe arrhythmias, recent surgical procedures, inflammatory diseases, active liver disease or
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bosis, bleeding tendency, serum triglycerides >350mg/dl, evidence of thyroid dysfunction, use
of systemic steroids or other anabolics, pernicious anaemia, impaired vitamin B12 or folate
acid levels, abnormal serum urate at baseline, serum creatinine phosphokinase elevation of
>1.5fold at baseline, pregnancy or lactation, and end-stage renal disease or dialysis.
Patients were allocated into two groups according to the degree of carotid artery stenosis: those
with arterial lumen occlusion of >70% in at least one common or internal carotid vessel
consisted group A; those with stenosis <70% comprised group B. Patients in both groups were
naive to statin therapy or if otherwise, a 6-month washout period was allowed before enrol‐
ment in the study. Group A underwent percutaneous transluminal carotid angioplasty with
stenting by the same interventional cardiologist, prior to the initiation of statin therapy. Those
patients were additionally administered clopidrogrel and salicylate. Both groups had to follow
an American Heart Association step II diet and were encouraged to exercise.
All patients were placed on atorvastatin once daily at bedtime in individualised doses, tittered
to achieve and maintain serum LDL cholesterol levels of <100mg/dl (and ideally <70mg/dl, if
hypertension, renal impairment, smoking, hyperlipidemia, symptomatic peripheral arterial
obstructive disease, or diabetes mellitus were present). The most common doses used to
achieve the above levels of LDL ranged between 10 to 40mg, while seldom it was required to
administer higher doses such as 60mg (median atorvastatin dose for the total population =
20mg, range 10 – 60mg). The use of other drugs known to act synergistically with statins
causing rhabdomyolysis was prohibited during the study. Adverse events were assessed in
every visit in a non-specific manner: every newly reported symptom was documented as
possible adverse reaction due to statin therapy and subsequently evaluated by an expert in
clinical biochemistry. Adherence to the medication regimen was assessed indirectly by the low
LDL levels compared with baseline.
Medical anamnesis, anthropometrics, smoking habits, blood pressure, and laboratory inves‐
tigations comprising of complete blood count, fasting glucose, HbA1c, liver and kidney
biochemistry, detailed lipid profile (TC, LDL cholesterol, high density lipoprotein [HDL]
cholesterol, serum triglycerides [TG], apoB, and apolipoprotein A), urate, B12 and folate,
thyroid function tests, homocysteine, Lp-a, and oxLDL were obtained at baseline and during
follow-up visits, which were arranged at baseline, one, three, and six months; the final
assessment was carried out in 12 months. Blood samples were collected after an at least 12-
hour fast and a light, low-fat meal the night before sample collection was advised. Venous
blood samples were collected in standard biochemistry vacutainer tubes. For the analysis of
homocysteine and whole blood count, ethylenediaminetetraacetic acid (EDTA) vacutainer was
used. Serum for biochemistry analysis was obtained by centrifugation (4000g) at 4°C for 7 min
and was immediately tested.
Lipid profiles (TC, HDL, TG) were determined using commercially available enzymatic
colourimetric methods (Dade Behring, Newark, USA) with a Dade Behring analyser. LDL was
calculated with the use of Friedewald's formula as all had TG <350mg/dl [27]. For the meas‐
urement of circulating oxLDL, a commercially available kit (Mercodia, Uppsala, Sweden),
based on a double antibody (4E6 and mouse monoclonal antiapoB) [28] capture ELISA test,
was used. This method primarily detects malondialdehyde LDL (MDA-LDL). The normative
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range (reference range) in our lab was 31-61mU/l. Apolipoprotein A, B and Lp-a were
measured using immuno-nephelometry with rabbit antisera (Dade Behring, Newark, USA) in
a Dade Behring analyser.
The evaluation of stenosis was conducted by Triplex ultrasonography using an Apogee 800
plus scanner with a 7.5 MHz transducer (ATL Inc., Bothell WA, USA) at baseline and 12
months. The stenosis was calculated in three sections in each common and internal carotid
artery, and the final measure was the mean value of the three. The value of stenosis in the most
occluded vessel was used in the statistical analysis. Specifically, the internal carotid artery
(ICA) and common carotid artery (CCA) bilaterally were evaluated for each patient using
coloured and grey Doppler ultrasonography. An effort was made to completely visualize the
vessels. Additionally, the pulse wave was estimated with Doppler phasmatometry as well as
the blood flow velocity of the two vessels. Results were recorded in a validated form. Stenosis
was defined as the presence of visual plaque in coloured or grey Doppler. The degree of
stenosis was calculated by measuring the decrease of the lumen diameter and the maximum
systolic blood flow velocity. In difficult cases, other parameters were taken into account, such
as ICA/CCA max blood flow velocity ratio and the ICA end-diastolic velocity. A degree of
stenosis >70% was considered as sever and angioplasty was advised. A degree of stenosis
between 60 – 70% was defined as high, between 50 – 60% as moderate and <50% as mild. High,
moderate and mild stenoses were treated conservatively. The intima media thickness (IMT)
and plaque morphology were not studied due to specific lab requirements, not readily
available in our institution.
2.1. Statistical analysis
Continuous variables were presented as mean values ± standard deviation, while qualitative
variables were presented as absolute and relative frequencies. Normality tests were applied
using the Kolmogorov-Smirnov criterion as well as Shapiro-Wilk test. Univariate analysis was
initially applied to test the associations of oxLDL with carotid stenosis for each patient group
as well as to identify first order correlations with various clinical parameters. Correlations
between skewed continuous or discrete variables were evaluated using Spearman's p-
coefficient, whereas correlations of normally distributed variables were evaluated by calcu‐
lating the Pearson's r-coefficient. Comparisons between normally distributed, continuous
variables and categorical variables were made using the Student t-test. Analysis of categorical
data was carried out with the [chi]2 test or Fischer's exact test when appropriate.
The association of oxLDL with carotid stenosis was also tested through multiple Cox propor‐
tional hazard model. The results obtained were presented as Hazard Ratios (HR) and the 95%
Confidence Intervals (CI). A backward elimination procedure was applied to all multivariate
models (using P<5% as the threshold for removing a variable from the models). All models
were adjusted for age, gender, SBP and TC. Kaplan-Meier curves concerning stenosis over the
study period were plotted and Log rank test was performed. All reported P-values were based
on two-sided tests and compared to a significance level of 5%. STATA 8.0 software (Stata
Corporation, 2003, Texas, USA) was used for the analysis.
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range (reference range) in our lab was 31-61mU/l. Apolipoprotein A, B and Lp-a were
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and plaque morphology were not studied due to specific lab requirements, not readily
available in our institution.
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as well as to identify first order correlations with various clinical parameters. Correlations
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lating the Pearson's r-coefficient. Comparisons between normally distributed, continuous
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A total of 612 patients were evaluated, of which 123 fulfilled the eligibility criteria; finally, 100
had complete data to enter the analysis, 76 males and 24 females, median age 68 years (range
45-81). Diabetes mellitus was recorded in 26 of the 100 patients and hypertension in 66. Twenty
patients had metabolic syndrome according to the national cholesterol education programme-
adult treatment panel III (NCEP-ATP III) criteria [29]. Active smoking (defined as current of
discontinued as far back as 5 years) was reported by 58 patients. Mean atorvastatin dose at
baseline was 24.31±11.49 mg for group A and 20.62±10.39 mg for group B (p=0.1). By the end
of the study period, the respective mean values were significantly increased to 30.45±16.27 mg
for group A (p=0.044) and 28.75±17.57 mg for group B (p=0.007).
Each of the study group (A and B) comprised 50 patients. The two groups were comparable
with regard of their baseline characteristics (table 1).
3.2. Lipid profile and oxidised LDL
Mean serum TC, LDL-cholesterol, TG, Lp-a, homocysteine, HDL-cholesterol, and oxLDL were
significantly reduced at 12 months compared to baseline (table 2). Specifically, mean oxLDL
dropped from 62.26±22.03 mU/l to 44.49±21.75 (p<0.001). A marked decrease was noticed
during the first 6 months and a plateau thereafter (Figure 5).
Characteristic Total Group A Group B p value
males / females 72 / 28 36 / 14 36 / 14
mean age in years ± SD 67.57±7.15 68.46±5.71 66.68±8.31 0.21
number of pts with DM (percentage) 37 ( 37% ) 18 (36%) 19 (38%) 0.83
number of pts with HTN (percentage) 67 ( 67% ) 36 (72%) 31 (62%) 0.29
number of smokers (percentage) 54 ( 54% ) 29 (54%) 25 (46%) 0.33
number of pts with CAD (percentage) 51 (51%) 24 (47%) 27 (53%) 0.55
mean ± SD total cholesterol (mg/dl) 232.23±47.8 235.24±49.2 229.22±46.7 0.53
mean ± SD LDL cholesterol (mg/dl) 151.27±41.7 154.16±42.8 148.84±40.9 0.52
mean ± SD HDL cholesterol (mg/dl) 51.97±12.7 52.12±12.1 51.82±13.4 0.9
mean ± SD triglycerides (mg/dl) 145.59±73.1 146.04±73.2 145.14±73.7 0.95
mean ± SD oxidized LDL (mU/l) 64.66±24.8 65.8±25.3 63.53±24.5 0.65
mean ± SD homocysteine (mU/l) 13.99±4.8 13.5±4.6 14.47±5.1 0.32
Pts: patients, DM: diabetes mellitus, HTN: arterial hypertension, MS: metabolic syndrome, SD: standard deviation, LDL:
low density lipoprotein, HDL: high density lipoprotein, CAD: coronary artery disease
Table 1. Study population baseline characteristics
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A significant correlation between LDL and oxLDL levels was detected (Pearson's correlation
coefficient r=0.7, p<0.01) (Figure 6). Similar correlation was found between oxLDL and apoB
levels (r=0.65, p<0.001), while no significant correlation was shown with Lp-a.
Between smokers mean oxidized LDL was reduced from 60.68±24.09 mU/l at baseline to
45.84±24.89 mU/l at the end of study period (difference 14.84 mU/l, p = 0.0036). Similarly,
between non-smokers it was reduced from 69.33±25.11 to 40.36±5.6 (difference 28.97, p<0.001).
Non-smokers had approximately double decline of oxidized LDL levels compared to smokers.
Carotid artery stenosis was reduced between smokers from 29.68±25.59% at baseline to
23.06±21.71% at 12 months (p = 0.002). Non-smokers also presented significant reduction of
stenosis during the study period 24.67±26.22% vs 20±21.45%, p = 0.004). Non-smokers and
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Figure 5. Time curve of change of total cholesterol, LDL cholesterol, triglycerides and oxidised LDL levels during the
observation period.
In further analysis, the group of smokers was subdivided to mild (≤5 cigarettes/day), moderate
(5 – 15 cigarettes/day) and heavy (≥15 cigarettes/day) smokers. The statistical significant
reduction of oxidized LDL levels and degree of carotid stenosis was apparent in the subgroup
of mild smokers (oxidized LDL at baseline 48.24±8.74 mU/l vs 41.54±9 mU/l at 12 months, p =
0.027 and stenosis at baseline 27.63±25.68% vs 23.42±21.74% at 12 months, p = 0.009), while it
was not apparent in the subgroups of moderate and heavy smokers (oxidized LDL at baseline
86.82±37.7 mU/l vs 42.92±10.77 mU/l at 12 months, p = 0.077 and stenosis at baseline 34±31.9%
vs 22±24.9% at 12 months, p = 0.186, for moderate smokers; respective values for oxidized LDL
were 66.29±15.88 mU/l vs 34.81±5.48 mU/l, p = 0.06 and for stenosis 32.14±24.13% vs
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In further analysis, the group of smokers was subdivided to mild (≤5 cigarettes/day), moderate
(5 – 15 cigarettes/day) and heavy (≥15 cigarettes/day) smokers. The statistical significant
reduction of oxidized LDL levels and degree of carotid stenosis was apparent in the subgroup
of mild smokers (oxidized LDL at baseline 48.24±8.74 mU/l vs 41.54±9 mU/l at 12 months, p =
0.027 and stenosis at baseline 27.63±25.68% vs 23.42±21.74% at 12 months, p = 0.009), while it
was not apparent in the subgroups of moderate and heavy smokers (oxidized LDL at baseline
86.82±37.7 mU/l vs 42.92±10.77 mU/l at 12 months, p = 0.077 and stenosis at baseline 34±31.9%
vs 22±24.9% at 12 months, p = 0.186, for moderate smokers; respective values for oxidized LDL
were 66.29±15.88 mU/l vs 34.81±5.48 mU/l, p = 0.06 and for stenosis 32.14±24.13% vs
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22.86±22.8%, p = 0.174, for heavy smokers). The above described effect of smoking was taken
into consideration during Cox-regression analysis.
Investigations Total Group A Group B
total cholesterol (mg/dl) baseline
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LDL: low density lipoprotein, HDL: high density lipoprotein
Table 2. Comparison of mean ± standard deviation and respective p values of measured laboratory investigations at
baseline and 12 months, in the total population, and the two groups.

























Correlation LDL with oxLDL
LDL: low density lipoprotein cholesterol, oxLDL: oxidised LDL, CI: confidence intervals.
Figure 6. Correlation of low density lipoprotein (LDL) with oxidised LDL (oxLDL) levels at baseline (Pearson’s correla‐
tion coefficient r=0.7, p<0.001)
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Table 3. Comparison of mean oxidized LDL values and degree of carotid stenosis change during the 1 year follow-up
period, between smokers and non-smokers.
Within group B, the subgroup of patients with high degree of stenosis (>60%) had oxLDL
63.47±19.18 mU/l at baseline, while those with moderate and mild degree of stenosis (<60%)
had 40.32±20.72 mU/l (p<0.001). Corresponding values at 12-months were 33.18±17.78 and
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Figure 6. Correlation of low density lipoprotein (LDL) with oxidised LDL (oxLDL) levels at baseline (Pearson’s correla‐
tion coefficient r=0.7, p<0.001)
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38.81±29.02, representing a marked decline for patients with >60% initial stenosis and a far less
decline for patients with <60% initial stenosis; yet the differences were not significant (table 4).
Stenosis >60<70% Stenosis <60% P value
Baseline
Mean oxidized LDL 63.47±19.18 mU/l 40.32±20.72 mU/l < 0.001
12 months Mean oxidized LDL 33.18±17.78 mU/l 38.81±29.02 mU/l NS
Table 4. Comparison of mean oxidized LDL levels at baseline and 12 months within patients of group Β (n = 50),
according to degree of stenosis at enrollment.
3.3. Anthropometrics
Body mass index (BMI), weight, waist circumference and waist:hip ratio did not change
significantly during the study period.
3.4. Carotid stenosis
Patients in group A had null stenosis at recruitment due to prior angioplasty with stenting. At
the end of the 12-month statin therapy, no case of clinically important restenosis (>70%) was
reported in this group (as restenosis was defined any increase of the carotid lumen diameter
>5%). Patients in group B had mean percentage of stenosis at baseline 47.6±13.2%, which was
significantly reduced following 12-month statin therapy (37.7±15.7%, p<0.001) (Table 5).
baseline 12 months p value
Mean % carotid stenosis ± standard deviation 47,6 ± 13,2 37,7 ± 15,7 0,001
Table 5. Change of the percentage of carotid artery stenosis between baseline and 12months for patients in group B.
3.5. Association of stenosis with oxidised LDL
Group B patients in the highest quartile of oxLDL values had a 12-month risk ratio for
restenosis of 1.025, 95%CI=1.006-1.044, p=0.0083 (figure 7). After adjusting for gender, age,
smoking, SBP, TC, and LDL levels, these patients demonstrated a HR for restenosis of 4.319
compared with those in the lowest quartile (p<0.001, figure 7). This means that an increase of
oxidized LDL by one unit increases the degree of carotid stenosis by 2.5%, for patients in group
B. A weak but significant correlation was detected between oxLDL levels and the degree of
carotid artery stenosis (r=0.17, p=0.018). Similar correlation was found between LDL choles‐
terol levels and carotid stenosis (r=0.18, p=0.0085). The strength of Pearson’s correlation of
mean oxidised LDL change with degree of carotid stenosis change during the 12-month period
was greater for smokers compared to non-smokers (table 3).
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3.6. The effect of LDL levels
Patients in group B who achieved LDL levels <70mg/dl during the observation period had a
greater (28.08±28% vs 22.31±22.7%, difference 5.77%, p =0.06) reduction of carotid stenosis
compared to those with LDL levels between 70 and 100 mg/dl (26.98±25.3% vs 21.35±21.3%,
difference 5.63%, p < 0.001), but this difference was not statistically significant. Thus, in
conservatively treated group B, further reduction of LDL than the limit of 100mg/dl was not
associated with additional improvement of stenosis.
4. Discussion
This study demonstrates that atorvastatin administered in indivudualised doses, tittered to
maintain serum LDL cholesterol levels <100mg/dl, significantly decreased lipid profile and
oxLDL, reduced carotid artery stenosis in patients managed conservatively and prevented
restenosis in patients with prior angioplasty. Oxidised LDL in this study correlated positively
with the degree of carotid artery stenosis; it was also shown by multivariate analysis that
oxLDL represented an independent risk factor for restenosis. To our knowledge this is the first
prospective study with a long observation period of 12 months to report such a clear, significant
reduction of oxLDL levels following atorvastatin therapy for carotid atheromatosis of various
causes and to report an association of the degree of oxLDL reduction with remission of carotid
stenosis. It is also of major importance that this robust, long-standing decline of oxLDL was
achieved with doses of atorvastatin used in everyday clinical practice. Interestingly, this
beneficial effect was completed in the first six months, while practically no further reduction
was noticed past this time point.
The mechanism by which statins modulate oxLDL levels has been controversial in the
literature. Moreover, the association of oxLDL level modification with improvement of carotid
atheromatosis and clinical outcome is not unequivocally established by large, double-blinded,
randomised trials. Under this perspective, the present observational study provides reasona‐
ble evidence that reducing oxLDL may independently improve carotid stenosis.
Carotid intima media thickness (IMT) is a validated measure of carotid atherosclerosis. It is
well established that carotid atherosclerosis, serves as an independent surrogate marker for
CHD [30] and CVD [31]. Nevertheless, in the present study it was preferred to estimate the
degree of carotid stenosis with a more direct approach, because this is more readily available
in most hospital settings and because there is an obvious relation with clinical symptoms and
signs. Besides, it represents a reliable method with sufficient reproducibility and it is practically
the method of choice when evaluated patients candidate for endarterectomy or angioplasty.
Evaluating carotid stenosis in turn, is an established method for estimating coronary risk [30]
and cardiovascular risk [31]. Other parameters of vessel wall function, such as IMT and plaque
morphology, even if clearly associated with cardiovascular risk in the literature, require well
equipped laboratory and are not readily available in our hospital. Future research on the field
should, ideally, comprise such measurements.
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Oxidised LDL has long been recognized as a risk factor for carotid atherosclerosis in asymp‐
tomatic men [32] and has also been linked with CVD [33]. Oxidized LDL levels [34], autoan‐
tibodies against epitopes of oxLDL [34] and oxLDL:LDL ratio [30] are independently
associated with increased risk for coronary atheromatosis and ischemic heart disease. In‐
creased levels of oxLDL [9] and MDA-LDL [10] in such cases are related to plaque instability.
On the other hand, it has been reported that oxLDL is weakly associated with carotid IMT, but
not with carotid plaque occurrence [35]. Oxidised LDL impairs endothelium relaxation [36] by
inhibition of the expression of eNOS and of the transport pathways of nitric oxide (NO) from
the endothelial cell, reduces the responsiveness of smooth muscle cell to NO [37], inhibits the
NO-mediated vasodilation [16,36,38], induces the expression of adhesion molecules [39], acts
directly chemotactic to circulating monocytes [16], stimulates endothelial cells to produce
monocyte chemoattractant protein-1 (MCP-1) [40], facilitates monocyte adhesion to intima
[41], exhibits cytotoxic properties against endothelial cells [16], and induces the expression of
inflammatory molecules [16]. All of the above contribute directly to dysfunction of the
endothelium [13] and foam cell formation, which is the first step in the development of fatty
streaks [18], the first visible step of atherosclerosis. These effects are mediated by preferential
binding of oxLDL with type A scavenger receptors (SRA, SRA-II and CD36) on subendothelial
resident macrophages and smooth muscle cells [42] and lectin-like oxLDL receptor-1 (LOX-1)
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Statins reduce the incidence of cardiovascular events, an effect attributable to their hypocho‐
lesterolemic properties [44]. However, the extent of clinical benefit and accumulating labora‐
tory evidence suggest additional mechanisms of action, the so-called pleiotropic effects [19].
The most important among such effects are the suppression of smooth muscle cell migration
and proliferation [45], the reduction of monocyte adhesion to the vascular endothelium [20],
the improvement of endothelial function [21], the inhibition of cell-mediated LDL oxidation
[22,23], the immuno-modulation of monocyte maturation and differentiation, and the modi‐
fication of production of inflammatory cytokines [46].
Atorvastatin suppresses cellular uptake of oxLDL from differentiating monocytes by reducing
the expression of LOX-1 and scavenger receptors [47] and accelerates the LDL-receptor-
mediated removal of the non oxidized LDL particles [48]. Hydroxymetabolites of atorvastatin
protect the LDL against oxidation [31]. The antioxidant potency of atorvastatin metabolites
has been confirmed by the reduction of IgG antibodies against LDL, a marker well-associated
with CHD [23]. It has even been reported that these active atorvastatin metabolites may have
greater anti-atherosclerotic effects than other statin molecules [49].
In acute coronary syndromes, atorvastatin therapy was linked to modulation of short- and
long-term immune response towards LDL due to inhibition of lipoprotein-associated phos‐
pholipase A2 (Lp-LPA2) enzyme [34]. The apparent benefit from statin therapy after acute
coronary events may also be attributed to the stabilization of the plaque and removal of oxLDL
from the vessel wall [50]. Increased mobilization of oxidized phospholipids from the vessel
wall, transient binding with apoB-100 particles and clearance from the circulation may be the
possible underlying mechanism. Under this perspective the increase in oxLDL:apoB ratio
detected with atorvastatin therapy might represent a marker of oxLDL efflux from the vessel
wall. Removal of oxLDL contributes to improved endothelial function as oxLDL is highly
immunogenic and vasoconstrictive. In our study there was no significant change in
oxLDL:apoB ratio. Atorvastatin also inhibits the oxLDL-mediated LOX-1 expression by
endothelial cells, the uptake of oxLDL in endothelium and the oxLDL-mediated reduction of
protein kinase B (PKB) phosphorylation [24]. The activation of PKB is critical for the expression
of eNOS, which promotes vessel relaxation. However, a meta-analysis provided no clear
evidence that statin therapy have a favourable effect on oxLDL [51].
In STAT trial [52] the antibodies against oxLDL were equally decreased with both aggressive
and conventional lipid-lowering therapy. This indicates that the statin-related reduction of
oxLDL is not a dose-dependent phenomenon, a finding which is in agreement with our results.
It might therefore represent a pleiotropic effect, independent -at least partially- from the hypo-
cholesterolemic action. A study by Orem et al detected a significant decrease of autoantibodies
against oxLDL with low doses of atorvastatin (10mg) [53], similar to doses used in our study.
In statin exposed patients, intensification of the regimen offers no additional benefit and only
those with LDL>125mg/dl benefited from a more aggressive statin therapy [52]. Statins have
a dose-related response with regard to clinical outcome, but this dose-related response has not
been confirmed with regard to oxidative stress [54]. This might alternatively be explained by
the hypothesis that statins achieve their uttermost benefit on oxLDL after a certain time point
[52], after which further continuation of treatment serves only the purpose of maintenance.
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Oxidised LDL has long been recognized as a risk factor for carotid atherosclerosis in asymp‐
tomatic men [32] and has also been linked with CVD [33]. Oxidized LDL levels [34], autoan‐
tibodies against epitopes of oxLDL [34] and oxLDL:LDL ratio [30] are independently
associated with increased risk for coronary atheromatosis and ischemic heart disease. In‐
creased levels of oxLDL [9] and MDA-LDL [10] in such cases are related to plaque instability.
On the other hand, it has been reported that oxLDL is weakly associated with carotid IMT, but
not with carotid plaque occurrence [35]. Oxidised LDL impairs endothelium relaxation [36] by
inhibition of the expression of eNOS and of the transport pathways of nitric oxide (NO) from
the endothelial cell, reduces the responsiveness of smooth muscle cell to NO [37], inhibits the
NO-mediated vasodilation [16,36,38], induces the expression of adhesion molecules [39], acts
directly chemotactic to circulating monocytes [16], stimulates endothelial cells to produce
monocyte chemoattractant protein-1 (MCP-1) [40], facilitates monocyte adhesion to intima
[41], exhibits cytotoxic properties against endothelial cells [16], and induces the expression of
inflammatory molecules [16]. All of the above contribute directly to dysfunction of the
endothelium [13] and foam cell formation, which is the first step in the development of fatty
streaks [18], the first visible step of atherosclerosis. These effects are mediated by preferential
binding of oxLDL with type A scavenger receptors (SRA, SRA-II and CD36) on subendothelial
resident macrophages and smooth muscle cells [42] and lectin-like oxLDL receptor-1 (LOX-1)
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Atorvastatin has been shown to reduce small dense LDL subfractions, remnant-like particles
cholesterol and oxLDL, and improve endothelial function, after just few weeks of therapy
[55,56]. Such time-related effect has not been fully elucidated, but may possibly account for
our finding that in the first six months there was an accelerated decline of oxLDL levels
followed by a milder reduction rate thereafter.
Additional pleiotropic effects of statins have been reported in the literature and might account
for the observed beneficial effects in the current study. Lysophosphatidylcholine is elevated
during LDL oxidation and is responsible for some of the biological effects of oxLDL. Atorvas‐
tatin alters the ability of oxLDL to impair the endothelium relaxation, by modulating the
hydrolysis of phosphatidylcholine to lysophosphatidylcholine when LDL is being oxidized
[57]. Statins remove predominately "aged LDL" from plasma, which is more prone to oxidation
[53], through stimulation of hepatic LDL receptor activity and inhibition of very-low density
lipoprotein (VLDL) and LDL production by the liver cells [53]. Statins also reduce oxygen
species generation [54]. Atorvastatin promotes adipocyte uptake of oxLDL in rabbits by
increasing the expression of CD36 and peroxisome proliferators-activated receptor γ (PPARγ)
in adipocytes [58]. The increased expression of such receptors by adipocytes results to
internalization of oxLDL and clearance from plasma, converting adipocytes to an oxLDL-
buffering pool [58]. Reduction of oxLDL in patients with CHD with atorvastatin 10mg parallel
with an increase of adiponectin, which has anti-atherogenic [55], anti-inflammatory and anti-
diabetic [55] properties through reduction of insulin resistance [55]. The CARDS study
reported a significant degree of preventive activity of atorvastatin against myocardial infarc‐
tion in eucholesterolemic diabetic patients, conceivably attributed to such improvement of
insulin sensitivity [55]. Statins also diminish the expression of CD40 and CD40 ligand in
vascular cells, smooth muscle cells and macrophages, which are promoted by oxLDL and are
considered proatherogenic [59]. Other anti-inflammatory pathways include reduction of C-
reactive protein [60], chemokines, major histocompatibility complex II molecules, matrix-
degrading enzymes, and procoagulant tissue factor [59]. Atorvastatin reverses the oxLDL-
mediated inhibition of vascular endothelial growth factor-induced endothelial progenitor cell
differentiation via the phosphatidylinositol 3 kinase/Akt pathway [61], which restores the
oxLDL-related inhibition of mature endothelial cells migration [61]. This could improve
neovascularization and collateral vessel formation in response to tissue ischemia. Atorvastatin
also suppresses platelet activity [62] by reducing the expression of CD36 and LOX-1, which
are present in platelets [43,62], thus inhibiting the oxLDL-mediated platelet hyperactivity [62].
Statins reduce the oxLDL-derived expression of adhesion molecules (E- and P-selectins,
vascular cell adhesion molecule 1 [VCAM-1] and intercellular adhesion molecule 1 [ICAM-1])
in human coronary artery endothelial cells [15], through up-regulation of eNOS expression
[15], which regulates the expression of adhesion molecules in endothelial cells [15]. Statins also
diminish the oxLDL-mediated activation of nuclear factor-κΒ (NF-κB) [15], which regulates
the transcription of adhesion molecule genes [33]. In diabetic patients with dyslipidemia
atorvastatin reduced CVD and markers of inflammation, adhesion and oxidation, such as CRP,
soluble ICAM-1, soluble VCAM-1, E-selectin, matrix metalloproteinase 9, secretory phospho‐
lipase A2 (sPLA2), and oxLDL, the latter by 38,4% [60]. Moreover, the change of oxLDL levels
correlated with the change of sICAM-1 and E-selectin levels, suggesting that statins could
Carotid Artery Disease - From Bench to Bedside and Beyond140
possibly counteract the oxLDL-associated increase of NF-κΒ, and therefore, the production of
such cell adhesion molecules [60]. Statins also enhance scavenger receptor expression in
macrophages [60], and increase plaque stability via reduction of metalloproteinases [60].
The reduction of oxidised LDL and of carotid stenosis in our study was relevant for both,
smokers and non-smokers. However, during subgroup analysis showed that the beneficial
effect of statin use concerns mostly the subgroup of mild smokers, while no such effect was
noticed for moderate and heavy smokers. How smoking may diminish the beneficial effect of
statins on oxidized LDL and carotid stenosis is not yet clarified in the literature. A reasonable
assumption might be that, since smoking increases the oxidative stress, it contributes to
enhanced LDL oxidation [63]. Moreover, studies in animal models, have demonstrated that
smoking alters the immunologic response to oxidized LDL by reducing the production of
antibodies against these molecules, i.e. causing a kind of immune suppression regarding the
response to oxidized LDL. Thus, it has been shown to increase carotid IMT [64].
The Mercodia oxLDL detects the MDA-modified apoB [28]. It has been proposed that oxLDL
looses its predictive value for CVD when adjustment for apoB level is performed [54]. In several
studies though, a significant reduction of Mercodia oxLDL with atorvastatin 10mg was still
detected even after adjustment for apoB, [10,31,54], while in other studies no adjustment for
LDL or apoB levels was made [54,65]. In our study the oxLDL:apoB ratio remained unchanged,
but in the multivariate analysis the reduction of oxLDL was still significant after adjustment
for apoB and LDL levels.
In patients with familial hypercholesterolemia a lack of association between oxLDL and IMT
was reported at baseline, however two years therapy with atorvastatin 80mg was associated
with regression of carotid IMT [66]. The LDL subfraction profile and autoantibodies against
oxLDL remained unchanged. Nevertheless, the rate of oxidation and the amount of dienes
formed decreased and this was linked to lessening of atherosclerosis. In our study the
reduction of carotid stenosis was associated with decreased oxLDL levels. Besides, the
unchanged oxLDL autoantibodies levels do not preclude the reduction of oxLDL, as was
indicated in another study involving dialysis patients, where atorvastatin therapy reduced
plasma oxLDL, whereas oxLDL autoantibodies did not changed significantly [67].
Disadvantages of the study were the relatively small size, the lack of a control group com‐
prising of patients with carotid stenosis not on statin therapy, which would be unethical, the
fact that researchers were not blinded to the patients’ status, the lack of randomization of the
dose-schedules and the use of only one method to detect oxLDL.
5. Conclusion
This prospective, cross-sectional study with such a long observation period provided enough
evidence to postulate a favourable effect of low-dose atorvastatin therapy on oxLDL, which
was additionally associated with improvement of stenosis in patients with carotid atheroma‐
tosis. We thus, assume that oxidised LDL may represent a far more sensitive risk factor for
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during LDL oxidation and is responsible for some of the biological effects of oxLDL. Atorvas‐
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species generation [54]. Atorvastatin promotes adipocyte uptake of oxLDL in rabbits by
increasing the expression of CD36 and peroxisome proliferators-activated receptor γ (PPARγ)
in adipocytes [58]. The increased expression of such receptors by adipocytes results to
internalization of oxLDL and clearance from plasma, converting adipocytes to an oxLDL-
buffering pool [58]. Reduction of oxLDL in patients with CHD with atorvastatin 10mg parallel
with an increase of adiponectin, which has anti-atherogenic [55], anti-inflammatory and anti-
diabetic [55] properties through reduction of insulin resistance [55]. The CARDS study
reported a significant degree of preventive activity of atorvastatin against myocardial infarc‐
tion in eucholesterolemic diabetic patients, conceivably attributed to such improvement of
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are present in platelets [43,62], thus inhibiting the oxLDL-mediated platelet hyperactivity [62].
Statins reduce the oxLDL-derived expression of adhesion molecules (E- and P-selectins,
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diminish the oxLDL-mediated activation of nuclear factor-κΒ (NF-κB) [15], which regulates
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correlated with the change of sICAM-1 and E-selectin levels, suggesting that statins could
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macrophages [60], and increase plaque stability via reduction of metalloproteinases [60].
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smokers and non-smokers. However, during subgroup analysis showed that the beneficial
effect of statin use concerns mostly the subgroup of mild smokers, while no such effect was
noticed for moderate and heavy smokers. How smoking may diminish the beneficial effect of
statins on oxidized LDL and carotid stenosis is not yet clarified in the literature. A reasonable
assumption might be that, since smoking increases the oxidative stress, it contributes to
enhanced LDL oxidation [63]. Moreover, studies in animal models, have demonstrated that
smoking alters the immunologic response to oxidized LDL by reducing the production of
antibodies against these molecules, i.e. causing a kind of immune suppression regarding the
response to oxidized LDL. Thus, it has been shown to increase carotid IMT [64].
The Mercodia oxLDL detects the MDA-modified apoB [28]. It has been proposed that oxLDL
looses its predictive value for CVD when adjustment for apoB level is performed [54]. In several
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detected even after adjustment for apoB, [10,31,54], while in other studies no adjustment for
LDL or apoB levels was made [54,65]. In our study the oxLDL:apoB ratio remained unchanged,
but in the multivariate analysis the reduction of oxLDL was still significant after adjustment
for apoB and LDL levels.
In patients with familial hypercholesterolemia a lack of association between oxLDL and IMT
was reported at baseline, however two years therapy with atorvastatin 80mg was associated
with regression of carotid IMT [66]. The LDL subfraction profile and autoantibodies against
oxLDL remained unchanged. Nevertheless, the rate of oxidation and the amount of dienes
formed decreased and this was linked to lessening of atherosclerosis. In our study the
reduction of carotid stenosis was associated with decreased oxLDL levels. Besides, the
unchanged oxLDL autoantibodies levels do not preclude the reduction of oxLDL, as was
indicated in another study involving dialysis patients, where atorvastatin therapy reduced
plasma oxLDL, whereas oxLDL autoantibodies did not changed significantly [67].
Disadvantages of the study were the relatively small size, the lack of a control group com‐
prising of patients with carotid stenosis not on statin therapy, which would be unethical, the
fact that researchers were not blinded to the patients’ status, the lack of randomization of the
dose-schedules and the use of only one method to detect oxLDL.
5. Conclusion
This prospective, cross-sectional study with such a long observation period provided enough
evidence to postulate a favourable effect of low-dose atorvastatin therapy on oxLDL, which
was additionally associated with improvement of stenosis in patients with carotid atheroma‐
tosis. We thus, assume that oxidised LDL may represent a far more sensitive risk factor for
Oxidised Low Density Lipoprotein (LDL) Modification with Statin Therapy is Associated with...
http://dx.doi.org/10.5772/57188
141
carotid stenosis, than LDL itself or apoB. Further studying is required to confirm such findings
and to establish a clear clinical and pathophsiologic link between oxLDL and carotid stenosis.
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Chapter 7
Cerebral Protection in Carotid Angioplasty – Is There a
Need? Advantages and Disadvantages of Each Type of
Protection Device
Antenor Tavares and José Guilherme Caldas
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57154
1. Introduction
Currently, ischemic cerebral vascular accident (ICVA; stroke) is an illness with a high incidence
and a high mortality rate [1,2]. In Brazil, depending on the state of the Brazilian Federation
and the period analyzed, cerebrovascular disease is the leading cause of mortality [3]. More‐
over, survivors present a continuous risk of developing serious complications [4]. Carotid
atherosclerotic disease is the cause of approximately 15 to 20% of cerebrovascular accidents [5].
Carotid stenosis is present in 7% of men and 5% of women aged 65 years or older [6]. In serious
cases (>70% stenosis), stenosis is an important cause of ICVA and transient ischemic attack
(TIA). The estimated risk of ipsilateral ICVA in 5 years is 4% in the population without carotid
stenosis; the risk increases to 18% in patients with asymptomatic stenosis above 75% and
reaches 27% in symptomatic patients with stenosis >75% [7]. Several authors have described
risk factors associated with carotid atherosclerosis, such as age, smoking, systemic arterial
hypertension (SAH), hypercholesterolemia, coronary artery disease, peripheral vascular
disease, and male gender [4,8,9].
2. Treatment of carotid stenosis
Treatment options for carotid stenosis include medication or surgery [10-12]. Clinical treat‐
ment includes antiplatelet agents and statins associated with the control of risk factors such as
arterial hypertension, dyslipidemia, hyperglycemia, diabetes, and smoking [13]. Relevant
studies comparing the outcomes of clinical treatment and surgery showed an important
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reduction in the risk of CVA among the patients selected for surgical treatment. In the NASCET
study, the risk of CVA was significantly reduced by surgery (9% in the surgical group versus
26% in the medication treatment) [10]. In another classical trial with asymptomatic patients,
surgical treatment was also associated with a better prognosis (4.8% versus 10.6% for medi‐
cation treatment) [14].
The two main effective treatment options for patients with serious carotid stenosis are carotid
endarterectomy (CEA) and carotid angioplasty with stent (CAS). CEA was the first surgical
option developed. It is indicated for symptomatic patients with carotid stenosis >60% and in
centers with surgical risk below 6%. In asymptomatic patients, a degree of stenosis >70% is
considered an indication for surgical treatment, but surgeons must notice morbi-mortality
lower than 3% [10,14-17].
The most recent surgical option is CAS, which consists of an approach to stenosis through a
natural route within the vessels. A flexible guide wire and catheter are inserted into the arterial
system through a peripheral venipuncture and are maneuvered to the stenosis site, where the
narrow portion is opened using the stent and balloon dilation.
CAS is considered less invasive than traditional surgery (CEA) and does not require an incision
on the lateral side of the cervical region [18]. CAS also has the advantages of being able to
maintain a steady flow of blood to the brain during CAS with a filter, generally using local
anesthesia, and allowing early hospital discharge [18]. Thus, the indications for CAS are the
same as those for CEA and also encompass other situations, such as comorbidities, occlusion
of the contralateral carotid artery, high carotid bifurcation, concomitant distally associated
stenosis, postradiotherapy stenosis, and restenosis after carotid endarterectomy [9,19,20].
The CREST trial compared CAS and CEA, examining complications, such as CVA, myocardial
infarction, or death during CAS and CEA, and CVA four years after these techniques were
applied. The authors observed similar rates of complications between CAS and CEA and
concluded that the techniques are equivalent in terms of short- and long-term clinical results,
but CAS carries a higher risk of ICVA and CEA carries a higher risk of heart attack during the
periprocedural period. This study also found that good results might be influenced by good
treatment and the expertise of the interventionists and surgeons [12].
Currently, CAS is considered a safe and effective technique for treating stenosis in the carotid
artery >70% in symptomatic patients, when assessed by noninvasive methods, and >50% when
assessed by catheter angiography, as indicated by the guidelines of the American Stroke
Association (ASA; Class I recommendation with evidence level B) [21].
The first angioplasty for carotid stenosis was performed by Mathis in 1979 in a patient with
fibromuscular dysplasia that caused symptomatic carotid stenosis [22]. The first angioplasty
for atherosclerotic lesions was reported in 1980 by Kerber et al. [23]. The first series of carotid
angioplasties was published in 1987 by Theron et al. and included 11 patients [24]. At the
beginning of the 1980s, publications regarding the use of balloon occlusion in the carotid artery
to reduce embolic complications began to appear [24-26].
The first balloon-expandable stent was used in a carotid artery in 1989; however, these early
stent models were prone to extrinsic compression and deformation. In this group of stents,
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adverse effects occurred in more than 10% of patients within the short 30-day follow-up
[27,28]. Subsequently, deformation was avoided using the self-expandable Wallstent® stent
[29] and later by self-expandable nitinol alloy stents. However, the risk of cerebral embolism
remained, although it was reduced compared with the risk associated with the first stents.
Restenosis, which occurred frequently after angioplasties without a stent, was reduced
drastically. Currently, all manufacturers of endovascular intervention materials produce
stents with rapid self-expanding technology compatible with the thin 0.014-inch guides
common to most cerebral protection systems [13]. Nonetheless, carotid stenosis treatment with
either CAS with cerebral protection or with CEA continues to carry an inherent risk of
embolism.
3. Is there a difference between materials used in carotid angioplasty?
As the CREST Trial showed, the risk of ICVA in CAS is a technical problem that remains
unsolved [12]. A heavily debated topic in the literature is the design of the metallic alloy used
to outline the empty spaces, which are called cells. Different types of frames for the metal
skeleton can promote plaque stabilization, depending on the size of the free area between the
metal brackets. Stents with a braided metallic mesh, which are dense throughout, can be more
effective at covering the plaque and reducing the risk of embolism [30]. These closed-cell stents
are characterized by small cells (areas enclosed by metal) joined together (Figure 1). Segmental
rings connected to each other by points that are welded together and large areas that are not
covered by metal are called open-cell stents [30]. Hybrid stents, which have a closed-cell design
in their central part and an open-cell design in their proximal and distal parts, can also be
found. These stents are rarely used in practice.
There are several examples of closed-cell stents, such as Wallstent® (Boston Scientific), Xact®
(Abbott), and NexStent® (Endotex). The Carotid Wallstent® is considered the prototype for
closed-cell design stents. Examples of stents with an open-cell design include Protégé® (Ev3),
Precise® (Cordis), Acculink® (Abbott), and Exponent® (Medtronic). The Carotid Wallstent®
model is manufactured with a stainless steel alloy and a closed-cell mesh, which may help to
prevent embolic complications. Because of its design, the Carotid Wallstent® (Boston Scien‐
tific) undergoes a shortening by approximately 30% [31], and caution must be used when
estimating its length. The Precise® (Cordis) stent is a nickel and titanium alloy (nitinol®)
mounted on rings, which promotes an open-cell aspect and offers great flexibility. The
Protégé® (Ev3) stent also uses nitinol and an open-cell design, and both conical and straight
versions are available. These last two stents cannot be collected after they begin to release;
therefore, they should only be opened when the implant site is certain. However, these stents
do not undergo shortening.
A study by Tadros et al. used photomicroscopy to analyze debris found in the filters after CAS
and showed that open-cell stents are associated with a larger mean particle size compared with
closed-cell stents [32].
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artery >70% in symptomatic patients, when assessed by noninvasive methods, and >50% when
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to outline the empty spaces, which are called cells. Different types of frames for the metal
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model is manufactured with a stainless steel alloy and a closed-cell mesh, which may help to
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tific) undergoes a shortening by approximately 30% [31], and caution must be used when
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mounted on rings, which promotes an open-cell aspect and offers great flexibility. The
Protégé® (Ev3) stent also uses nitinol and an open-cell design, and both conical and straight
versions are available. These last two stents cannot be collected after they begin to release;
therefore, they should only be opened when the implant site is certain. However, these stents
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The results for angioplasty should be analyzed considering that there are ongoing major
evolutions in methods and materials. The results of angioplasties after the introduction of
stents and cerebral protection systems cannot be compared with the results of studies con‐
ducted before the development of these materials [13,32-37].
Although the initial purpose of carotid stenosis treatment is the prevention of cerebral
infarction, both CEA and CAS carry risks of causing infarcts [13]. The materials and techniques
have been modified to reduce the risk of embolic complications during CAS. Several authors
[32-38] have shown the rare relative incidence of cerebral embolism and death after carotid
angioplasty with or without cerebral protection.
Our experience with carotid angioplasty began in 1998 and 2000. At that time, cerebral
protection systems were not available in Brazil. During this period, 72 CAS were performed,
and the combination of neurological complications and death reached 5.5%. In the subsequent
period (2001 to 2007), 1215 CASs were performed with filters for cerebral protection, and our
occurrence of neurological complications and death fell to 1.8% [38].
Although some authors defend the use of CAS without cerebral protection, we emphasize that
symptomatic embolism is rare and that the use of safety devices, such as cerebral protection
systems, functions as a reserve parachute: Although they are rarely needed, no one wants to
jump without one (recommendation class IIa, level of evidence: C, [39]).
Currently, several devices are capable of providing cerebral protection during carotid stenosis
treatment, but the morbimortality results differ for each device. The forms of protection for
each device are also different. Nonetheless, other authors using various methods (most notably
Figure 1. Typical arrangement of the metal mesh of an open-cell stent (A) and a closed-cell stent (B). The area of a cell
in each type of stent is highlighted in red
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Doppler and MRI) have shown that an enormous load of emboli to the brain may not determine
symptoms. This phenomenon is called an asymptomatic embolism associated with CAS.
There are two types of cerebral protection systems: proximal and distal. The protection systems
with filters are distal, and the protection devices with balloons can be proximal or distal.
Proximal devices have the theoretical advantage of exerting protection during all phases of
intervention, except during the positioning of the guide catheter or the long sheath. The
proximal devices use temporary occlusion of the common carotid artery with a balloon, and
a second balloon occludes the external carotid artery, resulting in the stagnation or reversal of
the flow of the internal carotid artery (example: the PAES® Parodi antiembolism system). With
this type of device, protection is initiated before the stenosis is crossed with the guide wire,
which can reduce the risk of distal embolization. After the stent is implanted, the blood is
aspirated from the carotid bifurcation to remove any fragments, and later, the proximal
protection device is removed [40-42].
In contrast, with the distal devices, it is necessary to cross the stenosis with the microguide
and then to use the distal device on the lesion. Therefore, the distal systems consist of a device
(filter or balloon) with an integrated guide wire. This set-up allows the CAS to be performed
along the guide wire. With the distal protection, embolization can occur when the guide
catheter or sheath is positioned and during the passage of the guide wire through the stenosis
before the distal device enters the action.
Distal protection systems allow two different forms of approach. One form is the occlusion of
the distal cervical internal carotid artery by a balloon (example: PercuSurge®). With this type
of system, there is a complete interruption of the antegrade flow, which provides protection
for the particles that do not reach the brain. After the CAS, manual aspiration is performed,
the balloon is deflated, and the system is removed [43,44].
The other form of distal protection is through the use of a filter (examples: EPI®, Angio‐
guard®, Spider®). In this device, the filter (Figure 2) crosses the stenosis and is implant‐
ed in the distal  cervical portion of the internal carotid artery.  The stent and balloon are
introduced over the guide to perform the CAS. There are different types of filters, but the
aim of all of them is to retain particles, thereby preventing embolisms from reaching the
brain and maintaining continuous blood flow. At the end of CAS, the filter is closed and
removed from the patient  with the embolic  material  inside [13].  In terms of  design,  the
filters  can be concentric  (examples:  Emboshield® and Angioguard® Cordis)  or  eccentric
(examples:  Filterwire  EPI/EZ®  Boston  Scientific/Target  and  Spider®eV3).  In  concentric
filters, the metallic guide occupies the center of the structure. In eccentric systems, the guide
is outside the center of the protection device [45,46].
Thus, the two main types of cerebral protection devices used in CAS are filters that allow distal
flow during the CAS and systems for the temporary occlusion of the carotid artery (balloons)
that promote the inversion or paralysis of flow to the brain. Some authors defend filtering
devices, but others defend the balloons because they are believed to offer more complete
protection of the brain. Furthermore, the use of these cerebral protection systems is not
supported in some patients.
Cerebral Protection in Carotid Angioplasty – Is There a Need? Advantages and Disadvantages of...
http://dx.doi.org/10.5772/57154
153
The results for angioplasty should be analyzed considering that there are ongoing major
evolutions in methods and materials. The results of angioplasties after the introduction of
stents and cerebral protection systems cannot be compared with the results of studies con‐
ducted before the development of these materials [13,32-37].
Although the initial purpose of carotid stenosis treatment is the prevention of cerebral
infarction, both CEA and CAS carry risks of causing infarcts [13]. The materials and techniques
have been modified to reduce the risk of embolic complications during CAS. Several authors
[32-38] have shown the rare relative incidence of cerebral embolism and death after carotid
angioplasty with or without cerebral protection.
Our experience with carotid angioplasty began in 1998 and 2000. At that time, cerebral
protection systems were not available in Brazil. During this period, 72 CAS were performed,
and the combination of neurological complications and death reached 5.5%. In the subsequent
period (2001 to 2007), 1215 CASs were performed with filters for cerebral protection, and our
occurrence of neurological complications and death fell to 1.8% [38].
Although some authors defend the use of CAS without cerebral protection, we emphasize that
symptomatic embolism is rare and that the use of safety devices, such as cerebral protection
systems, functions as a reserve parachute: Although they are rarely needed, no one wants to
jump without one (recommendation class IIa, level of evidence: C, [39]).
Currently, several devices are capable of providing cerebral protection during carotid stenosis
treatment, but the morbimortality results differ for each device. The forms of protection for
each device are also different. Nonetheless, other authors using various methods (most notably
Figure 1. Typical arrangement of the metal mesh of an open-cell stent (A) and a closed-cell stent (B). The area of a cell
in each type of stent is highlighted in red
Carotid Artery Disease - From Bench to Bedside and Beyond152
Doppler and MRI) have shown that an enormous load of emboli to the brain may not determine
symptoms. This phenomenon is called an asymptomatic embolism associated with CAS.
There are two types of cerebral protection systems: proximal and distal. The protection systems
with filters are distal, and the protection devices with balloons can be proximal or distal.
Proximal devices have the theoretical advantage of exerting protection during all phases of
intervention, except during the positioning of the guide catheter or the long sheath. The
proximal devices use temporary occlusion of the common carotid artery with a balloon, and
a second balloon occludes the external carotid artery, resulting in the stagnation or reversal of
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aspirated from the carotid bifurcation to remove any fragments, and later, the proximal
protection device is removed [40-42].
In contrast, with the distal devices, it is necessary to cross the stenosis with the microguide
and then to use the distal device on the lesion. Therefore, the distal systems consist of a device
(filter or balloon) with an integrated guide wire. This set-up allows the CAS to be performed
along the guide wire. With the distal protection, embolization can occur when the guide
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flow during the CAS and systems for the temporary occlusion of the carotid artery (balloons)
that promote the inversion or paralysis of flow to the brain. Some authors defend filtering
devices, but others defend the balloons because they are believed to offer more complete
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Although all devices have a common goal of preventing the entry of particles into distal
circulation, the perfect protection system does not exist [42]. Among proximal protection
systems with balloons, arterial occlusion is the weakest point because patients might not
tolerate it. Moreover, the contrast of vessels during the CAS is difficult because of flow
stagnation, which makes positioning the stent difficult. Moreover, this system is more
laborious and complex to use than filters. Additionally, proximal protection systems are very
high profile and tend to lead to hemorrhaging complications at the puncture site. The device’s
advantages include its ability to initiate cerebral protection at an early stage and to avoid
embolization during the initial passage of the wire through the stenosis [13,42].
The distal embolic protection devices with a balloon have the disadvantage of preventing
antegrade flow, which renders some patients intolerant of this type of device. The balloon may
also cause vascular lesions (example: pseudoaneurysm), and the affixture of the balloon may
be lost during the CAS. Moreover, images cannot be easily obtained while the balloon is in use
and, technically, the balloon is not very maneuverable. An advantage of distal protection
devices is their ease of use compared with proximal occlusion balloons [13].
Among the disadvantages of distal embolic protection devices with filters is that they may not
capture all particles and their delivery and recovery systems may cause embolisms. Some
filters may attach to the stent because of bad handling. The advantages of filters include the
preservation of antegrade flow to the brain during all stages of the CAS and the ability to obtain
graphic images easily. Some systems allow the operator to select which guide wire to use to
cross the lesion, which allows the filter to remain in contact with the arterial wall and the guide
wire to be moved during the CAS without mobilizing the filter [13].
Figure 2. Examples of cerebral protection devices: eccentric design (A) in the EPI® filter and concentric design (B) in
the Emboshield® system
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An advantage of using filters is their ability to maintain constant flow to the brain during all
stages of the angioplasty, unlike protection balloons, which promote the temporary halt of
flow to the brain. Carotid filters are also easier to use than occlusive or reverse flow protection
balloons.
4. Cerebral embolism in the surgical treatment of carotid stenosis
Despite the advantages of cerebral protection systems, Müller-Hülsbeck et al., in their 2005
study of ex vivo pig carotid arteries with four types of filters and one type of cerebral protection
balloon, found that particles were passed with all of the protection systems tested [47]. Piñero
et al. [48], using the transcranial Doppler technique, observed signs of embolism during several
phases of CAS, including the initial unprotected phase. Similarly, Schimidt et al. [49] divided
the carotid angioplasty into five phases from start to finish. This comparative study used one
type of filter (EPI®) and one type of occlusive system with balloons (MO.MA®) and found
that particles were passed in all phases of both systems.
The transcranial Doppler tool can help identify signs of embolism during an unprotected phase
(before using the filter) or during the passage of the filter, and it can identify embolisms when
the stent or balloon is applied or the filter is removed [50,51]. The transcranial Doppler can
provide information about the flow in the polygon vessels [52] and show changes in the cervical
segment after angioplasty [53]. However, the Doppler assessment has the disadvantage of
evaluating only one vessel, usually the middle cerebral artery or the distal cervical internal
carotid artery on the carotid stenosis side, leaving a vast territory of the brain uncovered during
the evaluation of embolic phenomena. No correlation can be observed between the quantity
of microemboli identified during ultrasound and new embolism outbreaks found during MRI
[54]. In contrast, MRI can evaluate the entire encephalon, which is particularly important
because embolic events may occur during the CAS or during the angiography preceding CAS
in other areas of the brain supplied by the carotid undergoing CAS [46,48].
According to several authors, the use of cerebral protection systems is an important factor in
reducing the risk of cerebral infarction during CAS [9,13,34,55]. However, although most
patients are asymptomatic after CAS, signs of embolism can be detected using the transcranial
Doppler technique and MRI [56] because of different factors, such as the existence of pores in
the protection systems that allow particles up to 100 microns pass, the manipulation of the
artery before the filter is opened, the filter not adapting to the artery wall, and crucially, a lack
of proper training in handling the systems [46,48,49,54,57-63].
5. Imaging evaluation of cerebral embolism
We consider MRI an excellent method for evaluating cerebral ischemia in its various presen‐
tations. An MRI study of various acute neurological presentations of an ischemic nature
includes several forms of ischemia presentation on the images [64].
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Although all devices have a common goal of preventing the entry of particles into distal
circulation, the perfect protection system does not exist [42]. Among proximal protection
systems with balloons, arterial occlusion is the weakest point because patients might not
tolerate it. Moreover, the contrast of vessels during the CAS is difficult because of flow
stagnation, which makes positioning the stent difficult. Moreover, this system is more
laborious and complex to use than filters. Additionally, proximal protection systems are very
high profile and tend to lead to hemorrhaging complications at the puncture site. The device’s
advantages include its ability to initiate cerebral protection at an early stage and to avoid
embolization during the initial passage of the wire through the stenosis [13,42].
The distal embolic protection devices with a balloon have the disadvantage of preventing
antegrade flow, which renders some patients intolerant of this type of device. The balloon may
also cause vascular lesions (example: pseudoaneurysm), and the affixture of the balloon may
be lost during the CAS. Moreover, images cannot be easily obtained while the balloon is in use
and, technically, the balloon is not very maneuverable. An advantage of distal protection
devices is their ease of use compared with proximal occlusion balloons [13].
Among the disadvantages of distal embolic protection devices with filters is that they may not
capture all particles and their delivery and recovery systems may cause embolisms. Some
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graphic images easily. Some systems allow the operator to select which guide wire to use to
cross the lesion, which allows the filter to remain in contact with the arterial wall and the guide
wire to be moved during the CAS without mobilizing the filter [13].
Figure 2. Examples of cerebral protection devices: eccentric design (A) in the EPI® filter and concentric design (B) in
the Emboshield® system
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An advantage of using filters is their ability to maintain constant flow to the brain during all
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evaluating only one vessel, usually the middle cerebral artery or the distal cervical internal
carotid artery on the carotid stenosis side, leaving a vast territory of the brain uncovered during
the evaluation of embolic phenomena. No correlation can be observed between the quantity
of microemboli identified during ultrasound and new embolism outbreaks found during MRI
[54]. In contrast, MRI can evaluate the entire encephalon, which is particularly important
because embolic events may occur during the CAS or during the angiography preceding CAS
in other areas of the brain supplied by the carotid undergoing CAS [46,48].
According to several authors, the use of cerebral protection systems is an important factor in
reducing the risk of cerebral infarction during CAS [9,13,34,55]. However, although most
patients are asymptomatic after CAS, signs of embolism can be detected using the transcranial
Doppler technique and MRI [56] because of different factors, such as the existence of pores in
the protection systems that allow particles up to 100 microns pass, the manipulation of the
artery before the filter is opened, the filter not adapting to the artery wall, and crucially, a lack
of proper training in handling the systems [46,48,49,54,57-63].
5. Imaging evaluation of cerebral embolism
We consider MRI an excellent method for evaluating cerebral ischemia in its various presen‐
tations. An MRI study of various acute neurological presentations of an ischemic nature
includes several forms of ischemia presentation on the images [64].
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Diffusion (DWI) is the best MRI technique to differentiate ischemia from chronic infarction.
While the latter shows an increase in diffusion, the former classically restricts diffusion [65].
The identification of acute lesions in patients with multiple chronic lesions makes DWI a tool
of unquestionable value in current imaging practice.
Water in tissues has a randomized translational movement (“Brownian motion”) in its
molecules caused by thermodynamic energy and the viscosity of the medium. This type of
movement is related to CDA, and MRI uses DWI to evaluate it [66,67].
Diffusion imaging is sensitive to the microscopic movement of water protons. Water protons
undergo a change during the transverse magnetization phase in the presence of a magnetic
field gradient. Thus, areas with greater diffusion (faster movement) are subject to a high degree
of signal attenuation compared with areas with lower diffusion (slow/restricted movement),
which show lower signal attenuation. Animals subjected to occlusion of the middle cerebral
artery (MCA) showed signs of ischemia in diffusion within 45 minutes. These findings are
believed to reflect the restriction of water movement by the cellular membrane. MRI’s greater
sensitivity for detecting acute ischemia in diffusion is believed to be a result of the movement
of water within the cell, which restricts the movement of water protons (cytotoxic edema),
while the T2-weighted images show a signal change that results mainly from vasogenic edema.
It is estimated that cytotoxic edema begins very soon after ischemic abuse, while the vasogenic
edema begins to develop 6 hours after the ischemic incident.
Moseley et al. [65] argued that significant diffusion decrease (restriction or reduction) in
ischemia reflects the deviation of an environment with extracellular water protons with a faster
diffusion to a more restricted intracellular environment, in addition to the depletion of the
sodium-potassium pump in the cellular membrane because of infarction. The cytotoxic edema
is thus responsible for reducing diffusion during ischemia.
Nonetheless, the diffusion of ischemia areas can be reversed after early reperfusion and are
potentially reversible if they occur after CAS. It has also been shown that ischemic lesions in
diffusion might not leave changes that appear in later MRI scans after TIA frames.
The embolic complications identified in DWI occur more frequently than the apparent low
rate of clinical complications would suggest. An MRI may quantify the ischemic foci, making
it an important method for validating the advantages and complications of CAS.
To examine this issue more deeply, we conducted a prospective randomized study (patients
chosen randomly from the outpatient neuroradiology service of INCOR) in a case-control
setting [68]. We used angiographic exams and MRI studies that showed cerebral embolism
represented by the diffusion sequence (DWI) before and after surgical endovascular treatment
to quantify, locate, and measure new restriction foci in diffusion MRI and to correlate the new
DWI restriction foci with demographic aspects (gender, age, side of the carotid treated, and
symptoms), risk factors for cerebrovascular disease, aspects of the angioplasty technique used,
and the presence of previous infarcts in MRI.
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6. Methods
Our sample consisted of 40 patients presenting carotid stenosis of atherosclerotic origin. The
patients were referred for MRI exams with diffusion techniques before and after CAS. All of
the patients in this prospective study signed an informed consent form. The inclusion criteria
were as follows: patients with serious carotid stenosis (shown by Doppler, ATC, or digital
subtraction angiography [DSA]) who were referred for endovascular treatment for carotid
atheromatous disease according to the local institutional guidelines, who agreed to participate
in the research protocol, and who had MRI studies conducted with diffusion techniques at
most 24 hours before and up to 72 hours after the CAS with a protection filter.
Exclusion criteria were the following: intra-arterial thrombi observed in the angiography
before CAS; patients with disabling complications from previous cerebral infarcts; contrain‐
dications for the MRI scan, such as a cardiac pacemaker or claustrophobia, patients with
macroemboli in the DSA after CAS, clinical conditions compatible with ischemia after CAS,
angiographic exam showing stenosis <60%, MRI exams with movement artifacts, and imaging
studies with serious stenosis in the contralateral cervical carotid, vertebral arteries, or intra‐
cranial arteries.
Three patients out of 40 were excluded because they showed stenosis <60%, and one patient
was excluded for having exceeded the maximum time established for MRI after CAS because
of coronary angina and hemodynamic instability.
The MRI studies were performed using commercially available single high-field equipment
(1.5 T, LX Horizon®, General Electric Healthcare) with a skull coil (“birdcage transmit/receive
quadrature”).
The MRI scans before and after CAS followed the same sequencing protocol:
• Locator: 256x128 matrix, FOV 27 cm, 10 mm thickness, 5 mm spacing, number of acquisitions
(“nex”): 1
• DWI: 128X128 matrix, FOV 22 cm, 5 mm thickness, 0 mm spacing, TE minimum 72.8 ms, TR
9000 ms, “b-value” 0 and 1000, diffusion direction: “all”, number of acquisitions: 2
• Coefficient of apparent diffusion: map of “ADC”
• T2W, axial, 288x224 matrix, FOV 22 cm, 6 mm thickness, 0.6 mm spacing, TE 102 ms, TR
4750 ms, echo train length 23, bandwidth 31.25 and number of acquisitions: 2
• T1W, axial, 256x192 matrix, FOV 22 cm, 6 mm thickness, 0.6 mm spacing, TE 14 ms, TR 475
ms, bandwidth 15.63 and number of acquisitions: 2
• Fluid-attenuated inversion recovery (FLAIR): axial,  256x192 matrix, FOV 22 cm, 6 mm
thickness, 0.6 mm spacing, TE 96 ms, TR 10000 ms, TI 2.100 ms and number of acquisitions: 1
• T2W, coronal, 288x224 matrix, FOV 22 cm, 6 mm thickness, 0.6 mm spacing, TE 102 ms, TR
4750 ms, bandwidth 31.25 and number of acquisitions: 2
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Diffusion (DWI) is the best MRI technique to differentiate ischemia from chronic infarction.
While the latter shows an increase in diffusion, the former classically restricts diffusion [65].
The identification of acute lesions in patients with multiple chronic lesions makes DWI a tool
of unquestionable value in current imaging practice.
Water in tissues has a randomized translational movement (“Brownian motion”) in its
molecules caused by thermodynamic energy and the viscosity of the medium. This type of
movement is related to CDA, and MRI uses DWI to evaluate it [66,67].
Diffusion imaging is sensitive to the microscopic movement of water protons. Water protons
undergo a change during the transverse magnetization phase in the presence of a magnetic
field gradient. Thus, areas with greater diffusion (faster movement) are subject to a high degree
of signal attenuation compared with areas with lower diffusion (slow/restricted movement),
which show lower signal attenuation. Animals subjected to occlusion of the middle cerebral
artery (MCA) showed signs of ischemia in diffusion within 45 minutes. These findings are
believed to reflect the restriction of water movement by the cellular membrane. MRI’s greater
sensitivity for detecting acute ischemia in diffusion is believed to be a result of the movement
of water within the cell, which restricts the movement of water protons (cytotoxic edema),
while the T2-weighted images show a signal change that results mainly from vasogenic edema.
It is estimated that cytotoxic edema begins very soon after ischemic abuse, while the vasogenic
edema begins to develop 6 hours after the ischemic incident.
Moseley et al. [65] argued that significant diffusion decrease (restriction or reduction) in
ischemia reflects the deviation of an environment with extracellular water protons with a faster
diffusion to a more restricted intracellular environment, in addition to the depletion of the
sodium-potassium pump in the cellular membrane because of infarction. The cytotoxic edema
is thus responsible for reducing diffusion during ischemia.
Nonetheless, the diffusion of ischemia areas can be reversed after early reperfusion and are
potentially reversible if they occur after CAS. It has also been shown that ischemic lesions in
diffusion might not leave changes that appear in later MRI scans after TIA frames.
The embolic complications identified in DWI occur more frequently than the apparent low
rate of clinical complications would suggest. An MRI may quantify the ischemic foci, making
it an important method for validating the advantages and complications of CAS.
To examine this issue more deeply, we conducted a prospective randomized study (patients
chosen randomly from the outpatient neuroradiology service of INCOR) in a case-control
setting [68]. We used angiographic exams and MRI studies that showed cerebral embolism
represented by the diffusion sequence (DWI) before and after surgical endovascular treatment
to quantify, locate, and measure new restriction foci in diffusion MRI and to correlate the new
DWI restriction foci with demographic aspects (gender, age, side of the carotid treated, and
symptoms), risk factors for cerebrovascular disease, aspects of the angioplasty technique used,
and the presence of previous infarcts in MRI.
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6. Methods
Our sample consisted of 40 patients presenting carotid stenosis of atherosclerotic origin. The
patients were referred for MRI exams with diffusion techniques before and after CAS. All of
the patients in this prospective study signed an informed consent form. The inclusion criteria
were as follows: patients with serious carotid stenosis (shown by Doppler, ATC, or digital
subtraction angiography [DSA]) who were referred for endovascular treatment for carotid
atheromatous disease according to the local institutional guidelines, who agreed to participate
in the research protocol, and who had MRI studies conducted with diffusion techniques at
most 24 hours before and up to 72 hours after the CAS with a protection filter.
Exclusion criteria were the following: intra-arterial thrombi observed in the angiography
before CAS; patients with disabling complications from previous cerebral infarcts; contrain‐
dications for the MRI scan, such as a cardiac pacemaker or claustrophobia, patients with
macroemboli in the DSA after CAS, clinical conditions compatible with ischemia after CAS,
angiographic exam showing stenosis <60%, MRI exams with movement artifacts, and imaging
studies with serious stenosis in the contralateral cervical carotid, vertebral arteries, or intra‐
cranial arteries.
Three patients out of 40 were excluded because they showed stenosis <60%, and one patient
was excluded for having exceeded the maximum time established for MRI after CAS because
of coronary angina and hemodynamic instability.
The MRI studies were performed using commercially available single high-field equipment
(1.5 T, LX Horizon®, General Electric Healthcare) with a skull coil (“birdcage transmit/receive
quadrature”).
The MRI scans before and after CAS followed the same sequencing protocol:
• Locator: 256x128 matrix, FOV 27 cm, 10 mm thickness, 5 mm spacing, number of acquisitions
(“nex”): 1
• DWI: 128X128 matrix, FOV 22 cm, 5 mm thickness, 0 mm spacing, TE minimum 72.8 ms, TR
9000 ms, “b-value” 0 and 1000, diffusion direction: “all”, number of acquisitions: 2
• Coefficient of apparent diffusion: map of “ADC”
• T2W, axial, 288x224 matrix, FOV 22 cm, 6 mm thickness, 0.6 mm spacing, TE 102 ms, TR
4750 ms, echo train length 23, bandwidth 31.25 and number of acquisitions: 2
• T1W, axial, 256x192 matrix, FOV 22 cm, 6 mm thickness, 0.6 mm spacing, TE 14 ms, TR 475
ms, bandwidth 15.63 and number of acquisitions: 2
• Fluid-attenuated inversion recovery (FLAIR): axial,  256x192 matrix, FOV 22 cm, 6 mm
thickness, 0.6 mm spacing, TE 96 ms, TR 10000 ms, TI 2.100 ms and number of acquisitions: 1
• T2W, coronal, 288x224 matrix, FOV 22 cm, 6 mm thickness, 0.6 mm spacing, TE 102 ms, TR
4750 ms, bandwidth 31.25 and number of acquisitions: 2
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New foci (NF) of ischemia were defined as the presence of a hypersignal (restriction) in
diffusion after CAS that was not present in the same sequence before CAS. These foci were
considered recent, additional infarcts compared with the first MRI.
The opposite of a recent infarction caused by DWI after CAS is an old infarction that is present
in the T2W sequencing of the MRI before CAS. Chronic cerebral infarction is the end result of
prolonged ischemia. Areas of hypersignal in the cerebral parenchyma in the T2 sequence with
areas corresponding to the variable signal in T1 (with the tendency to be isointense compared
with the fluid in T1 and T2) without restriction in DWI and with no enhancement after
paramagnetic contrast were considered old infarctions (“T2W infarction”). Other diseases that
may have a signal aspect similar to that of old infarctions (for example: porencephalic cysts,
arachnoid cysts, low-grade astrocytoma) were excluded from the count because of their
topographic characteristics, their appearance on the edge of the lesion, or their appearance on
the surrounding tissue or because they showed a signal that differed from that of the fluid in
the other sequences in the MRI study.
The MRI images were analyzed by the consensus of two experienced neuroradiologists using
the eFilm® software without access to the clinical data or angiography and CAS data. If there
were discrepancies between the two neuroradiologists’ findings, the studies were analyzed by
a third observer to reach a consensus.
The NF were correlated with age, gender, side of carotid artery treated, presence of previous
symptoms related to carotid stenosis, risk factors for atherosclerosis and ICVA (diabetes
mellitus, systemic arterial hypertension, hypercholesterolemia, ischemic coronary artery
disease, arrhythmia, ischemic peripheral vascular disease, transient ischemic attack [TIA], and
ischemic cerebrovascular accident [ICVA]), percentage of carotid stenosis, presence of ulcers
in the atheromatous plaque, previous infarction noted on the MRI, number of catheters used,
number of arteries on which angiographies were performed, contralateral carotid occlusion,
endovascular access technique used to reach the common carotid artery on the side of the
angioplasty, type of filter, type of stent, volume of contrast used in the CAS and angiography,
fluoroscopy time spent during the procedure, and the localization, number, and diameter of
these NF. These parameters were also correlated between patients with only one NF and those
with multiple NFs.
The localization (laterality) of the encephalic NF was defined as ipsilateral if it coincided with
the area supplied by the carotid artery undergoing angioplasty. The localization of the NF was
defined as contralateral if the cerebral area did not coincide with the side of the CAS, meaning
the area was nourished by the carotid artery contralateral to the angioplasty or the area located
on the posterior fossa. In cases when it was impossible to determine laterality, the patient was
excluded from the analysis, which occurred with two patients. Patients 16 and 27 showed
stenosis in the carotid artery (left) and contralateral occlusion (right), with NF identified in the
area supplied by the right carotid artery. Under this condition, the flow to the carotid area can
use the anastomotic Willis polygon or openings in other collateral pathways can be determined
(for example: flow through the vasa vasorum or retrograde flow through the ophthalmic
artery). Thus, with NF in the area of the occluded artery, it is not possible to say with certainty
whether the embolism originated directly in the CAS or migrated through the anastomosis of
areas that revascularized the cerebral territory of the occluded carotid artery. Because of the
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difficulty of relating the localization of the embolism precisely with the artery that underwent
angioplasty, we decided not to include these two cases in the analysis of laterality.
The diameter of each NF was noted using the maximum diameter of the lesion in the DWI
sequence through a metric analysis determined manually in the software (eFilm®). For
comparison, the NFs were divided into three groups of diameters (<5 mm, between 5 and 10
mm and >10 mm) according to the stratification method published by other authors [69,70].
The patients with carotid occlusion contralateral to the CAS were noted. To mark the occlusion
of the internal carotid artery, we used DSA or MRI. In the absence of DSA in the carotid artery,
we defined occlusion using MRI when there was no “flow-void” phenomenon and a high
intravascular signal in the FLAIR sequence, compatible with thrombus in sections focusing on
the internal intracranial carotid artery. Both imaging methods were accepted as sufficient for
proving that a vessel was occluded.
Areas with DWI restriction after CAS (ischemia indicators) were correlated with demographic
aspects, aspects of the angioplasty technique, stenosis characteristics, and the presence of
previous infarctions on MRI. The quantification of stenosis in the carotid bulb studied was
using the NASCET method [10] with DSA in all cases.
7. Angioplasty technique used
The patients were divided into two groups: “brief” angiography and “complete” angiography.
An angiographic exam before CAS is conventionally called a brief angiography when the exam
only includes an angiography of the carotid artery that is a candidate for treatment. A complete
angiography includes the study of other cervical arteries or the aortic arch.
Antiplatelet therapy was standardized, and all patients received 75 mg clopidogrel and 100
mg acetylsalicylic acid orally on a daily basis, beginning at least five days before the procedure.
In the preparation of the materials, all of the introducers, catheters, and sheaths were pre‐
washed with physiologic saline flow and subsequently packed in a sterile container with
physiologic serum and heparin before arterial puncture.
Under local anesthesia and light sedation from the anesthesiologist, arterial puncture was
performed and the valved introducer was deployed in the common femoral artery, which was
fixed to the skin with a wire suture for safety. If there was significant tortuosity of the iliac and
femoral vessels, long introducers were sufficient to help stabilize the catheter and the catheter
guide in the common carotid arteries.
A bolus injection of 10,000 units of heparin was administered intravenously after the valved
introducer was installed. An atropine solution was prepared before the angioplasty and stored
until the stent’s release. Intermittent verbal communication was maintained with the patient
during the procedure by the doctors performing the CAS, as in the eventual clinical tests.
In all cases, the angiography of the carotid artery undergoing CAS was initially performed
with a 5 Fr angiographic catheter to confirm the stenosis shown with other methods. At this
point in the procedure, angiographies of the cerebral vessels nourished by the carotid artery
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may have a signal aspect similar to that of old infarctions (for example: porencephalic cysts,
arachnoid cysts, low-grade astrocytoma) were excluded from the count because of their
topographic characteristics, their appearance on the edge of the lesion, or their appearance on
the surrounding tissue or because they showed a signal that differed from that of the fluid in
the other sequences in the MRI study.
The MRI images were analyzed by the consensus of two experienced neuroradiologists using
the eFilm® software without access to the clinical data or angiography and CAS data. If there
were discrepancies between the two neuroradiologists’ findings, the studies were analyzed by
a third observer to reach a consensus.
The NF were correlated with age, gender, side of carotid artery treated, presence of previous
symptoms related to carotid stenosis, risk factors for atherosclerosis and ICVA (diabetes
mellitus, systemic arterial hypertension, hypercholesterolemia, ischemic coronary artery
disease, arrhythmia, ischemic peripheral vascular disease, transient ischemic attack [TIA], and
ischemic cerebrovascular accident [ICVA]), percentage of carotid stenosis, presence of ulcers
in the atheromatous plaque, previous infarction noted on the MRI, number of catheters used,
number of arteries on which angiographies were performed, contralateral carotid occlusion,
endovascular access technique used to reach the common carotid artery on the side of the
angioplasty, type of filter, type of stent, volume of contrast used in the CAS and angiography,
fluoroscopy time spent during the procedure, and the localization, number, and diameter of
these NF. These parameters were also correlated between patients with only one NF and those
with multiple NFs.
The localization (laterality) of the encephalic NF was defined as ipsilateral if it coincided with
the area supplied by the carotid artery undergoing angioplasty. The localization of the NF was
defined as contralateral if the cerebral area did not coincide with the side of the CAS, meaning
the area was nourished by the carotid artery contralateral to the angioplasty or the area located
on the posterior fossa. In cases when it was impossible to determine laterality, the patient was
excluded from the analysis, which occurred with two patients. Patients 16 and 27 showed
stenosis in the carotid artery (left) and contralateral occlusion (right), with NF identified in the
area supplied by the right carotid artery. Under this condition, the flow to the carotid area can
use the anastomotic Willis polygon or openings in other collateral pathways can be determined
(for example: flow through the vasa vasorum or retrograde flow through the ophthalmic
artery). Thus, with NF in the area of the occluded artery, it is not possible to say with certainty
whether the embolism originated directly in the CAS or migrated through the anastomosis of
areas that revascularized the cerebral territory of the occluded carotid artery. Because of the
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difficulty of relating the localization of the embolism precisely with the artery that underwent
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sequence through a metric analysis determined manually in the software (eFilm®). For
comparison, the NFs were divided into three groups of diameters (<5 mm, between 5 and 10
mm and >10 mm) according to the stratification method published by other authors [69,70].
The patients with carotid occlusion contralateral to the CAS were noted. To mark the occlusion
of the internal carotid artery, we used DSA or MRI. In the absence of DSA in the carotid artery,
we defined occlusion using MRI when there was no “flow-void” phenomenon and a high
intravascular signal in the FLAIR sequence, compatible with thrombus in sections focusing on
the internal intracranial carotid artery. Both imaging methods were accepted as sufficient for
proving that a vessel was occluded.
Areas with DWI restriction after CAS (ischemia indicators) were correlated with demographic
aspects, aspects of the angioplasty technique, stenosis characteristics, and the presence of
previous infarctions on MRI. The quantification of stenosis in the carotid bulb studied was
using the NASCET method [10] with DSA in all cases.
7. Angioplasty technique used
The patients were divided into two groups: “brief” angiography and “complete” angiography.
An angiographic exam before CAS is conventionally called a brief angiography when the exam
only includes an angiography of the carotid artery that is a candidate for treatment. A complete
angiography includes the study of other cervical arteries or the aortic arch.
Antiplatelet therapy was standardized, and all patients received 75 mg clopidogrel and 100
mg acetylsalicylic acid orally on a daily basis, beginning at least five days before the procedure.
In the preparation of the materials, all of the introducers, catheters, and sheaths were pre‐
washed with physiologic saline flow and subsequently packed in a sterile container with
physiologic serum and heparin before arterial puncture.
Under local anesthesia and light sedation from the anesthesiologist, arterial puncture was
performed and the valved introducer was deployed in the common femoral artery, which was
fixed to the skin with a wire suture for safety. If there was significant tortuosity of the iliac and
femoral vessels, long introducers were sufficient to help stabilize the catheter and the catheter
guide in the common carotid arteries.
A bolus injection of 10,000 units of heparin was administered intravenously after the valved
introducer was installed. An atropine solution was prepared before the angioplasty and stored
until the stent’s release. Intermittent verbal communication was maintained with the patient
during the procedure by the doctors performing the CAS, as in the eventual clinical tests.
In all cases, the angiography of the carotid artery undergoing CAS was initially performed
with a 5 Fr angiographic catheter to confirm the stenosis shown with other methods. At this
point in the procedure, angiographies of the cerebral vessels nourished by the carotid artery
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were performed, and they were repeated at the end of the CAS to observe any possible arterial
occlusion. In all cases, a noniconic contrast with low osmolarity was used.
In all cases (n=36), an 8 Fr-caliber guide catheter was introduced into the common femoral
artery inside the valved introducer, and the distal extremity was positioned in the common
carotid artery undergoing CAS a few centimeters below the atherosclerotic plaque.
The possible methods for positioning the catheter guide safely in the common carotid artery,
close to the bulb, were defined as access techniques. The endovascular techniques for accessing
the carotid artery to be treated included direct access (DA), an exchange with the guide wire
in the external carotid artery (ECA), exchange with the guide wire in the common carotid artery
(ECC), and triaxial access (TRI). For the direct access technique (DA), the catheter guide was
introduced into the common carotid artery by sliding it over a guide wire (0.035 inches) that
had previously been placed in the artery.
The technique involving exchange with the guide in the external carotid artery (EEC) was as
follows: the tip of the guide wire (0.035 inches) was positioned in the external carotid artery
using a diagnostic catheter with a 5-Fr caliber (figure 3). It remained safely in this position
without colliding with the atheromatous plaque, providing a means for the catheter guide to
advance over the guide until it reached the common carotid artery. The ECC technique was
defined as when the guide was positioned in the common carotid artery, rather than the
external carotid artery, with the help of a catheter guide contained within a diagnostic catheter.
At this point, the catheter was removed, and the catheter guide reached the common carotid
artery by going over the guide. The TRI technique involved using a guide catheter with a
diagnostic catheter inside (the designs and materials varied for each case) and a guide (0.035
inches) placed inside the diagnostic catheter. The catheter was free to attempt several maneu‐
vers before the catheter guide penetrated the carotid artery for the angioplasty.
After positioning the catheter guide in the common carotid artery, one of the closed filter
cerebral protection systems can be extended beyond the stenosis by positioning it a few
centimeters above the stenosis close to the base of the skull, preferably in a rectilinear segment
open in this topography. We also observed whether the filter was adjusted to the size of the
artery to avoid dislocating the filter system during the subsequent maneuvers.
“Rapid exchange” filter systems were used, which consisted of a 0.014-inch microguide with
a polyurethane membrane filter with 100 to 140 µm pores (100 µm in AngioGuard® filters
[Cordis], 110 µm in EPI FilterWire EPI/EZ® filters [Boston Scientific/Target], and 140 µm in
EmboShield® filters [Abbott]).
All of the patients were scheduled for the primary technique (without prior dilation of the
stenosis via a balloon) using a stent with an appropriate diameter (7 to 8 mm) for each case
and sufficient length to cover the bulb and the entire atherosclerotic plaque distally and
inferiorly (at least 1 cm).
Self-expandable stents (Carotid Wallstent®, Boston Scientific/Target; Precise®, Cordis; and
Protégé®, ev3) designed for carotid use in a 0.014-inch guide system were used. Only the
straight version of the Protégé® stent was used in our study.
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After the stent was released, 0.5 mg of atropine was administered intravenously. After
tachycardia was observed, a catheter balloon was inserted and inflated inside the stent. The
angioplasty balloon had the function of shaping the stent smoothly. The same balloon size was
used for all of the procedures: 6 mm in diameter and 20 mm in length (Gazele®, Boston Scietific/
Target and Amiia®, Cordis). In this study, after the balloon was deflated, an immediate-control
cervical angioplasty was conducted with a smooth manual injection of the contrast medium
to avoid disturbing the filter and possibly mobilizing any waste that it retained.
Once control via cervical DSA at the end of the CAS was considered satisfactory (residual
stenosis at a maximum of 30%), the filter was collected. Later, after the removal of the filter
and the last stage of CAS, carotid angiographies for intracranial vascularization were per‐
formed in anteroposterior (AP) and profile to show that the artery subjected to CAS remained
patent. Additionally, the intracranial vessels were thoroughly studied and compared with the
preangioplasty angiograms to detect any macroemboli. The catheter guide was removed at
the end of the CAS, leaving only the arterial introducer in the inguinal region. Heparin was
not antagonized. After the CAS, the cases were monitored in the intermediate intensive care
unit for 12 to 24 hours with attention to the patient’s neurological state and especially his/her
blood pressure.
All of the procedures were performed by an experienced neuroradiologist (with over 20 years
of specialty experience) with the help of one or two residents. No patient showed any neuro‐
logical or other symptoms after the CAS. The follow-up for clinical observations was the in-
hospital period of four days.
The data were analyzed using several methods and logistic regression analysis. All cases were
evaluated using SPSS (Version 15.0). A p-value <0.005 was considered statistically significant.
Figure 3. Patient number 2, 70 years old, male with diabetes, hypertension and coronary ischemia, displayed transient
ischemic attack. . DWI exam after CAS (not shown) did not reveal micrusemboli. Angiography showed stenosis of 70%
(A) in the left carotid artery with additional imaging (ulcer). EPI® open carotid filter (arrow) and Wallstent (7 x 40 mm)
self-expandable stent (B). Control angiography after CAS (C)
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8. Clinical and demographic data for patients before CAS
Of the 40 patients who began the study, 36 completed the protocol. Their ages varied from 54
to 87 years (average: 72.08 years).
n (%)
n of patients 36 (100.00)
Male 25 (69.44)
Female 11 (30.56)
Right carotid artery 15 (41.67)
Left carotid artery 21 (58.33)
Symptomatic patients 27 (75.00)
Asymptomatic patients 09 (25.00)
Average age/standard deviation (years) 72.08 (±8.30)
Table 1. Distribution of demographic data for the 36 patients
Risk factors n (%)
TIA 17 (47.22)
ICVA 11 (30.56)
TIA or ICVA 26 (72.22)
Arrhythmia 04 (11.11)
Ischemic coronary artery disease 09 (25.00)
Diabetes 12 (33.33)




Table 2. Distribution of risk factors (n=36 patients)
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9. Data from the procedures and technical considerations of digital
subtraction angiography and carotid angioplasty with a stent
Degree of stenosis1 – average (variation) 76.31% (60-99%)
Ulcerated plaques – n (%) 14 (38.89%)
Contralateral carotid occlusion – n (%) 7 (17.95%)
“Broad” examn (%) 24 (66.67%)
“Brief” examn (%) 12 (33.33%)
Filter – n (%): Angioguard® 4 (11.11%)
Emboshield® 7 (19.44%)
EPI® 25 (69.44%)
Stent – n (%): Precise® 9 (25.00%)
Protégé® 5 (13.89%)
Wallstent® 22 (61.11%)
Catheterization technique – n Direct access 12
Exchange in the external carotid artery 10
Exchange in the common carotid artery 11
Triaxial 08
Fluoroscopy time (minutes; average) 665; 22.93 min/CAS2
N of catheters used (n; average) 83; 2.31 cat/patient
Contrast volume (milliliters; average) 5480 ml; 182.67 ml/CAS3
Vessels submitted to DSA (n; average) 106; average 2.94
1 Percentage of stenosis evaluated by angiography
2 Regarding fluoroscopy time, only 29 procedures were recorded (n=29). In seven patients, there were technical
problems that prevented precise measurement.
3 For contrast volume, only 30 procedures were recorded (n=30). In six patients, there were technical problems that
prevented precise measurement.
Table 3. Technical aspects and characteristics of the angiographic exams (n=36)
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10.1. Aspects of MRI before the CAS
The preliminary MRI study before CAS showed six restriction foci in diffusion in four (11.11%)
patients (Table 4 and Figure 4). These foci were not recorded as NF after CAS.
n (%) patients
Infarctions in T2 23 (63.9)
Foci of restriction in DWI (1ª MR) 4 (11.1)
Table 4. MRI data before CAS (n = 36)
Among the restriction foci in DWI before CAS, five out of six (83.33%) were ipsilateral to the
carotid artery for CAS, and only one focus was not ipsilateral to the carotid that was treated
(cerebellum). All hypersignal foci in DWI before CAS occurred in patients with symptomatic
stenosis.
Figure 4. Patient number 7, male, 60 years old, underwent angioplasty of the left carotid artery. Restriction foci in
DWI in the MRI scan before CAS (A). Manifestation found in 11.11% of patients. No NF were observed after CAS (B)
11. Aspects of MRI after CAS
There were no new areas of cerebral infarction after CAS in the analysis of conventional MRI
sequences.
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A comparison between the MRI diffusion sequences acquired before and after angioplasty
showed 59 NF of restriction compatible with cerebral ischemia, which were distributed in 18/36
(50%) patients (Figures 5 and 6). The average NF in the 36 patients was 1.6 NF/patient (Table
5), and the diameter varied between 1 and 25 mm.
NF number 59 (18 patients)
NF size - n (%)
<5 mm 35 (59.33)
5 – 10 mm 19 (32.21)
>10 mm 05 (8.46)




1 Two patients were excluded from the analysis of laterality
Table 5. Characteristics of new foci (NF) of hypersignal in DWI after angioplasty of the carotid artery
Figure 5. Patient number 9, 59 years old, underwent right CAS. DWI before CAS (A) without images of restriction.
After CAS (B): ipsilateral NF (including primary motor rotation) and contralateral NF. Asymptomatic patient.
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Figure 6. Patient 27, male, 73 years old with right carotid artery occlusion and stenosis of the left carotid artery esti‐
mated at 70% by DSA (not shown). Before CAS: T2 sequence (A) shows old infarction in the territory of the right MCA
and diffusion sequence (C) without recent ischemia foci. The patient underwent DSA of both common carotid arteries
and CAS of the left. In the MRI study, the T2 sequence was unchanged after CAS (B) and the DWI sequence showed NF
in the head of the caudate nucleus to the right (D)
Laterality of NF % of NF n of NF Average2 P
IP 77.19 44 2.75
CL 22.81 13 0.81 0.063
Total 100.00 57 3.56
CL – NF contralateral to the area for CAS; IP – NF ipsilateral to the area for CAS
1 Two patients were excluded from the analysis of laterality.
2 NF/patients
Wilcoxon test
Table 6. Number and average of NF by laterality (n=16 patients1)
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Presentation of NF per patient n of NF n of pt Average
(NF/pt)
SD p
Single NF (1 nf/ pt) 9 9 1.00 0.00




Table 7. Distribution of NF (single or multiple)
Laterality Number of patients % of patients
IP pure 5 14.71
CL pure 5 14.71
Intersection (IP+CL in the same patient) 6 17.65
IP pure + intersection (IP+CL in the same patient)=11 patients=32.35%
IP pure: patients with only ipsilateral NF; CL pure: patients with only contralateral NF
1 Two patients were excluded from the analysis of laterality.
No statistical test
Table 8. Distribution of NF based on laterality per patient (n=34 patients1)
Laterality by patient n of NF Average2 p
IP pure 14 NF 2.80
CL pure 5 NF 1.00 0.053
Bilateral 38 NF 6.33
IP pure: patients with only ipsilateral NF; CL pure: patients with only contralateral NF; Bilateral: patients with both
ipsilateral and contralateral NF
1 Two patients were excluded from the analysis of laterality.
2 NF per case
Kruskal-Wallis test
Table 9. Number and average of NF according to laterality per patient (n=34 patients1)
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NF after CAS Average age (years) SD p
Without NF 71.83 9.03
With NF 72.33 7.75 0.855
Mann-Whitney U test





n % n %
AGE (years)
<75 8 44.4 7 38.9
≥75 10 55.6 11 61.1 0.855
TOTAL 18 100.0 18 100.0
GENDER
Male 15 83.3 10 55.6
Female 3 16.7 8 44.4 0.080
TOTAL 18 100.0 18 100.0
CAROTID ARTERY
Right 8 44.4 7 38.9
Left 10 55.6 11 61.1 0.735
TOTAL 18 100.0 18 100.0
Logistic regression analysis




n factors SD2 n factors SD2
Risk factors1(n=116) 60 1.75 56 1.18
n of patients Average (NF/pt3) n patients Average (NF/pt3)
Patients (n=36) 18 3.33 18 3.11 0.743
1 Risk factors for atherosclerosis/ICVA
2 Standard deviation for risk factors
3 Patient
Mann-Whitney U test
Table 12. Correlation of all risk factors with NF after CAS




N % n %
TIA 8 44.44 9 50.00 0.800
ICVA 4 22.22 7 38.89 0.612
ICVA or TIA 12 66.67 14 77.78 0.845
ARR 2 11.11 2 11.11 1.000
COL 8 44.44 4 22.22 0.164
COR 4 22.22 5 27.78 0.701
DM 5 27.78 7 38.89 0.481
PVD 10 55.56 9 50.00 0.738
HBP 15 83.33 17 94.44 0.311
TIA: transient ischemic attack; ICVA: ischemic cerebral vascular accident; TIA or ICVA: cases with at least one ischemic condition;
ARR: arrhythmia; COL: hypercholesterolemia; COR: ischemic coronary artery disease; DM: diabetes; PVD: peripheral vascular dis‐
ease; HBP: high blood pressure
Logistic regression analysis
Table 13. Distribution of risk factors in relation to the appearance of NF after CAS
NF
pNo Yes
Patients n of pt1 % pt n of pt % pt
Asymptomatic (n=9) 7 77.8% 2 22.2%
Symptomatic (n=27) 11 40.7% 16 59.26% 0.121
1 Patient
Chi-squared test
Table 14. Occurrence of NF based on the presence of symptoms before CAS
Clinical status of the patient before CAS n of NF % of NF p
Asymptomatic 11 18.6
Symptomatic 48 81.4 0.263
TOTAL 59 100.0
Mann-Whitney U test
Table 15. Correlation between the presence of carotid disease symptoms before the procedure and the number of NF
after CAS
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n pt1 %2 n pt %
Without 10 55.6 3 16.7
With 8 44.4 15 83.3 0.037
TOTAL 18 100.0 18 100.0
1 Patient
2 Percentage of patients in the group with NF (n=18)
Logistic regression analysis
Table 16. Distribution of NF according to the presence of previous cerebral infarct (in T2) in the first MRI
Infarct in T2 n of NF %1 n of pt2 Average3 SD4 p
Without 3 5.08 13 0.23 0.44
With 56 94.92 23 2.43 3.31 0.011
TOTAL 59 100.0
1 Percentage related to the complete NF group (n=59)




Table 17. Distribution of the number of NF (after CAS) based on the presence of previous cerebral infarcts in T2 in the
first MRI
Figure 7. Patient number 19, 81 years old with bilateral stenosis in the carotid arteries. A DSA was performed in the
aortic arch, common carotid arteries, left subclavian artery, and brachiocephalic trunk before the CAS of the left caro‐
tid artery. Diffusion study before the DSA and angioplasty (A). After DSA and CAS, an NF was identified in the DWI in
the left hemisphere of the cerebellum (B). A new MRI performed 40 days after the CAS (not as part of the study proto‐
col) showed the absence of lesions in the DWI (C) and in T2 (not shown).
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One patient (Number 19) showed one NF in the cerebellum after angioplasty of the left carotid
artery (Figure 7). Forty days later, the same patient was admitted for an angioplasty of the
right carotid artery. Another MRI was performed at this opportunity (not as part of the research
protocol), and it did not show diffusion lesions in the infarct area in T2 or in the enhancement,
which is common for subacute cerebral infarctions.
12. Aspects of angiography and angioplasty
NF N Average P
Yes 18 73.83
No 18 78.78 0.239
Mann-Whitney U test
Table 18. Average degree of stenosis in the groups with and without NF after CAS
NF
pNo Yes
N % N %
Ulcers 7 38.89 7 38.89 1.000
Logistic regression analysis
Table 19. Presence of ulcers and appearance of NF after CAS
NF
Occlusion of contralateral carotid artery
pYes No
N % n %
Yes 3 16.66 15 83.33
No 4 22.22 14 77.77 0.674
Chi-squared test
Table 20. Distribution of NF according to the presence of contralateral carotid occlusion.
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Table 18. Average degree of stenosis in the groups with and without NF after CAS
NF
pNo Yes
N % N %
Ulcers 7 38.89 7 38.89 1.000
Logistic regression analysis
Table 19. Presence of ulcers and appearance of NF after CAS
NF
Occlusion of contralateral carotid artery
pYes No
N % n %
Yes 3 16.66 15 83.33
No 4 22.22 14 77.77 0.674
Chi-squared test
Table 20. Distribution of NF according to the presence of contralateral carotid occlusion.
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Without (n=14) 323 23.07 10.48
With (n=15) 342 22.80 8.59 0.880
min: minute
Mann-Whitney U test









Without (n=16) 2910 181.88 73.50
With (n=14) 2570 183.57 54.01 0.918
ml: milliliter
Mann-Whitney U test
Table 22. Correlation of contrast volume used in the CAS and the appearance of NF after CAS
Patients n of catheters1 Average2 p
Without NF 43 2.39
With NF 40 2.22 0.462
1 Total number of catheters used in each group
2 Average catheter/patient
Mann-Whitney U test
Table 23. Number and average of catheters used in the CAS according to the presence of NF in the final MRI
Patients n of vessels undergoing DSA Average1 p
With NF 56 3.11
Without NF 50 2.78 0.628
1 Vessels subjected to angiography per patient
Mann-Whitney U test
Table 24. Number and average of vessels subjected to DSA according to the presence of NF after CAS




pNo (n=18) Yes (n=18)
n % n %
RCCA 13 72.22 16 88.89 0.220
RSUB1 4 22.22 2 11.11 0.379
BAT 6 33.33 9 50.00 0.313
ARCH 4 22.22 5 27.78 0.701
LSUB2 8 44.44 10 55.56 0.506
LCCA 15 83.33 14 77.78 0.675
RCCA: right common carotid artery; LCCA: left common carotid artery; ARCH: aortic arch; RSUB: right subclavian artery;
LSUB: left subclavian artery; BAT: brachiocephalic arterial trunk
1 RSUB includes angiography of the ipsilateral vertebral artery
2 LSUB includes angiography of the ipsilateral vertebral artery
Logistic regression analysis





n of pt % of exams n of pt % of exams
“Brief” (n=12) 7 58.33 5 41.67
“Broad” (n=24) 11 45.83 13 54.17 0.480
pt: patients
Logistic regression analysis
Table 26. Type of angiographic exam used and the appearance of NF after CAS
Technique used to access
carotid
Catheterization techniques
pWithout NF With NF
n1 %2 n1 %2
DA 6 50.00 6 50.00 1.000
ECC 5 50.00 5 50.00 1.000
EEC 4 36.37 7 63.64 0.283
TRI 6 75.00 2 25.00 0.124
DA: direct access; ECC: exchange in the common carotid artery; EEC: exchange in the external carotid artery; TRI: triaxial
1 Number of times that each technique is used in the group with and without NF
2 Percentage of access technique
Logistic regression analysis
Table 27. Correlation of catheterization techniques with NF after CAS
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n %1 n %1
Precise® 4 44.45 5 55.56
Protégé® 2 40.00 3 60.00
Wallstent® 12 54.55 10 45.45 0.493
1 Stent/brand
Chi-squared
Table 28. Correlation of types of stent with NF after CAS
Stent brand n of stents with NF IP NF IP Average1 p
Precise® 9 18 2.00
Protégé® 5 5 1.00 0.245
Wallstent® 20 21 1.05
IP: ipsilateral
1 NF IP/stent
NOTE: In this data analysis, CASs with NF outside the area where the stent was implanted were excluded.
Kruskal-Wallis test
Table 29. Correlation of stent brands with NF after CAS considering only the side where the stent was implanted
Stent design n of stent with NF IP NF IP Average2 p
Closed cell 20 21 1.05
Open cell 14 23 1.77 0.128
IP: ipsilateral
In this aggregation of the elements, CASs with NF outside the area where the stent was implanted were excluded
1 Two patients were excluded from the analysis of laterality.
2 NF IP/stent
Mann-Whitney U test
NOTE: Open-cell stent: Wallstent®; closed-cell stents: Precise® and Protégé®
Table 30. Correlation of stent designs with NF after CAS considering only the side where the stent was implanted
(n=34 patients1)





n % n %
Angioguard® 2 50.00 2 50.00
Emboshield® 2 28.57 5 71.43 0.367
EPI® 14 56.00 11 44.00
Chi-squared test
NOTE: 100 µm pores in AngioGuard®, 110 µm in EPI FilterWire EZ®, and 140 µm in EmboShield®
In this series, there was not a case in which excess thrombus or atheroma plaque materials determined acute occlusion
of the filter during the CAS.
Table 31. Occurrence of NF based on filter brand (n=36)
Filter brand n of uses NF IP2 Average3 p
Angioguard® 4 9 2.250
Emboshield® 6 12 2.000
EPI® 24 23 0.958 0.582




NOTE: 100 µm pores in AngioGuard®, 110 µm in EPI FilterWire EZ®, and 140 µm in EmboShield®
Table 32. Distribution of NF ipsilateral to the use of the filter, considering the different models (n=34 filters1)
Filter design n of uses NF IP2 Average3 p
Eccentric 24 23 0.958
Concentric 10 21 2.100 0.515
1 Two patients were excluded from the analysis of laterality.
2 NF ipsilateral
3 NF IP/filter system protection design
NOTE: Eccentric, EPI®; Concentric, Angioguard® and Emboshield®
Mann-Whitney U test
Table 33. Distribution of NF ipsilateral to the use of the filters, considering filter design (n=34 filters1)
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Table 33. Distribution of NF ipsilateral to the use of the filters, considering filter design (n=34 filters1)
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In summary, our DWI MRI study after CAS found that 50.00% of patients showed NF of
restriction/ischemia in DWI after CAS. All of the NF were clinically silent (100%). These NF
were located in a cerebral area fed by the cerebral artery subjected to CAS in 77.19% of patients
and an area smaller than 10 mm in 91.53% of patients. The NF in cerebral areas not fed by the
cerebral artery undergoing angioplasty corresponded to 22.81% of NFs. The presence of
previous cerebral infarcts on the MRI influenced the appearance of NF (p=0.037).
13. Discussion
13.1. Aspects of MRI imaging before CAS
The MRI scan before CAS showed great variety in the changes in the 36 patients, with special
attention to ischemic aspects. We found four (11.1%) patients with hypersignal foci (a total of
six foci) in the DWI MRI before CAS. These foci are considered recent ischemia foci, and they
are not reported as NF involved with CAS, although most remained after treatment. This rate
is similar to that reported by Jaeger et al. [56] In a study involving 70 CAS, the authors
discovered hypersignal lesions in diffusion before CAS in 10 (14%) of the patients, with a total
of 24 foci [56]. Images of ischemia in DWI were detected in 10 (19%) patients before CAS by
Hammer et al. [61]. Hammer et al. [61] suggested that recent ischemia foci presented by some
patients on the initial MRI indicate the relevance of performing an MRI scan before CAS to
guarantee that any foci in the MRI after CAS are related to the procedure.
Piñero et al. [48] found lesions in the DWI ipsilateral to the carotid artery undergoing CAS in
11% of the patients. In our data, 88.33% of the lesions found in the DWI before the CAS were
ipsilateral to the carotid artery treated. This result supports the idea that these plaques are
constantly forming emboli that can be sent to the brain.
Our data showed that carotid atherosclerotic plaques are probable causes of hypersignal
lesions in DWI before CAS and can be considered causes of ischemia symptoms. This finding
is corroborated by the fact that most patients were symptomatic (75.0%). Most of the patients
(63.9%) showed old cerebral infarcts in the T2 sequence of the MRI before CAS. In our series,
a strong correlation between the rates of old infarcts and positive symptoms was found (75.0%).
13.2. Diffusion MRI study after CAS
According to Bates et al. [13], while the primary purpose of revascularizing the carotid artery
is preventing cerebral infarction, current treatments, both CAS and endarterectomy, carry a
risk of triggering brain infarction.
All interventional procedures performed in craniofacial vascular regions carry an inherent risk
of causing embolisms to the brain with different levels of severity. In these cases, the diffusion
MRI technique is the most efficient tool for detecting acute focal cerebral ischemia [46,71,72].
Angioplasty is certainly the interventional procedure in the craniofacial region that carries the
greatest risk of embolism. This risk is well documented in various studies and varies greatly
among the different groups that it effects [35,37,73].
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The institution wherein the present study was conducted published data pertaining to 1,037
carotid angioplasties with stent implantation and cerebral protection in 2006. The incidence of
disabling neurological complications and death was 2.2% [38]. Despite the low morbi-mortality
of the method, the real incidence of embolism is not known because the patients remained
asymptomatic.
We found restriction foci in the diffusion MRIs of 18 of the 36 (50%) patients in our series. These
NF in the DWI after CAS are additional to those in the first MRI, which implies that the
procedure or some aspect of it is related to the appearance of NF. The fact that all of the patients
in this series were asymptomatic after CAS and remained so during the intrahospital obser‐
vation period should also be taken into account.
The percentage of patients with NF in DWI in similar studies is quite variable: 9 to 78% (9%
[74]; 15.8% [71]; 17.3% [48]; 20.4% [75]; 29% [56]; 30% [36]; 40% [61]; 41.5% [73]; 42% [46]; 42.6%
[69]; 43% [59]; 49% [34]; 52% [35], 54% [58], 59.2% [76]; 9 and 78% [77]; 70% [70]).
The comparison of different studies is very difficult because even a small variation in the period
after the CAS during which DWI was conducted might affect the result. In the study by Rapp
et al. [77], a total of 23 patients underwent two MRI exams after the CAS. The first MRI scan
was performed immediately after the procedure (1 to 2 h) and the second exam was performed
48 h later. The results indicated only two (9%) cases with NF in the DWI immediately after the
procedure and 18 (78%) cases with NF 48 h later [77]. In a recent meta-analysis that included
studies that followed the evolution of CAS by DWI (1,363 CAS), NF were found in 37% of
patients [37].
The study that is most similar to ours is Kastrup et al. (2006); this study found microembolia
in 49% of patients with cerebral protection. Two years later, the authors updated their series
and published that NF occurred after CAS with a cerebral protection filter in 52% of patients
[35].
du Mesnil de Rochemont et al. [46] found NF in 42% of CAS and, similar to our study, found
no neurological deficit. In addition to this study, several others [35,37,48,61,69,73] have found
that most patients remained asymptomatic after CAS, despite the presence of NF. These
findings encouraged us to look for factors that lead to ischemic changes.
Jaeger et al. [56] demonstrated that smaller NF are less likely to become definitive lesions. His
study showed that of the 59 restriction foci in the diffusion after CAS, only 17 (29%) were
observed in the T2 sequence. They found that 17% of the lesions smaller than 5 mm in the DWI
were visible in T2; 36% of the lesions in DWI between 5 and 10 mm were observed in T2, and
100% of the larger lesions (larger than 10 mm) were apparent in T2 [56]. As in Tedesco et al.
[70], we considered the hypersignal images in T2 as already defined and permanent ischemia
foci, unlike the lesions in DWI, which may be reversible.
In a series of 59 CASs, Jaeger et al. [56] found that 75% of NF were smaller than 5 mm; in the
series by Piñero [48], the lesions were smaller than 5 mm in 57% of patients. However, in a
series of 22 CASs in Roh et al. [78], all of the NF were smaller than 10 mm. In our study, small
NF (<10 mm) corresponded to a large majority (91.53%) of the NF, while large NF (>10 mm)
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In summary, our DWI MRI study after CAS found that 50.00% of patients showed NF of
restriction/ischemia in DWI after CAS. All of the NF were clinically silent (100%). These NF
were located in a cerebral area fed by the cerebral artery subjected to CAS in 77.19% of patients
and an area smaller than 10 mm in 91.53% of patients. The NF in cerebral areas not fed by the
cerebral artery undergoing angioplasty corresponded to 22.81% of NFs. The presence of
previous cerebral infarcts on the MRI influenced the appearance of NF (p=0.037).
13. Discussion
13.1. Aspects of MRI imaging before CAS
The MRI scan before CAS showed great variety in the changes in the 36 patients, with special
attention to ischemic aspects. We found four (11.1%) patients with hypersignal foci (a total of
six foci) in the DWI MRI before CAS. These foci are considered recent ischemia foci, and they
are not reported as NF involved with CAS, although most remained after treatment. This rate
is similar to that reported by Jaeger et al. [56] In a study involving 70 CAS, the authors
discovered hypersignal lesions in diffusion before CAS in 10 (14%) of the patients, with a total
of 24 foci [56]. Images of ischemia in DWI were detected in 10 (19%) patients before CAS by
Hammer et al. [61]. Hammer et al. [61] suggested that recent ischemia foci presented by some
patients on the initial MRI indicate the relevance of performing an MRI scan before CAS to
guarantee that any foci in the MRI after CAS are related to the procedure.
Piñero et al. [48] found lesions in the DWI ipsilateral to the carotid artery undergoing CAS in
11% of the patients. In our data, 88.33% of the lesions found in the DWI before the CAS were
ipsilateral to the carotid artery treated. This result supports the idea that these plaques are
constantly forming emboli that can be sent to the brain.
Our data showed that carotid atherosclerotic plaques are probable causes of hypersignal
lesions in DWI before CAS and can be considered causes of ischemia symptoms. This finding
is corroborated by the fact that most patients were symptomatic (75.0%). Most of the patients
(63.9%) showed old cerebral infarcts in the T2 sequence of the MRI before CAS. In our series,
a strong correlation between the rates of old infarcts and positive symptoms was found (75.0%).
13.2. Diffusion MRI study after CAS
According to Bates et al. [13], while the primary purpose of revascularizing the carotid artery
is preventing cerebral infarction, current treatments, both CAS and endarterectomy, carry a
risk of triggering brain infarction.
All interventional procedures performed in craniofacial vascular regions carry an inherent risk
of causing embolisms to the brain with different levels of severity. In these cases, the diffusion
MRI technique is the most efficient tool for detecting acute focal cerebral ischemia [46,71,72].
Angioplasty is certainly the interventional procedure in the craniofacial region that carries the
greatest risk of embolism. This risk is well documented in various studies and varies greatly
among the different groups that it effects [35,37,73].
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disabling neurological complications and death was 2.2% [38]. Despite the low morbi-mortality
of the method, the real incidence of embolism is not known because the patients remained
asymptomatic.
We found restriction foci in the diffusion MRIs of 18 of the 36 (50%) patients in our series. These
NF in the DWI after CAS are additional to those in the first MRI, which implies that the
procedure or some aspect of it is related to the appearance of NF. The fact that all of the patients
in this series were asymptomatic after CAS and remained so during the intrahospital obser‐
vation period should also be taken into account.
The percentage of patients with NF in DWI in similar studies is quite variable: 9 to 78% (9%
[74]; 15.8% [71]; 17.3% [48]; 20.4% [75]; 29% [56]; 30% [36]; 40% [61]; 41.5% [73]; 42% [46]; 42.6%
[69]; 43% [59]; 49% [34]; 52% [35], 54% [58], 59.2% [76]; 9 and 78% [77]; 70% [70]).
The comparison of different studies is very difficult because even a small variation in the period
after the CAS during which DWI was conducted might affect the result. In the study by Rapp
et al. [77], a total of 23 patients underwent two MRI exams after the CAS. The first MRI scan
was performed immediately after the procedure (1 to 2 h) and the second exam was performed
48 h later. The results indicated only two (9%) cases with NF in the DWI immediately after the
procedure and 18 (78%) cases with NF 48 h later [77]. In a recent meta-analysis that included
studies that followed the evolution of CAS by DWI (1,363 CAS), NF were found in 37% of
patients [37].
The study that is most similar to ours is Kastrup et al. (2006); this study found microembolia
in 49% of patients with cerebral protection. Two years later, the authors updated their series
and published that NF occurred after CAS with a cerebral protection filter in 52% of patients
[35].
du Mesnil de Rochemont et al. [46] found NF in 42% of CAS and, similar to our study, found
no neurological deficit. In addition to this study, several others [35,37,48,61,69,73] have found
that most patients remained asymptomatic after CAS, despite the presence of NF. These
findings encouraged us to look for factors that lead to ischemic changes.
Jaeger et al. [56] demonstrated that smaller NF are less likely to become definitive lesions. His
study showed that of the 59 restriction foci in the diffusion after CAS, only 17 (29%) were
observed in the T2 sequence. They found that 17% of the lesions smaller than 5 mm in the DWI
were visible in T2; 36% of the lesions in DWI between 5 and 10 mm were observed in T2, and
100% of the larger lesions (larger than 10 mm) were apparent in T2 [56]. As in Tedesco et al.
[70], we considered the hypersignal images in T2 as already defined and permanent ischemia
foci, unlike the lesions in DWI, which may be reversible.
In a series of 59 CASs, Jaeger et al. [56] found that 75% of NF were smaller than 5 mm; in the
series by Piñero [48], the lesions were smaller than 5 mm in 57% of patients. However, in a
series of 22 CASs in Roh et al. [78], all of the NF were smaller than 10 mm. In our study, small
NF (<10 mm) corresponded to a large majority (91.53%) of the NF, while large NF (>10 mm)
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composed only 8.46% of the NF; this result shows that the eventual emboli caused by the
procedure are small in size.
According to several authors, some lesions in DWI after CAS also occur in vascular regions
independent from the CAS and are most likely related to the catheterization procedure
[35,37,61,73]. Our data showed that most (77.19%) of the NF occurred in the region of the
carotid artery that underwent angioplasty. However, a significant difference was not observed
between the side of the CAS and the contralateral side in relation to NF.
In the publication by Piñero et al. [48], 67.9% of the NF were in the vascular area compatible
with the CAS. However, Hammer et al. [61] found a similar number by studying 53 carotid
angioplasties: 60% of the NF were in an ipsilateral situation to CAS and 40% occurred in
contralateral topography.
By studying carotid angioplasty, Poppert et al. [58found NF in DWI in area of contralateral
carotid or vertebral artery in 9.7% of patients. Poppert et al. [58] stated that during catheteri‐
zation, to reach the right internal carotid artery, the materials must pass the aortic arch at the
origin of other cerebral arterial trunks, such as the common carotid artery and left subclavian
artery, in addition to the brachiocephalic trunk next to the right vertebral artery. Thus, material
from plaques along this route can cause emboli in various brain regions beyond the area
nourished by the carotid artery undergoing CAS [58].
Maleux et al. [73] described their surprise at finding that 35.3% of the NF (26.3% in contralateral
anterior circulation and 9% in the cerebellum) occurred in regions not nourished by the carotid
artery ipsilateral to the CAS. They considered the manipulation of the guide wire, catheter, or
guide catheter in the aortic arch as a possible cause of the lesions [73].
A meta-analysis with data collected from CAS studies between 2000 and 2007 found lesions
in diffusion in 14.5% of CAS outside the region treated, and NF were observed in 35% of the
procedures in the region of the carotid artery treated by CAS [37]. Thus, catheterization was
one of the main causes of the microemboli.
In our study, half of the patients with NF had a single lesion (single NF), and the other half
showed multiple foci (varying from 2 to 11 NF), which totaled 50 NF. Thus, patients with
multiple NF accounted for 84.75% of the NFs found in diffusion. Our study reproduced the
finding of Piñero et al. [48]. These studies found a single focus in DWI in 53.6% of patients,
and multiple foci were found in 46.4% of the patients in diffusion after CAS [48].
In our study, we found five patients who showed ipsilateral NF, five patients who showed
contralateral NF, and another six who showed ipsilateral and contralateral NF simultaneously.
Thus, the ipsilateral situation was the main localization of the NF occurrence in absolute terms,
but the most common presentation was associated to the contralateral NF than isolated. A
similar distribution of laterality was found in a retrospective study by Tedesco et al. [70] of 27
CAS. Similar numbers were also observed by Hammer et al. [61], who, in a series of CAS under
cerebral protection, found eight cases with only ipsilateral NF, seven cases with exclusively
contralateral NF, and six cases with a combination of ipsilateral and contralateral NF. Accord‐
ing to these authors, these events can be related to the doctor’s skill in catheterizing the aortic
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arch and the supra-aortic trunks and to the prevention of emboli formation beyond the
collateral circulation by the Willis polygon or other routes [61].
When patients with NF in an area other than the carotid artery for angioplasty are excluded
(i.e., emboli resulting from catheterization), our risk of cerebral embolism from angioplasty
alone is reduced from 50.00% (18 patients) to 32.35% (11 patients).
du Mesnil de Rochemont et al. [46] found an average of one NF per patient in the ipsilateral
area, while Jaeger et al. found that the average number of NF ipsilateral to the CAS was 2.6
per patient and that the average number of NF contralateral to the CAS was 1.2 per patient [56].
In our study, the average number of ipsilateral NF was 2.8 per patient, and the average number
of contralateral NF was 1.0 per patient.
The highest mean (6.33) NF per patient was for the presentation of ipsilateral and contralateral
NF simultaneously. This finding justifies the idea that the initial angiography or the catheter‐
ization technique and the CAS are involved in the high average number of bilateral NF.
Our average number of NF per patient, which was higher than that reported by most authors,
may reflect the fact that most (66.7%) of our cases underwent a broad diagnostic exam before
the angioplasty. Thus, the hypothesis can be applied that, because most of the cases had
bilateral NF, these NF were more likely related to the catheterization than to the angioplasty
itself.
Because of the risk of embolism during angiographic exams (diagnostic) and in interventional
procedures such as CAS, we believe that the exams should be performed by certified and
experienced neuroradiologists only. This statement is supported by other authors [71,79].
Moreover, modern noninvasive methods can be used with good reproducibility in some
centers, allowing a definition of the anatomy, degree of stenosis, and intracranial circulation,
which enables decisions about the CAS to be made without the use of a broad angiography
before the CAS.
Several other authors [8,48,56,58,71,80-82] studied risk factors for the occurrence of athero‐
sclerotic disease and ICVA, including diabetes, hypertension, coronary artery disease,
ischemic peripheral vascular disease, hypercholesterolemia, arrhythmia, previous ischemic
stroke, previous TIA, vasculitis, and hemorrhagic cerebrovascular accident. Most authors did
not find significant differences related to the appearance of hypersignal foci in DWI. Some
authors found some relevant factors, but those were not confirmed by other authors.
Clinical risk factors were not significant determinants of the formation of NF after CAS in our
study. The only risk factor statistically proven to be involved in the creation of lesions in DWI
after CAS was a radiological factor: old cerebral infarcts shown on MRI images, especially in
T2W.
Our study found a tendency toward a greater number of NF in older patients (≥75 years) and
those who underwent angioplasty of the left carotid artery. Hammer et al. [61] identified a
tendency for NF to be found in patients with advanced age (>75 years); however, as in our
study, they failed to prove it statistically (p=0.1).
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composed only 8.46% of the NF; this result shows that the eventual emboli caused by the
procedure are small in size.
According to several authors, some lesions in DWI after CAS also occur in vascular regions
independent from the CAS and are most likely related to the catheterization procedure
[35,37,61,73]. Our data showed that most (77.19%) of the NF occurred in the region of the
carotid artery that underwent angioplasty. However, a significant difference was not observed
between the side of the CAS and the contralateral side in relation to NF.
In the publication by Piñero et al. [48], 67.9% of the NF were in the vascular area compatible
with the CAS. However, Hammer et al. [61] found a similar number by studying 53 carotid
angioplasties: 60% of the NF were in an ipsilateral situation to CAS and 40% occurred in
contralateral topography.
By studying carotid angioplasty, Poppert et al. [58found NF in DWI in area of contralateral
carotid or vertebral artery in 9.7% of patients. Poppert et al. [58] stated that during catheteri‐
zation, to reach the right internal carotid artery, the materials must pass the aortic arch at the
origin of other cerebral arterial trunks, such as the common carotid artery and left subclavian
artery, in addition to the brachiocephalic trunk next to the right vertebral artery. Thus, material
from plaques along this route can cause emboli in various brain regions beyond the area
nourished by the carotid artery undergoing CAS [58].
Maleux et al. [73] described their surprise at finding that 35.3% of the NF (26.3% in contralateral
anterior circulation and 9% in the cerebellum) occurred in regions not nourished by the carotid
artery ipsilateral to the CAS. They considered the manipulation of the guide wire, catheter, or
guide catheter in the aortic arch as a possible cause of the lesions [73].
A meta-analysis with data collected from CAS studies between 2000 and 2007 found lesions
in diffusion in 14.5% of CAS outside the region treated, and NF were observed in 35% of the
procedures in the region of the carotid artery treated by CAS [37]. Thus, catheterization was
one of the main causes of the microemboli.
In our study, half of the patients with NF had a single lesion (single NF), and the other half
showed multiple foci (varying from 2 to 11 NF), which totaled 50 NF. Thus, patients with
multiple NF accounted for 84.75% of the NFs found in diffusion. Our study reproduced the
finding of Piñero et al. [48]. These studies found a single focus in DWI in 53.6% of patients,
and multiple foci were found in 46.4% of the patients in diffusion after CAS [48].
In our study, we found five patients who showed ipsilateral NF, five patients who showed
contralateral NF, and another six who showed ipsilateral and contralateral NF simultaneously.
Thus, the ipsilateral situation was the main localization of the NF occurrence in absolute terms,
but the most common presentation was associated to the contralateral NF than isolated. A
similar distribution of laterality was found in a retrospective study by Tedesco et al. [70] of 27
CAS. Similar numbers were also observed by Hammer et al. [61], who, in a series of CAS under
cerebral protection, found eight cases with only ipsilateral NF, seven cases with exclusively
contralateral NF, and six cases with a combination of ipsilateral and contralateral NF. Accord‐
ing to these authors, these events can be related to the doctor’s skill in catheterizing the aortic
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arch and the supra-aortic trunks and to the prevention of emboli formation beyond the
collateral circulation by the Willis polygon or other routes [61].
When patients with NF in an area other than the carotid artery for angioplasty are excluded
(i.e., emboli resulting from catheterization), our risk of cerebral embolism from angioplasty
alone is reduced from 50.00% (18 patients) to 32.35% (11 patients).
du Mesnil de Rochemont et al. [46] found an average of one NF per patient in the ipsilateral
area, while Jaeger et al. found that the average number of NF ipsilateral to the CAS was 2.6
per patient and that the average number of NF contralateral to the CAS was 1.2 per patient [56].
In our study, the average number of ipsilateral NF was 2.8 per patient, and the average number
of contralateral NF was 1.0 per patient.
The highest mean (6.33) NF per patient was for the presentation of ipsilateral and contralateral
NF simultaneously. This finding justifies the idea that the initial angiography or the catheter‐
ization technique and the CAS are involved in the high average number of bilateral NF.
Our average number of NF per patient, which was higher than that reported by most authors,
may reflect the fact that most (66.7%) of our cases underwent a broad diagnostic exam before
the angioplasty. Thus, the hypothesis can be applied that, because most of the cases had
bilateral NF, these NF were more likely related to the catheterization than to the angioplasty
itself.
Because of the risk of embolism during angiographic exams (diagnostic) and in interventional
procedures such as CAS, we believe that the exams should be performed by certified and
experienced neuroradiologists only. This statement is supported by other authors [71,79].
Moreover, modern noninvasive methods can be used with good reproducibility in some
centers, allowing a definition of the anatomy, degree of stenosis, and intracranial circulation,
which enables decisions about the CAS to be made without the use of a broad angiography
before the CAS.
Several other authors [8,48,56,58,71,80-82] studied risk factors for the occurrence of athero‐
sclerotic disease and ICVA, including diabetes, hypertension, coronary artery disease,
ischemic peripheral vascular disease, hypercholesterolemia, arrhythmia, previous ischemic
stroke, previous TIA, vasculitis, and hemorrhagic cerebrovascular accident. Most authors did
not find significant differences related to the appearance of hypersignal foci in DWI. Some
authors found some relevant factors, but those were not confirmed by other authors.
Clinical risk factors were not significant determinants of the formation of NF after CAS in our
study. The only risk factor statistically proven to be involved in the creation of lesions in DWI
after CAS was a radiological factor: old cerebral infarcts shown on MRI images, especially in
T2W.
Our study found a tendency toward a greater number of NF in older patients (≥75 years) and
those who underwent angioplasty of the left carotid artery. Hammer et al. [61] identified a
tendency for NF to be found in patients with advanced age (>75 years); however, as in our
study, they failed to prove it statistically (p=0.1).
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du Mesnil de Rochemont et al. [46] confirmed this trend by finding that age above 70 years old
was a predictor for the occurrence of foci in diffusion, and they wondered whether this finding
could be related to the fact that more elderly patients have more diffuse atherosclerosis
compared with younger patients. These authors did not find a significant correlation for factors
such as gender, degree of stenosis, type of stent, type of filter, and risk factors, such as
hypertension, diabetes, smoking, hypercholesterolemia, coronary heart disease, and periph‐
eral arterial occlusive disease [46].
Generally, our group without NF showed fewer risk factors (56 factors) than the group with
NF after CAS did (60 factors). While not significant, the difference shows a tendency that the
more comorbidities the patient has, the greater his or her risk of developing NF in a CAS. The
difference was also not significant for the clinical conditions of previous ischemic cerebrovas‐
cular accident and transient ischemia attack. Similarly, for the risk factor of cerebral ischemia,
which was associated with both TIA and ICVA, the difference was also not significant.
In our group (n=36), which was characterized by advanced age (average of 72 years), serious
stenosis (average narrowing of 76.31%) and symptoms of previous ischemic conditions in most
patients (72.22%), the subgroup of previously asymptomatic patients showed a lower risk of
NF: only 18.6% of the observed NF. Moreover, a large majority, 48/59 (81.4%) of the NF
occurred in symptomatic patients. Despite this tendency, there was not a significant difference.
Hammer et al. [61], in a series of 53 CAS, identified a tendency to find NF in symptomatic
patients, although no statistical proof was found.
According to Kastrup et al. [35], it is conceivable that the high prevalence of active plaques
with thrombotic activity in recently symptomatic patients may determine the high rate of NF
in this group. When our patients are regrouped into asymptomatic (9 patients) and sympto‐
matic (27 patients) groups to evaluate the interference of previous symptoms with the
occurrence of NF, the hypothesis is confirmed. The asymptomatic patients did not develop NF
in most (77.8%) of the CAS cases, while the symptomatic patients showed NF in most cases
(59.3%). Again, the analysis did not prove a significant difference (p=0.121), but it confirms the
tendency for symptomatic patients to be at greater risk in the procedure. Piñero et al. [48] also
showed an increased risk of embolism in angioplasty for symptomatic patients in their series
(19.8%) compared to asymptomatic patients (10%; p = 0.155). This ratio is approximately 2:1,
while ours was approximately 2.7:1.
We found a significant difference in the NF lesions in DWI after CAS in patients with previous
infarcts (based on the T2 sequence) compared with those without. Cerebral infarct was present
in 63.9% of patients in our entire series. It was observed that most (83.3%) of the patients with
NF after CAS showed cerebral infarcts on the MRI before the CAS. Nonetheless, the patients
who did not show cerebral infarcts on the MRI before the CAS mostly evolved (55.6%) without
NF in the DWI after CAS (p=0.037). Again, the average number of NF varies enormously in
relation to whether the patient had or not a previous infarct on T2 (initial MRI). The average
NF in the group with a previous cerebral infarct was 2.43 NF/patient, while the average in the
group without a previous infarct was only 0.23 NF/patient (p=0.011).
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This association makes it clear that a definitive ischemic lesion in imaging (in T2W) is a great
risk factor for developing microembolic complications during carotid angioplasty. Thus, the
patients who have infarcts caused by embolism or other factors are the same patients who
present NF after CAS. Additionally, the tendency for symptomatic patients (who do not
necessarily always present infarcts on MRI) to exhibit more NF after CAS indicates that the
main cause of microemboli during CAS may be the patients’ condition, including the plaque
composition, risk factors, and how the atherosclerosis presents in their bodies. It is possible
that the NF are signs of the underlying disease, and they may be exacerbated during CAS. Our
idea about the vulnerability of plaque is shared by Piñero at al. [71], who evaluated the
composition of the material found in the filters after CAS and stated that the atheromatous
plaque and the vessel wall are the main sources of microemboli during CAS.
Despite several publications on signs compatible with microemboli after CAS and CEA, no
consensus can be found among authors regarding the real clinical representation of NF.
According to some authors [62,69], the clinical value of NF after CAS is not adequately clear.
In our study, although 50% of patients showed foci compatible with ischemia in the diffusion
after angioplasty, none showed ischemic neurological syndrome. Some published series have
obtained a similar result, meaning most patients with NF after CAS were asymptomatic [46,54].
While the brain shows some tolerance for microemboli [83,84], the fact that subclinical deficits
promoted in the NF areas after CAS may cause long-term neurological deterioration cannot
be neglected. Long-term studies on cognitive function are needed.
The clinical impact of these clinically “silent” lesions in the brain that do not cause motor,
sensory, or linguistic deficits (i.e., in non-eloquent brain areas) was debated by Bendszus [63,
80]. According to these authors, there is evidence that the cumulative load of ischemic brain
injury can cause neuropsychological deficits or aggravate vascular dementia.
However,  the discrepancy between the clinical  safety of  CAS and the number of  NF of
ischemia is intriguing. It is known that there can be TIA abnormalities in DWI that undergo
regression  and  do  not  cause  lesions  that  remain  as  ischemic  scares  in  T2.  Despite  the
normalization of DWI after TIA, structural damage caused by late neuronal apoptosis may
be present, even in the absence of tissue necrosis [63]. For these authors, DWI shows the
entire picture of emboli during different procedures, and the ischemic conditions are only
the visible tip of the iceberg [63].
Studying the DWI sequence in patients with clinical conditions of TIA, Kidwell et al. showed
that in five of nine patients with ischemia foci in DWI after TIA, no evidence of infarcts was
found in follow-up imaging scans, indicating that almost half of the lesions from DWI in TIA
may be completely reversible on imaging [85]. Thus, we most likely overestimate the true
incidence of cerebral ischemic lesion after CAS when we base it only on DWI of MRI.
Although not part of research protocol, an MRI scan was conducted 40 days after CAS in a
patient who showed NF in the MRI after CAS. The third MRI scan did not show ischemic
lesions in the DWI or in T2. Thus, the NF indicated in the MRI after CAS proved evanescent
(like short-lived). This suggests that small lesions in the DWI that occur after CAS and are
clinically silent may not be definitive ischemic lesions.
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eral arterial occlusive disease [46].
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more comorbidities the patient has, the greater his or her risk of developing NF in a CAS. The
difference was also not significant for the clinical conditions of previous ischemic cerebrovas‐
cular accident and transient ischemia attack. Similarly, for the risk factor of cerebral ischemia,
which was associated with both TIA and ICVA, the difference was also not significant.
In our group (n=36), which was characterized by advanced age (average of 72 years), serious
stenosis (average narrowing of 76.31%) and symptoms of previous ischemic conditions in most
patients (72.22%), the subgroup of previously asymptomatic patients showed a lower risk of
NF: only 18.6% of the observed NF. Moreover, a large majority, 48/59 (81.4%) of the NF
occurred in symptomatic patients. Despite this tendency, there was not a significant difference.
Hammer et al. [61], in a series of 53 CAS, identified a tendency to find NF in symptomatic
patients, although no statistical proof was found.
According to Kastrup et al. [35], it is conceivable that the high prevalence of active plaques
with thrombotic activity in recently symptomatic patients may determine the high rate of NF
in this group. When our patients are regrouped into asymptomatic (9 patients) and sympto‐
matic (27 patients) groups to evaluate the interference of previous symptoms with the
occurrence of NF, the hypothesis is confirmed. The asymptomatic patients did not develop NF
in most (77.8%) of the CAS cases, while the symptomatic patients showed NF in most cases
(59.3%). Again, the analysis did not prove a significant difference (p=0.121), but it confirms the
tendency for symptomatic patients to be at greater risk in the procedure. Piñero et al. [48] also
showed an increased risk of embolism in angioplasty for symptomatic patients in their series
(19.8%) compared to asymptomatic patients (10%; p = 0.155). This ratio is approximately 2:1,
while ours was approximately 2.7:1.
We found a significant difference in the NF lesions in DWI after CAS in patients with previous
infarcts (based on the T2 sequence) compared with those without. Cerebral infarct was present
in 63.9% of patients in our entire series. It was observed that most (83.3%) of the patients with
NF after CAS showed cerebral infarcts on the MRI before the CAS. Nonetheless, the patients
who did not show cerebral infarcts on the MRI before the CAS mostly evolved (55.6%) without
NF in the DWI after CAS (p=0.037). Again, the average number of NF varies enormously in
relation to whether the patient had or not a previous infarct on T2 (initial MRI). The average
NF in the group with a previous cerebral infarct was 2.43 NF/patient, while the average in the
group without a previous infarct was only 0.23 NF/patient (p=0.011).
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present NF after CAS. Additionally, the tendency for symptomatic patients (who do not
necessarily always present infarcts on MRI) to exhibit more NF after CAS indicates that the
main cause of microemboli during CAS may be the patients’ condition, including the plaque
composition, risk factors, and how the atherosclerosis presents in their bodies. It is possible
that the NF are signs of the underlying disease, and they may be exacerbated during CAS. Our
idea about the vulnerability of plaque is shared by Piñero at al. [71], who evaluated the
composition of the material found in the filters after CAS and stated that the atheromatous
plaque and the vessel wall are the main sources of microemboli during CAS.
Despite several publications on signs compatible with microemboli after CAS and CEA, no
consensus can be found among authors regarding the real clinical representation of NF.
According to some authors [62,69], the clinical value of NF after CAS is not adequately clear.
In our study, although 50% of patients showed foci compatible with ischemia in the diffusion
after angioplasty, none showed ischemic neurological syndrome. Some published series have
obtained a similar result, meaning most patients with NF after CAS were asymptomatic [46,54].
While the brain shows some tolerance for microemboli [83,84], the fact that subclinical deficits
promoted in the NF areas after CAS may cause long-term neurological deterioration cannot
be neglected. Long-term studies on cognitive function are needed.
The clinical impact of these clinically “silent” lesions in the brain that do not cause motor,
sensory, or linguistic deficits (i.e., in non-eloquent brain areas) was debated by Bendszus [63,
80]. According to these authors, there is evidence that the cumulative load of ischemic brain
injury can cause neuropsychological deficits or aggravate vascular dementia.
However,  the discrepancy between the clinical  safety of  CAS and the number of  NF of
ischemia is intriguing. It is known that there can be TIA abnormalities in DWI that undergo
regression  and  do  not  cause  lesions  that  remain  as  ischemic  scares  in  T2.  Despite  the
normalization of DWI after TIA, structural damage caused by late neuronal apoptosis may
be present, even in the absence of tissue necrosis [63]. For these authors, DWI shows the
entire picture of emboli during different procedures, and the ischemic conditions are only
the visible tip of the iceberg [63].
Studying the DWI sequence in patients with clinical conditions of TIA, Kidwell et al. showed
that in five of nine patients with ischemia foci in DWI after TIA, no evidence of infarcts was
found in follow-up imaging scans, indicating that almost half of the lesions from DWI in TIA
may be completely reversible on imaging [85]. Thus, we most likely overestimate the true
incidence of cerebral ischemic lesion after CAS when we base it only on DWI of MRI.
Although not part of research protocol, an MRI scan was conducted 40 days after CAS in a
patient who showed NF in the MRI after CAS. The third MRI scan did not show ischemic
lesions in the DWI or in T2. Thus, the NF indicated in the MRI after CAS proved evanescent
(like short-lived). This suggests that small lesions in the DWI that occur after CAS and are
clinically silent may not be definitive ischemic lesions.
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Similarly, a small study (seven patients) from Schlüter et al. [86] identified reversal on imaging
in 76% (5/21) of the NF after CAS at an average MRI follow-up four months later. A recent
study showed that 92.1% of the signs of microemboli disappeared and that 5.2% remained in
an MRI study three months after the CAS [72]. Thus, the NF after CAS are potentially reversible
on imaging and without neurological developments [60,75,86].
Some authors [69,87] correlated the neurological deficits after CAS with the diameter of the
foci of ischemia in the DWI. Small lesions were associated with good clinical evaluation. Small
NF (>5 mm) were reported as having the highest chance of not becoming definitive ischemic
lesions in later MRI scans compared with NF larger than 5 mm [75]. In addition to the size of
the foci in DWI, the topography may also determine whether the lesion will be clinically silent
or not [56,71].
For Piñero et al. [48], the position of the lesions in the diffusion was predominantly cortical
and subcortical in 67.9%.The study by Jaeger et al. showed that 95% of the NF had a cortical/
subcortical localization, mainly in the area of the ACA and MCA. Jaeger et al. considered this
distribution to be more compatible with standard cerebral embolism than with types of
cerebral ischemia [56].
Similar to Piñero et al. [48] and Jaeger et al. [56], the predominant pattern of the NF in our
study were lesions with small diameters and apparently random distribution. This finding is
compatible with the topography of the distal arteries, including the cortical and subcortical
vessels and perforating branches. There was also no predominance in border (“watershed”)
areas of vascularization.
Although we found NF in various areas, such as the motor cortex and basal ganglia, the
patients presented no clinical deficit during the hospitalization period. It may be that because
the NF had a small volume, they were less relevant for clinical lesions due to collateral
circulation, despite being in eloquent area. Nonetheless, improvement in cerebral perfusion
was shown after CAS in publications by Tavares and Caldas and may counterbalance clinical
damage resulting from microemboli that occur after CAS [68,88,89].
13.3. Aspects of angiography, angioplasty, and cerebral protection
In addition to maintaining a constant flow to the brain in all phases of CAS, cerebral protection
with a filter is likely to be used in all cases (unlike the occlusive balloon technique, which is
reserved for patients who are candidates for temporary carotid occlusion) [42]. Other limita‐
tions of techniques that use balloon for cerebral protection include severe tortuosity of the
cervical and thoracic arteries and increased diameter of the external carotid >6 mm [72]. These
were our reasons for choosing filters as a means of protection in our cases.
Angiographic factors and factors in the angioplasty, such as percentage of stenosis, presence
of ulceration in the plaque, and number of catheters used, did not show a statistically signifi‐
cant difference in our study with respect to the appearance of NF after CAS. In contrast to our
findings, Ohki et al., studying ex vivo angioplasty with stent, found that the greatest number
of particles during the procedure was associated with serious stenosis >90% [90]. Gauvrit et
al. [74], similar to our findings, did not find a significant difference between the degree of
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stenosis in groups of patients with and without NF after CAS. Schnaudigel et al. [37], in a meta-
analysis, considered that the degree of stenosis influenced the incidence of NF after CAS;
however, it was difficult to compare the articles because of great variation in the diagnostic
methods (DSA, CTA, MRA, and Doppler) and methodologies (NASCET, ECST or not men‐
tioned) used to grade the stenosis [37]. Roh et al. [78] found NF after CAS in eight of 22 (36%)
cases. Thus, similar to us, they did not find a significant difference in the presence of NF in
relation to the presence or absence of ulcers in the plaque. Among our patients, the percentages
with ulcers were identical in the groups with and without embolism in CAS.
We note that ulcers did not influence the result of embolism, although one of the steps,
overcoming the ulcerated stenosis by the still-closed closed filter, occurred without cerebral
protection. This fact may suggest the safety of filters in crossing stenotic lesions, even ana‐
tomically complex ones, such as ulcerated plaques. More studies are needed to prove this
hypothesis. Lacroix et al. [69], in a series of 61 CASs, analyzed technical conditions such as the
procedure duration and presence of ulcers in atheromatous plaque. They did not find a
correlation between these elements and the frequency of NF in DWI.
We did  not  find  a  significant  difference  between contralateral  occlusion  and the  occur‐
rence of NF after CAS. This finding confirms the clinical reasoning that patients with carotid
stenosis and contralateral carotid occlusion have an embolism risk similar to that of other
patients  during  CAS  treatment.  This  fact  contrasts  with  endarterectomy,  for  which  the
clinical results are materially negatively influenced by the presence of contralateral carotid
occlusion [10,91-93].
The fluoroscopy time used in CAS may reflect the technical difficulty of the procedure as
this time is equivalent to the set of short intervals in which X-ray was applied during the
maneuvers necessary for the catheters,  guides,  balloons,  stents,  and other materials [82].
Pinheiro et al. [48] used fluoroscopy for 21 min (average) per CAS, a result similar to our
series (22.93 min per CAS). As in our study, Tedesco et al. [70] did not find a correlation
between long fluoroscopy times or greater amounts of contrast and the appearance of NF
after CAS. Conversely, Rapp et al. [77] found an increase in NF after CAS depending on
the fluoroscopy time used. However, the fact that we did not find a significant difference
in the fluoroscopy time between the groups with and without embolism suggests that cases
in which the angioplasty is technically difficult may require longer times for the interven‐
tionist, but theoretically, the increased time does not increase in the risks of embolism. The
CASs in this study were always conducted by an individual with a considerable amount
of experience. The only way to exclude this bias would be to evaluate the learning curve
of a technician in training, which may explain the results of [77].
Although each contrast injection has an unknown theoretical risk of carrying emboligenic
particles, this was not proven in our series, but there was not a significant difference in volume
between the groups with and without NF. Nonetheless, we remember that, in medical services
such as ours with a neuroradiology practice, the cases of embolism are possibly not due to the
technique used because the contrast volume and the fluoroscopy time are similar for both
groups. Moreover, it is possible that the risk of embolism may be endogenous to patients at a
neuroradiology institution where the iatrogenic embolism factor is studied and controlled. The
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the foci in DWI, the topography may also determine whether the lesion will be clinically silent
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distribution to be more compatible with standard cerebral embolism than with types of
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study were lesions with small diameters and apparently random distribution. This finding is
compatible with the topography of the distal arteries, including the cortical and subcortical
vessels and perforating branches. There was also no predominance in border (“watershed”)
areas of vascularization.
Although we found NF in various areas, such as the motor cortex and basal ganglia, the
patients presented no clinical deficit during the hospitalization period. It may be that because
the NF had a small volume, they were less relevant for clinical lesions due to collateral
circulation, despite being in eloquent area. Nonetheless, improvement in cerebral perfusion
was shown after CAS in publications by Tavares and Caldas and may counterbalance clinical
damage resulting from microemboli that occur after CAS [68,88,89].
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In addition to maintaining a constant flow to the brain in all phases of CAS, cerebral protection
with a filter is likely to be used in all cases (unlike the occlusive balloon technique, which is
reserved for patients who are candidates for temporary carotid occlusion) [42]. Other limita‐
tions of techniques that use balloon for cerebral protection include severe tortuosity of the
cervical and thoracic arteries and increased diameter of the external carotid >6 mm [72]. These
were our reasons for choosing filters as a means of protection in our cases.
Angiographic factors and factors in the angioplasty, such as percentage of stenosis, presence
of ulceration in the plaque, and number of catheters used, did not show a statistically signifi‐
cant difference in our study with respect to the appearance of NF after CAS. In contrast to our
findings, Ohki et al., studying ex vivo angioplasty with stent, found that the greatest number
of particles during the procedure was associated with serious stenosis >90% [90]. Gauvrit et
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stenosis in groups of patients with and without NF after CAS. Schnaudigel et al. [37], in a meta-
analysis, considered that the degree of stenosis influenced the incidence of NF after CAS;
however, it was difficult to compare the articles because of great variation in the diagnostic
methods (DSA, CTA, MRA, and Doppler) and methodologies (NASCET, ECST or not men‐
tioned) used to grade the stenosis [37]. Roh et al. [78] found NF after CAS in eight of 22 (36%)
cases. Thus, similar to us, they did not find a significant difference in the presence of NF in
relation to the presence or absence of ulcers in the plaque. Among our patients, the percentages
with ulcers were identical in the groups with and without embolism in CAS.
We note that ulcers did not influence the result of embolism, although one of the steps,
overcoming the ulcerated stenosis by the still-closed closed filter, occurred without cerebral
protection. This fact may suggest the safety of filters in crossing stenotic lesions, even ana‐
tomically complex ones, such as ulcerated plaques. More studies are needed to prove this
hypothesis. Lacroix et al. [69], in a series of 61 CASs, analyzed technical conditions such as the
procedure duration and presence of ulcers in atheromatous plaque. They did not find a
correlation between these elements and the frequency of NF in DWI.
We did  not  find  a  significant  difference  between contralateral  occlusion  and the  occur‐
rence of NF after CAS. This finding confirms the clinical reasoning that patients with carotid
stenosis and contralateral carotid occlusion have an embolism risk similar to that of other
patients  during  CAS  treatment.  This  fact  contrasts  with  endarterectomy,  for  which  the
clinical results are materially negatively influenced by the presence of contralateral carotid
occlusion [10,91-93].
The fluoroscopy time used in CAS may reflect the technical difficulty of the procedure as
this time is equivalent to the set of short intervals in which X-ray was applied during the
maneuvers necessary for the catheters,  guides,  balloons,  stents,  and other materials [82].
Pinheiro et al. [48] used fluoroscopy for 21 min (average) per CAS, a result similar to our
series (22.93 min per CAS). As in our study, Tedesco et al. [70] did not find a correlation
between long fluoroscopy times or greater amounts of contrast and the appearance of NF
after CAS. Conversely, Rapp et al. [77] found an increase in NF after CAS depending on
the fluoroscopy time used. However, the fact that we did not find a significant difference
in the fluoroscopy time between the groups with and without embolism suggests that cases
in which the angioplasty is technically difficult may require longer times for the interven‐
tionist, but theoretically, the increased time does not increase in the risks of embolism. The
CASs in this study were always conducted by an individual with a considerable amount
of experience. The only way to exclude this bias would be to evaluate the learning curve
of a technician in training, which may explain the results of [77].
Although each contrast injection has an unknown theoretical risk of carrying emboligenic
particles, this was not proven in our series, but there was not a significant difference in volume
between the groups with and without NF. Nonetheless, we remember that, in medical services
such as ours with a neuroradiology practice, the cases of embolism are possibly not due to the
technique used because the contrast volume and the fluoroscopy time are similar for both
groups. Moreover, it is possible that the risk of embolism may be endogenous to patients at a
neuroradiology institution where the iatrogenic embolism factor is studied and controlled. The
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study by Kato et al. [94], as well as ours, did not find a significant difference in the groups with
and without NF regarding contrast volume, duration of the procedure, and the use of addi‐
tional catheters.
In our series, greater number of angiographies was found in the group that showed NF, and
the occurrence of NF varied based on the type of exam applied. Most of the exams defined as
broad were associated with emboli, and most of the brief exams did not show any NF after
CAS. However, there was no statistical confirmation.
Following the same trend, the average DSA per patient was greater in the patients with NF
(average 3.11) than among patients (average 2.78) without NF. Despite the theoretical risk of
increasing embolism with the diagnostic exam, the statistical analysis was not sufficient to
prove this hypothesis. Thus, the greater the number of vessels on which angiographies were
performed, the higher the occurrence of NF. The logical deduction is that conventional
angiography has the same responsibility for causing NF as angioplasty alone.
The catheter itself is a potential source of embolism, although complication rates are low [95],
and most complications are asymptomatic ischemic complications [61]. Bendszus et al. were
the first to publish diffusion MRI as a detection method for clinically silent emboli after cerebral
angiographies. They found 42 hypersignal foci in the DWI in 23 out of 100 (23%) patients after
DSA with manual injection of the contrast, all without neurological deficits [80].
Britt et al., in a short series, estimated an incidence of less than 9% of asymptomatic cerebral
infarcts in diffusion in patients undergoing cerebral angiography for diagnostic purposes [96].
Kato et al. [94], in a study of 50 patients, observed NF in the diffusion after DSA in 8 of the 41
(19.51%) patients. Chuah et al. [97] found NF after angiographies in 3 of 20 (15%) patients, all
of which were smaller than 10 mm and occurred at a rate of only one per patient.
Angiography of the aortic arch before CAS was associated with a high risk of microemboli,
according to a publication of 27 CASs by Tedesco et al. [70]. This study reports that the
aortography by catheter was avoided in cases where ulcers or stenosis were identified in the
aortic arch during the revision of exams conducted immediately before CAS. Some authors
have reduced the use of aortography by catheter. After the inclusion of MRI angiography in
the protocol by Rapp et al. [77], digital angiography by catheter was abolished in 81% of CASs.
In the detailed statistical analysis using logistic regression of our data, we did not find a
significant difference between DSA of the aortic arch (p = 0.701) and the appearance of NF in
diffusion after CAS. In addition to CAS and DSA, several other catheter techniques show risks
of cerebral embolism during the procedure. Rordorf et al. [98] found lesions in diffusion in 8
of 14 (57%) patients after embolization of unruptured cerebral aneurysms. In this series, the
majority, with the exception of one new focus, was ipsilateral to the treated aneurysm [98].
Cronqvist et al. [99] published a series of 21 patients suffering from cerebral arteriovenous
malformation who underwent 50 embolization procedures. In their study, NF were less
frequent (22% of procedures). Of the 35 NF found in DWI, 23 (66%) were of ischemic origin, 8
(23%) represented perinidal venous clots, and 4 (11%) were of uncertain origin [99].
Brain catheterization is not the only cause of brain embolism. In prospective studies, there was
an incidence of up to 15% for cerebral NF after cardiac catheterization [100]. Ischemia foci in
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DWI are found in a substantial number of carotid surgeries (endarterectomy), heart and
coronary surgeries, and interventions with cerebral angiographies [63,101,102]. Cardiac
bypass surgery may induce NF for cerebral ischemia in up to 45% of patients [103].
Willinsky et al. [82] point to mechanisms related to brain catheterization, such as throm‐
boembolism resulting from the withdrawal of the guide within the catheter. The withdrawal
causes the empty space of the catheter to fill with blood. This space is subjected to stagnation,
unnoticed by the inexperienced practitioner, and causes the formation of emboli [79]. Other
mechanisms cited are the dissection and fracture of plaques; the fragmentation of plaques with
catheters, guide catheters and guide wires; platelet activation; changes in clotting factors; and
the introduction of air bubbles [36,46].
Willinsky et al.  [82] published a five-year retrospective study of 2,899 cerebral angiogra‐
phies and found neurological complications in 39 (1.3%), 20 of which were transitory (0.7%),
five (0.2%) were reversed, and 14 (0.5%) were permanent. Neurological events in angiogra‐
phy  were  significantly  more  frequent  in  older  patients  (>55  years)  and  patients  with
concomitant cardiovascular disease and when the fluoroscopy was longer [82]. Kaufmann
et  al.  [95]  published the  widest  series  of  cerebral  angiographies  that  resulted in  clinical
complications by evaluating 19,827 consecutive patients in a 22-year retrospective study at
the Mayo Clinic. They found neurological complications in 2.63% of patients, permanent
infarcts in 0.14%, and deaths in 0.06% [95]. Hematoma at the puncture site was the most
common occurrence (4.2%). The independent factors identified as associated with neurolog‐
ical  complications  included  atherosclerotic  cerebrovascular  disease,  transient  ischemic
attacks, and subarachnoid hemorrhage [95].
Therefore, we assume that there is a theoretical risk of brain embolism, including possible
severe ischemic events, with all of the interventional procedures.
According to some authors, the diffusion MRI technique is the most efficient tool for detecting
acute focal brain ischemia [68,71,76].
Among the interventional procedures, carotid angioplasty achieved a significant reduction in
embolism with the introduction of protection systems, but emboli were not avoided com‐
pletely [35,37,46,68,73]. Good practice in neuroradiology procedures appears to be a mitigating
factor for embolic damage during carotid angioplasty procedures. Consistent with our idea,
Verzini et al. and Piñero et al. said that the interventionist’s experience is a factor for reducing
periprocedural complications [68,71,104]. For du Mesnil de Rochemont et al. [46], uninten‐
tional movement of the filter during the intervention is a potential cause of microemboli and
mainly occurs during the initial learning curve. This movement can largely be avoided with
improved interventional technique and new materials [46,68]. We believe that the learning
curve for CAS might be long and could exceed 200 cases.
Tedesco et al. [70] stated that their CAS program was modified to include the omission of the
aortic arch. This change began when MRI images provided sufficient anatomic detail and
initiated anticoagulation before the passage of guides and catheters in the ascending and
transverse aorta [70]. Thus, these authors state that aortography should be reserved for patients
for whom the MRI before CAS does not provide anatomic details to guide the catheter. In
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study by Kato et al. [94], as well as ours, did not find a significant difference in the groups with
and without NF regarding contrast volume, duration of the procedure, and the use of addi‐
tional catheters.
In our series, greater number of angiographies was found in the group that showed NF, and
the occurrence of NF varied based on the type of exam applied. Most of the exams defined as
broad were associated with emboli, and most of the brief exams did not show any NF after
CAS. However, there was no statistical confirmation.
Following the same trend, the average DSA per patient was greater in the patients with NF
(average 3.11) than among patients (average 2.78) without NF. Despite the theoretical risk of
increasing embolism with the diagnostic exam, the statistical analysis was not sufficient to
prove this hypothesis. Thus, the greater the number of vessels on which angiographies were
performed, the higher the occurrence of NF. The logical deduction is that conventional
angiography has the same responsibility for causing NF as angioplasty alone.
The catheter itself is a potential source of embolism, although complication rates are low [95],
and most complications are asymptomatic ischemic complications [61]. Bendszus et al. were
the first to publish diffusion MRI as a detection method for clinically silent emboli after cerebral
angiographies. They found 42 hypersignal foci in the DWI in 23 out of 100 (23%) patients after
DSA with manual injection of the contrast, all without neurological deficits [80].
Britt et al., in a short series, estimated an incidence of less than 9% of asymptomatic cerebral
infarcts in diffusion in patients undergoing cerebral angiography for diagnostic purposes [96].
Kato et al. [94], in a study of 50 patients, observed NF in the diffusion after DSA in 8 of the 41
(19.51%) patients. Chuah et al. [97] found NF after angiographies in 3 of 20 (15%) patients, all
of which were smaller than 10 mm and occurred at a rate of only one per patient.
Angiography of the aortic arch before CAS was associated with a high risk of microemboli,
according to a publication of 27 CASs by Tedesco et al. [70]. This study reports that the
aortography by catheter was avoided in cases where ulcers or stenosis were identified in the
aortic arch during the revision of exams conducted immediately before CAS. Some authors
have reduced the use of aortography by catheter. After the inclusion of MRI angiography in
the protocol by Rapp et al. [77], digital angiography by catheter was abolished in 81% of CASs.
In the detailed statistical analysis using logistic regression of our data, we did not find a
significant difference between DSA of the aortic arch (p = 0.701) and the appearance of NF in
diffusion after CAS. In addition to CAS and DSA, several other catheter techniques show risks
of cerebral embolism during the procedure. Rordorf et al. [98] found lesions in diffusion in 8
of 14 (57%) patients after embolization of unruptured cerebral aneurysms. In this series, the
majority, with the exception of one new focus, was ipsilateral to the treated aneurysm [98].
Cronqvist et al. [99] published a series of 21 patients suffering from cerebral arteriovenous
malformation who underwent 50 embolization procedures. In their study, NF were less
frequent (22% of procedures). Of the 35 NF found in DWI, 23 (66%) were of ischemic origin, 8
(23%) represented perinidal venous clots, and 4 (11%) were of uncertain origin [99].
Brain catheterization is not the only cause of brain embolism. In prospective studies, there was
an incidence of up to 15% for cerebral NF after cardiac catheterization [100]. Ischemia foci in
Carotid Artery Disease - From Bench to Bedside and Beyond184
DWI are found in a substantial number of carotid surgeries (endarterectomy), heart and
coronary surgeries, and interventions with cerebral angiographies [63,101,102]. Cardiac
bypass surgery may induce NF for cerebral ischemia in up to 45% of patients [103].
Willinsky et al. [82] point to mechanisms related to brain catheterization, such as throm‐
boembolism resulting from the withdrawal of the guide within the catheter. The withdrawal
causes the empty space of the catheter to fill with blood. This space is subjected to stagnation,
unnoticed by the inexperienced practitioner, and causes the formation of emboli [79]. Other
mechanisms cited are the dissection and fracture of plaques; the fragmentation of plaques with
catheters, guide catheters and guide wires; platelet activation; changes in clotting factors; and
the introduction of air bubbles [36,46].
Willinsky et al.  [82] published a five-year retrospective study of 2,899 cerebral angiogra‐
phies and found neurological complications in 39 (1.3%), 20 of which were transitory (0.7%),
five (0.2%) were reversed, and 14 (0.5%) were permanent. Neurological events in angiogra‐
phy  were  significantly  more  frequent  in  older  patients  (>55  years)  and  patients  with
concomitant cardiovascular disease and when the fluoroscopy was longer [82]. Kaufmann
et  al.  [95]  published the  widest  series  of  cerebral  angiographies  that  resulted in  clinical
complications by evaluating 19,827 consecutive patients in a 22-year retrospective study at
the Mayo Clinic. They found neurological complications in 2.63% of patients, permanent
infarcts in 0.14%, and deaths in 0.06% [95]. Hematoma at the puncture site was the most
common occurrence (4.2%). The independent factors identified as associated with neurolog‐
ical  complications  included  atherosclerotic  cerebrovascular  disease,  transient  ischemic
attacks, and subarachnoid hemorrhage [95].
Therefore, we assume that there is a theoretical risk of brain embolism, including possible
severe ischemic events, with all of the interventional procedures.
According to some authors, the diffusion MRI technique is the most efficient tool for detecting
acute focal brain ischemia [68,71,76].
Among the interventional procedures, carotid angioplasty achieved a significant reduction in
embolism with the introduction of protection systems, but emboli were not avoided com‐
pletely [35,37,46,68,73]. Good practice in neuroradiology procedures appears to be a mitigating
factor for embolic damage during carotid angioplasty procedures. Consistent with our idea,
Verzini et al. and Piñero et al. said that the interventionist’s experience is a factor for reducing
periprocedural complications [68,71,104]. For du Mesnil de Rochemont et al. [46], uninten‐
tional movement of the filter during the intervention is a potential cause of microemboli and
mainly occurs during the initial learning curve. This movement can largely be avoided with
improved interventional technique and new materials [46,68]. We believe that the learning
curve for CAS might be long and could exceed 200 cases.
Tedesco et al. [70] stated that their CAS program was modified to include the omission of the
aortic arch. This change began when MRI images provided sufficient anatomic detail and
initiated anticoagulation before the passage of guides and catheters in the ascending and
transverse aorta [70]. Thus, these authors state that aortography should be reserved for patients
for whom the MRI before CAS does not provide anatomic details to guide the catheter. In
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contrast, these same authors affirm that more complex and challenging aortic arches (described
as Type II and Type III) were not identified as high risk for embolization [70]. Most authors
describe rates of non-symptomatic NF in DWI in the area contralateral to CAS that are similar
to brain angiography rates.
The initial catheterization of CAS cannot be excluded because the procedures cannot be
separated. Although the catheterization occurs alone for diagnostic purposes [80], angiogra‐
phy is a mandatory initial stage for all angioplasties [36]. Bendszus et al. [105] subsequently
published that the use of heparin and air filters materially reduced ischemic events in brain
catheterization.
Most studies on the relationship between NF in DWI and CAS only mention the material used;
few describe a single access technique for the common carotid artery, usually direct access. In
all cases, we used a standardized form for the highest-caliber (8 Fr) guide catheter, believing
that the good stabilization of the system achieved by this material facilitates the manipulation
of materials (filter, stent, balloons).
In our experience, direct access without exchanges is preferable only in technically simple cases
with favorable anatomy. According to our review, our study is the only one that comparatively
analyzes the catheterization access technique with the guide catheter in the carotid artery
undergoing angioplasty. The risk for each technique to be involved with embolism was 50.00%,
50.00%, 63.64%, and 25.00%, respectively, for direct access, exchange in the external carotid
artery, exchange in the common carotid artery, and triaxial. Thus, the triaxial technique
showed a tendency for greater safety, possibly by having a more gradual progression of size
(from the guide wire to the guide catheter) and causing less aggravation of the aortic arch and
supra-aortic trunks. We can add that the triaxial technique should be used as a first attempt
when technically possible.
Because the triaxial form of access showed a small number of NF, although without statistical
significance, it is possible to predict that replacing the set (a short-valved introducer and guide
catheter) with a long sheath (110 cm), which is currently available, in a single product that is
also used triaxially (introducer, sheath, and guide) may reduce the index of embolic compli‐
cations. More comparative studies of compatible techniques (guide, catheter, sheath) and other
techniques are needed to prove this trend.
Although the filter is the central focus of discussion in most articles cited here for preventing
embolization during CAS, the stent is the material used to effectively treat plaque to prevent
embolic ischemic conditions in the long run. Our data do not show important significant
differences between the brands of stent tested and the brands of protection filters used, as in
Kastrup et al. [35] and Palombo et al. [75]. However, it is possible to identify a tendency for a
smaller number of NF with a closed-cell stent (Wallstent®) compared with the open-cell stents.
The Protégé® stent showed a reasonable resolve for the appearance of NF ipsilateral to CAS,
but the small number of times this material was used precludes reliable statements about this
relationship.
Schillinger et al. [30], studying the impact of open-cell versus closed-cell stents, reviewed data
from 10 European centers totaling 1,684 patients and did not identify a significant difference
Carotid Artery Disease - From Bench to Bedside and Beyond186
regarding neurological complications and death up to 30 days after CAS. Additionally, du
Mesnil de Rochemont et al. [46] found a tendency for a greater number of ischemic lesions
with the use of segmented nitinol stents (open cells) compared to Wallstent®. They suggested
that open-cell stents are used in more technically complex cases with marked vascular
tortuosity. In our study, we obtained the same result, but the types of stents were used without
differentiation regarding tortuosity. A prospective study by Sahin at al. analyzing patients
with closed-cell and open-cell stents showed that open-cell stents were less associated with
clinical events of brain ischemia [106]. Moreover, Hart et al. [45], studying 701 CASs, stated
that closed-cell stents and eccentric filters had lower rates of TIA/ICVA/death combination 30
days after the procedure in symptomatic patients and patients with echolucent plaques in
ultrasound. Our results and from other authors led to the theory that these stent and filter
designs may be intrinsically more effective at preventing brain embolism from fractured
plaque or other thrombogenic material.
The retrospective analysis of 3,179 consecutive CASs by Bosiers et al. [107] showed a significant
difference with a greater rate of neurological complications (symptomatic or not) with open-
cell stents. Using DWI specifically to study NF after CAS, the recent meta-analysis from
Schnaudigel et al. [37] shows that the incidence of NF after CAS was significantly greater in
open-cell stents than in closed-cell stents. Thus, our study is in agreement with those of other
authors [32,37] and supports the idea that closed-cell stents are sufficient to cover plaque and
prevent the embolization of large plaque particles post-CAS through the struts of the stent.
Several studies with separated groups with and without cerebral protection support the
effectiveness of protection systems [34,35,37]. Kastrup et al. [33] found a combined frequency
of CVA and death after 30 days of 1.8% for the group with protection and 5.5% for the group
without protection (p<0.001). Additionally, a lower incidence of serious neurological compli‐
cations was found when a filter was used (2.2%) than without a filter (5.5%) [38]. By studying
groups with and without protection and the relationship with NF formation, Kastrup et al.
found emboli in 49% of patients with cerebral protection and 67% of patients without protec‐
tion [34]. Two years later, this group updated their data and published the occurrence of NF
after CAS without a filter in 68% of patients and 52% of patients with a filter [35].
As expected, the meta-analysis by Schnaudigel et al. [37] found a lower index of foci ipsilateral
to the CAS in DWI in patients with the use of cerebral protection systems (33%) than in patients
without the use of protection (45%). The same authors cited no change in the risk of NF
occurrence in the contralateral area with or without cerebral protection (respectively, 14% and
13%; p=0.6) [37]. In our study, all cases were performed with a protection filter. The use of a
control group without a filter would be considered unethical according to our research group.
However, different types of filters were compared, and the technique used to place the guide
catheter was analyzed.
In addition to innovation of materials, proper training is needed for each type of filter.
Attention to the correct apposition of the filter device should be a mandatory stage in the CAS
[108], as it requires experience in executing the procedure because of the natural tortuosity of
carotids. Positioning can be hampered by vascular tortuosity, which is sometimes excessive.
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contrast, these same authors affirm that more complex and challenging aortic arches (described
as Type II and Type III) were not identified as high risk for embolization [70]. Most authors
describe rates of non-symptomatic NF in DWI in the area contralateral to CAS that are similar
to brain angiography rates.
The initial catheterization of CAS cannot be excluded because the procedures cannot be
separated. Although the catheterization occurs alone for diagnostic purposes [80], angiogra‐
phy is a mandatory initial stage for all angioplasties [36]. Bendszus et al. [105] subsequently
published that the use of heparin and air filters materially reduced ischemic events in brain
catheterization.
Most studies on the relationship between NF in DWI and CAS only mention the material used;
few describe a single access technique for the common carotid artery, usually direct access. In
all cases, we used a standardized form for the highest-caliber (8 Fr) guide catheter, believing
that the good stabilization of the system achieved by this material facilitates the manipulation
of materials (filter, stent, balloons).
In our experience, direct access without exchanges is preferable only in technically simple cases
with favorable anatomy. According to our review, our study is the only one that comparatively
analyzes the catheterization access technique with the guide catheter in the carotid artery
undergoing angioplasty. The risk for each technique to be involved with embolism was 50.00%,
50.00%, 63.64%, and 25.00%, respectively, for direct access, exchange in the external carotid
artery, exchange in the common carotid artery, and triaxial. Thus, the triaxial technique
showed a tendency for greater safety, possibly by having a more gradual progression of size
(from the guide wire to the guide catheter) and causing less aggravation of the aortic arch and
supra-aortic trunks. We can add that the triaxial technique should be used as a first attempt
when technically possible.
Because the triaxial form of access showed a small number of NF, although without statistical
significance, it is possible to predict that replacing the set (a short-valved introducer and guide
catheter) with a long sheath (110 cm), which is currently available, in a single product that is
also used triaxially (introducer, sheath, and guide) may reduce the index of embolic compli‐
cations. More comparative studies of compatible techniques (guide, catheter, sheath) and other
techniques are needed to prove this trend.
Although the filter is the central focus of discussion in most articles cited here for preventing
embolization during CAS, the stent is the material used to effectively treat plaque to prevent
embolic ischemic conditions in the long run. Our data do not show important significant
differences between the brands of stent tested and the brands of protection filters used, as in
Kastrup et al. [35] and Palombo et al. [75]. However, it is possible to identify a tendency for a
smaller number of NF with a closed-cell stent (Wallstent®) compared with the open-cell stents.
The Protégé® stent showed a reasonable resolve for the appearance of NF ipsilateral to CAS,
but the small number of times this material was used precludes reliable statements about this
relationship.
Schillinger et al. [30], studying the impact of open-cell versus closed-cell stents, reviewed data
from 10 European centers totaling 1,684 patients and did not identify a significant difference
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regarding neurological complications and death up to 30 days after CAS. Additionally, du
Mesnil de Rochemont et al. [46] found a tendency for a greater number of ischemic lesions
with the use of segmented nitinol stents (open cells) compared to Wallstent®. They suggested
that open-cell stents are used in more technically complex cases with marked vascular
tortuosity. In our study, we obtained the same result, but the types of stents were used without
differentiation regarding tortuosity. A prospective study by Sahin at al. analyzing patients
with closed-cell and open-cell stents showed that open-cell stents were less associated with
clinical events of brain ischemia [106]. Moreover, Hart et al. [45], studying 701 CASs, stated
that closed-cell stents and eccentric filters had lower rates of TIA/ICVA/death combination 30
days after the procedure in symptomatic patients and patients with echolucent plaques in
ultrasound. Our results and from other authors led to the theory that these stent and filter
designs may be intrinsically more effective at preventing brain embolism from fractured
plaque or other thrombogenic material.
The retrospective analysis of 3,179 consecutive CASs by Bosiers et al. [107] showed a significant
difference with a greater rate of neurological complications (symptomatic or not) with open-
cell stents. Using DWI specifically to study NF after CAS, the recent meta-analysis from
Schnaudigel et al. [37] shows that the incidence of NF after CAS was significantly greater in
open-cell stents than in closed-cell stents. Thus, our study is in agreement with those of other
authors [32,37] and supports the idea that closed-cell stents are sufficient to cover plaque and
prevent the embolization of large plaque particles post-CAS through the struts of the stent.
Several studies with separated groups with and without cerebral protection support the
effectiveness of protection systems [34,35,37]. Kastrup et al. [33] found a combined frequency
of CVA and death after 30 days of 1.8% for the group with protection and 5.5% for the group
without protection (p<0.001). Additionally, a lower incidence of serious neurological compli‐
cations was found when a filter was used (2.2%) than without a filter (5.5%) [38]. By studying
groups with and without protection and the relationship with NF formation, Kastrup et al.
found emboli in 49% of patients with cerebral protection and 67% of patients without protec‐
tion [34]. Two years later, this group updated their data and published the occurrence of NF
after CAS without a filter in 68% of patients and 52% of patients with a filter [35].
As expected, the meta-analysis by Schnaudigel et al. [37] found a lower index of foci ipsilateral
to the CAS in DWI in patients with the use of cerebral protection systems (33%) than in patients
without the use of protection (45%). The same authors cited no change in the risk of NF
occurrence in the contralateral area with or without cerebral protection (respectively, 14% and
13%; p=0.6) [37]. In our study, all cases were performed with a protection filter. The use of a
control group without a filter would be considered unethical according to our research group.
However, different types of filters were compared, and the technique used to place the guide
catheter was analyzed.
In addition to innovation of materials, proper training is needed for each type of filter.
Attention to the correct apposition of the filter device should be a mandatory stage in the CAS
[108], as it requires experience in executing the procedure because of the natural tortuosity of
carotids. Positioning can be hampered by vascular tortuosity, which is sometimes excessive.
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The choice of filter is also important because, if it has a smaller diameter than the vessel, blood
and particles pass between the filter and the artery wall [46,104,109].
Two articles from Müller-Hulsbeck et al. [47,57] using an animal model of the carotid artery
showed that miniscule particles of debris smaller than 100 µm can pass the pores of the filters
[57]. Additionally, the filters can damage the vessel walls [47], which may subsequently result
in the displacement of fragments and thrombi due to accidental movement of the filtering
device. Other authors claim that we cannot exclude the possibility that when the filters are
closed and removed, the collection system may swing the tool and loosen some of the captured
particles, freeing them in the vessel lumen [46,68].
It is possible that because the stent and balloon use a microguide for the devices, in the case
of the EPI/EZ® and Angioguard® filters used in this study, they may mobilize the filter and
release free particles. The Emboshield® device does not carry this theoretical risk because it
stays no fixed to the guide while it is in action. However, in our study, the Emboshield® device
has an average appearance of NF similar to the other concentric device, Angioguard®, and
both have a higher average than the eccentric device EPI®. This result reflects the need for
training with each device because the only way of preventing the displacement of materials is
the correct use of the devices.
In 2000, Coggia et al. [110] published the passage of particles in all stages of CAS in an ex vivo
study. Most of the particles were smaller than 60 µm, and the pores of the commercially
available filters were approximately 100 µm. The passage of these particles through the
protection devices and entrapment in capillaries or cerebral arteries is possible [110]. Angelini
et al. [50] showed through electronic microscopy that 83.7% of filters have particles adhered
to them and, on average, the filters contained 33.7 particles (24 to 46). In that study, the average
diameter of the fragments captured in the filters was 289.5 µm (1.08 to 5043.5 µm). The main
particles found by this group were soft acellular material, lipid-laden macrophages, and
cholesterol clefts. Less frequently, they found calcium particles and platelet aggregates. All of
these materials are typically identified in atherosclerotic plaques, whether they are compli‐
cated or not. When a protective balloon was used, similar materials were found [50].
In 2009, Piñero et al. [111] published a structural analysis of the material contained in filters
after angioplasties and stated that atherosclerotic plaques and vessel walls are the main sources
of microemboli during CAS [71,111]. However, a study on the action of cerebral protection
devices found that 88% of particles were retained in the filters in an ex vivo simulation of CAS
[112]. Piñero et al. [48,71,111] considered filter diameter to be very important but not the only
factor in the formation of NF. They claimed that bad positioning of the filter on the carotid
wall due to tortuosity, displacement of the filter while handling the materials, and high profile
crossover are technical difficulties that await future studies and improvements in materials.
Rough handling can promote the formation of emboli during the positioning and removal of
the filter.
Some authors explain that the size of debris removed from the filters differs from the real size
at the moment of embolization and that most of the small emboli may be the result of the
fragmentation of particles trying to pass through the grid of the filter [113]. Thus, continuous
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flow predisposes the fragmentation of content retained in the filter. Physician experience and
speed are necessary to reduce the time of the procedure and avoid this fragmentation and
potential emboli between the pores [68].
The filters that were used in the protocol of this study had mesh with pores from 100 to 140
µm, reducing the migration of cholesterol crystals and clots, platelet aggregations, and
macrofragments of atheromatous plaques through filtering. The diameter of the filter pores
used was smaller than the particles described by Theron et al. [114] and Ohki et al. [90] and
than most of the particles described by Angelini et al. [50].
Our series showed an average of 1.6 NF per patient, a number well below the average of 33
particles found adhered to filters in the study by Angelini et al. [50]. It is possible that filters
provide real protection, given the disparity between these numbers. Nonetheless, the action
of each individual’s thrombolysis system cannot be excluded as also drastically, or at least
partially, reducing the permanence of emboli at its distal point.
The disparity between the low number of ischemic events after CAS [33,38] and the relatively
high frequency of multiple small restriction foci in diffusion after CAS [35,69,70,73] that are
compatible with embolism suggests that filters mainly act by retaining large particles that
could evolve into clinical conditions of ischemia, rather than by grasping small particles. In
our series, the eccentric filter EPI® had embolism in diffusion in 44% of cases, suggesting
apparently superior protection compared to other models. The Angioguard® filter contained
emboli in 50% of cases, while the Emboshield® device showed the highest rate of emboli
(71.43%) in the group. Our data establish a strong tendency for superior protection measured
in the eccentric filter (0.958 NF ipsilateral) compared to the concentric designs (2.100 NF
ipsilateral). A study from Tedesco et al. [70] found a high rate of NF (70% of patients). These
authors used a combination of the concentric filter and the open-cell stent, which may have
contributed to the high rate of emboli. While there may be unequal protection between these
filters, the difference shown in this series is not statistically significant. Our data cannot
completely indicate greater protection of the eccentric model compared to the concentric
model. Furthermore, poor distribution among types of filters with very small groups (Angio‐
guard®, n=4) was observed. Thus, we avoid speculative comparison regarding the safety of
each device.
A retrospective study of 3,160 CAS published Iyer et al. [115] found that the type of protection
(nine different systems, including concentric and eccentric filters and proximal and distal
occlusion balloons) had no influence on the clinical result. However, these authors did not
study the brain using MRI after CAS.
For Piñero et al. [48,111], the difficulty of correctly positioning the filter on the wall of tortuous
vessels, the displacement of material during the release, the creation of emboli by the relatively
high-profile crossover and low flexibility, the loss of accumulated particles during the removal
of the filter, and the diameter of the filter’s pores appear to be very important to the appearance
of ischemia related to embolization. This finding should lead to future studies that help to
perfect protection systems [48,111].
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our series, the eccentric filter EPI® had embolism in diffusion in 44% of cases, suggesting
apparently superior protection compared to other models. The Angioguard® filter contained
emboli in 50% of cases, while the Emboshield® device showed the highest rate of emboli
(71.43%) in the group. Our data establish a strong tendency for superior protection measured
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ipsilateral). A study from Tedesco et al. [70] found a high rate of NF (70% of patients). These
authors used a combination of the concentric filter and the open-cell stent, which may have
contributed to the high rate of emboli. While there may be unequal protection between these
filters, the difference shown in this series is not statistically significant. Our data cannot
completely indicate greater protection of the eccentric model compared to the concentric
model. Furthermore, poor distribution among types of filters with very small groups (Angio‐
guard®, n=4) was observed. Thus, we avoid speculative comparison regarding the safety of
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In 2006, du Mesnil de Rochemont et al. [46] found three (6%) occlusions of filters by debris or
clots in a series of 50 CASs. In a series of 162 CASs, Piñero et al. found filter occlusion in four
(2.5%) patients during the procedure [48]. It is predicted that these cases will become significant
infarcts due to the large size of the particles because it was sufficient to obstruct the filter pores
up to total occlusion of the flow. Piñero et al. [48] assume that, without the use of a filter in
these cases, the morbidity of their series would increase from 4 to 6.5%.
There was no case of filter occlusion by debris or thrombi in our series. Vasospasms related to
the filtering devices were short-lived and without hemodynamic impairment. Other compli‐
cations related to the filters were not found in this series. Filter occlusion leading to a stopped
flow is a rare occurrence. It was more observed with the use of the first generation of EPI®
filters, where the diameters of the pores were only 80 µm [46,116].
While the first step in CAS, which includes catheterization, the positioning of the guide catheter
and the passage of the filter over the stenosis, occurs without protection, the phases with the
greatest number of emboli released from plaque are the implantation of the stent and the
angioplasty by balloon. An overload of the filter protection system is the angioplasty by
balloon. Piñero at al. [111] showed that the more balloon dilations are applied to CAS, the
greater the load of emboli found in the filters. Therefore, physician experience is necessary to
use the balloon as delicately as possible.
Unfortunately, the other technique currently used in the treatment of carotid stenosis – CEA
– also has ischemic complications [59] and more brain emboli than CAS [37,83]. Another
common complication in CEA is lesions to the cranial nerves and cardiac infarction [117,118].
Comparative studies between CEA and CAS found a greater number of NF after CAS than
after CEA. However, the lesions in the DWI after CAS are significantly smaller than after
the endarterectomy. Analyzing the NF in the DWI after CAS and endarterectomy, Roh et
al.  [78] reasoned that the lesions in diffusion after CAS are generally asymptomatic and
that the lesions in DWI associated with symptoms are more frequent in CEA [37,78].  In
recent years, the materials used in CAS have been improved to reduce complications. DWI
can  be  used  as  a  tool  in  this  evolving  analysis  of  materials  and  also  in  the  technical
improvement of neurointervention.
Our study shows some limitations. Data collection of a control group without the use of
cerebral protection to prove the device’s effectiveness is incorrect based on our ethical views
of the procedure, but it is a limitation of the study. However, other published studies that
conducted CAS with and without protection systems clearly show a smaller number of NF
[35,37] and lower risk of ischemic events [33,38] after CAS in the groups where the devices
were used.
The formation of emboli can be impeded by antiplatelet and anticoagulant medications [76],
but this is not the focus of our research shown here. In neuroradiology procedures, the
prevalence of resistance to aspirin varied from 2 to 21%, and resistance to clopidogrel varied
from 43 to 52% [119-121]. This result is extremely important because atheromatous plaques
and superimposed thrombi are the main source of microemboli during CAS. A recent study
from Song et al. [76] using the VerifyNow system showed that the frequency of resistance to
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clopidogrel was significantly higher in patients with foci of microemboli in DWI after CAS
than in patients without foci of microemboli in MRI after CAS. In their series, all the patients
who showed clinical ischemic events had resistance to antiplatelets [76].
A randomized prospective study evaluated platelet activation after coronary stents in pigs and
showed that the closed-cell stent produced less intimal prolapse and thus a smoother stent-
vessel wall interface than the stent with open-cells and that platelet activation was greater
during the 30 days following implantation of an open-cell versus a closed-cell stent [122].
Our study concentrates on the designs of stents and filters, but other particularities of con‐
structing the materials can interfere in the safety of CAS, such as the type of filtering element.
A study considered that perforated membrane filters have greater resistance to cerebral blood
flow [123], but it did not evaluate whether there was greater capture of emboli. Our study also
had a relatively short follow-up time. We only used the period when the patients were
hospitalized, generally three to four days. We consider that this peri-procedure period is
sufficient to evaluate the late appearance of NF because the disappearance of NF is described
in some cases [60,68,75].
14. Conclusions
The use of protection systems aims to avoid massive embolism, which occasionally happens.
However, a perfect cerebral protection system is not commercially available. While cerebral
protection with filters is effective, it is necessary to develop new protection devices that are
more effective and can be occlusive systems with a lower profile and greater ease of use. Both
techniques, angioplasty with stent (with filter or flow occlusion systems) and endarterectomy,
are involved in cases of intracranial embolism per treatment.
New restriction foci (NF) in diffusion were present in half of the patients after CAS with
cerebral protection and were most frequently located in the ipsilateral area (77.19%), suggest‐
ing that the filters did not prevent all microemboli. New restriction foci in DWI after CAS were
located in regions (22.81%) different than in the angioplasty and were associated with
diagnostic catheterization. Therefore, long neurointerventionist medical training should be
required before CASs are performed.
The NF in DWI after CAS were mostly small in diameter (<10 mm in 91.53%) and were always
clinically silent (100%) in our study.
The presence of cerebral infarcts in the T2 sequence in the initial MRI was the only factor that
significantly predisposed the appearance of new restriction foci in DWI after CAS. Thus, the
risk of microemboli was directly related to intrinsic factors of the patient. Other demographic
factors and aspects related to the angioplasty technique were not statistically significant to the
occurrence of NF in our study. There was a tendency for other factors, such as the triaxial access
technique, asymptomatic patients, and an eccentric filter, to be involved in the appearance of
a smaller number of NF after CAS.
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clinically silent (100%) in our study.
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significantly predisposed the appearance of new restriction foci in DWI after CAS. Thus, the
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The appearance of microemboli attributed to catheterization and not angioplasty with stent
shows that proper training for medical specialists in cervical and cerebral circulation (neuro‐
interventionists) can be key to reducing risks for patients. General specialists in vessels
(vascular surgeons) and coronary circulation (cardiologists) generally do not have specific
training for cervicocerebral circulation; most of their training focuses on the aorta and coronary
arteries, respectively. We therefore recommend that angiographies to diagnose cervical and
cerebral circulation and carotid angioplasty be conducted by interventional neuroradiologists
to reduce the risk of emboli.
To maintain cerebral flow during the endovascular carotid treatment, CAS with filter is the
first choice in cases of serious stenosis. The use of occlusive systems is promising but requires
more technical development to reduce the risks associated current systems.
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1. Introduction
Ischemic stroke is a leading cause of morbidity and mortality worldwide. Common etiologies
of ischemic stroke include cardioembolic events, intracranial arterial stenosis, extracranial
large vessel dissection (spontaneous and traumatic), genetic or familial causes such as Moya-
Moya Disease and fibromuscular dysplasia, and carotid artery stenosis. The latter is respon‐
sible for a significant percentage of ischemic strokes due to carotid atherosclerotic disease and
will be the focus of this chapter. Diagnosis is often made based on physical exam by the primary
care physician and routine ultrasonic or radiographic screening. Detection of carotid artery
stenosis typically results in the eventual referral to a general vascular surgeon or a cerebro‐
vascular neurosurgeon when revascularization is indicated for intervention. Selecting
candidates for medical treatment or revascularization is guided by data obtained from
excellently performed trials including the North American Symptomatic Carotid Endarterectomy
Trial (NASCET) and the Asymtomatic Carotid Artery Stenosis (ACAS) Trial. Treatment depends
upon the severity of carotid stenosis and the absence or presence of stroke symptoms. Medical
management, carotid endarterectomy, and carotid artery stenting with angioplasty, each have
important roles in the appropriate treatment of carotid stenosis. It is the surgeon’s responsi‐
bility to assess the patient’s history, physical exam findings, imaging studies, and risk factors,
to make appropriate recommendations on the best treatment for the patient at hand. The
purpose of this chapter is to review the management of atherosclerotic carotid artery disease
based on available data in the literature and to provide information useful in daily practice.
2. Epidemiology
Approximately 750,000 persons in the United States alone experience an ischemic stroke each
year [1]. Stroke care expense for the United States healthcare system was 74 billion dollars
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based on 2010 economic data and with the aging American population and higher incidence
of obesity and diabetes in young adults, this cost to the American economy will increase [2].
An interesting analysis was published demonstrating that approximately 120 million neurons
(equivalent to 714 kilometers or 444 miles of myelinated fibers) are lost each hour after a large
arterial occlusion, thereby accelerating brain aging by 3.6 years per hour of ischemia time [3].
This neuronal loss often translates into permanent and devastating neurological sequelae.
It has been estimated that 20-30% of ischemic strokes result from extracranial carotid artery
stenosis secondary to atherosclerotic disease [4,5]. Atherosclerosis is a chronic progressive
process associated with modifiable risk factors that promote chronic inflammatory events
within the arterial wall. Progression of atherosclerotic plaque formation causes ischemic stroke
generally by one of two mechanisms: either a flow-limiting stenosis of the arterial lumen
resulting in cerebral hypoperfusion typically in the watershed territories or more commonly,
thromboembolic events from ruptured atherosclerotic plaque. Until one of these events causes
a stroke, carotid stenosis remains asymptomatic and often goes undetected.
The prevalence of carotid stenosis can vary widely with geographic location due to cultural,
genetic, and socioeconomic differences. The acquired nature of atherosclerotic disease implies
that several of the risk factors that contribute to its development can be modified by individual
changes in lifestyle, diet, and medical management.
3. Risk factors
Important modifiable risk factors for developing carotid atherosclerotic disease include
smoking, hypertension, dyslipidemia and poor glycemic control in diabetic patients. Smoking
is strongly associated with development of carotid atherosclerotic disease whereby comparing
age-matched non-smokers, former smokers and current smokers, the prevalence of clinically
significant carotid stenosis (>50%) was seen in 4.4%, 7.3% and 9.5% (P<0.0001), respectively.
Treatment of hypertension has been associated with reduced risk of developing carotid
stenosis and stroke. For every 20mmHg increase in systolic blood pressure the odds ratio of
developing moderate carotid stenosis is 2.11. Additionally, every 10mg/dL increase in serum
cholesterol level was associated with an odds ratio of 1.10 for developing hemodynamically
significant carotid stenosis. Strict control of postprandial glucose levels in diabetic patients has
been associated with a reduction of carotid intimal media thickness and may also help to
reduce the incidence of stroke from carotid stenosis [6].
4. Histopathology of atherosclerotic disease
It has been well established that carotid stenosis tends to occur at the bifurcation, which
corresponds to vascular shear stresses as determined by in vivo measurements and in vitro flow
models. The healthy artery is composed of three distinct layers, the tunica intima, tunica media
and tunica adventitia, as seen from the lumen to the outer vessel wall. The tunica intima is
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composed of a luminal endothelial layer consisting of an internal elastic lamina and a fibro‐
collagenous tissue layer, the latter two of which are thrombogenic. This tissue layer is covered
externally by the tunica media consisting of smooth muscle cells followed by a fibrocollage‐
nous layer composed of the external elastic lamina and an external fibrous serosa layer, which
composes the tunica adventitia layer. Carotid stenosis is thought to form as a result of intimal
endothelial injury by mechanical hemodynamic shear stresses and metabolic and inflamma‐
tory processes. The plaque material often contains macrophages, inflammatory cells, calcium,
lipid and cholesterol deposits, thought to be formed as part of the healing process after
endothelial injury [1].
After disruption of the arterial endothelial lining, expression of inflammatory cell adhesion
markers such as VCAM-1, ICAM and other receptors are upregulated [1,7]. Additionally,
platelets adhere to the disrupted endothelium after balloon angioplasty and they degranu‐
late, thereby releasing various cytokines and growth factors including transforming growth
factor beta (TGF-β), epidermal growth factor (EGF) and platelet derived growth factor (PDGF)
[1,8]. These result in migration and proliferation of the vascular smooth muscle cells of the tunica
media to form a neointimal layer in an attempt to heal the disrupted endothelium. This neointima
becomes more permeable to inflammatory cells as degranulated platelets adhere and remod‐
el the site of the injured intima [1,9,10]. T-cells, monocytes and lipid laden macrophages are
seen in these plaques as they become more chronic, and calcium is often deposited during this
process in an attempt to stabilize the plaque. Plaques with less calcification tend to be more
vulnerable to rupture or thrombosis, indicating that the deposition of calcium appears to be
protective and helps to stabilize the plaque by encasing the inflammatory materials, rather than
leaving them exposed for further exacerbation of the inflammatory process [1,11].
The proliferation of smooth muscle cells is accompanied by an increase in matrix metallopro‐
teinases (MMPs) such as MMP-2 and MMP-9, which help to remodel the vessel by dilating the
stenotic segment, thereby initially compensating for the loss of intimal diameter by the early
plaque. However, with progression of the plaque thickness, the vessel eventually can no longer
dilate further to compensate once the plaque occupies about 40-50% of the luminal diameter,
and the lumen becomes progressively more narrowed [1].
Vascular stenosis alone does not appear to correlate well with predicting which asymptomatic
plaques will result in cerebrovascular symptoms, and therefore additional information about
the plaque characteristics are important to assess the vulnerability of the plaque to progress
and become symptomatic. Factors which appear to be important in identifying vulnerable
plaques include echolucency of the plaque on high resolution B-mode ultrasound, absence of
calcification, presence of intraplaque hemorrhage, surface irregularity, fibrous cap thickness,
plaque volume and presence and location of a necrotic core [12].
5. Presentation and radiographic evaluation
The history alone can often give a great clue to the underlying cause of the carotid stenosis,
once identified. Atherosclerotic disease is the most common cause of carotid stenosis, and is
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more prevalent in older patients. In patients with a history of head and neck cancer and
exposure to radiation therapy, intimal hyperplasia and other radiation changes would be the
most likely underlying cause of the stenosis, and are typically more difficult to treat compared
with atherosclerotic lesions [13]. Patients involved in a recent trauma or neck manipulation
may have an arterial dissection that can lead to significant arterial stenosis or occlusion [14].
All of these causes could present with or without symptoms, and although the likelihood of
symptoms may be more prevalent in higher degrees of stenosis, it is important to correlate the
clinical history and presentation with the radiographic findings when evaluating carotid
stenosis, as this will help to drive the decisions for conservative or invasive treatment of lesions
identified. Currently, the US Preventive Services Task Force recommends against screening
for carotid stenosis in the general asymptomatic population [15].
Several clinical trials have been performed to evaluate the patient populations who will benefit
from various treatment options, including medical management, surgical intervention with
carotid endarterectomy (CEA) or carotid angioplasty with or without stent placement (CAS),
and also with or without distal embolic protection devices for endovascular treatments.
One publication from the Netherlands reviewed four major population based studies for a
meta-analysis to determine the prevalence of moderate (50-70%) and severe (>70%) carotid
stenosis in men and women at various ages [16]. The investigators determined that the
prevalence of asymptomatic moderate carotid stenosis ranged from 0.2% (95% CI, 0.0% to
0.4%) in men aged <50 years to 7.5% (5.2% to 10.5%) in men aged ≥80 years, and severe carotid
stenosis ranged from 0.1% (0.0% to 0.3%) in men aged <50 years to 3.1% (1.7% to 5.3%) in men
aged ≥80 years. For women, the prevalence of asymptomatic moderate carotid stenosis ranged
from 0% (0% to 0.2%) in those aged<50 years to 5.0% (3.1% to 7.5%) in women aged ≥80 years,
while severe asymptomatic carotid stenosis for women ranged from 0% (0.0% to 0.2%) to 0.9%
(0.3% to 2.4%), between these age groups. Although this data helps to understand the preva‐
lence of this condition, it can only be applied to this particular population that was studied.
Traditionally, patients who presented with stroke or TIA symptoms would undergo diagnostic
catheter angiography for the diagnosis of carotid stenosis. With the advent of current non-
invasive vascular imaging since the 1980’s such as carotid duplex ultrasound, MRA and CTA,
the most common presentation of carotid stenosis is an incidental finding of asymptomatic
stenosis noted on one of these imaging studies which could be performed for a variety of
reasons other than for stroke or TIA, including screening imaging studies performed to follow
up clinical exam findings such as auscultation of a carotid bruit. The sensitivity and specificity
of auscultation of a carotid bruit when used to evaluate for carotid stenosis are extremely poor.
One study compared the sensitivity and specificity of detecting carotid or vertebral stenosis
with duplex ultrasound evaluation compared with the gold standard catheter angiogram and
also reviewed the presence or absence of a cervical bruit on examination. This study showed
that the location and estimated degree of stenosis was accurately identified in 97% of carotid
and 90% of vertebral stenosis cases with duplex ultrasound compared with catheter angiog‐
raphy, but the presence of a bruit on exam would only correctly diagnose 27.6% of patients
with confirmed hemodynamically significant stenosis, and was falsely positive in 22.6% of
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patients with confirmed normal vasculature, making the positive and negative predictive
correlation of a cervical bruit auscultated on physical exam extremely unreliable [17].
CTA and MRA imaging modalities can often have a greater than 95% sensitivity and specificity
for detecting hemodynamically significant vascular stenosis when compared with diagnostic
catheter angiography as the gold standard imaging modality [18]. These non-invasive imaging
studies have shown to be of benefit in screening for and following stability or progression of
vascular stenosis, but it should be noted that in evaluating the accuracy of each of these imaging
modalities and comparing with that of digital subtraction angiography (DSA) using an in
vitro stenosis model, Smith et al found that the CTA and MRA studies tended to underestimate
the stenosis whereas the DSA tended to overestimate the stenosis when evaluating the >70%
stenosis model, while there was no significant difference between these imaging studies in the
estimated stenosis when evaluating the <70% stenosis model [19].
6. Treatment options
The medical management of carotid stenosis has revolved around anti-inflammatory and anti-
platelet agents as the drugs of choice. Marquardt et al studied the UK population and docu‐
mented the frequency of ipsilateral ischemic stroke in the setting of asymptomatic carotid
stenosis ≥50% [20]. It was reported that with adequate medical management, the risk was 0.34%
for any ipsilateral non-disabling stroke, 0.0% for severe disabling stroke, and 1.78% for
ipsilateral TIA. These results would support best medical management for all asymptomatic
carotid stenosis, irrespective of the degree of stenosis. Aspirin is known to have anti-inflam‐
matory properties by irreversible blockade of the cyclooxygenase (COX)-1 and COX-2
pathways of arachidonic acid metabolism. Carotid fibrous plaque formation and remodeling
are influenced by several factors including MMPs secreted by leukocytes in the intima which
remodel the extracellular matrix, and this results in thrombosis with vulnerable plaques in
which the fibrous cap has become significantly thinned and embolic events resulting in TIA
and stroke may ensue [1]. The Clopidogrel and Aspirin for the Reduction of Emboli in
Symptomatic Carotid Stenosis (CARESS) trial evaluated the use of aspirin alone vs aspirin
with clopidogrel in symptomatic carotid stenosis >50% and found that combination therapy
reduced the frequency of asymptomatic microembolization as detected by transcranial
doppler ultrasound more effectively than aspirin alone [21].
Several major trials evaluating asymptomatic carotid stenosis include the Veterans Adminis‐
tration Trial (VA, 1993 [22]), the Asymptomatic Carotid Surgery Trial (ACST, 1994 [23]) and
the Asymptomatic Carotid Artery Stenosis Trial (ACAS, 1995 [24]). The VA trial looked at
medical management alone with aspirin 650mg po BID versus combined medical management
with the same aspirin dose and with CEA for asymptomatic carotid stenosis of 50% or greater
in 444 men in the VA medical system. This study failed to show any statistically significant
differences in clinical outcome between these two groups [22]. The ACST group evaluated the
timing of CEA for patients with asymptomatic carotid stenosis of 60% or greater. Patients were
treated with best medical management and the treatment group received CEA as soon as
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while severe asymptomatic carotid stenosis for women ranged from 0% (0.0% to 0.2%) to 0.9%
(0.3% to 2.4%), between these age groups. Although this data helps to understand the preva‐
lence of this condition, it can only be applied to this particular population that was studied.
Traditionally, patients who presented with stroke or TIA symptoms would undergo diagnostic
catheter angiography for the diagnosis of carotid stenosis. With the advent of current non-
invasive vascular imaging since the 1980’s such as carotid duplex ultrasound, MRA and CTA,
the most common presentation of carotid stenosis is an incidental finding of asymptomatic
stenosis noted on one of these imaging studies which could be performed for a variety of
reasons other than for stroke or TIA, including screening imaging studies performed to follow
up clinical exam findings such as auscultation of a carotid bruit. The sensitivity and specificity
of auscultation of a carotid bruit when used to evaluate for carotid stenosis are extremely poor.
One study compared the sensitivity and specificity of detecting carotid or vertebral stenosis
with duplex ultrasound evaluation compared with the gold standard catheter angiogram and
also reviewed the presence or absence of a cervical bruit on examination. This study showed
that the location and estimated degree of stenosis was accurately identified in 97% of carotid
and 90% of vertebral stenosis cases with duplex ultrasound compared with catheter angiog‐
raphy, but the presence of a bruit on exam would only correctly diagnose 27.6% of patients
with confirmed hemodynamically significant stenosis, and was falsely positive in 22.6% of
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patients with confirmed normal vasculature, making the positive and negative predictive
correlation of a cervical bruit auscultated on physical exam extremely unreliable [17].
CTA and MRA imaging modalities can often have a greater than 95% sensitivity and specificity
for detecting hemodynamically significant vascular stenosis when compared with diagnostic
catheter angiography as the gold standard imaging modality [18]. These non-invasive imaging
studies have shown to be of benefit in screening for and following stability or progression of
vascular stenosis, but it should be noted that in evaluating the accuracy of each of these imaging
modalities and comparing with that of digital subtraction angiography (DSA) using an in
vitro stenosis model, Smith et al found that the CTA and MRA studies tended to underestimate
the stenosis whereas the DSA tended to overestimate the stenosis when evaluating the >70%
stenosis model, while there was no significant difference between these imaging studies in the
estimated stenosis when evaluating the <70% stenosis model [19].
6. Treatment options
The medical management of carotid stenosis has revolved around anti-inflammatory and anti-
platelet agents as the drugs of choice. Marquardt et al studied the UK population and docu‐
mented the frequency of ipsilateral ischemic stroke in the setting of asymptomatic carotid
stenosis ≥50% [20]. It was reported that with adequate medical management, the risk was 0.34%
for any ipsilateral non-disabling stroke, 0.0% for severe disabling stroke, and 1.78% for
ipsilateral TIA. These results would support best medical management for all asymptomatic
carotid stenosis, irrespective of the degree of stenosis. Aspirin is known to have anti-inflam‐
matory properties by irreversible blockade of the cyclooxygenase (COX)-1 and COX-2
pathways of arachidonic acid metabolism. Carotid fibrous plaque formation and remodeling
are influenced by several factors including MMPs secreted by leukocytes in the intima which
remodel the extracellular matrix, and this results in thrombosis with vulnerable plaques in
which the fibrous cap has become significantly thinned and embolic events resulting in TIA
and stroke may ensue [1]. The Clopidogrel and Aspirin for the Reduction of Emboli in
Symptomatic Carotid Stenosis (CARESS) trial evaluated the use of aspirin alone vs aspirin
with clopidogrel in symptomatic carotid stenosis >50% and found that combination therapy
reduced the frequency of asymptomatic microembolization as detected by transcranial
doppler ultrasound more effectively than aspirin alone [21].
Several major trials evaluating asymptomatic carotid stenosis include the Veterans Adminis‐
tration Trial (VA, 1993 [22]), the Asymptomatic Carotid Surgery Trial (ACST, 1994 [23]) and
the Asymptomatic Carotid Artery Stenosis Trial (ACAS, 1995 [24]). The VA trial looked at
medical management alone with aspirin 650mg po BID versus combined medical management
with the same aspirin dose and with CEA for asymptomatic carotid stenosis of 50% or greater
in 444 men in the VA medical system. This study failed to show any statistically significant
differences in clinical outcome between these two groups [22]. The ACST group evaluated the
timing of CEA for patients with asymptomatic carotid stenosis of 60% or greater. Patients were
treated with best medical management and the treatment group received CEA as soon as
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possible. The second group only received CEA if symptoms developed while on medical
therapy. A total of 3120 patients were enrolled and this study failed to show any statistically
significant differences in long term clinical outcome between groups [23]. In 1995, the ACAS
trial was published which reviewed the results of 1662 asymptomatic patients with >60%
carotid stenosis. Patients were randomized into two groups, the first consisting of medical
therapy alone with aspirin 325mg daily and the second group treated with medical therapy
and CEA within 2 weeks of randomization [24]. This trial found a reduced 5-year stroke risk
from 11.0% in the medical arm to 5.1% in the surgical arm with a 3% perioperative morbidity
and mortality.
Catheter based diagnostic cerebral angiography remains the gold standard imaging modality
for diagnosing and measuring carotid stenosis. The risk of stroke for asymptomatic patients
is 2-3% annually and 12% in symptomatic stroke patients [20,25]. Clinical trials have demon‐
strated measurable differences in the treatment strategy for symptomatic versus asymptomatic
carotid stenosis. A majority of data advocates best medical management for asymptomatic
carotid stenosis because of the very low incidence of ipsilateral stroke, regardless of the degree
of stenosis. According to the ACAS and NASCET trial results, revascularization is recom‐
mended for symptomatic male patients with ≥50% ipsilateral cervical internal carotid artery
stenosis, while revascularization is not recommended for symptomatic female patients until
the severity of ipsilateral cervical carotid stenosis reaches ≥70% [26], however, this difference
between men and women has remained somewhat controversial and these results have not
been consistently reproduced [27]. Currently, carotid endarterectomy continues to be the gold
standard for revascularization. If the patient has significant risk factors placing them at a high
risk for endarterectomy, then revascularization via carotid angioplasty and stenting is an
alternative therapy. Such risk factors typically include: previous ipsilateral carotid endarter‐
ectomy, recent myocardial infarction within previous thirty days, contralateral carotid
occlusion, radiation to the neck, chronic obstructive pulmonary disease, and previous carotid
stent.
Carotid stent placement is offered to patients who have no contraindications to long-term anti-
platelet agent use and who are at a high risk for surgery. Distal embolic protection devices are
generally used to lower the risk of embolic events from stent placement and balloon angio‐
plasty, but recent recommendations vary; cases where there is a reasonably high potential for
distal embolic events during the angioplasty procedure may benefit from distal protection
devices [28–32]. Carotid angioplasty alone without stent placement is associated with a very
high rate of re-stenosis. The CAVATAS trial examined the treatment of carotid stenosis with
angioplasty alone (N=145) versus carotid angioplasty and stent placement (N=50) vs carotid
endarterectomy (N=213). This trial showed that carotid endarterectomy resulted in signifi‐
cantly lower rates of carotid re-stenosis >70% 5 years after treatment compared with endovas‐
cular therapy (30.7% vs 10.5%). Additionally, in the endovascular treatment group, the patients
treated with angioplasty alone had a higher rate of re-stenosis >70% compared with those
treated with stent placement (36.2% vs 16.6%) [33]. With the placement of a stent, the in-stent
re-stenosis rate has been reported to be as low as 5% after four years [34]. Risk factors that may
increase the likelihood of recurrent stenosis after carotid angioplasty, stent or endarterectomy
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have been examined and in a report from Skelly et al, these risk factors include prior stroke,
transient ischemic attack, amaurosis fugax, and prior neck cancer [35].
Large trials designed to evaluate surgical versus medical treatment for symptomatic carotid
stenosis include the Veterans Administration 309 Trial (VA309, 1991 [36]), the European
Carotid Surgery Trial (ECST, 1998 [37]), and the North American Symptomatic Carotid
Endarterectomy Trial (NASCET, 1998 [26]). VA309 evaluated the results of treating 189
symptomatic patients with >50% carotid stenosis ipsilateral to the symptoms with best medical
management or a combined approach of best medical management with CEA. The study found
a statistically significant reduction in the stroke risk over 11.9 months for the surgical arm
compared to the medical arm (7.7% vs 19.4%, P=0.11) [36]. In 1998, both ECST and NASCET
were published. ECST evaluated 3024 patients with some degree of symptomatic carotid
stenosis that was determined by varying modality and varying quality vascular imaging
studies. The trial randomized 1811 patients to the surgical arm and 1213 patients to the medical
arm, and the overall risk of surgery was determined to be about 7%, which did not vary with
the degree of stenosis. For symptomatic carotid stenosis (as measured by the ECST method)
of greater than 80%, the three-year major stroke or death rate was 14.9% for the surgical arm
and 26.5% in the medical arm, revealing a statistically significant benefit for surgery in that
group [37]. NASCET evaluated 1108 patients with symptomatic carotid stenosis in the CEA
arm and 1118 demographically similar patients in the best medical management arm. The
results showed no benefit for surgery below 50% stenosis, some benefit particularly in men
with moderate stenosis (50-69%) and clear benefit for surgery with severe stenosis (>70%). The
rate of any ipsilateral stroke over five-year follow up for moderate carotid stenosis (50-69%)
was 15.7% in the surgical arm and 22.2% in the medical arm (P=0.045), with the immediate
perioperative stroke or death risk being reported as 2% [26].
The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) evaluated 2502
symptomatic and asymptomatic carotid stenosis patients who were randomly assigned to CEA
or CAS [38]. The study found no significant differences in combined stroke, myocardial
infarction and death risk over 4 year follow up between these groups, however, there was a
trend toward more myocardial infarctions in the surgical arm (6.8% vs 7.2%, CAS vs CEA,
P=0.51) and a statistically significant higher rate of periprocedural stroke in the endovascular
arm (6.4% vs 4.7%, CAS vs CEA, P=0.03). A study published in February 2013 evaluated the
effect of these perioperative complications on long term survival. According to this trial,
having a stroke within the first year resulted in a two-fold lower survival rate (HR=6.6;
CI=3.7-12) than those patients who suffered a perioperative myocardial infarction two years
after intervention (HR=3.6;CI=2-6.8), but this difference becomes negligible at 5 years (HR=2.7;
CI=1.7-4.3 vs HR=2.8; CI=1.8-4.3) [39].
The Carotid and Vertebral Transluminal Angioplasty Study (CAVATAS) examined the
treatment of carotid stenosis with carotid endarterectomy (N=213) vs endovascular treatment
with angioplasty alone (N=145) or angioplasty and stent placement (N=50). The rate of
recurrent stenosis >70% after endovascular therapy for all patients treated with or without
stent placement was about 3 times higher than the restenosis rate after endarterectomy after 5
years of follow up (30.7% vs 10.5%, p=<0.0001). However, of the endovascular treated patients,
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possible. The second group only received CEA if symptoms developed while on medical
therapy. A total of 3120 patients were enrolled and this study failed to show any statistically
significant differences in long term clinical outcome between groups [23]. In 1995, the ACAS
trial was published which reviewed the results of 1662 asymptomatic patients with >60%
carotid stenosis. Patients were randomized into two groups, the first consisting of medical
therapy alone with aspirin 325mg daily and the second group treated with medical therapy
and CEA within 2 weeks of randomization [24]. This trial found a reduced 5-year stroke risk
from 11.0% in the medical arm to 5.1% in the surgical arm with a 3% perioperative morbidity
and mortality.
Catheter based diagnostic cerebral angiography remains the gold standard imaging modality
for diagnosing and measuring carotid stenosis. The risk of stroke for asymptomatic patients
is 2-3% annually and 12% in symptomatic stroke patients [20,25]. Clinical trials have demon‐
strated measurable differences in the treatment strategy for symptomatic versus asymptomatic
carotid stenosis. A majority of data advocates best medical management for asymptomatic
carotid stenosis because of the very low incidence of ipsilateral stroke, regardless of the degree
of stenosis. According to the ACAS and NASCET trial results, revascularization is recom‐
mended for symptomatic male patients with ≥50% ipsilateral cervical internal carotid artery
stenosis, while revascularization is not recommended for symptomatic female patients until
the severity of ipsilateral cervical carotid stenosis reaches ≥70% [26], however, this difference
between men and women has remained somewhat controversial and these results have not
been consistently reproduced [27]. Currently, carotid endarterectomy continues to be the gold
standard for revascularization. If the patient has significant risk factors placing them at a high
risk for endarterectomy, then revascularization via carotid angioplasty and stenting is an
alternative therapy. Such risk factors typically include: previous ipsilateral carotid endarter‐
ectomy, recent myocardial infarction within previous thirty days, contralateral carotid
occlusion, radiation to the neck, chronic obstructive pulmonary disease, and previous carotid
stent.
Carotid stent placement is offered to patients who have no contraindications to long-term anti-
platelet agent use and who are at a high risk for surgery. Distal embolic protection devices are
generally used to lower the risk of embolic events from stent placement and balloon angio‐
plasty, but recent recommendations vary; cases where there is a reasonably high potential for
distal embolic events during the angioplasty procedure may benefit from distal protection
devices [28–32]. Carotid angioplasty alone without stent placement is associated with a very
high rate of re-stenosis. The CAVATAS trial examined the treatment of carotid stenosis with
angioplasty alone (N=145) versus carotid angioplasty and stent placement (N=50) vs carotid
endarterectomy (N=213). This trial showed that carotid endarterectomy resulted in signifi‐
cantly lower rates of carotid re-stenosis >70% 5 years after treatment compared with endovas‐
cular therapy (30.7% vs 10.5%). Additionally, in the endovascular treatment group, the patients
treated with angioplasty alone had a higher rate of re-stenosis >70% compared with those
treated with stent placement (36.2% vs 16.6%) [33]. With the placement of a stent, the in-stent
re-stenosis rate has been reported to be as low as 5% after four years [34]. Risk factors that may
increase the likelihood of recurrent stenosis after carotid angioplasty, stent or endarterectomy
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have been examined and in a report from Skelly et al, these risk factors include prior stroke,
transient ischemic attack, amaurosis fugax, and prior neck cancer [35].
Large trials designed to evaluate surgical versus medical treatment for symptomatic carotid
stenosis include the Veterans Administration 309 Trial (VA309, 1991 [36]), the European
Carotid Surgery Trial (ECST, 1998 [37]), and the North American Symptomatic Carotid
Endarterectomy Trial (NASCET, 1998 [26]). VA309 evaluated the results of treating 189
symptomatic patients with >50% carotid stenosis ipsilateral to the symptoms with best medical
management or a combined approach of best medical management with CEA. The study found
a statistically significant reduction in the stroke risk over 11.9 months for the surgical arm
compared to the medical arm (7.7% vs 19.4%, P=0.11) [36]. In 1998, both ECST and NASCET
were published. ECST evaluated 3024 patients with some degree of symptomatic carotid
stenosis that was determined by varying modality and varying quality vascular imaging
studies. The trial randomized 1811 patients to the surgical arm and 1213 patients to the medical
arm, and the overall risk of surgery was determined to be about 7%, which did not vary with
the degree of stenosis. For symptomatic carotid stenosis (as measured by the ECST method)
of greater than 80%, the three-year major stroke or death rate was 14.9% for the surgical arm
and 26.5% in the medical arm, revealing a statistically significant benefit for surgery in that
group [37]. NASCET evaluated 1108 patients with symptomatic carotid stenosis in the CEA
arm and 1118 demographically similar patients in the best medical management arm. The
results showed no benefit for surgery below 50% stenosis, some benefit particularly in men
with moderate stenosis (50-69%) and clear benefit for surgery with severe stenosis (>70%). The
rate of any ipsilateral stroke over five-year follow up for moderate carotid stenosis (50-69%)
was 15.7% in the surgical arm and 22.2% in the medical arm (P=0.045), with the immediate
perioperative stroke or death risk being reported as 2% [26].
The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) evaluated 2502
symptomatic and asymptomatic carotid stenosis patients who were randomly assigned to CEA
or CAS [38]. The study found no significant differences in combined stroke, myocardial
infarction and death risk over 4 year follow up between these groups, however, there was a
trend toward more myocardial infarctions in the surgical arm (6.8% vs 7.2%, CAS vs CEA,
P=0.51) and a statistically significant higher rate of periprocedural stroke in the endovascular
arm (6.4% vs 4.7%, CAS vs CEA, P=0.03). A study published in February 2013 evaluated the
effect of these perioperative complications on long term survival. According to this trial,
having a stroke within the first year resulted in a two-fold lower survival rate (HR=6.6;
CI=3.7-12) than those patients who suffered a perioperative myocardial infarction two years
after intervention (HR=3.6;CI=2-6.8), but this difference becomes negligible at 5 years (HR=2.7;
CI=1.7-4.3 vs HR=2.8; CI=1.8-4.3) [39].
The Carotid and Vertebral Transluminal Angioplasty Study (CAVATAS) examined the
treatment of carotid stenosis with carotid endarterectomy (N=213) vs endovascular treatment
with angioplasty alone (N=145) or angioplasty and stent placement (N=50). The rate of
recurrent stenosis >70% after endovascular therapy for all patients treated with or without
stent placement was about 3 times higher than the restenosis rate after endarterectomy after 5
years of follow up (30.7% vs 10.5%, p=<0.0001). However, of the endovascular treated patients,
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the occurrence of restenosis >70% in the angioplasty alone group compared to the stent group
was more than twice as frequent (36.2% vs 16.6%, p=0.04). Of all patients with >70% restenosis
in the first year after treatment with CEA or CAS compared to the patients with <70% restenosis
in this same time period, there was a trend toward a higher ipsilateral stroke rate in the greater
stenosis group, but this result did not reach clinical significance (9.7% vs 5.4%, p=0.4) [33].
These results suggest that CEA provides the greatest durability of treatment with fewer cases
of hemodynamically significant recurrent stenosis compared with stent placement, although
stent placement is significantly superior to angioplasty alone for long-term durability. Treated
patients should be followed for recurrent stenosis, and although the greater stenosis group did
not have a statistically significant increase in the number of ipsilateral stroke events, it would
be wise to more closely monitor these patients, be more aggressive with medical management
with anti-platelet agents, or even offer repeat treatment for those patients with progressively
worsening stenosis during the follow up period.
7. Operative techniques for carotid endarterectomy
Patients with symptomatic carotid stenosis >50% or asymptomatic carotid stenosis >70%, or
who had a stroke ipsilateral to the carotid stenosis while on best medical management should
be offered a carotid revascularization procedure. CEA remains the gold standard of care for
carotid stenosis. It should be considered for those patients who have a low medical risk for
general anesthesia, have not had prior radical neck surgery or radiation to the neck and who
have a surgically accessible carotid bifurcation.
Because the surgery involves clamping the carotid artery temporarily, some surgeons will
decide to place a silicone tubing to shunt the blood and allow continuous carotid flow
throughout the operation, however, this can be associated with a higher rate of thromboem‐
bolic events and some surgeons will choose to place a shunt in only select cases [40,41]. If the
surgeon chooses to selectively shunt only those patients who do not tolerate carotid clamping
for the surgery, he or she can decide to perform this surgery either awake under local anesthesia
allowing for intra-operative neurological exams or under general anesthesia with neuromo‐
nitoring to evaluate for changes in somatosensory evoked potentials (SSEPs) and motor evoked
potentials (MEPs) while the carotid artery is clamped. If the surgeon chooses to shunt all
carotids, then the routine use of neuromonitoring would not typically be required or justified.
Some surgeons will measure stump pressures from the external carotid artery (ECA) after
clamping to help determine if the patient will require selective placement of a carotid shunt,
however, this has not been shown to be a good predictor of whether a patient will go on to
have a stroke from the surgery. The authors here routinely use neuromonitoring for all patients
under general anesthesia in order to choose the patients who will require selective shunting.
Pre-operative medical preparation is important, and patients undergoing CEA should be
taking an anti-platelet such as aspirin daily. The use of clopidogrel, although not required,
would not necessarily prevent the surgeon from performing the CEA, although there is a
slightly higher risk of local hematoma for patients taking combination anti-platelet agents. A
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drain is often recommended in selected cases, particularly if the patient is taking both aspirin
and clopidogrel at the time of the surgery, and if it is difficult to maintain a dry surgical field
at the time of the operation.
The approach to the carotid sheath for the CEA begins with positioning the patient in the
supine position on the operating table with the head turned slightly toward the contralateral
side and the neck slightly extended for optimum exposure. The planned incision line should
be marked with a skin marker along the anterior border of the sternocleidomastoid muscle,
which would be approximately parallel to the expected course of the carotid artery, for
optimum exposure. The neck should be prepped behind and below the ear from just above
the mastoid down to the upper chest, just below the clavicle, and from midline out laterally to
the anterolateral border of the trapezius muscle above the shoulder. After proper sterile
technique for preparation and draping of the operative field, the skin is incised along the
previously marked incision site. The platysma muscle is encountered and split parallel to the
muscle fibers, which is also parallel to the incision. The omohyoid muscle is separated as
needed for adequate exposure of the common carotid artery (CCA) and at least 2-3cm of the
ECA and internal carotid artery (ICA). If additional exposure is required superiorly, the
superior aspect of the planned incision should be extended superiorly and posteriorly just
below the mastoid, and care should be taken to not injure the hypoglossal nerve at this level
during the deeper dissection. Care should be taken to avoid injury to the recurrent laryngeal
nerve or the esophagus during the dissection to the carotid sheath. The carotid artery typically
resides medially in the carotid sheath, the internal jugular vein typically lies lateral to the
carotid artery, and the vagus nerve typically lies deep to both of these structures and between
them.
The systolic blood pressure (SBP) is raised prior to placing the clamp, typically to 140-160
mmHg for patients who are normotensive at baseline, to help promote perfusion through
collateral circulation. Generally, raising the SBP by about 20% of the baseline should allow for
adequate collateral circulation. The carotid artery is then clamped in the following order when
the surgeon is ready to perform the endarterectomy, with the ICA being clamped first followed
by the CCA (typically with a Fogarty carotid clamp or other atraumatic clamp device), followed
by the ECA. If neuromonitoring is used, these signals are also monitored continuously, and
changes in the SSEP and or MEP signals that would be consistent with ischemia changes should
prompt the surgeon to selectively place a shunt into that carotid artery.
The arteriotomy is performed with a #11 scalpel blade until a pair of Potts scissors can be
inserted into the true lumen and the incision can be extended from the CCA to the ICA full
thickness through the plaque. Care must be taken to identify the superior thyroid artery origin,
especially if there is back-bleeding after performing the arteriotomy, as this may arise very
near the carotid bifurcation, unless a temporary clip is applied to this arterial branch. The
plaque is then carefully but quickly teased from the endothelial layer of the carotid artery and
the plaque is transected as far as possible with the exposure and the carotid artery wall is
inspected for loose debris which is carefully removed and irrigated with heparinized saline.
The carotid artery is then sutured with 6-0 prolene in simple running fashion, using a minimal
full thickness stitch to reapproximate the incised vessel edges without causing additional
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the occurrence of restenosis >70% in the angioplasty alone group compared to the stent group
was more than twice as frequent (36.2% vs 16.6%, p=0.04). Of all patients with >70% restenosis
in the first year after treatment with CEA or CAS compared to the patients with <70% restenosis
in this same time period, there was a trend toward a higher ipsilateral stroke rate in the greater
stenosis group, but this result did not reach clinical significance (9.7% vs 5.4%, p=0.4) [33].
These results suggest that CEA provides the greatest durability of treatment with fewer cases
of hemodynamically significant recurrent stenosis compared with stent placement, although
stent placement is significantly superior to angioplasty alone for long-term durability. Treated
patients should be followed for recurrent stenosis, and although the greater stenosis group did
not have a statistically significant increase in the number of ipsilateral stroke events, it would
be wise to more closely monitor these patients, be more aggressive with medical management
with anti-platelet agents, or even offer repeat treatment for those patients with progressively
worsening stenosis during the follow up period.
7. Operative techniques for carotid endarterectomy
Patients with symptomatic carotid stenosis >50% or asymptomatic carotid stenosis >70%, or
who had a stroke ipsilateral to the carotid stenosis while on best medical management should
be offered a carotid revascularization procedure. CEA remains the gold standard of care for
carotid stenosis. It should be considered for those patients who have a low medical risk for
general anesthesia, have not had prior radical neck surgery or radiation to the neck and who
have a surgically accessible carotid bifurcation.
Because the surgery involves clamping the carotid artery temporarily, some surgeons will
decide to place a silicone tubing to shunt the blood and allow continuous carotid flow
throughout the operation, however, this can be associated with a higher rate of thromboem‐
bolic events and some surgeons will choose to place a shunt in only select cases [40,41]. If the
surgeon chooses to selectively shunt only those patients who do not tolerate carotid clamping
for the surgery, he or she can decide to perform this surgery either awake under local anesthesia
allowing for intra-operative neurological exams or under general anesthesia with neuromo‐
nitoring to evaluate for changes in somatosensory evoked potentials (SSEPs) and motor evoked
potentials (MEPs) while the carotid artery is clamped. If the surgeon chooses to shunt all
carotids, then the routine use of neuromonitoring would not typically be required or justified.
Some surgeons will measure stump pressures from the external carotid artery (ECA) after
clamping to help determine if the patient will require selective placement of a carotid shunt,
however, this has not been shown to be a good predictor of whether a patient will go on to
have a stroke from the surgery. The authors here routinely use neuromonitoring for all patients
under general anesthesia in order to choose the patients who will require selective shunting.
Pre-operative medical preparation is important, and patients undergoing CEA should be
taking an anti-platelet such as aspirin daily. The use of clopidogrel, although not required,
would not necessarily prevent the surgeon from performing the CEA, although there is a
slightly higher risk of local hematoma for patients taking combination anti-platelet agents. A
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drain is often recommended in selected cases, particularly if the patient is taking both aspirin
and clopidogrel at the time of the surgery, and if it is difficult to maintain a dry surgical field
at the time of the operation.
The approach to the carotid sheath for the CEA begins with positioning the patient in the
supine position on the operating table with the head turned slightly toward the contralateral
side and the neck slightly extended for optimum exposure. The planned incision line should
be marked with a skin marker along the anterior border of the sternocleidomastoid muscle,
which would be approximately parallel to the expected course of the carotid artery, for
optimum exposure. The neck should be prepped behind and below the ear from just above
the mastoid down to the upper chest, just below the clavicle, and from midline out laterally to
the anterolateral border of the trapezius muscle above the shoulder. After proper sterile
technique for preparation and draping of the operative field, the skin is incised along the
previously marked incision site. The platysma muscle is encountered and split parallel to the
muscle fibers, which is also parallel to the incision. The omohyoid muscle is separated as
needed for adequate exposure of the common carotid artery (CCA) and at least 2-3cm of the
ECA and internal carotid artery (ICA). If additional exposure is required superiorly, the
superior aspect of the planned incision should be extended superiorly and posteriorly just
below the mastoid, and care should be taken to not injure the hypoglossal nerve at this level
during the deeper dissection. Care should be taken to avoid injury to the recurrent laryngeal
nerve or the esophagus during the dissection to the carotid sheath. The carotid artery typically
resides medially in the carotid sheath, the internal jugular vein typically lies lateral to the
carotid artery, and the vagus nerve typically lies deep to both of these structures and between
them.
The systolic blood pressure (SBP) is raised prior to placing the clamp, typically to 140-160
mmHg for patients who are normotensive at baseline, to help promote perfusion through
collateral circulation. Generally, raising the SBP by about 20% of the baseline should allow for
adequate collateral circulation. The carotid artery is then clamped in the following order when
the surgeon is ready to perform the endarterectomy, with the ICA being clamped first followed
by the CCA (typically with a Fogarty carotid clamp or other atraumatic clamp device), followed
by the ECA. If neuromonitoring is used, these signals are also monitored continuously, and
changes in the SSEP and or MEP signals that would be consistent with ischemia changes should
prompt the surgeon to selectively place a shunt into that carotid artery.
The arteriotomy is performed with a #11 scalpel blade until a pair of Potts scissors can be
inserted into the true lumen and the incision can be extended from the CCA to the ICA full
thickness through the plaque. Care must be taken to identify the superior thyroid artery origin,
especially if there is back-bleeding after performing the arteriotomy, as this may arise very
near the carotid bifurcation, unless a temporary clip is applied to this arterial branch. The
plaque is then carefully but quickly teased from the endothelial layer of the carotid artery and
the plaque is transected as far as possible with the exposure and the carotid artery wall is
inspected for loose debris which is carefully removed and irrigated with heparinized saline.
The carotid artery is then sutured with 6-0 prolene in simple running fashion, using a minimal
full thickness stitch to reapproximate the incised vessel edges without causing additional
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stenosis with the suturing. Multiple simple interrupted sutures can also be used, but this tends
to be significantly more time consuming and is no more effective than the simple running
suture. The use of heparinized saline throughout the procedure and back bleeding from the
ECA to flush out any loose particles just prior to placing the last 6-0 prolene suture into the
carotid artery is also recommended. The clamps are then removed in the reverse order that
they were placed, with the ECA clamp removed first, followed by the CCA clamp, followed
lastly by the ICA clamp. There are several standard techniques to close a cervical approach
incision, which would typically include a subcutaneous layer of absorbable suture placed in
inverted simple interrupted fashion followed by a cosmetic skin edge reapproximation with
absorbable running subcuticular sutures, sterile adhesive strips or skin glue.
8. Interventional techniques for carotid angioplasty and stent
Patients who are not candidates for CEA due to high surgical risk factors are defined by
Medicare guidelines, and include patients with recurrent stenosis after prior ipsilateral CEA,
prior radiation therapy to the neck or previous ablative neck surgery such as radical neck
dissection, surgically inaccessible cervical lesion above the C2 level, presence of a CCA lesion
below the clavicle, contralateral vocal cord palsy, presence of a tracheostomy stoma, or patients
with a contralateral ICA occlusion. Additionally, patients who are medically unstable and high
risk for surgery, with COPD or other pulmonary condition which would make removal of the
endotracheal tube at the end of the surgery difficult or dangerous for the patient, or recent
acute myocardial infection within 30 days would also be considered high surgical risk, and a
carotid artery stent procedure could be considered.
All patients receiving angioplasty of the carotid bulb should be prepared with cardiac
defibrillator pads pre-procedurally, and atropine should be readily available for immediate
injection in the event of severe bradycardia or asystole. Advanced cardiac life support (ACLS)
materials should be readily available in the event of a potentially fatal cardiac arrhythmia that
could occur as a result of the parasympathetic reflex from carotid bulb stretch during the
angioplasty. The operator can choose whether to use distal embolic protection devices,
however, there is no general recommendation available from the literature to support the use
of distal embolic protection devices for all cases [28–32]. The authors here will routinely use a
distal embolic protection filterwire device to allow continuous perfusion while providing a
barrier to capture potentially large particulate matter during stent and angioplasty for carotid
atherosclerotic disease when it is safe and feasible to place such a device. Additionally,
Medicare requires that all carotid stent procedures be performed with distal embolic protection
devices, whenever feasible.
The patient should be pre-medicated with anti-platelet agents such as aspirin and clopidogrel,
and the authors here use 325mg aspirin and 75mg clopidogrel daily for 7 days prior to a
scheduled elective stent placement, or a loading dose of 325mg aspirin and 300mg clopidogrel
the day prior to a semi-urgent stent placement, or the day of an emergency stent placement
with supplemental abciximab given as a bolus of 0.25mg/kg up to a maximum of 20mg bolus,
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followed by a continuous drip of 0.125mcg/kg/min to a maximum of 10mcg/min for 24h, and
then followed by 325mg aspirin and 75mg clopidogrel daily for 3 months before the next follow
up angiogram. At the time of the follow up angiogram, if there is no in-stent stenosis or other
reason for additional procedures, then the clopidogrel can be stopped, and the patient is
continued on low-dose aspirin 81mg daily indefinitely.
One potential complication with stent placement is thromboembolic events that have been
found to occur in up to 10% of cases where the patient was found to not have adequate platelet
inhibition with the standard anti-platelet therapy described above, and these individuals are
described as “non-responders” [42]. It is now known that the incidence of non-responders to
clopidogrel is potentially very high, ranging from 5-40% of treated patients, and appears to be
more prevalent in the Asian population compared with the Caucasian or African populations.
Clopidogrel is a pro-drug that is metabolized by the cytochrome P450 emzyme pathway in the
liver into the active thiol metabolite. Factors such as platelet ADP receptor heterogeneity, poor
drug absorption, drug-drug interactions, and differences in metabolism of the drug by the
cytochrome P450 system, as well as patient non-compliance may all contribute to the variability
of drug efficacy between individuals. Variant alleles of the CYP2C19 and CYP2C9 enzymes
(CYP2C19 I331V, CYP2C9 R144C and CYP2C9 I359L) have been described to have a reduced
conversion rate of the clopidogrel pro-drug into the active thiol metabolite [43]. Alternative
anti-platelet agents such as prasugrel (Effient) may be used, as non-responders to clopidogrel
typically will respond adequately to prasugrel. Other alternative anti-platelet agents should
be evaluated with the most current pharmacological literature. A pharmacy consultation may
be needed to find an effective alternative anti-platelet drug for patients who do not respond
to a therapeutic level with these medications. It would be wise to test all patients who require
elective pre-medication with aspirin and clopidogrel using a P2Y12 activity test before
performing the procedure, whenever possible, in order to identify those patients who may be
non-responders to the standard therapy.
The patient is placed in the supine position on the angiography table with the femoral artery
access site prepared in the usual sterile fashion. Using the modified Seldinger technique, the
femoral artery is accessed with a long access catheter typically with at least a 6F inner diameter
(ID) to allow room for placement of a distal protection device and the stent device simultane‐
ously, along with any additional 0.014 or 0.018 inch microwires, termed “buddy wires,” which
may be placed to improve the stability of the guide catheter in the CCA. The guide catheter is
positioned in the CCA just proximal to the carotid bifurcation and appropriate digital sub‐
traction angiography (DSA) is performed to optimally visualize the stenosis and the takeoff
of the ICA. A 0.014 inch microwire is guided beyond the ICA stenosis using a road map. The
distal protection device is deployed over the microwire into a straight segment of the ICA
proximal to the petrous segment. Occasionally, the stenosis will be so severe that pre-dilation
angioplasty of the stenosis with a balloon that has a low crossing profile, such as a 2.5mm x
30mm Maverick or Mini-Trek balloon, before the placement of the distal protection device or
the stent may be required. Cardiovascular instability or arrhythmias are uncommon when
inflating a small balloon such as this at the ICA origin. An appropriately sized stent is selected,
which is typically about 30-40mm in length to cover the lesion completely and about 1-2mm
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carotid artery is also recommended. The clamps are then removed in the reverse order that
they were placed, with the ECA clamp removed first, followed by the CCA clamp, followed
lastly by the ICA clamp. There are several standard techniques to close a cervical approach
incision, which would typically include a subcutaneous layer of absorbable suture placed in
inverted simple interrupted fashion followed by a cosmetic skin edge reapproximation with
absorbable running subcuticular sutures, sterile adhesive strips or skin glue.
8. Interventional techniques for carotid angioplasty and stent
Patients who are not candidates for CEA due to high surgical risk factors are defined by
Medicare guidelines, and include patients with recurrent stenosis after prior ipsilateral CEA,
prior radiation therapy to the neck or previous ablative neck surgery such as radical neck
dissection, surgically inaccessible cervical lesion above the C2 level, presence of a CCA lesion
below the clavicle, contralateral vocal cord palsy, presence of a tracheostomy stoma, or patients
with a contralateral ICA occlusion. Additionally, patients who are medically unstable and high
risk for surgery, with COPD or other pulmonary condition which would make removal of the
endotracheal tube at the end of the surgery difficult or dangerous for the patient, or recent
acute myocardial infection within 30 days would also be considered high surgical risk, and a
carotid artery stent procedure could be considered.
All patients receiving angioplasty of the carotid bulb should be prepared with cardiac
defibrillator pads pre-procedurally, and atropine should be readily available for immediate
injection in the event of severe bradycardia or asystole. Advanced cardiac life support (ACLS)
materials should be readily available in the event of a potentially fatal cardiac arrhythmia that
could occur as a result of the parasympathetic reflex from carotid bulb stretch during the
angioplasty. The operator can choose whether to use distal embolic protection devices,
however, there is no general recommendation available from the literature to support the use
of distal embolic protection devices for all cases [28–32]. The authors here will routinely use a
distal embolic protection filterwire device to allow continuous perfusion while providing a
barrier to capture potentially large particulate matter during stent and angioplasty for carotid
atherosclerotic disease when it is safe and feasible to place such a device. Additionally,
Medicare requires that all carotid stent procedures be performed with distal embolic protection
devices, whenever feasible.
The patient should be pre-medicated with anti-platelet agents such as aspirin and clopidogrel,
and the authors here use 325mg aspirin and 75mg clopidogrel daily for 7 days prior to a
scheduled elective stent placement, or a loading dose of 325mg aspirin and 300mg clopidogrel
the day prior to a semi-urgent stent placement, or the day of an emergency stent placement
with supplemental abciximab given as a bolus of 0.25mg/kg up to a maximum of 20mg bolus,
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followed by a continuous drip of 0.125mcg/kg/min to a maximum of 10mcg/min for 24h, and
then followed by 325mg aspirin and 75mg clopidogrel daily for 3 months before the next follow
up angiogram. At the time of the follow up angiogram, if there is no in-stent stenosis or other
reason for additional procedures, then the clopidogrel can be stopped, and the patient is
continued on low-dose aspirin 81mg daily indefinitely.
One potential complication with stent placement is thromboembolic events that have been
found to occur in up to 10% of cases where the patient was found to not have adequate platelet
inhibition with the standard anti-platelet therapy described above, and these individuals are
described as “non-responders” [42]. It is now known that the incidence of non-responders to
clopidogrel is potentially very high, ranging from 5-40% of treated patients, and appears to be
more prevalent in the Asian population compared with the Caucasian or African populations.
Clopidogrel is a pro-drug that is metabolized by the cytochrome P450 emzyme pathway in the
liver into the active thiol metabolite. Factors such as platelet ADP receptor heterogeneity, poor
drug absorption, drug-drug interactions, and differences in metabolism of the drug by the
cytochrome P450 system, as well as patient non-compliance may all contribute to the variability
of drug efficacy between individuals. Variant alleles of the CYP2C19 and CYP2C9 enzymes
(CYP2C19 I331V, CYP2C9 R144C and CYP2C9 I359L) have been described to have a reduced
conversion rate of the clopidogrel pro-drug into the active thiol metabolite [43]. Alternative
anti-platelet agents such as prasugrel (Effient) may be used, as non-responders to clopidogrel
typically will respond adequately to prasugrel. Other alternative anti-platelet agents should
be evaluated with the most current pharmacological literature. A pharmacy consultation may
be needed to find an effective alternative anti-platelet drug for patients who do not respond
to a therapeutic level with these medications. It would be wise to test all patients who require
elective pre-medication with aspirin and clopidogrel using a P2Y12 activity test before
performing the procedure, whenever possible, in order to identify those patients who may be
non-responders to the standard therapy.
The patient is placed in the supine position on the angiography table with the femoral artery
access site prepared in the usual sterile fashion. Using the modified Seldinger technique, the
femoral artery is accessed with a long access catheter typically with at least a 6F inner diameter
(ID) to allow room for placement of a distal protection device and the stent device simultane‐
ously, along with any additional 0.014 or 0.018 inch microwires, termed “buddy wires,” which
may be placed to improve the stability of the guide catheter in the CCA. The guide catheter is
positioned in the CCA just proximal to the carotid bifurcation and appropriate digital sub‐
traction angiography (DSA) is performed to optimally visualize the stenosis and the takeoff
of the ICA. A 0.014 inch microwire is guided beyond the ICA stenosis using a road map. The
distal protection device is deployed over the microwire into a straight segment of the ICA
proximal to the petrous segment. Occasionally, the stenosis will be so severe that pre-dilation
angioplasty of the stenosis with a balloon that has a low crossing profile, such as a 2.5mm x
30mm Maverick or Mini-Trek balloon, before the placement of the distal protection device or
the stent may be required. Cardiovascular instability or arrhythmias are uncommon when
inflating a small balloon such as this at the ICA origin. An appropriately sized stent is selected,
which is typically about 30-40mm in length to cover the lesion completely and about 1-2mm
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greater diameter than the widest measured carotid diameter into which the stent will be
deployed, typically at the bifurcation [44]. Because the carotid artery bulb is typically signifi‐
cantly larger than the cervical segment of the ICA, some carotid stents are designed with a
tapered diameter, such as 6mm diameter distally and 8mm diameter proximally, to accom‐
modate for this and to prevent the stent from being significantly oversized distally for an
appropriately selected diameter for the proximal ICA. The appropriately selected stent is then
positioned across the ICA stenosis, taking care to avoid placement of the distal end of the stent
at a curved segment of the ICA, as some patients may have a relatively tortuous ICA course.
This will help to avoid kinking of the stent or occlusion or dissection of the ICA. After the stent
is deployed across the lesion, a DSA run is performed to confirm the location of the stent and
to evaluate for residual stenosis. An appropriately selected balloon is then chosen and
positioned along the center of the greatest stenosis. At the time of balloon inflation, care should
be taken to watch the heart rate and blood pressure, as stretching of the carotid bulb could
result in significant bradycardia or asystole. The balloon should be inflated only a few seconds,
and should not remain inflated for more than 10-20 seconds during the initial post-stent
angioplasty. The balloon may be left inflated longer as long as the patient remains asympto‐
matic with the occlusion of carotid blood flow, but this should not be done for longer than 1-2
minutes at a time. The distal protection device is then recovered, taking care to avoid inad‐
vertently snagging on the stent tines and potentially dislodging the position of the stent. The
femoral arteriotomy access site is then closed and the patient should remain flat with the
accessed leg straight for at least 1 hour after placement of an arterial closure device, or for 4-6
hours with a sandbag or clamp to hold pressure on the femoral arteriotomy site if no closure
device is used.
9. Conclusions
The NASCET evidence supports the treatment of symptomatic hemodynamically significant
carotid artery stenosis of ≥50% by NASCET criteria for men, and ≥70% for women. The only
trial that advocates surgical intervention for asymptomatic carotid stenosis is the ACAS trial,
and surgical intervention for asymptomatic carotid artery stenosis ≥60% was supported, but
other trials would support best medical management because of the very low incidence of
ipsilateral stroke from asymptomatic carotid stenosis, regardless of the degree of stenosis.
Carotid endarterectomy remains the gold standard treatment for patients who are medically
stable enough to tolerate the surgery. Carotid angioplasty without stent placement has a high
rate of recurrence of stenosis, and therefore with current devices available, patients in whom
endovascular treatment has been chosen for carotid stenosis should be treated with stent
placement and should be pre-medicated with anti-platelet agents such as aspirin and clopi‐
dogrel, or alternative drugs such as prasugrel in clopidogrel non-responder patients. These
medications should be continued for at least 3 months post-procedurally and the low dose
(81mg) aspirin should be continued indefinitely.
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approaches for better understanding of the mechanisms and useful therapies for 
these disease. We hope that would be a new current trend understanding new aspects 
regarding this scientific problematic involving not only anatomical, functional but also 
clinical questions.
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